<?xml version='1.0' encoding='UTF-8'?><S:Envelope xmlns:S="http://schemas.xmlsoap.org/soap/envelope/"><S:Body><ns2:searchStudyResponse xmlns:ns2="http://services.ctep.nci.nih.gov/"><Documents><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-8861</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8861</localDocumentNumber></localDocumentNumberList><documentTitle>Monitoring CA 15-3 Antigen in Patients During and After Adjuvant Therapy For Stage II, Node Positive Carcinoma of the Breast</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>EST-P-B478</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B478</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study for the evaluation of chlorozotocin in patients with refractory lymphoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>EST-P-A377</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A377</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study for pulsed doses of bcnu and high-dose radiation therapy for malignant gliomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>EST-P-C477</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C477</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II pilot study for the treatment of drug resistant myelomatosis with hemi-body radiation</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>EST-P-B278</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B278</localDocumentNumber></localDocumentNumberList><documentTitle>Combined streptozotocin and adriamycin therapy in carcinoma of the upper gastrointestinal tract</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-6810</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-6810</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive combination chemotherapy for lymphosarcoma and reticulum cell sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>RTOG-80-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-80-04</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II protocol to study fast neutron radiation therapy in the treatment of metastatic malignant melanoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>RTOG-78-03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-78-03</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of adjuvant chemotherapy prior to definitive therapy of inoperable squamous cell carcinomas of the oral cavity, oropharynx, nasopharynx and hypopharynx</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-08</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-08</localDocumentNumber></localDocumentNumberList><documentTitle>A study of the comparative effect of intermittent 6-mercaptopurine and methotrexate administered intravenously to patients with acute leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-7113</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7113</localDocumentNumber></localDocumentNumberList><documentTitle>L-asparaginase/vincristine induction of all in adults followed by a comparison of daily 6-mp, weekly methotrexate and monthly vincristine/prednisone reinforcement doses with high dose intensive courses of parenteral methotrexate and 6-mp</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-7254</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7254</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of advanced lsa and rcs with adriamycin in two dose schedules &amp; with prednisone following by maintenance with pcb or pcb + ccnu</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>NCCTG-91-19-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-91-19-51</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized double-blind trial of G-CSF versus placebo at the time of chemotherapy-induced Neutropenia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-9013</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9013</localDocumentNumber></localDocumentNumberList><documentTitle>Subcutaneous Interferon-Alpha-2b and Low Dose Cytarabine (lodac) in Previously Untreated Chronic Phase Chronic Myelogenous Leukemia: A Phase II Study of Philadelphia Chromosome-Positive Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>SWOG-9035</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9035</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized trial of adjuvant immunotherapy with an allogeneic melanoma vaccine for patients with intermediate thickness, node negative malignant melanoma (t3nomo)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>GOG-9102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9102</localDocumentNumber></localDocumentNumberList><documentTitle>The effect of Alopecia on Cancer patients' body image and the role of audiovisual information on body image</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>SWOG-7716</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7716</localDocumentNumber></localDocumentNumberList><documentTitle>Study of Tamoxifen (ICI 46474) in Metastatic Renal Cell Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>SWOG-7520</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7520</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of 1,2:5,6 dianhydrogalactitol in advanced cancer patients</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CCG-B957</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-B957</localDocumentNumber></localDocumentNumberList><documentTitle>Genetic Etiology of Acute Leukemia in Down Syndrome</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>POG-9466</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9466</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Pyrazoloacridine in children with refractory solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>NCCTG-95-20-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-95-20-52</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study and Pharmacokinetics of Oral Etoposide and Intravenous Paclitaxel in Extensive Stage Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CCG-1953</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-1953</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of newly diagnosed acute lymphoblastic leukemia in infants less than 1 year of age</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>S9622</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9622</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of CI-980 in Patients with Disseminated Malignant Melanoma and No Prior Chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>POG-8016</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8016</localDocumentNumber></localDocumentNumberList><documentTitle>PCNU Phase II recurrent childhood Medullablastoma and Ependymoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>NCCTG-96-24-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-96-24-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of LU 103793 in the treatment of advanced Non-small cell lung cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>GOG-8091</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8091</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of vinblastine, Bleomycin and Cisplatinum as second trial therapy in patients with Recurrent or Persistent Ovarian Carcinoma - Phase II</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>GOG-5</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-5</localDocumentNumber></localDocumentNumberList><documentTitle>Study of the relationship between growth pattern and Lymphatic Involvement in stage IA Cervical Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>POG-8615</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8615</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of large cell Lymphomas in children and adolescents: a comparison of two treatment regimens-ACOP + versus APO</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>POG-9343</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9343</localDocumentNumber></localDocumentNumberList><documentTitle>Interleukin-6 in children receiving autologous Bone Marrow Transplantation for advanced Neuroblastoma: A Pediatric Oncology Group Phase I trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>SWOG-9349</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9349</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Trial of CHOP with G-CSF Support or Promace-Cytabom with G-CSF Support for Treatment of Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>RTOG-94-17</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-94-17</localDocumentNumber></localDocumentNumberList><documentTitle>A Single-Arm, Open Label, Phase II Study of Intravenously Administered Tirapazamine Plus Radiation Therapy for High Grade Glioblastoma Multiforme</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>NSABP-B-26</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-26</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized trial in patients with metastatic or locally advanced breast cancer comparing the effect of 3-hour vs. 24-hour infusion of high-dose Taxol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>SWOG-8949</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8949</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Comparison of Nephrectomy Followed by Interferon Alpha-2b (Intron-a) vs. Intron-a Alone in Patients with Advanced Renal Cell Carcinoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>CCG-1922</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-1922</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized comparison of intravenous vs oral mercaptopurine and dexamethasone vs prednisone for favorable and intermediate all</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>E1E96</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1E96</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Clinical Trial of Interleukin-12  in Patients with Advanced, Recurrent or Inoperable Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>RTOG-96-08</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-96-08</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial of total androgen suppression versus total androgen suppression plus definitive external beam irradiation for pathologic lymph node positive (pn+) adenocarcinoma of the prostate</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>NSABP-B-27.1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-27.1</localDocumentNumber></localDocumentNumberList><documentTitle>A trial to Evaluate the Worth of Serum ErbB-2 Extracellular Domain and Serum ErbB-2 Antibodies in Predicting Response to Preoperative Chemotherapy and Long-Term Outcome in Patients with Operable Breast Cancer Who Are Participating in NSABP Protocol B-27</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>NCCTG-94-78-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>94-78-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Fludarabine and Sandostatin(R) LAR Depot  for Relapsed Low-Grade Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>RTOG-94-13</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-94-13</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial comparing whole pelvic irradiation followed by a conedown boost to boost irradiation only and comparing neodjuvant to adjuvant total androgen suppression (tas)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>CALGB-9662</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9662</localDocumentNumber></localDocumentNumberList><documentTitle>CLONALITY ANALYSIS in patients undergoing AUTOLOGOUS BONE MARROW TRANSPLANT for NON-HODGKIN'S LYMPHOMA</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>SWOG-9520</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9520</localDocumentNumber></localDocumentNumberList><documentTitle>Controlled Phase II Study of  Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>T95-0034</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTC-9404</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I trial and pharmacokinetic study of the sequential administration of carmustine (bcnu) and temozolomide in patients with cns or systemic tumors refractory to standard therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>INT-0070</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NWTS-4</localDocumentNumber><localDocumentNumber>CCG-461</localDocumentNumber><localDocumentNumber>POG-8650</localDocumentNumber></localDocumentNumberList><documentTitle>National wilms' tumor study-4: therapeutic trial and late follow-up study/favorable or anaplastic histology</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>D9502</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>D9502</localDocumentNumber><localDocumentNumber>D9502</localDocumentNumber><localDocumentNumber>D9502</localDocumentNumber></localDocumentNumberList><documentTitle>Irs v:  a pilot study of vincristine (vcr), actinomycin-d (amd), and escalating dose cyclophosphamide (ctx) therapy for children with intermediate risk rhabdomyosarcoma and certain patients with metastatic rhabdomyosarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>T95-0079</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM95-033</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Topotecan (SKF 104864, Hycamptamine) and Cytarabine (ARA-C) Combination in Myelodysplastic Syndrome (MDS)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>NCCTG-96-41-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-96-41-52</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of CPT-11 in Patients with Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Incorporating Pretreatment  and  Posttreatment Biopsies for Evaluation of Tumor Thymidylate Synthase, MIB-1, Topoisomerase I, and p53</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>GOG-P-12</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-P-12</localDocumentNumber></localDocumentNumberList><documentTitle>Response of Endometrial Adenocarcinoma to Progestin therapy related to the concentration of Progesterone Receptors in the Cancer Cells</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>POG-7607B</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7607B</localDocumentNumber><localDocumentNumber>SWOG-7607B</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Lithium Carbonate in the amelioration of Hematopoietic toxicity following cancer chemotherapy in children with solid Tumors being treated with Ad-Con-Fu, Phase II</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>POG-8022</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8022</localDocumentNumber><localDocumentNumber>SWOG-8022</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Vindesine twice weekly plus Prednisone and a cross-over study in Pediatric ALLl,Hodgkin's and Non-Hodgkin's disease</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>POG-7675</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7675</localDocumentNumber><localDocumentNumber>SWOG-7675</localDocumentNumber></localDocumentNumberList><documentTitle>Immunological method protocol: classification of Acute Lymphoblastic Leukemia into subgroups (T Leukemia and Non-T Leukemia) based on spontaneous formation of E-Rosettes</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>POG-7819</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7819</localDocumentNumber><localDocumentNumber>SWOG-7819</localDocumentNumber></localDocumentNumberList><documentTitle>Maytansine in refractory childhood Acute Lymphocytic Leukemia: A Pediatric Oncology Group study V</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CALGB-7541</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7541</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy and immunotherapy in previously untreated stage iii and iv neuroblastoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-7717</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7717</localDocumentNumber></localDocumentNumberList><documentTitle>Management of patients with a metastatic adenocarcinoma of unknown origin</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CALGB-8179</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8179</localDocumentNumber></localDocumentNumberList><documentTitle>Bisantrene straight Phase II advanced colorectal cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CALGB-8078</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8078</localDocumentNumber></localDocumentNumberList><documentTitle>Cisplatin in patients with gastric cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>T92-0114</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM 92-035</localDocumentNumber></localDocumentNumberList><documentTitle>Post-radiation therapy Phase III randomized study of DFMO-PCV  versus PCV chemotherapy for the treatment of malignant gliomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CALGB-9761</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9761</localDocumentNumber></localDocumentNumberList><documentTitle>Detection of Occult Micrometastases in Patients With Clinical Stage I NSCLC: A Prospective Analysis</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>E6892</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E6892</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of topotecan in advanced carcinoma of the urothelium</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>NCCTG-90-70-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-90-70-51</localDocumentNumber><localDocumentNumber>90-70-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of Cisplatin, BCNU, DTIC +/- Tamoxifen in advanced malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>EST-P-A277</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A277</localDocumentNumber></localDocumentNumberList><documentTitle>Neocarzinostatin Phase II pilot in hepatocellular carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-541</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-541</localDocumentNumber></localDocumentNumberList><documentTitle>Phase iii: acute leukemia in adults</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-9023</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9023</localDocumentNumber></localDocumentNumberList><documentTitle>Cytogenetic and flow cytometric analysis of solid tumors:  renal cell carcinoma:  a companion protocol to swog-8949</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>NCCTG-92-46-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-92-46-52</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial:  Evaluation of the Role of Multiple Metastasectomy Combined with Systemic and Hepatic Artery Infusion Chemotherapy for Colorectal Carcinoma Metastatic to the Liver</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>POG-9315</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9315</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of large Cell Lymphomas in children and adolescents; comparison of APO vs APO + IDMTX/HDARA-C and continuous vs bolus infusion of Doxorubicn</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>POG-9379</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9379</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of the Thymidylate synthase inhibitor ZD1694 administered as a short intravenous infusion in Pediatric patients with Acute Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-02-2012 12:45:43" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>A0935A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-0935</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Chimeric Human/Murine Anti-GD2 Monoclonal Antibody (CH14.18) with GM-CSF and Interleukin-2 (IL-2) in Children with Neuroblastoma and Other GD2 Positive Malignancies Immediately Post Autologous BMT or PBSC Rescue</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>NCCTG-93-20-53</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>93-20-53</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Trial of Different Schedules of Topotecan for the Treatment of Extensive-Stage Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>P9457</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9457</localDocumentNumber><localDocumentNumber>POG-9457</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive  therapy  with growth  factor support for Patients  with  EWING'S   TUMOR METASTATIC at  Diagnosis:  A  Pediatric  ONCOLOGY group Phase II trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>NCCTG-94-24-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>94-24-52</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Trial of Etoposide Plus Cisplatin Chemotherapy Plus Standard Versus Accelerated Hyperfractionated Thoracic Radiation Therapy in Stage IIIA/B Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>E3194</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E3194</localDocumentNumber></localDocumentNumberList><documentTitle>Phase IB/II evaluation of the Bispecific Murine Monoclonal Antibody 2b1 in patients with Advanced Breast Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>NSABP-B-27</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-27</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Trial Comparing Preoperative Doxorubicin (Adriamycin) Cyclophosphamide (AC) to Preoperative AC Followed by Preoperative Docetaxel (Taxotere) and to Preoperative AC Followed by Postoperative Docetaxel in Patients with Operable Carcinoma of the Breast</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>CCG-7951</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-7951</localDocumentNumber></localDocumentNumberList><documentTitle>Induction chemotherapy followed by melphalan/etoposide/tbi and autologous stem cell reconstitution for patients with newly diagnosed high risk ewing's sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-02-2012 12:45:43" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>CCG-0955</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-0955</localDocumentNumber></localDocumentNumberList><documentTitle>A PHASE I study of GEMCITABINE (NSC# 613327) in children with relapsed or refractory LEUKEMIA and NON-HODGKIN'S LYMPHOMA</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>CCG-1951</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-1951</localDocumentNumber></localDocumentNumberList><documentTitle>Extramedullary relapse and occult bone marrow involvement in childhood acute lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>CCG-0957</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-0957</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of B43-PaP Immunotoxin in combination with standard 4 drug induction for patients with CD19 + all in relapse</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>NCCTG-93-72-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-93-72-02</localDocumentNumber><localDocumentNumber>PENDING</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Preirradiation PCV Chemotherapy in Patients with Supratentorial Low-Grade Gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>S9617</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9617</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of PSC833 as Chemotherapy-Resistance Modifier in Patients Over Age 55 with Previously Untreated Acute Myeloid Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>CCG-1961</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-1961</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Patients with Acute Lymphoblastic Leukemia with Unfavorable Features</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>CCG-2961</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-2961</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Study in Children with Untreated Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>E1494</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1494</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and g-csf in patients with hiv-related intermediate and high-grade non-hodgkin's lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>NCCTG-96-42-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-96-42-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of KW2189 in patients with advanced Hepatocellular Carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>SWOG-7962</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7962</localDocumentNumber></localDocumentNumberList><documentTitle>Ccun and cis-platinum combination chemotherapy for refractory lymphoma; Phase I/II pilot study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>NCCTG-95-24-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-95-24-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Preoperative Paclitaxel and Carboplatin in Patients with Resectable Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>CALGB-9650</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9650</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of oral etoposide with pharmacodynamic modeling in relapsed non-hodgkin's lymphoma (iwf grades a-h)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>SWOG-7980</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7980</localDocumentNumber></localDocumentNumberList><documentTitle>Cis-platinum Phase II Recurrent Gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>NCCTG-83-70-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-83-70-51</localDocumentNumber></localDocumentNumberList><documentTitle>PHASE II studies of the combination PALA (NSC-224131) plus L-ALANOSINE (NSC-153353) and CIMETIDINE as a single agent in ADVANCED MALIGNANT MELANOMA</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>N9431</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N9431</localDocumentNumber><localDocumentNumber>N9431</localDocumentNumber></localDocumentNumberList><documentTitle>Menstrual Cycle and Surgical Treatment of Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>POG-7831</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7831</localDocumentNumber><localDocumentNumber>SWOG-7831</localDocumentNumber></localDocumentNumberList><documentTitle>Neocarzinostatin Phase II in children with ALL and ANLL  in relapse</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>E4592</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4592</localDocumentNumber><localDocumentNumber>CALGB-9466</localDocumentNumber><localDocumentNumber>NCCTG-91-24-51</localDocumentNumber><localDocumentNumber>RTOG-94-09</localDocumentNumber><localDocumentNumber>SWOG-9323</localDocumentNumber></localDocumentNumberList><documentTitle>Laboratory/clinical correlative studies in non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>INT-0128</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-9891</localDocumentNumber><localDocumentNumber>POG-9130</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Newly Diagnosed Low-Grade Astrocytomas: A Phase III Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>INT-0097</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9049</localDocumentNumber><localDocumentNumber>CCG-8882</localDocumentNumber></localDocumentNumberList><documentTitle>A study of high-risk malignant germ cell tumors in children a Phase III study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-P-E277</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-E277</localDocumentNumber></localDocumentNumberList><documentTitle>Cyclocytidine Phase II in advanced colorectal cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-P-E477</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-E477</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study for the treatment of patients with hodgkin's disease who have relapsed following radiation therapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-P-F379</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-F379</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of combination chemotherapy of advanced head and neck cancer using methotrexate, bleomycin, cis-diamminedichloroplatinum (ii) and hydroxyurea</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-P-D277</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-D277</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of combination chemotherapy of advanced colorectal carcinoma with 5-fu, meccnu, icrf-159 and triazinate</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-P-C881</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C881</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of intravesical bcg alone for recurrent superficial bladder cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-2578</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2578</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II master protocol for the evaluation of new agents in patients with small cell bronchogenic carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-1874</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1874</localDocumentNumber></localDocumentNumberList><documentTitle>Controlled Phase II studies in the treatment of advanced renal cell carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7438</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7438</localDocumentNumber></localDocumentNumberList><documentTitle>Cis-diamminedichloroplatinum (ii) for malignancies of the gynecologic and genitourinary organs</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7502</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7502</localDocumentNumber></localDocumentNumberList><documentTitle>Combination therapy of 5-azacytidine, prednisone and vincristine for induction and maintenance therapy in acute non-lymphocytic leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7204/05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7204/05</localDocumentNumber></localDocumentNumberList><documentTitle>Non-hodgkin's lymphoma chop vs hop combination chemotherapy for remission induction and cop vs oap combination chemotherapy for maintenance: Phase III </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7821</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7821</localDocumentNumber></localDocumentNumberList><documentTitle>Maytansine in the treatemnt of relapsing hodgkin's and non-hodgkin's lymphoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7762</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7762</localDocumentNumber></localDocumentNumberList><documentTitle>10-day simultaneous oap in combination with adriamycin in adult leukemia patients under 50</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7805</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7805</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Pilot Study of Medroxyprogesterone Acetate (MPA) plus Yoshi 864 in Adult Patients with Adenocarcinoma of the Kidney</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7626</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7626</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of acute leukemia in patients over the age of 50</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7969</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7969</localDocumentNumber></localDocumentNumberList><documentTitle>Hepatic infusion and systemic combination chemotherapy in the treatment of unresectable heptoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7910</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7910</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of estrogen-antagonist in the management of refractory large bowel tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-8213</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8213</localDocumentNumber></localDocumentNumberList><documentTitle>Aclacinomycin-a Phase II in refractory multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-8039</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8039</localDocumentNumber></localDocumentNumberList><documentTitle>A trial of chemotherapy, radiation therapy, and surgery for locally advanced carcinoma of the maxillary sinus</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-7887</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-7887</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase III Evaluation of Pelvic Lymphadenectomy Plus Hormonal Therapy Versus Pelvic Lymphadenectomy and Expectant Management in Patients with Pelvic Nodal Metastases (Stage D1) Adenocarcinoma of the Prostate</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>NSABP-B-20</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-20</localDocumentNumber></localDocumentNumberList><documentTitle>A Clinical Trial to Compare Tamoxifen (TAM) with Sequential Methotrexate, 5-Fluorouracil and TAM (M-F+T) or CMF and TAM (CMF+T) in Patients with Primary Breast Cancer, Negative Axillary Nodes and Estrogen Receptor Positive Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>POG-7376</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7376</localDocumentNumber><localDocumentNumber>SWOG-7376</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for the evaluation of the natural history of Histiocytosis Y in childhood</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>NSABP-B-02/03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-02/03</localDocumentNumber></localDocumentNumberList><documentTitle>A protocol for a cooperative study to evaluate the effectiveness of adjuvants to surgery in the treatment of cancer of the female breast</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>SWOG-920</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-920</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy study of patients with acute leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>SWOG-8735</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8735</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of recombinant human interferon-alfa and recombinant human interferon-gamma in previously untreated patients with chronic myelogenous leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>E2394</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2394</localDocumentNumber><localDocumentNumber>E2394</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study comparing three cycles of infusional bcnu/cisplatin followed by radiation therapy with radiation therapy and concurrent bcnu for patients with newly diagnosed supratentorial glioblastoma multiforme</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>POG-8157</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8157</localDocumentNumber></localDocumentNumberList><documentTitle>Multi-agent chemotherapy with adjuvant whole-body irradiation in half-body increments in patients with clinical group IV Rhabdomyosarcoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>POG-8069</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8069</localDocumentNumber></localDocumentNumberList><documentTitle>Toxicity studies of Indicine-N-Oxide (Phase I ) plus evaluation of response in children with Acute Lymphoblastic Leukemia (Phase II )</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>CALGB-9334</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9334</localDocumentNumber><localDocumentNumber>C9334</localDocumentNumber><localDocumentNumber>C9334</localDocumentNumber><localDocumentNumber>RTOG-95-11</localDocumentNumber><localDocumentNumber>PENDING</localDocumentNumber></localDocumentNumberList><documentTitle>Sclerosis of pleural effusions by talc thoracoscopy versus talc slurry</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>SWOG-9239</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9239</localDocumentNumber><localDocumentNumber>S9239</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of sequential modification of immunosuppression, interferon alpha, and promace-cytabom for treatment of post-cardiac transplant lymphoproliferation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>EST-3887</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3887</localDocumentNumber><localDocumentNumber>CALGB-8991</localDocumentNumber><localDocumentNumber>SWOG-8997</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Chemotherapy of disseminated advanced stage Testicular cancer with Cisplatin plus Etoposide with either Bleomycin or Ifosfamide</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>INT-0004</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7450</localDocumentNumber><localDocumentNumber>CCG-742</localDocumentNumber><localDocumentNumber>SWOG-7450</localDocumentNumber></localDocumentNumberList><documentTitle>Clinical trial of radiation therapy and chemotherapy in the treatment of patients with metastatic ewing's sarcoma who had no prior chemotherapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>EST-1069</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1069</localDocumentNumber></localDocumentNumberList><documentTitle>Phenestrin Phase II dose schedule comparison in neoplastic diseases</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>C88-0004</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Anxiety in chemotherapy:  methods of control</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>C95-0001</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>URCC-C95-0001</localDocumentNumber></localDocumentNumberList><documentTitle>Oral antibiotic prophylaxis of early infection in multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>CCG-S9704</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-S9704</localDocumentNumber></localDocumentNumberList><documentTitle>Parent's experience with the informed consent process</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>I88-0001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-84-46-51</localDocumentNumber><localDocumentNumber>84-46-51</localDocumentNumber></localDocumentNumberList><documentTitle>Hemoquant detection of colorectal neoplasia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-88-39-51</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-88-39-51</localDocumentNumber></localDocumentNumberList><documentTitle>Prevention of excessive weight gain in premenopausal patients receiving adjuvant chemotherapy for breast cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-90-92-56</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-90-92-56</localDocumentNumber></localDocumentNumberList><documentTitle>S/N - controlled evaluation of Chamomile for preventing Stomatitis in patients receiving 5-FU-based chemotherapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-95-92-57</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Short Term Phase III Chemoprevention Trial in Men with PIN Using Flutamide as an Androgen Deprivation Agent</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-96-92-56</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase III double-blind study of Glutamine vs placebo in prevention of acute diarrhea in patients receiving pelvic radiation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>SWOG-8807</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8807</localDocumentNumber></localDocumentNumberList><documentTitle>An investigation of the relationship between an integrated, system education approach and Breast self exam (bse) compliance</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>SWOG-9220</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9220</localDocumentNumber></localDocumentNumberList><documentTitle>A cancer control feasibility trial of a protocol specific patients educational video (pspev)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>URCC-9994</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>U9994</localDocumentNumber></localDocumentNumberList><documentTitle>Supportive Expressive Group Therapy for Men with Primary Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>POG-9571</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9571</localDocumentNumber></localDocumentNumberList><documentTitle>A Trial of Irinotecan in Children with Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>INT-0079</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2886</localDocumentNumber><localDocumentNumber>NCCTG-87-50-02</localDocumentNumber><localDocumentNumber>SWOG-8792</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of interferon alfa-nl (wellferon) as adjuvant treatment for resectable renal cell carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>EST-1572</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1572</localDocumentNumber></localDocumentNumberList><documentTitle>Adriamycin in the treatment of far-advanced Lung cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>NSABP-B-16</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-16</localDocumentNumber><localDocumentNumber>MAOP-1684</localDocumentNumber><localDocumentNumber>NCOG-NSABP-B-16</localDocumentNumber></localDocumentNumberList><documentTitle>A Three-Arm Clinical Trial Comparing Tamoxifen Alone with L-PAM, 5-FU, Adriamycin &amp; Tamoxifen or with Short Intensive Adriamycin-Cycloposphamide and Tamoxifen in Positive Node Patients Having the Following Age and Receptor Criteria: 50-59 yrs - PR >/= 10fmol, Regardless of ER; 60-70 yrs - All Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>RTOG-88-08</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-88-08</localDocumentNumber><localDocumentNumber>EST-4588</localDocumentNumber><localDocumentNumber>SWOG-8992</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of Radiation Therapy alone or in combination with Chemotherapy for patients with Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>CCG-B969</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-B969</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Genetic Lesions and Clinical Outcome in Pediatric ALL Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>POG-9720</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9720</localDocumentNumber></localDocumentNumberList><documentTitle>Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>CALGB-9733</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9733</localDocumentNumber></localDocumentNumberList><documentTitle>Cpt-11 (Irinotecan) for Malignant Mesothelioma: A Phase II Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>S9802</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9802</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Gemcitabine in Advanced Soft Tissue Sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>E3297</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E3297</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of isis 5132 CGP 69846A), C-RAF antisense in patients with advanced Pancreatic cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>NSABP-B-17</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-17</localDocumentNumber><localDocumentNumber>CALGB-8793</localDocumentNumber><localDocumentNumber>MAOP-1285</localDocumentNumber><localDocumentNumber>NCOG-NSABP-B-17</localDocumentNumber></localDocumentNumberList><documentTitle>A Clinical Trial to Evaluate Natural History and Treatment of Patients with Non-Invasive Intraductal Adenocarcinoma and Lobular In-Situ Registry</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>GOG-81D</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-81D</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial of high vs intermediate dose Medroxyprogesterone Acetate (MPA) in patients with Advanced or Recurrent Endometrial Carcinoma positive for either Estrogen or Progesterone Receptors but not both</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>GOG-81E</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-81E</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial of high vs inermediate dose Medroxyprogesterone Acetate (MPA) in patients with Advanced or Recurrent Endometrial Carcinoma with unknown Estrogen and Progesterone Receptors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>SWOG-9124</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9124</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of edatrexate (edx) in patients with relapsed or refractory germ cell tumors:  Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>NSABP-P-1</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-P-1</localDocumentNumber></localDocumentNumberList><documentTitle>A Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>CALGB-9234</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9234</localDocumentNumber></localDocumentNumberList><documentTitle>Taxol (nsc# 125973) plus g-csf for malignant mesothelioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>SWOG-9142</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9142</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of continuous infusion gallium nitrate for advanced bladder carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>T95-0035</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM 95-061</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Evaluation of Bryostatin-1 (NSC 339555) in Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>POG-9675</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9675</localDocumentNumber></localDocumentNumberList><documentTitle>A trial of Tirapazamine and Cyclophosphamide in children with refractory solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>NCCTG-96-73-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-96-73-51</localDocumentNumber></localDocumentNumberList><documentTitle>Primary Central Nervous System Non-Hodgkin's Lymphoma (PCNSL): A Phase II Clinical Trial of Radiation Therapy and High Dose Corticosteroids for Elderly Patients (70 Years of Age and Older)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>N9771</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N9771</localDocumentNumber><localDocumentNumber>N9771</localDocumentNumber><localDocumentNumber>N9771</localDocumentNumber><localDocumentNumber>N9771</localDocumentNumber></localDocumentNumberList><documentTitle>Study to evaluate effectiveness of follow-up evaluations for detection of tumor progression in newly diagnosed brain tumor patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>E1392</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1392</localDocumentNumber><localDocumentNumber>SWOG-9059</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III comparison of standard Radiotherapy, vs. Radiotherapy + simultaneous Cisplatin vs. split-course Radiotherapy and simultaneous Cisplatin and 5-FU, in patients with unresectable squamous cell carcinoma of the Head and Neck.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>PBT01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PBT01</localDocumentNumber><localDocumentNumber>T90-0180</localDocumentNumber><localDocumentNumber>T90-0180</localDocumentNumber><localDocumentNumber>T90-0180</localDocumentNumber><localDocumentNumber>T90-0180</localDocumentNumber><localDocumentNumber>PBT-1</localDocumentNumber><localDocumentNumber>T90-0180</localDocumentNumber><localDocumentNumber>T90-0180</localDocumentNumber><localDocumentNumber>T90-0180</localDocumentNumber><localDocumentNumber>SWOG-9412</localDocumentNumber><localDocumentNumber>T90-0180</localDocumentNumber><localDocumentNumber>PBT01</localDocumentNumber><localDocumentNumber>T90-0180</localDocumentNumber><localDocumentNumber>PBT01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized comparison of maintenance chemotherapy w/CTX ,MTX,and 5-FU vs. high dose chemotherapy w/ CTX,Thiotepa,and CBDCA and ABMT support for women w/ metastatic Breast CA responding to conventional induction chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:55"><nciDocumentNumber>POG-8828</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8828</localDocumentNumber></localDocumentNumberList><documentTitle>Late effects of treatment of Hodgkin's Disease: A Pediatric Oncology Group Non-therapeutic study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:55"><nciDocumentNumber>E2E93</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2E93</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II clinical trial of an outpatient Taxol and Carboplatin regimen in the treatment of suboptimally debulked Epithelial carinoma of the Ovary</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:55"><nciDocumentNumber>SWOG-8733</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8733</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluations of Operable Bladder Cancer Patients with Pre-operative Irradiation + 5-FU Alone, Phase II , a Pilot Study for Patients Ineligible for SWOG-8710</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>SWOG-9505</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9505</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy; Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>NCCTG-91-62-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-91-62-51</localDocumentNumber><localDocumentNumber>91-62-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Neoadjuvant MVAC + radical surgery + postoperative irradiation in locally advanced cervical cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>NSABP-BP-58</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-BP-58</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study in Patients with Metastatic or Locally Advanced Breast Cancer to Evaluate the Worth of the Combination of Adriamycin (Doxorubicin), Taxotere (Docetaxel), and Cyclophosphamide (ATC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>E4397</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4397</localDocumentNumber><localDocumentNumber>E4397</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults with "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>GOG-0114</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-114</localDocumentNumber><localDocumentNumber>G0114</localDocumentNumber><localDocumentNumber>SWOG-9227</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III randomized study of intravenous CDDP and CPM vs. intravenous CDDP and Taxol vs. high dose intravenous CBDCA followed by intravenous Taxol and intraperitineal CDDP in patients with optimal stage III Epithelial Ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0127K</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-127K</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Gemcitabine in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0127L</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-127L</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Vinorelbine (Navelbine) in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0128D</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-128D</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Tamoxifen in Persistent or Recurrent Non-Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0131D</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-131D</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Trimetrexate in the treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0137</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-137A</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women with Stage I or II Endometrial Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0148</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-148</localDocumentNumber></localDocumentNumberList><documentTitle>The clinical utility of soluble TNF/LT membrane receptors in the serum of patients with all stages of Primary Epithelial Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0158</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-158</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III randomized study of Cisplatin and Paclitaxel (24-hour infusion) versus Carboplatin and Paclitaxel (3 hour infusion) in optimal stage III Epithelial Ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0169</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-169</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase III study of Cisplatin versus Cisplatin plus Paclitaxel in stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0172</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-172</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III randomized trial of intravenous Paclitaxel and Cisplatin versus intravenous Paclitaxel, intraperitoneal Cisplatin and intraperitoneal Paclitaxel in patients with optimal stage III Epithelial Ovarian Carcinoma or primary peritoneal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0026C</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-26C</localDocumentNumber></localDocumentNumberList><documentTitle>Cis-Platinum Phase II in Advanced Gynecologic Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>GOG-0076W</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-76W</localDocumentNumber></localDocumentNumberList><documentTitle>A Limited Access Phase II Trial of CPT-11 (Irinotecan) (NSC #616348) in Patients with Advanced, Persistent or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>GOG-0087H</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-87H</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Topotecan (NSC # 609699) in patients with Advanced, Persistent or Recurrent Uterine Sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>GOG-0129I</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-129I</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Pyrazoloacridine (PZA) (NSC #366140) in the treatment of Recurrent or Persistent Endometrial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:00"><nciDocumentNumber>T98-0011</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>98-C-0074</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of intravenous cereport(rmp-7) and carboplatin in childhood brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:00"><nciDocumentNumber>CALGB-9870</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9870</localDocumentNumber></localDocumentNumberList><documentTitle>Quality of life and cost analysis of a prospective randomized Phase III trial comparing trimodality therapy to surgery alone for esophageal cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:00"><nciDocumentNumber>E2496</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2496</localDocumentNumber><localDocumentNumber>E2496</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial of ABVD Versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>JMA17</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MA.17</localDocumentNumber><localDocumentNumber>CALGB-49805</localDocumentNumber><localDocumentNumber>JMA.17</localDocumentNumber><localDocumentNumber>JMA.17</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant  Tamoxifen (NCIC CTG MA.17)</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>POG-9779</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9779</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial of Tomudex in Children with Leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>NCCTG-98-72-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-98-72-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Pre-Irradiation Chemotherapy with BCNU, Cisplatin and Oral Etoposide Combined with Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>T98-0020</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>98-15</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial of Interleukin-12 Followed by Interferon-Alpha</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>T98-0036</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>98-C-0142</localDocumentNumber></localDocumentNumberList><documentTitle>Immunization of Patients with Metastatic Melanoma Using the gp100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>NCCTG-97-95-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-97-95-51</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Markers in American Indian/Alaska Native Women with Breast Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-02-2012 12:45:43" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>A09717</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-09717</localDocumentNumber></localDocumentNumberList><documentTitle>A PHASE  I study of THROMBOPOIETIN (RHTPO) plus G-CSF in children receiving IFOSFAMIDE, CARBOPLATIN, and ETOPOSIDE (i.c.e.) chemotherapy for recurrent or refractory SOLID TUMORS</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>76-050</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>76-050</localDocumentNumber></localDocumentNumberList><documentTitle>Clinico-pharmacologic study of hepatic artery infusion therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POG-8398</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8398</localDocumentNumber><localDocumentNumber>V83-0192</localDocumentNumber></localDocumentNumberList><documentTitle>Up front alternating chemotherapy for childhood Acute Lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>T84-0515</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>182</localDocumentNumber></localDocumentNumberList><documentTitle>Autologous and allogenic bone marrow transplantation in the mamagement of advanced stage neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>71-05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>5-azacytidine in advanced gi tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>T84-0476</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-84-113</localDocumentNumber></localDocumentNumberList><documentTitle>Proposal for Phase II trial of chip in patients with advanced Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POG-7829</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7829</localDocumentNumber><localDocumentNumber>SWOG-7829</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of two dose regimens of intrathecal Methotrexate for treatment of CNS Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>GOG-15</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-15</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy for Mustard Resistant Ovarian Adenocarcinoma: a randomized trial of CCNU and Methyl-CCNU</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>GOG-17</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-17</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Advanced Adenocarcinoma of the Endometrium with radiotherapy and progestin or no progestin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>GITSG-6179</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-6179</localDocumentNumber><localDocumentNumber>MAOP-5583</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant combination therapy of Resectable Adenocarcinoma of the Colon with whole-liver irradiation and 5-Fluorouracil</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>GITSG-8480</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-8480</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study in Advanced Gastric Cancer, measurable or Evaluable Disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POA-74180</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-74180</localDocumentNumber><localDocumentNumber>BGSM-74180</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant chemotherapy for stage II  Carcinoma of Breast</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POA-83182</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-83182</localDocumentNumber><localDocumentNumber>BGSM-83182</localDocumentNumber></localDocumentNumberList><documentTitle>A prospective study using the Human Tumor Stem assay to plan chemotherapy regimens for patients having advanced previously untreated Ovarian Carcinomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>GITSG-4H85</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-4H85</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Alpha-2-Interferon in Hepatocellular Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>T84-0329</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>6G-83-1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of infusional cis-platinum in the treatment of high grade astrocytoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>SWOG-8904</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8904</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trials of merbarone and piroxantrone in ovarian cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>POA-24180</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-24180</localDocumentNumber><localDocumentNumber>BGSM-24180</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of advanced Non-Hodgkin's Lymphomas with unfavorable histologies: Vincristine infusion plus CCNU-CHOP (V-PACC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>NCCTG-89-69-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-89-69-51</localDocumentNumber><localDocumentNumber>89-69-51</localDocumentNumber></localDocumentNumberList><documentTitle>Flow cytometric DNA analysis of cervical and ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>T84-0325</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2N-82-3</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of advanced squamous and adenosquamous lung cancer with 13-cis-retinoic acid</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>WPL-73-31</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WPL-73-31</localDocumentNumber></localDocumentNumberList><documentTitle>Therapy of limited extent adenocarcinoma and large cell carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>T89-0214</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-89-110</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of suramin in patients with hormone refractory carcinoma of the prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>T84-0220</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCP-84-1</localDocumentNumber></localDocumentNumberList><documentTitle>Cell kinetic analysis of human brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T84-0164</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-84-02</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of spirogermanium in metastatic prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>CALGB-8922</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8922</localDocumentNumber></localDocumentNumberList><documentTitle>Interleukin-2 in acute myeloid leukemia in second remission-a randomized Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCOG-6G-80-1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-6G-80-1</localDocumentNumber></localDocumentNumberList><documentTitle>Pcnu Phase II study of recurrent primary malignant brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCOG-7H-81</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-7H-81</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase III study of platinum with or without Methotrexate for recurrent squamous cell carcinoma of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCOG-5O-83-1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-5O-83-1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Megestrol acetate in the palliative treatment of women with advanced Ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCOG-3P-62C</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-3P-62C</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study comparing Adriamycin plus 5-FU vs. BCNU plus Adriamycin plus Ftorafur for patients with disseminated Pancreatic cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1336</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>158</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of cutaneous t-cell lymphoma with monoclonal antibody</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1338</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>170</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Aplastic Anemia in patients without an HLA-matched donor: A trial of Antihuman Thymocyte Globulin (ATG) and Methylprednisolone therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1230</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UAB-253</localDocumentNumber></localDocumentNumberList><documentTitle>Combined modality treatment of loco-regional non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1191</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-5</localDocumentNumber><localDocumentNumber>IRB-2-83-6A</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II single agent chemotherapy cbdca for non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T89-0103</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>89-06-151</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of merbarone in primary brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCOG-P-4P-83-1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-P-4P-83-1</localDocumentNumber></localDocumentNumberList><documentTitle>The effect of high-dose Ketoconazole on stage D prostate carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCCTG-87-42-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-87-42-51</localDocumentNumber><localDocumentNumber>87-42-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of combined Doxorubicin and Alpha Interferon in the therapy of Advanced Hepatocellular Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCCTG-87-32-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-87-32-51</localDocumentNumber><localDocumentNumber>87-32-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of VP-16 and Cisplatin chemotherapy in Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCCTG-83-41-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-83-41-51</localDocumentNumber><localDocumentNumber>83-41-51</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy studies in advanced Gastric cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCCTG-79-60-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-79-60-51</localDocumentNumber></localDocumentNumberList><documentTitle>Tamoxifen Phase II in Advanced Endometrial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCCTG-79-20-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-79-20-51</localDocumentNumber></localDocumentNumberList><documentTitle>Extensive Stage Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>CALGB-8856</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8856</localDocumentNumber></localDocumentNumberList><documentTitle>Chope/abvd for advanced hodgkin's disease: a Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>SWOG-8824</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8824</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of continuous infusion recombinant interleukin-2 (ril-2) in patients with advanced renal cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>GOG-8804</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8804</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of a chemosensitivity assay base on ATP Bioluminescence</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>VASOG-27B</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VASOG-27B</localDocumentNumber></localDocumentNumberList><documentTitle>Colon,mer immunotherapy trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>VAP-802A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VAP-802A</localDocumentNumber></localDocumentNumberList><documentTitle>Dibromodulcitol Phase II solid tumor malignant disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T88-0015</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>87-083</localDocumentNumber></localDocumentNumberList><documentTitle>Trimetrexate (nsc #352122) for advanced sarcomas: a Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T88-0023</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>87-494</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of intraperitoneal carboplatin and etoposide</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0310</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>H-715-87</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I evaluation of iv melphalan (l-pam) and whole body hyperthermia (wbh)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0244</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>URCC-6487M</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of myelodysplastic syndromes with "attenuated d.a.t." (daunorubicin, cytosine arabinoside, 6-thioguanine)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0182</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RPC-2376</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of continuous infusion interleukin-2 (ril-2) and interferon alpha (rhuifn-a2a)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0147</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BGSM-62384</localDocumentNumber></localDocumentNumberList><documentTitle>Extensive small cell carcinoma of the lung: chemotherapy with or without cis-platinum</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0084</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-87U1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of new agents in advanced renal cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8723</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8723</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of amonafide in disseminated malignant melanoma: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8712</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8712</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of trimetrexate in the treatment of hepatoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8714</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8714</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of amonafide in colorectal carcinoma: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8464</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8464</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of fludarabine phosphate in advanced non-small cell carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8367</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8367</localDocumentNumber></localDocumentNumberList><documentTitle>Combined modality treatment of regional non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8277</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8277</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of fab-fam and radiotherapy in gastric carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8303</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8303</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of 2'deoxycoformycin in refractory multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8319</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8319</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of fludarabine phosphate in patients with ovarian cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8263</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8263</localDocumentNumber></localDocumentNumberList><documentTitle>Combined radiation therapy and chemotherapy as adjuvant treatment for duke's b2c colon cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8209</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8209</localDocumentNumber></localDocumentNumberList><documentTitle>Azq Phase II in soft tissue and bony sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-7931</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7931</localDocumentNumber></localDocumentNumberList><documentTitle>Amsa in metastatic advanced adenoca of the stomach and pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-7827</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7827</localDocumentNumber><localDocumentNumber>EST-4186</localDocumentNumber></localDocumentNumberList><documentTitle>Combined modality therapy for Breast carcinoma, Phase III </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-7519</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7519</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of squamous cell carcinoma of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SWOG-7315/16</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7315/16</localDocumentNumber></localDocumentNumberList><documentTitle>10-day oap induction with oap vs oap + bcg maintenance for all</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-78-GU-232</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-78-GU-232</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of nolvadex, tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-355</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-355</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of chronic lymphocytic leukemia with biweekly chlorambucil and prednisone randomizing responders to consolidation therapy with same induction therapy or to cyclophosphamide and cytosine arabinoside</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-SAR-80-281</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-SAR-80-281</localDocumentNumber></localDocumentNumberList><documentTitle>Mitoxantrone Phase II in sarcomas in both previously treated and untreated pts</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-SAR-82-262</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-SAR-82-262</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II protocol of weekly intravenous icrf-187 treatment of kaposi's sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-217</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-217</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of acute leukemia in adults using combination therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-RAL-83-212</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-RAL-83-212</localDocumentNumber></localDocumentNumberList><documentTitle>Aclacinomycin-a Phase II in refractory acute leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-MM-80-275</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-MM-80-275</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16,213 Phase II in refractory multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-NHL-82-283</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-NHL-82-283</localDocumentNumber></localDocumentNumberList><documentTitle>Prospective study of lymphocyte markers and proliferative activity related to treatment of non-hodgkins lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-MEL-77-313</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-MEL-77-313</localDocumentNumber></localDocumentNumberList><documentTitle>Phase iii randomized adjuvant study of corynebacterium parvum vs. no therapy in stage i melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-LUN-203</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-203</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of gallium nitrate in small cell carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-LUN-81-214</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-81-214</localDocumentNumber></localDocumentNumberList><documentTitle>Azq straight Phase II ca lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-LUN-P40</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-P40</localDocumentNumber></localDocumentNumberList><documentTitle>Guanazole Phase II pilot in bronchogenic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-5282</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-5282</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II protocol for the evaluation of new treatments in patients with advanced Gastric cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-4274</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4274</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II-III studies in advanced Gastric cancer patients without measurable disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-2887</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2887</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Trimetrexate in advanced carcinoma of the Urothelium</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1885</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1885</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II protocol for ovarian cancer of coelomic epithelial origin n-methylformamide, menogaril</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1576</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1576</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of high-dose MTX with Citrovorum factor rescue in patients with inoperable Bronchogenic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1581</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1581</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Chemotherapy of metastatic non-small cell Bronchogenic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1277-G1/2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1277-G1/2</localDocumentNumber></localDocumentNumberList><documentTitle>Generations I and II Phase II master protocol for Chemotherapy of patients with advanced large Bowel cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-P-Z886</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-Z886</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of recombinant Alpha 2 Interferon in carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-P-E584</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-E584</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of Adriamycin, Vincristine and Verapamil for refractory small cell Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-P-C178</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C178</localDocumentNumber></localDocumentNumberList><documentTitle>The combination of Adriamycin, Vincriastine, Dibromodulcitol and Hexamethylmelamine in advanced Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>D83-048-0628</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-8213</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment program for primary therapy of Breast cancer, stages 1&amp;2</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>D83-050-0441</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0151</localDocumentNumber></localDocumentNumberList><documentTitle>Continuous infusion vm-26 in refractory childhood leukemia &amp; neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>D82-050-0085</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BLEOVM</localDocumentNumber></localDocumentNumberList><documentTitle>Sequential synchronization of refractory b-cell lymphomas with bleomycin and vm-26</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>D82-043-0946</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-82-16</localDocumentNumber></localDocumentNumberList><documentTitle>Intralesional immunotherapy of human cancer with bcg</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D82-004-0687</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0099</localDocumentNumber><localDocumentNumber>ANL-01</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of refractory and relapsed adult acute non-lymphocytic</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D82-012-0696</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-81M2</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of bisantrene straight in patients with metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D80-035-0287</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>The treatment of advanced refractory non-hodgkin's lymphoma with the combination of ifosfamide and vp-16</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D79-018-0152</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>3377</localDocumentNumber></localDocumentNumberList><documentTitle>Dibromodulcitol Phase II osteogenic sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D79-009-0127</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>79-03</localDocumentNumber></localDocumentNumberList><documentTitle>Phase ii: clinical trial of vm-26 plus vp-16 combination chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D78-006-0183</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Evaluation of cis-diamminedichloroplatinum in epidermoid carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>SEG-HM-P55</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-HM-P55</localDocumentNumber></localDocumentNumberList><documentTitle>Cyclophosphamide total body irradiation and autologous bone marrow transplantation for hematologic malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>DT-77-75</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-77-75</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of hycanthone in metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>DT-73-34A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-73-34A</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of pepa program in chemotherapy of soft tissue sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>T86-0028</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM 86-52</localDocumentNumber></localDocumentNumberList><documentTitle>Consolidation therapy for responsive multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>T85-0268</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC-3750</localDocumentNumber></localDocumentNumberList><documentTitle>Leucovorin-floxuridine (fudr) chemotherapy for metastatic carcinoma of the colon</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>T85-0227</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>85-493</localDocumentNumber></localDocumentNumberList><documentTitle>Intracavitary thioguanine for advanced intraperitoneal malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>C77-0170</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>75-114</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy for small cell carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>SEG-AML-83-236P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-AML-83-236P</localDocumentNumber><localDocumentNumber>EST-4483</localDocumentNumber><localDocumentNumber>INT-0037</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of low dose ara-c in the treatment of myelodysplastic syndromes and aml</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CIC-76-59</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-76-59</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of head and neck cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CCG-086</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-086</localDocumentNumber></localDocumentNumberList><documentTitle>Bisantrene Phase II group-wide study eval of treatment of refractory childhood acute leukemia and solid tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CCG-105PH</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-105PH</localDocumentNumber><localDocumentNumber>T84-0259</localDocumentNumber></localDocumentNumberList><documentTitle>Pharmacology of orally administered maintenance chemotherapy in acute lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CALGB-8841</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8841</localDocumentNumber></localDocumentNumberList><documentTitle>Amonafide (nsc# 308847) for advanced Breast cancer: a Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-8651</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8651</localDocumentNumber></localDocumentNumberList><documentTitle>Trimetrexate (nsc#352122) for non-hodgkin"s lymphoma: a Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-8533</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8533</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II studies of extensive small cell lung cancer: high dose etoposide (vp-16)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-7983</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7983</localDocumentNumber></localDocumentNumberList><documentTitle>Surgical adjuvant systemic chemotherapy with 5-fluorouracil adriamycin, and mitomycin-c versus observation only in gastric adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-7784</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7784</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy with mastectomy or radiotherapy for stage iii Breast carcinoma-Phase III </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-7921</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7921</localDocumentNumber></localDocumentNumberList><documentTitle>A comparative study of three remission induction regimens and two maintenance regimens for acute myelocytic leukemia - Phase III </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-84-16</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-84-16</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II dose-searching randomized study of fast neutrons for Tumors located in the upper Abdomen</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>T85-0058</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU-8503</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial of azq versus bcnu for malignant tumors of the central nervous system</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-83-09</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-83-09</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II pilot study of  -131 Antiferritin in the treatment of Advanced Hodgkin's Disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>INT-0092</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IRS-IV PILOT</localDocumentNumber><localDocumentNumber>CCG-6881</localDocumentNumber><localDocumentNumber>POG-8889</localDocumentNumber></localDocumentNumberList><documentTitle>Intergroup rhabdomyosarcoma study-iv pilot study for clinical group iv disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>T85-0043</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-85-25</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II trial of dfmo and mgbg in adenocarcinoma of the prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>INT-0067</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8516</localDocumentNumber><localDocumentNumber>EST-3487</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III comparison of chop versus m-bacod vs. pro-mace-cytabom vs. macop-b in patients with intermediate or high grade non-hodgkin's lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-78-16</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-78-16</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II study of therapeutic efficacy of Radiation and Hyperthermia (43.5 C) in the treatment of Human Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-76-07</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-7607</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of RO 07-0582 (NSC# 361037)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-61-71</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-61-71</localDocumentNumber></localDocumentNumberList><documentTitle>Palliation of Brain Metastases: Phase I</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-71-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-71-02</localDocumentNumber></localDocumentNumberList><documentTitle>Split course Radiation Therapy of Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-72-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-72-01</localDocumentNumber></localDocumentNumberList><documentTitle>The Hyperbaric Oxygen protocol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>INT-0039</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IRS-EPI</localDocumentNumber><localDocumentNumber>CCG-E-10</localDocumentNumber><localDocumentNumber>POG-8552</localDocumentNumber></localDocumentNumberList><documentTitle>A case-control study of childhood rhabdomyosarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>INT-0025</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IRS-II</localDocumentNumber><localDocumentNumber>CALGB-7891</localDocumentNumber><localDocumentNumber>CCG-681</localDocumentNumber><localDocumentNumber>POG-7898</localDocumentNumber><localDocumentNumber>SWOG-7898</localDocumentNumber></localDocumentNumberList><documentTitle>Intergroup rhabdomyosarcoma study - ii</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>POG-8821/22</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8821/22</localDocumentNumber></localDocumentNumberList><documentTitle>AML#3: intensive multiagent therapy +/- maintenance +/- autologous transplant: A POG Phase III study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>POG-8760</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8760</localDocumentNumber></localDocumentNumberList><documentTitle>Trimetrexate in the treatment of childhood Acute Leukemia: Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>POG-8774</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8774</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I trial ofMenogaril in children with Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>GOG-86J</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-86J</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Tumor Necrosis Factor (TNF) in patients with Advanced or Recurrent Endometrial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T85-0007</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Cbdca in the treatment of recurrent primary brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>GOG-41</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-41</localDocumentNumber></localDocumentNumberList><documentTitle>Surgical staging of Ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>CCG-S901</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-S901</localDocumentNumber><localDocumentNumber>056-181</localDocumentNumber></localDocumentNumberList><documentTitle> comparative study of fluconazole and nystatin in the prevention of fungal infections in pediatric oncology patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T90-0202</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.61</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of (nsc 626715) 10-edam in patients with metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0072</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HRRC-244-90</localDocumentNumber></localDocumentNumberList><documentTitle>Determination of cell cycle kinetics and natural killer cell lytic function in previously untreated head and neck cancer patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0099</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>91-100</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of Taxol and g-csf in patients with unresectable malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>B91-0021</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I trial of Interleukin-1/Interleukin-2 in patients with metastatic cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0191</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Acivicin: Phase II study in advanced pancreatic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>NCCTG-91-20-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-91-20-52</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of Taxol in previously untreated patients with extensive stage small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>SWOG-9060</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9060</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot evaluation of multimodality treatment of local regional esophageal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0264</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>92-006</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of topotecan in advanced carcinoma of the pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T92-0052</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>9202-08</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot trial of alternating Taxol and adriamycin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T92-0110</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I trial of Taxol in children with refractory leukemias: a targeted systemic exposure study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T92-0124</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO9295</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of 3-hour infusion of Taxol plus or minus g-csf</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T92-0229</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>92-141</localDocumentNumber></localDocumentNumberList><documentTitle>Taxotere for Advanced Squamous Cell Carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T92-0247</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>106-68-6692-001</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of all trans-retinoic acid with chemotherapy in non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>GOG-127B</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-127B</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Isotretinoin &amp; Alpha Interferon in Advanced or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>SWOG-9242</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9242</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Evaluation of Taxotere in Small Cell Lung Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T93-0016</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BRMP #9301</localDocumentNumber></localDocumentNumberList><documentTitle>Standard care and treatment for patients with cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>RTOG-93-07</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-93-07</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II evaluation of Ethyol as an Esophageal Mucosal protectant in the treatment of limited disease Small Cell Lung Cancer with Chemotherapy and twice-daily radiation (WR-36A)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>E2192</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2192</localDocumentNumber></localDocumentNumberList><documentTitle>Outcome prediction by Histologic grading in EST-1180</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T95-0007</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>94-01-02</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of dolastatin-10 in patients with advanced cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>78-32-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>78-32-02</localDocumentNumber></localDocumentNumberList><documentTitle>A clinical trial assessing cytoxan, 5-fluorouracil cisplatin compared with cytoxan, 5-fluorouracil and prednisone in patients with advanced Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>79-012</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>79-012</localDocumentNumber></localDocumentNumberList><documentTitle>High dose bcnu with autologous bone marrow support in glioblastoma multiforme and other tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>T84-0541</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>57-85-2</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for a Phase II study comparing diaziquone (azq) with fludarabine in the treatment of patients with primary anaplastic brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>76-041</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>76-041</localDocumentNumber></localDocumentNumberList><documentTitle>Multidisciplinary approach to soft tissue sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8441</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8441</localDocumentNumber></localDocumentNumberList><documentTitle>Four drug combination chemotherapy for children with stage D Neuroblastoma older than 365 days at diagnosis -A Phase III study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8464</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8464</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Carboplatin in the therapy of children with progressive or recurrent Brain Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>T84-0485</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>6M-82-1</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of unresectable meningioma with a progestational agent</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8158</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8158</localDocumentNumber></localDocumentNumberList><documentTitle>National Wilm's Tumor long-term survivors' study - a Non-Therapeutic study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8303</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8303</localDocumentNumber><localDocumentNumber>SWOG-8303</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy for first Bone Marrow and/or Testicular relapse of childhood ALL during or shortly following initial continuation chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>70-56-31</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>70-56-31</localDocumentNumber></localDocumentNumberList><documentTitle>An evaluation of therapeutic oophorectomy with or without adjuvant chemotherapy in premenopausal patients with advanced Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>115-393A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-70-10</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of superficial tumors with bcg or mer (a component of bcg)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8035/36</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8035/36</localDocumentNumber></localDocumentNumberList><documentTitle>Laboratory subclassification and evaluation of treatment regimens in Acute Lymphoid Leukemia of childhood (ALINC-13)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8021</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8021</localDocumentNumber></localDocumentNumberList><documentTitle>Methyl-G straight Phase II in children w/ANLL and ALL in relap and w/Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>T84-0469</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-84-111</localDocumentNumber></localDocumentNumberList><documentTitle>Clinical evaluation of continuous infusion of 5-fu plus cisplatin in colorectal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>T84-0475</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-84-116</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II clinical and pharmacologic study of oral idarubicin in patients with advanced Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-7721</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7721</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of induction, remission maintenance with and without periodic reinforcement, and CNS Prophylaxis in AcuteNon-Lymphocytic Leukemia - Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-7818</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7818</localDocumentNumber><localDocumentNumber>SWOG-7818</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Rubidazone in children  with Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia in relapse - Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GOG-26W</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-26W</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Echinomycin (NSC #526417) in patients with Advanced Pelvic Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GOG-26Y</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-26-Y</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Vinblastine (NSC #049842) in patients with Advanced Pelvic Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GOG-18</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-18</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of women with Adenocarcinoma (and Adeno-Acanthoma) of the Endometrium Figo stage II by surgery, radiation therapy or combinations of both</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GOG-20</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-20</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III randomized comparison of Adriamycin versus no further therapy in patients with Uterine Sarcomas, stage I and II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GOG-22</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-22</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized comparison of melphalan alone vs adriamycin and cyclophosphamide vs hexamethylmelamine and melphalan in patients with ovarian adenocarcinoma: suboptimal stage iii, stage iv and recurrent equivalent to stage iii or iv</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GITSG-9273</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-9273</localDocumentNumber></localDocumentNumberList><documentTitle>A controlled evaluation of high dose radiation therapy, high dose radiation therapy plus 5-FU and medium dose plus 5-FU in the treatment of Locally Unresectable Carcinoma of the Pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GITSG-9485</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-9485</localDocumentNumber></localDocumentNumberList><documentTitle>Master protocol Phase II - trials in patients with Advanced Measurable Pancreatic Carcinoma (previously untreated with chemotherapy)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>W83-0339</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCIC-OTT-82-07</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of new chemotherapeutic agents: riboxamide</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>POG-7621</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7621</localDocumentNumber><localDocumentNumber>SWOG-7621</localDocumentNumber></localDocumentNumberList><documentTitle>MOPP versus OPP in the treatment of children with recurrent Brain Tumors - a Phase III study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>T84-0439</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DXDX1-2</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for the Phase I/II clinical and pharmacokinetic evaluation of 4'-deoxy-doxorubicin hydrochloride (dxdx) in children with malignant solid tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>T84-0409</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-84-74</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized trial comparing the combination of cisplatin vindesine and mitomycin-c (mvp) with cisplatin and vindesine (vp) in patients with stage iii non-small cell lung cancer (nsclc)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>W81-1034</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>W81-1034</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I and pharmacological study of henckel compound administered on single day and on daily for 5 day schedules</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GITSG-6384</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-6384</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase III study of Advanced Measurable Colorectal Carcinoma - clinical evaluation of biochemical and pharmacological modulation of 5-Fluorouracil</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GITSG-6584</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-6584</localDocumentNumber></localDocumentNumberList><documentTitle>Therapeutic results of surgically resectable Liver Metastases from Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GITSG-8274</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-8274</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant therapy of locally advanced, surgically incurable Gastric Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>POA-74285</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BGSM-74285</localDocumentNumber></localDocumentNumberList><documentTitle>High vs. low dose Progestin therapy for patients with Advanced Breast Cancer - a Phase III study comparing Megestrol Acetate in low vs. high dosage</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:15"><nciDocumentNumber>T84-0353</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-84-71</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I evaluation and clinical pharmacologic study of 4'-deoxydoxorubicin in children with acute leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:15"><nciDocumentNumber>T84-0359</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-84-10</localDocumentNumber></localDocumentNumberList><documentTitle>Autologous bone marrow transplantation for patients with rhabdomyosarcomas resistant to conventional therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:15"><nciDocumentNumber>POA-59184</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-59184</localDocumentNumber></localDocumentNumberList><documentTitle>Cis-Platinum and 5-Fluorouracil as combination chemotherapy for advanced or recurrent Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:15"><nciDocumentNumber>POA-62181</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-62181</localDocumentNumber></localDocumentNumberList><documentTitle>HD-large field half-body irradiation, local chest irradiation and Cyclophosphamide in Non-Small Cell Broncho- Genic Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:15"><nciDocumentNumber>GITSG-4C85</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-4C85</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Recombinant Gamma Interferon in patients with measurable, Metastatic Carcinoid</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:16"><nciDocumentNumber>T90-0100</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IL4-1148</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I dose escalation study of continuous infusion rhuil-4 alone and in conjunction with rhuil-2</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:16"><nciDocumentNumber>PAHO-0202</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GYC-83-01</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II study of CBDCA and Chip in recurrent &amp; metastatic SquamousCell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:17"><nciDocumentNumber>T90-0099</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Double high dose melphalan therapy for previously treated multiple myeloma patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:17"><nciDocumentNumber>N81-0903</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>81-C-13</localDocumentNumber><localDocumentNumber>NMOB-81-10</localDocumentNumber></localDocumentNumberList><documentTitle>AZG straight Phase II previously treated small cell ca</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:18"><nciDocumentNumber>T90-0066</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>90-19-01</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of combined levamisole with recombinant interleukin-2(il-2) in patients with advanced cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:19"><nciDocumentNumber>NSABP-B-10</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-10</localDocumentNumber></localDocumentNumberList><documentTitle>A clinical trial to compare combination chemotherapy with and without CPparvum in surgically curable Breast Cancer patients who have one or more positive axillary nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:19"><nciDocumentNumber>NSABP-B-13</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-13</localDocumentNumber><localDocumentNumber>MAOP-1484</localDocumentNumber><localDocumentNumber>NCOG-NSABP-B-13</localDocumentNumber><localDocumentNumber>SEG-NSABP-B-13</localDocumentNumber></localDocumentNumberList><documentTitle>A Clinical Trial to Assess Sequential MTX then 5-FU in Patients with Primary Breast Cancer and Negative Axillary Nodes Whose Tumors are Negative for Estrogen Receptors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:20"><nciDocumentNumber>T90-0050</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I study of etanidazole (sr2508) and radiotherapy in malignant glioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:20"><nciDocumentNumber>W79-0283</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-79-106</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of amsa in combination in patients with refractory acute leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:21"><nciDocumentNumber>EST-P-A889</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A889</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Ifosfamide and Cisplatin plus either Etoposide or Vinblastine with high dose consolidation and autologous bone marrow rescue as initial salvage therapy for recurrent germ cell neoplasms (VIP/HD consolidation)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:21"><nciDocumentNumber>WPL-72-23</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WPL-72-23</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive chemotherapy of progressive small cell carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>T84-0266</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>4133</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of 4'deoxydoxorubicin (dxdx) for advanced measurable adenocarcinoma of the stomach</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>T84-0281</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.12</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of cbdca in ovarian carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>T89-0244</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>90-11</localDocumentNumber></localDocumentNumberList><documentTitle>  Phase II study of recombinant interleukin 2(cetus) and recombinant tumor necrosis factor in the treatment of patients with advanced non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>GOG-110</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-110</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized study of Cisplatin versus Cisplatin plus Dibromodulcitol (NSC#104800) versus Cisplatin plus Ifosfamide and Mesna in Advanced (stage III or IV), Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>CALGB-8945</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8945</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of toremifene in metastatic Breast cancer: a limited access study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>T89-0213</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-89-105</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I evaluation of eflornithine with pcv(ccnu,procarbazine,and vincristine) chemotherapy for the treatment of malignant gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>T89-0218</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RPC-3209</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of til expanded in vitro with rhuil-4 and ril-2 and autologous tumor restimulation in patients with renal cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>SWOG-8857</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8857</localDocumentNumber></localDocumentNumberList><documentTitle>Alternating cisplatin/vp-16 with continuous cav and consolidation chemoradiotherapy for extensive small cell lung cancer with pci for complete responders</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>T84-0182</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>82-80</localDocumentNumber></localDocumentNumberList><documentTitle>Regional stage iii lung cancer: a randomized prospective trial comparing high dose radiation with pre-radiation chemotherapy followed by high dose radiation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>SWOG-8922</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8922</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of doxorubicin, dtic and ifosfamide with recombinant granulocyte-macrophage colony stimulating factor in advanced soft tissue sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>SWOG-8999</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8999</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of radiation treatment following surgical resection of solitary brain metastasis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NPCP-1000</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NPCP-1000</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of long term adjuvant chemotherapy with Cyclophosphamide, Emcyt, or no-additional-treatment in patients who have had definitive rt for Adenocarcinoma of Prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NPCP-500</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NPCP-500</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of Cyclophosphamide, plus Estracyt vs. Cyclophosphamide plus Diethylstilbestrol vs. Diethylstilbestrol or Orchiectomy in newly diagnosed patients with clinical Stage D Cancer of the Prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-6G-61</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-6G-61</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of radiotherapy plus Hydroxyurea and BCNU vs. radiotherapy plus Hydroxyurea and Procarbazine , CCNU, Vincristine (PCV) for the treatment of primary malignant brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>POG-9061</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9061</localDocumentNumber></localDocumentNumberList><documentTitle>The treatment of isolated Central Nervous System Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-5O-83</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-5O-83</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I - II study of limited field irradiation plus Adriamycin and Cyclophosphamide (ACE) in Ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-3C-83-1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-3C-83-1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized trial of single agent 5-Fu vs. high-dose Folinic Acid and 5-Fu vs. Methotrexate and 5-Fu and Folinic Acid in patients with disseminated Measurable Large Bowel Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>NCOG-4B-82</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-4B-82</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of Adjuvant Cis-Platinum for patients undergoing Cystectomy and pre-operative radiotherapy for Invasive Bladder Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T89-0125</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SCCC-8959</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of low dose pala and high dose 5-fu as a short term infusion  concomitantly with radiation therapy in the treatment of adenocarcinoma of the pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1343</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-8241</localDocumentNumber></localDocumentNumberList><documentTitle>Vinzolidine: A Phase II study in patients with Hodgkin's and Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1283</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-83-45</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of antracendione and high dose ara-c in relapsed acute leukemia and the blast crisis of chronic myelogenous leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1263</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-83-75</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of intravenous procarbazine hydrochloride in adults with recurrent primary central nervous system tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>NCOG-1B-83-1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-1B-83-1</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase II trial comparing the efficacy and toxicity of 4-Deoxydoxorubicin and Doxorubicin in the treatment of metastatic carcinoma of the Breast</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1229</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UAB-154</localDocumentNumber></localDocumentNumberList><documentTitle>Regional cisplatin/dichloromethotrexate chemotherapy for advanced head and neck cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1193</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CHP-449</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of acute lymphoblastic leukemia  and non-hodgkin's lymphoma following first bone marrow relapse</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCOG-P-7H-83-2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-P-7H-83-2</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of Cis-Platinum and Cytosine Arabinoside for recurrent squamous cell carcinoma of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCOG-0C-61</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-0C-61</localDocumentNumber></localDocumentNumberList><documentTitle>Triazinate Phase II broad study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>EST-P-A087</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A087</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of adjuvant intraperitoneal Chemotherapy for Gastric cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-89-61-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-89-61-52</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of 5-Fluorouracil and Leucovorin in women with Advanced Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-85-81-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-85-81-51</localDocumentNumber><localDocumentNumber>85-81-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study for attenuated high dose ARA-C  in the treatment of Acute Nonlymphocytic Leukemia in patients older than 65</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>GOG-8901</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8901</localDocumentNumber></localDocumentNumberList><documentTitle>A phase i evaluation of multiple daily fraction radiation and 5-flourouracil plus cisplatin in stage ii-b, iii and iv-a carcinoma of the cervix with negative para-aortic nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>T87-0274</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A randomized study of etoposide + cisplatin and etoposide + carboplatin (cbdca) in the management of good risk patients with advanced germ cell tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>T89-0051</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID-89-010</localDocumentNumber></localDocumentNumberList><documentTitle>The distribution of ex-vivo expanded indium-111 labeled autologous cytotoxic lymphocytes in patients with advanced malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-89-32-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-89-32-51</localDocumentNumber><localDocumentNumber>89-32-51</localDocumentNumber></localDocumentNumberList><documentTitle>Dose intensification of the CFP regimen followed by integration of Leucovorin: a dose-seeking trial in women with Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-83-43-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-83-43-51</localDocumentNumber><localDocumentNumber>83-43-51</localDocumentNumber></localDocumentNumberList><documentTitle>A prospective Phase II /III randomized comparison of 5-Fu alone vs. 5-Fu plus adriamycin plus Cis-Platinum vs. the Mallinson regimen in the treatment of Advanced Pancreatic Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-80-61-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-80-61-51</localDocumentNumber><localDocumentNumber>C80-0169</localDocumentNumber></localDocumentNumberList><documentTitle>Comparison of Cyclophosphamide, and Cis-Platinum vs. Cyclophosphamide, Adriamycin, Cis-Platinum, and Hexamethylmelamine in Stage III and IV Ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>NCCTG-79-32-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-79-32-51</localDocumentNumber><localDocumentNumber>C79-0213</localDocumentNumber></localDocumentNumberList><documentTitle>Trial of Adriamycin versus Adriamycin + DBD in advanced Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>CCG-9883</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-9883</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive chemotherapy and autologous bone marrow reconstitution for children with resistant malignant brain tumors: a Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T89-0038</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-89-L1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of new agents in treatment of incurable small cell carcinoma of lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T89-0035</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>8902-2</localDocumentNumber></localDocumentNumberList><documentTitle>Effect of nutrition on cell cycle kinetics in head and neck cancer patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T89-0022</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UTSMC-8901</localDocumentNumber></localDocumentNumberList><documentTitle>Alternating intensive consolidation for adult acute lymphoblastic leukemia, with monitoring for minimal residual disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T83-1120</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HSC-81-10</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II investigation of local retinyl acetate delivered via a collagen sponge and cervical cap in mild and moderate dysplasia of the cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>NBCCGA-10</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NBCCGA-10</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III randomized study to compare the ablative effects of Thio-Tepa with Mitomycin-C in patients with a diagnosis of Superficial Bladder Carcinoma with residual tumor</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>NBCCGA-5</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NBCCGA-5</localDocumentNumber></localDocumentNumberList><documentTitle>Comparative evaluation of Cis-Platinum alone and the combination of Cis-Platinum plus Cyclophosphamide in the treatmentof patients with Advanced Carcinoma of the urinary bladder</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T88-0270</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I study of mismatched dsrna(ampligen) in combination with recombinant interleukin 2 in patients with solid tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T88-0268</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID-88-024</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I pilot study of combination chemo-immunotherapy with okt3,tumor necrosis factor(tnf), and interleukin-2(il-2) in patients with unresectable or metastatic(stage iiib or stage iv) non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T88-0262</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-88-144</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of arabinosyl-5-azacytidine(fazarabine,nsc 281271)(ara-ac) in patients with leukemia and lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T88-0238</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>88-83</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of high-dose 24 hour continuous infusion of 5-fu and leucovorin and low dose pala</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>CALGB-8812</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8812</localDocumentNumber></localDocumentNumberList><documentTitle>Didemnin b for multiple myeloma - a Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>NCCTG-88-46-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-88-46-51</localDocumentNumber><localDocumentNumber>88-46-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III a prospectively randomized trial of high dose Leucovorin + weekly 5Fu (GITSG Regimen) versus low dose Leucovorin + intensive course 5Fu (NCCTG Regimen) for the treatment of Advanced Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>T88-0187</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BGSM-89188</localDocumentNumber><localDocumentNumber>POA-89188</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II trial continuous 5-day intravenous fudr infusion for renal cell carcinoma: a clinical study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>RTOG-88-14</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-88-14</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II study of intraoperative radiotherapy as Boost Therapy for selected patients with invasive Bladder Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>CALGB-8811</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8811</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of a 5-drug induction regimen with intensive consolidation in adult acute lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>EST-P-Z388</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-Z388</localDocumentNumber></localDocumentNumberList><documentTitle>Phase 1B trial of the effect of peritumoral and intranodal injections of Interleukin-2 in patients with advanced Squamous Cell carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>CCG-9882</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-9882</localDocumentNumber></localDocumentNumberList><documentTitle>Hyperfractionated radiation therapy in pediatric brainstem gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>RTOG-88-10</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-88-10</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II study to evaluate Hyperfractionated Irradiation of unresectable extremity Soft Tissues Sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>T88-0134</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BTRC-8891</localDocumentNumber></localDocumentNumberList><documentTitle>In situ cell kinetic study of human brain tumors (diagnostic budr-iudr)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>T88-0062</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>88-980</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of the sequential administration of recombinant tumor necrosis factor (rtnf) and recombinant interleukin-2 (ril-2) in patients with advanced malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>T88-0076</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>88-024</localDocumentNumber></localDocumentNumberList><documentTitle>Stamp v intensification for metastatic Breast cancer responsive to standard dose chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T88-0009</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-87-147</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of pala + methotrexate (mtx) + 5-fluorouracil (fura) + leucovorin (lv) in the treatment of patients with metastatic cancer with the addition of uridine (ur) as a rescue agent for fura</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0226</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>5 Phase I trial of the radiosensitizer sr2508 (etanidazole) combined with radiotherapy and chemotherapy for treatment of localized carcinoma of the esophagus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0227</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>M1184</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot Phase I clinical pharmacologic study of intra-arterial radiosensitization with bromodeoxyuridine (budr) and intersticial radiation therapy for malignant gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0213</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>1731</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of the combination of indomethacin and recombinant interleukin-2 in patients with advanced melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0183</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>88-12-30-4</localDocumentNumber><localDocumentNumber>DS-87-35</localDocumentNumber></localDocumentNumberList><documentTitle>Efficacy of pentostatin in chronic phase of chronic myelocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0038</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>277</localDocumentNumber></localDocumentNumberList><documentTitle>Use of monoclonal antibody b72.3 to diagnose and stage ovarian carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0008</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>8H-85-2</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of alternating non-cross resistant tx w/procarbazine, l-phenylalanine mustard, vinblastine &amp; total lymphoid irradiation vs. alternating non-cross resistant chemo w/mopp/abvd in advanced stage hodgkin's disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0294</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CHP-475</localDocumentNumber></localDocumentNumberList><documentTitle>Gamma interferon in the treatment of neuroblastoma: a Phase I study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0280</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-85-94</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of intraperitoneally administered cisplatin and mitomycin in peritoneal mesothelioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0243</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>8H-85-1</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of subtotal lymphoid irradiation (stli) or total lymphoid irradiation (tli) versus involved field irradiation  (if) plus vinblastine, bleomycin and methotrexate (vbm) in favorable hodgkin's disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0258</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WCC-1186</localDocumentNumber></localDocumentNumberList><documentTitle>Pharmacokinetic and Phase I studies in patients with peritoneal carcinomatosis from colorectal cancer using ip il-2 via a tenckhoff catheter</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0200</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-87-6</localDocumentNumber></localDocumentNumberList><documentTitle>Proposal for Phase II trial of pala + dipyrimadole (persantine) in patients with advanced soft tissue sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0190</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-86H2</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of new agents in the treatment of diffuse well differentiated lymphoma/leukemia (chronic lymphocytic leukemia, diffuse well-differentiated lymphocytic lymphoma, and waldenstrom's macroglobulinemia)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T83-1082</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>81-064</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy of advanced penile cancer, urethral cancers, and misc. cancer of the genitourinary tract</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T94-0065</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>COMIRB 93-426</localDocumentNumber></localDocumentNumberList><documentTitle>Intracavitary allogeneic cytotoxic t lymphocytes and human recombinant interleukin-2 therapy for recurrent primary brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8734</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8734</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of low-dose pala and high-dose 5-fu as a short term infusion in the treatment of adenocarcinoma of the stomach</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8640</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8640</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of didemnin-b or trimetrexate in the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8719</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8719</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluations of didemnin b and ifosfamide/mesna in endocrine resistant prostate cancer: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8608</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8608</localDocumentNumber></localDocumentNumberList><documentTitle>Mitoxantrone plus cis-platinum in patients with advanced Breast cancer:  Phase I - ii</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8610</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8610</localDocumentNumber></localDocumentNumberList><documentTitle>Prospective randomized clinical trial of the capillary cloning system for patients with extensive small-cell lung cancer - Phase III </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8623</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8623</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of trimetrexate in untreated advanced gastric carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8411</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8411</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of dtic in metastatic carcinoid</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8412</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8412</localDocumentNumber><localDocumentNumber>NCOG-5O-84-2J</localDocumentNumber></localDocumentNumberList><documentTitle>Carboplatin/cyclophosphamide vs. cisplatin/cyclophosphamide in patients with measurable and non-measurable (sub-optimal) disease stages iii and iv ovarian cancer: phase iii</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8326/27</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8326/27</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of combination chemotherapy using high dose ara-c in adult acute leukemia and chronic granulocytic leukemia in blast crisis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8360</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8360</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot use of the surgically implanted "infusaid" pump for ambulatory outpatient hepatic arterial chemotherapy for patients with colon cancer metastatic to the liver</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8302</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8302</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of doxorubicin, mitomycin-c and 5-fluorouracil in the treatment of metastatic adenocarcinoma of the prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8233</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8233</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of AZQ in Gastric Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8245</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8245</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of unfavorable histology nhl with chop and cvb (alternating)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8264</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8264</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy with AMSA, Cis-Platinum and MGBG for Refractory Lymphoma, Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8215</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8215</localDocumentNumber></localDocumentNumberList><documentTitle>Comparison of VP-16,213, Cis-Platinum vs BCNU, Thiotepa, Vincristine, and Cyclophosphamide in patients with Small Cell Carcinoma of the Lung who have failed or relapsed primary chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8077</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8077</localDocumentNumber></localDocumentNumberList><documentTitle>Combined chemotherapy and hormonal therapy for recurrent or disseminated Breast cancer, pact, Phase II -pilot</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8111</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8111</localDocumentNumber></localDocumentNumberList><documentTitle>The treatment of resected, poor prognosis malignant melanoma: stage ii: surgical excision vs surgical excision + vitamin a vs surgical excision + actinomycin d and dtic</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8042</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8042</localDocumentNumber></localDocumentNumberList><documentTitle>Methyl-G Phase II portion of appendix-VII SWOG-8040 in Pancreatic Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8004</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8004</localDocumentNumber></localDocumentNumberList><documentTitle>Mitoxantrone in Soft Tissue and Bone Sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8006</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8006</localDocumentNumber></localDocumentNumberList><documentTitle>Preoperative Reductive Chemotherapy for stage III or IV Operable Epidermoid Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx or Larynx</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7959</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7959</localDocumentNumber></localDocumentNumberList><documentTitle>Methyl-G straight Phase II Metastatic Renal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7923</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7923</localDocumentNumber></localDocumentNumberList><documentTitle>Gallium Nitrate Phase II in metastatic and/or locally recurrent SQ Cell Cancer of Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7727/28</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7727/28</localDocumentNumber></localDocumentNumberList><documentTitle>Chemiommunotherapy in disseminated Malignant Melanoma (BHD with/without Levamisole vs. DTIC + Actinomycin-D)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7701</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7701</localDocumentNumber></localDocumentNumberList><documentTitle>Ifosfamide random study in Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7426/27</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7426/27</localDocumentNumber></localDocumentNumberList><documentTitle>Chemoimmunotherapy in Non-Hodgkin's Lymphoma Chop-Bleomycin vs. Chop + BCG  vs. Cop + Bleomycin induction therapy; no maintenance vs. BCG for maintenance</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7409</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7409</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant chemotherapy for Medulloblastoma and Ependymoma using iv Vincristine, Intrathecal Methotrexate, and Intrathecal Hydrocortisone</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-76P-AML-0102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-76P-AML-0102</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of chemotherapy, splenectomy, and immunotherapy to achieve long-term remission in Acute Myelogenous Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-79-HN-235</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-79-HN-235</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized study of Cis-Diamminedichloroplatinum plus Vinblastine plus Bleomycin vs Methotrexate in patients with recurrent or Metastatic Squamous Carcinoma of the head and neck origin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-341</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-341</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized clinical trial or remission, induction, consolidation and chemo-immunotherapy maintenance in Adult Myeloblastic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-349</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-349</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase III study of BCNU, CTX, VCR &amp; prednisone vs CTX, VCR &amp; prednisone in Non-Hodgkin's Lymphoma randomizing responders to same therapy or to cyclic MTX, ARAC and TG</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-SAR-82-259</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-SAR-82-259</localDocumentNumber></localDocumentNumberList><documentTitle>AZQ Phase II in Antracycline-resistant adult Soft Tissue and Bone Sarcoma patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-OVCA-76-204</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-OVCA-76-204</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of BCNU and Cyclophosphamide followed by Adriamycin in patients with Ovarian Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-RAL-81-235</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-RAL-81-235</localDocumentNumber></localDocumentNumberList><documentTitle>Mitoxantrone Phase II in refractory adult acute leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-MEL-81-320</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-MEL-81-320</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized evaluation of elective cranial irradiation in Metastatic Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-LUN-81-342</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-81-342</localDocumentNumber></localDocumentNumberList><documentTitle>VP-16,213 in the treatment of recurrent Small Cell Carcinoma of the Lung-dose response &amp; tox eval of three dose levels</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-LUN-81-343R</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-81-343R</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized study of simultaneously administered radiotherapy to the chest and combination chemotherapy (CAV) versus CAV alone in limited stage Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-LUN-301</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-301</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II comparison of Vindesine versus Vindesine plus  Mitomycin versus Vindesine plus Cisplatin in the treatment of patients with advanced Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-LUN-79-252</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-79-252</localDocumentNumber></localDocumentNumberList><documentTitle>Study of high dose CTX and Adriamycin with Vincristine in good risk Metastatic Small Cell Lung Carcinoma, responders to continue the same combination of conventional doses</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-LUN-P32</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-P32</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot Phase II study of VP-16, Methotrexate with Citrovorum rescue and CCNU in patients with recurrent or progressive Oat Cell Carcinoma of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-8284</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-8284</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Domperidone in advanced recurrent or metastatic malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-7283</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-7283</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of Megestrol Acetate in advanced Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-2383</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-2383</localDocumentNumber></localDocumentNumberList><documentTitle>Master protocol for Phase II study of locally advanced bulky unresectable and metastatic Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-7282</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-7282</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of combination Mitomycin-c, Adriamycin, Cis-platinum and Bleomycin-ccnu in the treatment of advanced cancer of the Anal canal</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-4687</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4687</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of recombinant Gamma Interferon in malignant melanoma: determination of optimal antitumor dose and biological response modification</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-4181</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4181</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant therapy for postmenopausal women with Breast cancer (CTX, MTX,5-FU, Pred, Tam)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-4282-14/15/16</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4282</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II protocol for the evaluation of new treatments in patients with advanced Large Bowel cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-4581</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4581</localDocumentNumber></localDocumentNumberList><documentTitle>Aclacinomycin-A (vs/azq) master protocol in pts w/small cell Bronchogenic cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-3484</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3484</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Burkitt's lymphoma and undifferentiated Non-Burkitt's lymphoma with alternating cycles of comp and high-dose Ara-c</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2881-13/14</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2881-G1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of disseminated Transistional Cell carcinoma of the urinary tract</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-3272</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3272</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Streptozotocin combined with 5-FU or (Cardinoid) Cyclophosphamide in the treatment of Cardinoid tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2877-9</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2877-G1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II master protocol for Ovarian cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2483</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2483</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II high-dose Cytosine Arabinoside intensification and macho consolidation therapy in the treatment of adult acute lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2375</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2375</localDocumentNumber><localDocumentNumber>N81-1002</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III comparative study of Adriamycin versus Adriamycin plus Cis-diammine-dichloroplatinum in patients with Thyroidcarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1979</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1979</localDocumentNumber></localDocumentNumberList><documentTitle>Comparison of anxiety levels in patients receiving adjuvant therapy versus patients receiving no adjuvant therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1880-13/14</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1880-G1</localDocumentNumber></localDocumentNumberList><documentTitle>Master protocol for controlled Phase II studies in the treatment of advanced Renal Cell cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1483</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1483</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study for the evaluation of 2'-Deoxycoformycin in therapy of refractory Lymphoid Neoplasms</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1574</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1574</localDocumentNumber></localDocumentNumberList><documentTitle>Study of CCNU, Cytoxan, Procarbazine, Adriamycin, Vincristine, and VP-16 in Small (Oat Cell) carcinoma of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1583</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1583</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II-III Chemotherapy of Metastatic Non-small Cell Bronchogenic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1585</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1585</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II master protocol for chemotherapy in metastatic non-small cell bronchogenic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1476</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1476</localDocumentNumber></localDocumentNumberList><documentTitle>Combined modality treatment protocol for advanced stages IIIB, III and IV Hodgkin's disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1276</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1276</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy following resection of Colorectal carcinoma with non-measurable intra-abdominal metastases (Dukes' D)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-E482</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-E482</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot protocol to evaluate combination Chemotherapy in unfavorable (diffuse) histologic subtypes of non-hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-D578</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-D578</localDocumentNumber></localDocumentNumberList><documentTitle>Radiation therapy Hmm, Adr, and Mtx for unresectable non-oat cell Bronchogenic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-C584</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C584</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Homoharringtonine in advanced Non-small Cell Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-C587</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C587</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of alternating Chemotherapy with Cisplatin/etoposide and accelerated Radiotherapy as treatment of patients with locally advanced Non-small Cell Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-C877</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C877</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of combination Chemotherapy of advanced Ovarian cancer with: Cyclophosphamide, Hexamethylmelamine, Adriamycin, and Cis-diamminedichloroplatinum (II).</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-B887</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B887</localDocumentNumber><localDocumentNumber>T87-0298</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of high-dose Carboplatin/Etoposide and autologous bone marrow rescue for refractory Germ Cell neoplasms</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-C385</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C385</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study for the evaluation of simultaneous Cisplatin/5-Fu infusion Chemotherapy and limited Radiation therapy in regionally recurrent Head and Neck cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-B387</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B387</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of simultaneous Radiation therapy and Chemotherapy with 5-Fluorouracil and Cisplatin in patients with locally unresectable Squamous Cell carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-B487</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B487</localDocumentNumber></localDocumentNumberList><documentTitle>Carboplatin in the treatment of refractory multiple Myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-A482</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A482</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II: a pilot study of Vindesine, Methyl-G, and Cis-platinum combination Chemotherapy for refractory Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-A581</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A581</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of MGBG, Vindesine, and Cis-platinum in advanced Non-small Cell Bronchogenic Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-A185</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A185</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot study of Cisplatin and 5-Fluorouracil for previously treated metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D83-061-0566</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>1165-82</localDocumentNumber></localDocumentNumberList><documentTitle>Dibromodulcitol in advanced previously treated Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-055-0883</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>80-219-NPD</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy of advanced lung cancer with two alterning regimens</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D83-003-0122</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ALL-1</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of adult acute lymphoblastic leukemia &amp; lymphoblastic lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D83-035-0565</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU-8217</localDocumentNumber></localDocumentNumberList><documentTitle>The treatment of advanced refractory non-hodgkin's lymphoma with the combination of ifosfamide, vp-16, ddp &amp; bleomycin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-046-0543</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DMO-182</localDocumentNumber></localDocumentNumberList><documentTitle>Combo. chemotherapy for nscl:  high dose ddp, vin- blastine and etoposide (vp-16)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-047-0140</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0033</localDocumentNumber><localDocumentNumber>D81-047-0140</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III pilot for the treatment of non-small cell lung cancer with bleomycin, vp-16 and cis-platinum (bep)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-048-0362</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>0354-02-81</localDocumentNumber></localDocumentNumberList><documentTitle>Small cell cancer of the lung with cyclophosphamide, adriamycin and vincristine followed by vp-16 as consolidation therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-050-0308</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AML-80</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II therapy of children with acute non-lymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-051-0826</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0120</localDocumentNumber><localDocumentNumber>V85-0177</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of vm-26, ara-c, and cisplatin for non-hodgkin's lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-035-0648</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0063</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy with ddp, vinblastine &amp; mgbg in epidermoid carcinoma of the esophagus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-039-1496</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-441</localDocumentNumber></localDocumentNumberList><documentTitle>Vm-26 and vincristine protocol for recurrent brain tumors in childhood</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-043-0188</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IM-81-04</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16-213 cytoxan &amp; cis-platinum combination chemotherapy for stage iii testis cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-014-0968</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>3583</localDocumentNumber></localDocumentNumberList><documentTitle>Vincristine-predisone-daunomycin. induction therapy for acute lymphocytic leukemia with intensive consolidation with high dose ara-c plus l-aspariginase, whole brain irradiation and cyclophosphamide-daunomycin-vincristine-prednisone</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-018-0613</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0101</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of azq straight in refractory lymphoma and leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-011-0270</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HOG-7902</localDocumentNumber></localDocumentNumberList><documentTitle>Adriamycin, mitomycin-c, 5-fu, and streptozotocin in the treatment of advanced gi tract carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D81-047-0516</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Regional heated perfusion using melphalan as therapy for malignant melanoma in a limb</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D81-050-475</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>D81-050-475</localDocumentNumber></localDocumentNumberList><documentTitle>High dose methotrexate/high dose ara-c</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D81-043-0374</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I/II trial of systemic hyperthermia and chlorozotocin in malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D81-043-0712</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-78-25</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy w/adriamycin, dibromoduulcitol &amp; mit-c for stage iv Breast cancer patients who have failed therapy w/cmf</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D81-026-0157</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PPC-629</localDocumentNumber></localDocumentNumberList><documentTitle>Dibromodulcitol Phase II study in stage iv metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D81-032-0300</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Adriamycin, dibromodulcitol, and cis-platinum in advanced non-oat cell carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D81-043-0056</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-80-41</localDocumentNumber></localDocumentNumberList><documentTitle>High dose combination chemotherapy with autologous bone marrow transplantation in patients with relapse leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D80-049-0224</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-9879</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy plus radiotherapy of small cell bronchogenic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D80-062-0290</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DMS-7908</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16, adriamycin +/- bleomycin +/- platinum for testicular cancer in relapse</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D80-043-0057</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-79-89</localDocumentNumber></localDocumentNumberList><documentTitle>High dose combination chemotherapy with autologous bone marrow transplantation in patients with testicular carcinoma refractory to front line chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D80-010-0382</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>683-80</localDocumentNumber></localDocumentNumberList><documentTitle>Autologous marrow transplantation following cyclophosphamide and total body irradiation in refractory lymphoma - a pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D80-018-0371</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>80-036</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of vm-26 and ara-c in childhood all</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D79-027-0228</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>79-26</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II -iii study of chemotherapy of advanced measurable colorectal cancer with 5-fu and standard or intensive doses of methotrexate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>T86-0120</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-2685</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for pilot and Phase II study of dichloromethotrexate, infusional cisplatin and infusional 5-fu for stage iii metastatic or locally advanced (t>5cm) non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>T86-0068</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC-8609</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of carboplatin and etoposide for non-small cell lung carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>T86-0074</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>388-85-7</localDocumentNumber><localDocumentNumber>T89-0167</localDocumentNumber></localDocumentNumberList><documentTitle>Protection of the rectosigmoid mucosa from radiation effects by topical application of wr-2721 in patients undergoing external beam therapy to pelvis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D79-004-0153</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II isolation perfusion therapy with l-pam plus excisional surgery for melanoma confined to one limb</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D78-035-0150</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Vp-16 + procarbazine + hexamethylmelamine (vph) in refractory small cell undifferentiated lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D78-047-0233</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>77</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of advanced non-hodgkin's lymphomas of agressive histologic type in adults - study no. 2</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D78-024-0164</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-78-86</localDocumentNumber></localDocumentNumberList><documentTitle>Phase ii evaluation of cis-diamminedichloroplatinum ii (ddp) in children and adolescents with metastatic bone sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D78-026-0201</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PPC-541</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy for non-small cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>SEG-GU-212</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-GU-212</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Acivicin in patients with advanced Bladder Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>SEG-GU-78-P29</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-GU-78-P29</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomization of surgically ablated stage II Non-Seminomatous Testicular Carcinoma: Vinblastine, Bleomycin and Diamminedichloroplatinum vs. no chemotherapy until disease recurrence</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>D77-020-0222</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>77-01-01</localDocumentNumber></localDocumentNumberList><documentTitle>Early clinical trial of the combination of cytoxan, adriamycin, methotrexate, vp-16 and vincristine</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>D77-050-0258</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Protocol for Phase II evaluation of cis-platinumdiamminedichloride</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>D78-001-0265</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>L10A</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of extensive stage small cell carcinoma of the lung: randomization to cytoxan, adriamycin, vincristine and high dose mtx with leucovorin factor rescue vs. cytoxan, adr., vincr. and stand. dose mtx and leuco. fact. resc.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>DT-76-02A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-76-02A</localDocumentNumber></localDocumentNumberList><documentTitle>Chemoimmunotherapy of malignant melanoma with iv c.parvum, dic plus actinomycin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>T85-0262</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DCF-II</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of 2'-deoxycoformycin (pentostatin) in t-cell leukemias, hairy cell leukemia and related b-cell disorders</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>T85-0279</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>85-12-02-01</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of the toxicity and efficacy of suramin for the treatment of aids and aids related complex</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:39"><nciDocumentNumber>T85-0218</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.29</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of the combination of adriamycin, dtic and ifosfamide in advanced soft tissue sarcomas of adults</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:40"><nciDocumentNumber>C77-0247</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>77-03-04</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of combinations of 5-fu plus icrf-159, 5-fu plus triazinate, methyl-ccnu plus triazinate and of icrf-159 plus triazinate two combinations of agents with established activity in large bowel carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:40"><nciDocumentNumber>C77-0249</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>77-033</localDocumentNumber></localDocumentNumberList><documentTitle>Schedule intensification of methotrexate with single dose of leucovorin rescue</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:40"><nciDocumentNumber>T85-0170</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-85U1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of new agents in advanced hormone-resistant prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:41"><nciDocumentNumber>C77-0161</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-77-01</localDocumentNumber></localDocumentNumberList><documentTitle>High-dose methotrexate with citrovorum factor rescue in Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:41"><nciDocumentNumber>SEG-BRE-83-307</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-BRE-83-307R-T</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III comparison of CTX, ADR, and 5-FU vs CTX, MTX, and 5-FU both given to maximal tolerated dosage as adjuvant therapy after Masectomy for Carcinoma of the Breast w/1-3 +Axillary Nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:41"><nciDocumentNumber>C76-0606</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAYO-76-76-01</localDocumentNumber></localDocumentNumberList><documentTitle>Post surgical adjuvant therapy for osteogenic sarcoma:  a prospective randomized study-postsurgical observation vs. postsurgical observation + high dose methotrexate with citrovorum rescue</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:42"><nciDocumentNumber>SEG-BRE-201</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-BRE-201</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Fludarabine Phosphate in patients with Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:42"><nciDocumentNumber>SEG-BRE-302</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-BRE-302</localDocumentNumber></localDocumentNumberList><documentTitle>Phase 3 study in ER+ or PGR+ positive Metastatic Breast Cancer using AG and HC plus Cyclophosphamide, Adriamycin and 5-Fluorouracil (CAF) with or without hormonal synchronization (premarin priming)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:42"><nciDocumentNumber>CIC-77-12</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-77-12</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy of germ cell carcinomas stage iii and unresectable stage ii</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:42"><nciDocumentNumber>CIC-80-104</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-80-104</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of cis-platinum in previously treated patients with advanced soft tissue sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:42"><nciDocumentNumber>SEG-AML-305</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-AML-305</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial comparing Daunorubicin and Idarubicin in combination with Cytosine Arabinoside in patients with Acute Myelogenous Leukemia greater than or equal to 51 years of age</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:43"><nciDocumentNumber>CCG-984</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-984</localDocumentNumber></localDocumentNumberList><documentTitle>Histiocytosis x: a study of the biology, clinical and histiologic staging, treatment and prognosis in previously untreated children</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:43"><nciDocumentNumber>CIC-74-17</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-74-17</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy in disseminated malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:43"><nciDocumentNumber>CIC-75-84</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-75-84</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy in lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>CCG-961</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-961</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized study between no chemotherapy and adjuvant chemotherapy for childhood localized unilateral retinoblastoma reese-ellsworth group 5</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>SEG-A-05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-A-05</localDocumentNumber></localDocumentNumberList><documentTitle>Ancillary protocol: Randomized comparison of BCG plus BCNU and Cytosine Arabinoside vs BCG plus BCNU plus Splenectomy vs BCG plus BCNU plus Allogeneic Leukemic Cells in Acute Myelogenous Leukemia in remission</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>CCG-321P4</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-321P4</localDocumentNumber></localDocumentNumberList><documentTitle>'6 in 1' chemotherapy for children with newly diagnosed advanced stage neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>CCG-181P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-181P</localDocumentNumber></localDocumentNumberList><documentTitle>Reinduction of remission following first bone marrow relapse in children with acute lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:45"><nciDocumentNumber>CCG-161</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-161</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of newly diagnosed acute lymphoblastic leukemia for patients with "low risk" prognostic characteristics</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:45"><nciDocumentNumber>CCG-163</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-163</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of newly diagnosed acute lymphoblastic leukemia for patients with "high risk" prognostic characteristics</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:45"><nciDocumentNumber>CCG-171</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-171</localDocumentNumber></localDocumentNumberList><documentTitle>All/aul relapse: vincristine, prednisone, and l-asparaginase followed by vincristine, methotrexate and l-asparaginase for reinduction and maintenance of second remissions in children with all/aul</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:45"><nciDocumentNumber>CCG-107</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-107</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of newly diagnosed acute lymphoblastic leukemia and acute undifferentiated leukemia in infants less than 12 months of age: chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:45"><nciDocumentNumber>CCG-111</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-111</localDocumentNumber></localDocumentNumberList><documentTitle>Interferon in childhood acute lymphoblastic leukemia at second or third bone marrow relapse three dose levels by two routes of administration followed by vincristine, prednisone, asparaginase-coli and asparaginase-erwinia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:45"><nciDocumentNumber>CCG-S871</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-S871</localDocumentNumber></localDocumentNumberList><documentTitle>Study of pattern and frequency of splenic involvement in hodgkin's disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CCG-071A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-071A</localDocumentNumber></localDocumentNumberList><documentTitle>Cis-platinum Phase II in children with brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CCG-E-09</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-E-09</localDocumentNumber></localDocumentNumberList><documentTitle>Epidemiologic study of Acute Leukemia in children less than 18 months of age</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CALGB-8711</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8711</localDocumentNumber></localDocumentNumberList><documentTitle>Idarubicin, a new analog of Daunorubicin in Adult Acute Lymphoblastic Leukemia (ALL): At first relapse or following failure of first line therapy: Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CALGB-8562</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8562</localDocumentNumber></localDocumentNumberList><documentTitle>Comparative assessment of psychosocial and psychosexual sequelae in three treatment regimens for Advanced Hodgkin's Disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CALGB-8653</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8653</localDocumentNumber></localDocumentNumberList><documentTitle>Recombinant Interleukin-2 and B-Interferon for Relapsed or Refractory Lymphoma: A limited access Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>T85-0100</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Pilot study protocol for the evaluation of Pentostatin (2'Deoxycoformycin) in therapy of T-Lymphoid Neoplasms</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8412</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8412</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive treatment of Adult Acute Lymphocytic Leukemia (ALL):  Phase II :  patients in First Relapse or Failing First Line Therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8431</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8431</localDocumentNumber></localDocumentNumberList><documentTitle>CBDCA vs CHIP in Advanced Non-Small Cell Lung Cancer: Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8482</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8482</localDocumentNumber></localDocumentNumberList><documentTitle>DXDX in patients with Advanced Primary Liver Cancer:  A Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8121</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8121</localDocumentNumber></localDocumentNumberList><documentTitle>High dose Cytosine Arabinoside alone or given sequentially with L-Asparaginase in AML Failed or Relapsed, or in CML in Blast Crisis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8176</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8176</localDocumentNumber></localDocumentNumberList><documentTitle>AZQ master section Phase II previously treated Myeloma plus drug therapy section</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8221</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8221</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot limited access comparative study of Post-Remission Intensive Cytosine Arabinoside in patients with Acute Non-Lymphocytic Leukemia in first remission, a Phase III study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-7751</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7751</localDocumentNumber></localDocumentNumberList><documentTitle>The comparative effectiveness of combination Chemotherapy alone or with Radiation Therapy by involved or extended field, in poor risk patients with stage I &amp; II Hodgkin's Disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-7811</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7811</localDocumentNumber></localDocumentNumberList><documentTitle>Remission induction and T-COAP versus T-MOP Maintenance for the treatment of Recurrent Childhood A.L.L.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-7901</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7901</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive Methotrexate Chemotherapy following Remission Induction in patients at increased risk with untreated Childhood Acute Lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-7902</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7902</localDocumentNumber></localDocumentNumberList><documentTitle>Methotrexate, Leucovorin Rescue, VM-26, Procarbazine and Dexamethasone in the treatment of Poor Histology Lymphoma or Nodular Poorly Differentiated Lymphocytic Lymphoma Refractory to prior therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-7521</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7521</localDocumentNumber></localDocumentNumberList><documentTitle>A comparative study of the value of Immunotherapy with MER as adjuvant to induction and Two Maintenance Chemotherapy Programs in Acute Myelocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-7551</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7551</localDocumentNumber></localDocumentNumberList><documentTitle>Combination Chemotherapy and Radiotherapy for stage IV Hodgkin's Disease, no prior treatment</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-7682</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7682</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy or Chemo-Immunotherapy for Metastatic Recurrent or Inoperable Carcinoma of the Breast-Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-7251</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7251</localDocumentNumber></localDocumentNumberList><documentTitle>A study of four-drug combination chemotherapy designed to evaluate the contribution of Vinca Alkaloids and Alkylating agents to remission induction and maintenance therapies of stage III and IV Hodgkin's Disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-83-19</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-83-19</localDocumentNumber><localDocumentNumber>NCOG-3L-83-1J</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized prospective trial comparing Adriamycin and 5-FU and 131I Antiferritin IGG plus Adriamycin and 5-FU in the treatment of Malignant Hepatoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-82-03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-82-03</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II protocol: WR-2721 and half-body irradiation for the palliation of widespread symptomatic Metastases</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-83-12</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-83-12</localDocumentNumber></localDocumentNumberList><documentTitle>Feasibility study of treatment of Locally Advanced Non-Oat Cell Lung Cancer w/high-dose radiotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-83-13</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-83-13</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II trial randomized study twice daily radiotherapy for locally advanced Squamous Cell Carcinoma of the Upper Respiratory and Digestive Tract</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-80-03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-80-03</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III protocol to compare the value of radiation therapy combined with Misonidazole vs radiation therapy alone in the treatment of Liver Metastasis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-81-12</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-81-12</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II protocol for the evaluation of adjuvant chemotherapy in high grade Carcinoma of the Prostate treated with primary radiotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-81-16</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-81-16</localDocumentNumber></localDocumentNumberList><documentTitle>Combined surgery, chemotherapy and radiotherapy in resectable Squamous Cell Cancer of the Head and Neck - A Phase I/II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-78-31</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-78-31</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II protocol for the evaluation of Misonidazole combined with radiation in the treatment of patients with advanced or recurrent Squamous Cell Carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-79-27</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-79-27</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study for postoperative irradiation alone or combined with Non-Specific Immunotherapy of Non-Oat Cell Carcinoma of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>INT-0056</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Evaluation of the efficacy of 1,25 dihydroxyvitamin d3 and 13-cis retinoic acid in the treatment of myelodysplastic disorders, myeloproliferative disorders and acute non-lymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-78-10</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-78-10</localDocumentNumber></localDocumentNumberList><documentTitle>A protocol to study multiple (symptomatic) Osseous Metastases with several doses of Half-Body Irradiation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>T85-0020</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.22</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of 2'deoxycoformycin in hairy cell leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>RTOG-73-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-73-01</localDocumentNumber></localDocumentNumberList><documentTitle>Definitive Radiation Therapy in inoperable Cancer of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>INT-0048</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>8507-25</localDocumentNumber><localDocumentNumber>ICC-86M1</localDocumentNumber><localDocumentNumber>POA-71185</localDocumentNumber><localDocumentNumber>VU-SAR-4</localDocumentNumber><localDocumentNumber>UAB-273</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of cisplatin plus ifosfamide plus mesna plus vp-16 (vip) as salvage therapy in refractory small cell sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>BTSG-8001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BTSG-8001</localDocumentNumber></localDocumentNumberList><documentTitle>Surgery, Radiotherapy and BCNU vs. surgery, radiotherapy and Procarbazine vs. surgery, radiotherapy, BCNU + Hydroxyurea + Procarbazine + VM-26</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>INT-0031</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/><localDocumentNumber>EST-2285</localDocumentNumber><localDocumentNumber>GITSG-9184</localDocumentNumber><localDocumentNumber>MAOP-5484</localDocumentNumber><localDocumentNumber>BGSM-57184</localDocumentNumber><localDocumentNumber>RTOG-84-20</localDocumentNumber><localDocumentNumber>POA-57184</localDocumentNumber><localDocumentNumber>SWOG-8492</localDocumentNumber></localDocumentNumberList><documentTitle>Radiation therapy + 5-fluorouracil versus "sandwich" smf chemotherapy + radiation therapy as an adjuvant to surgical treatment of pancreatic cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>POG-8844</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8844</localDocumentNumber></localDocumentNumberList><documentTitle>Stage D NBL  #4 Bone Marrow Transplant in the treatment of children >/= 365 days at diagnosis with stage D Neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>PVSG-09</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PVSG-09</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized trial comparing Splenectomy vs 32-P vs Alkeran for the complications of Splenomegaly in Myeloproliferative disorders</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>PVSG-10</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PVSG-10</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized trial comparing 32-P vs Alkeran and Persantine plus Aspirin vs Placebo in the treatment of primary Thrombocythemia and Thrombocytosis Myeloproliferative disorders</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>INT-0016</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/><localDocumentNumber>CALGB-8392</localDocumentNumber><localDocumentNumber>EST-3782</localDocumentNumber><localDocumentNumber>NCOG-OC-83-5J</localDocumentNumber><localDocumentNumber>SEG-SAR-81-322</localDocumentNumber></localDocumentNumberList><documentTitle>Intergroup adult adjuvant soft tissue sarcoma study- a randomized trial of adjuvant adriamycin versus standard therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>T89-0112</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>5683</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of high dose Amonafide with Autologous Bone Marrow rescue</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>POG-8739</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8739</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Alpha Interferon in the treatment of recurrent Brain Tumors in children - a Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>POG-8672</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8672</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I trial of recombinant IL-2 in children with Acute Leukemia or Lymphoma with Bone Marrow Metastases: a Pediatric Oncology Group single institution study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>POG-8710</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8710</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for second induction and maintenance in childhood Acute Lymphoblastic Leukemia (SIMAL #5)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>GOG-8491</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8491</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot dose-finding study of Doxorubicin plus Cyclophosphamide plus Cisplatin plus Interferon (Wellferon) in the treatment of Ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>GOG-57</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-57</localDocumentNumber></localDocumentNumberList><documentTitle>A study of multiple agent chemotherapy with Methotrexate, Dactinomycin and Chlorambucil in the treatment of "Poor Prognosis" Metastatic Gestational Trophoblastic Disease:  Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>GOG-4</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-4</localDocumentNumber></localDocumentNumberList><documentTitle>Th treatment of women with Cervical Cancer, stage IIIB and IV confined to the pelvis, with Hydroxyurea or Placebo - both in combination with radiation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>GOG-46</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-46</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized comparison of Melphalan versus Intraperitonal Chromic Phosphate in the treatment of women with stage I ( exclusive of stage IA (I) GI and IB (I) GI) Epithelial Carcinoma of the Ovary</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>POG-8602</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8602</localDocumentNumber></localDocumentNumberList><documentTitle>0valuation of treatment regimens in Acute Lymphoid Leukemia of childhood (ALINC #14): A Pediatric Oncology Group Phase III study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>80-03-05/80-74-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>80-03-05/80-74-02</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot and Phase II study of the combination cyclophosphamide, adriamycin, followed by 24-hour infusion of cisplatin in patients with advanced cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>90-80</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>90-80-</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II trial of fam chemotherapy plus irradiation in the treatment of locally advanced gastric and pancreatic cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>T88-0118</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C-762-88</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of ifosfamide and etoposide for advanced or metastatic sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>POG-9072</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9072</localDocumentNumber></localDocumentNumberList><documentTitle>Ifosfamide, Carboplatin, Etoposide (ICE) treatment of recurrent/resistant Malignant Solid Tumors of childhood-A Pediatric Oncology Group pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>T90-0148</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>991</localDocumentNumber></localDocumentNumberList><documentTitle>Adoptive cellular therapy of Cancer with tumor-primed Anti-CD3 activated Lymphocytes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>T90-0172</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PCI 92-36</localDocumentNumber><localDocumentNumber>DUGU 90-02</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of high dose intravenous Cyclophosphamide with GM-CSF in Hormone-Refractory Metastatic Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>SWOG-9037</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9037</localDocumentNumber><localDocumentNumber>CALGB-9196</localDocumentNumber></localDocumentNumberList><documentTitle>Prediction of recurrence and survival in Node-Negative Breast Cancer patients using a panel of prognostic factors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>T90-0190</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-90X1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of Piroxantrone and GM-CSF in patients with Advanced Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>GOG-9001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9001</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I limited access study of weekly Cisplatin and whole abdominal radiation for the treatment of stage III and IV Endometrial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>EST-1491</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1491</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of Fludarabine plus Cyclophosphamide in patients with low-grade Lymphoma previously untreated with Chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>CCG-B902</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-B902</localDocumentNumber></localDocumentNumberList><documentTitle>Specimen Accrual System for Cytogenetic and Molecular Biologic Studies of Childhood Astrocytomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>SWOG-9031</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9031</localDocumentNumber></localDocumentNumberList><documentTitle>A double blind Placebo controlled trial of Daunomycin and Cytosine Arabinoside with or without RHG-CSF in elderly patients with Acute Myeloid Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T90-0238</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>JCC-90I1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/Phase II Study of 5-FU, Leucovorin, and Hydroxyurea in the treatment of Advanced Colorectal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>GOG-0026LL</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-26LL</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of prolonged Oral Etoposide (VP-16) in patients with Advanced Pelvic Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T91-0039</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>90-46-01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of combined 5-Fluorouracil and Levamisole in patients with Advanced Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T92-0208</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>89-13-51</localDocumentNumber><localDocumentNumber>NCCTG-89-13-51</localDocumentNumber></localDocumentNumberList><documentTitle>Pre-irradiation chemotherapy for central nervous system germ cell malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>CCG-0912</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-0912</localDocumentNumber></localDocumentNumberList><documentTitle>Intravenous Recombinant Beta-Interferon (INF-BSER) and hyperfractionated radiation therapy in children with Newly Diagnosed Brainstem Gliomas: A Phase I/II pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>SWOG-9062</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9062</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of 96 hour Infusion 5-FU and Cisplatin and Alpha Interferon in patients with Recurrent/Metastatic Squamous Cell Carcinoma of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T91-0076</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NYU-9114</localDocumentNumber></localDocumentNumberList><documentTitle>Intraventricular IL-2/LAK in recurrent or progressive primary pediatric brain tumors arising in the Posterior Fossa</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>EST-P-X990</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-X990</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of Interleukin-1 Alpha and Cyclophosphamide in patients with Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T91-0113</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>91-LA-6</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive multimodal therapy and autologous bone marrow transplantation for high risk Neuroblastoma patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T91-0117</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID-91-009</localDocumentNumber></localDocumentNumberList><documentTitle>A comparative study of Taxol and parenteral Hydroxyurea in patients with Cisplatin/Carboplatin Refractory Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>POG-9264</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9264</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy regimen for initial induction failures in childhood Acute Llymphoblastic Leukemia: A Pediatric Oncology Group Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>T91-0173</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>92-37</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I toxicity reduction trial of All Trans-Retinoic Acid with Alpha-Tocopherol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>T91-0175</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UPCC-1591</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of All-Trans-Retinoic Acid in metastatic Non- Small Cell Lung Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>SWOG-9026</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9026</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I , open label multicenter study of the safety, tolerability &amp; biological effects of Sdzile 964 (Recombinant il-3), administered to patients with Metastatic Cancer prior to &amp; after receiving a CBDCA/VP-16 chemotherapy regimen</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>T91-0194</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-4991</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Topotecan given by continuous Intravenous infusion over 72 hours weekly in patients with Advanced Malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>RTOG-91-17</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-91-17</localDocumentNumber></localDocumentNumberList><documentTitle>An observational clinical study of the significance of positive Prostatic biopsies following full dose external beam irridation of patients with Adenocarcinoma of the Prostate, treated on RTOG-86-10</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>CCG-0916</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-0916</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Carboplatin in children with Acute Lymphoblastic Leukemia and Acute Non-Lymphoblastic Leukemia in Bone Marrow Relapse, and Chronic Myelocytic Leukemia in Blast Crisis following therapy of higher priority</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>GOG-125</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-125</localDocumentNumber></localDocumentNumberList><documentTitle>Extended field RADIATION THERAPY with CONCOMITANT 5-FU infusion and CISPLATIN chemotherapy in patients with CERVICAL CARCINOMA metastatic to PARA-AORTIC LYMPH NODES</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>RTOG-92-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-92-04</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable Non-Small Cell Lung Cancer (NSCLC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>T92-0027</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase II trial of All-Trans-Retinoic Acid in Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>SWOG-9157</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9157</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of all Trans-Retinoic Acid in Hepatoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>GOG-9202</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9202</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I limited access study of Taxol (NSC #125973) and Carboplatin (NSC # 241240) in patients with suboptimal stage III and IV Epithelial Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>RTOG-92-06</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-92-06</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II study to evaluate the effect of Recombinant Human Interleukin-1 (RH IL-1) on Granulothrombocytopenia associated with Hemibody Irradiation (HBI)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>T92-0109</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>1B-92-3</localDocumentNumber></localDocumentNumberList><documentTitle>Taxol in Patients with Locally Advanced or Metastatic Breast Cancer: A Phase II Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>SWOG-9058</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9058</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of intravenous Vinorelbine (Navelbine) in previously untreated extensive Small Cell Lung Carinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>GOG-9205</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9205</localDocumentNumber></localDocumentNumberList><documentTitle>Correlation of Human Papillomavirus Genotype with clinical and histopathological features of Vulvar Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>T92-0166</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>92-127</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Taxol as a 3-hour infusion in the treatment of patients with Metastatic Breast Cancer who have received at least two prior chemotherapy regimens for advanced disease (and one Anthracycline)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>T92-0165</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I/II Study of Interleukin-2 to Enhance the Antileukemic Effect of Alpha Interferon in the Treatment of Chronic Phase-Chronic Myeloid Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>CALGB-9267</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9267</localDocumentNumber></localDocumentNumberList><documentTitle>Analysis of Neuroendocrine Markers in patients with Locally Advanced Unresectable Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>T92-0209</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM 92-089</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Taxol (NSC 125973), Cisplatin, and Etoposide with G-CSF in patients with Non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>T92-0233</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I Study of combined Chemoradiation therapy with Topotecan plus Thoracic Radiotherapy for locally advanced inoperable or locally recurrent Non-small cell Lung Cancer (NSCICA)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>RTOG-93-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-93-02</localDocumentNumber><localDocumentNumber>R9302</localDocumentNumber></localDocumentNumberList><documentTitle>A prospective randomized Phase III clinical trial evaluating the use of post-operative adjuvant radiotherapy in the treatment of patients with Cutaneous Melanoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>CCG-B925</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-B925</localDocumentNumber></localDocumentNumberList><documentTitle>Cellular Pharmacokinetics of Mercaptopurine and Methotrexate in Children with Acute Lymphoblastic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T93-0098</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C-1057-92</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of Adriamycin and Taxol in combination as front line therapy in the treatment of metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T93-0112</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>High dose ARA-C &amp; Mitoxantrone w/ PIXY 321 as remission induction therapy of relapsed or refractory Acute Myelogenous Leukemia(AML) or untreated, poor prognosis AML &amp; Chro. Myelogenous Leukemia in Myeloid blast crisis: A Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>SWOG-9229</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9229</localDocumentNumber></localDocumentNumberList><documentTitle>Concurrent Cisplatin prolonged Oral Etoposide and Vincristine plus chest and brain irradiation for limited Small Cell Lung Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>POG-9375</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9375</localDocumentNumber></localDocumentNumberList><documentTitle>Topotecan plus Cyclophosphamide in children with Solid Tumors: a Pediatric Oncology Group Phase I trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T94-0069</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PCI 94-87</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Suramin in relapsed or metastatic head and neck cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T94-0012</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.82</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II study of two schedules of Topotecan in previously treated patients with Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>SWOG-9348</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9348</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of the standard BCNU/DTIC/Cisplatin/Tamoxifen regimen in Disseminated Malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T94-0115</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>94-C-0175</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I and pharmacokinetic trial of 21-day continuous infusion Etoposide in pediatric patients with advanced malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T94-0116</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I trial of vaccine combining a Mage-3 peptide with helper Peptide Padre-965.10 emulsified with incomplete Freund's adjuvant for patients with resected Stages IIB, III and IV Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>GOG-129C</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-129C</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Paclitaxel (Taxol) in the treatment of Recurrent of Persistent Endometrial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T95-0012</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM 95-010</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase II trial of Ketoconazole alone and Ketoconazole/Doxorubicin in hormone refractory Prostate Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T95-0026</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I Trial of HUM195 (Recombinant Humanized Anti-CD33) Monoclonal Antibody and Recombinant Interleukin-2 (IL-2) in Myelogenous Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T95-0091</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A randomized Phase II study of Sodium Phenylacetate in adults with inoperable or metastatic cancer of the exocrine pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T83-1365</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>URCC-1282M</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of metastatic colon cancer with 5-FU and high dose folic acid</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>SEG-LUN-80-278</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-80-278</localDocumentNumber></localDocumentNumberList><documentTitle>Mitoxantrone Phase II in Carcinoma of  the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>D80-018-0372</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>80-044</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16,213 Phase II neoplastic disease, non-randomized</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T84-0234</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>84-039-NPD</localDocumentNumber></localDocumentNumberList><documentTitle>Sequential ARA-C and Mitoxantrone for refractory Myelogenous Leukemia (A Phase I/II Study)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T94-0101</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I study of Interleukin-4 in pediatric patients with refractory relapsed acute Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>EST-P-D878</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-D878</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II, Chemotherapy of advanced Ovarian Cancer using high-dose Cisplatin with Hexamethylmelamine</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>T91-0011</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RWMC-91-81840</localDocumentNumber></localDocumentNumberList><documentTitle>Effect of Interferon therapy on tumor Antigen expression in patients with Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>T84-0355</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>84-056</localDocumentNumber><localDocumentNumber>UMCC-8437</localDocumentNumber></localDocumentNumberList><documentTitle>Doxorubicin, Ifosfamide and DTIC (id) with Mesna uroprotector for advanced untreated Sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>RTOG-80-07</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-80-07</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II dose-searching randomized study of mixed beam (neutron/photon) radiation therapy for Anaplastic Astrocytomas and Glioblastomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>T97-0069</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID 97-077</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Prospective Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer - Patients at High Risk for Recurrence</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>P9645</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9645</localDocumentNumber><localDocumentNumber>POG-9645</localDocumentNumber></localDocumentNumberList><documentTitle>Intergroup Protocol for Treatment of Children with Hepatoblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>T92-0250</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UPCC-7397</localDocumentNumber></localDocumentNumberList><documentTitle>Radiation Therapy with Concomitant Continuous Infusion Taxol for Glioblastoma Multiforme,  A Phase I Study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>T94-0080</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I Trial of BCNU Plus 06-Benzylguanine in the Treatment of Patients with Recurrent, Persistent or Progressive Cerebral Anaplastic Gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>GOG-0126J</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-126J</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Docetaxel in recurrent, Platinum Resistant, Refractory and Paclitaxel Refractory Ovarian Cancer and Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>T97-0106</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VCC THO 9817</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of 6-Hydroxymethylacylfulvene (MGI-114, NSC #683863) in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-12-1999 16:44:22"><nciDocumentNumber>AB9804</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-B9804</localDocumentNumber></localDocumentNumberList><documentTitle>CLINICAL AND BIOLOGICAL PREDICTORS OF THERAPY-RELATED LEUKEMIA</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-12-1999 16:48:37"><nciDocumentNumber>POG-9705</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9705</localDocumentNumber></localDocumentNumberList><documentTitle>ALINC 17: PROTOCAL FOR PATIENTS WITH NEWLY DIAGNOSED BETTER RISK ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) : A POG STUDY</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-12-1999 17:05:29"><nciDocumentNumber>POG-9806</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9806</localDocumentNumber></localDocumentNumberList><documentTitle>ALINC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-12-1999 17:12:07"><nciDocumentNumber>T98-0046</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>9710-07</localDocumentNumber></localDocumentNumberList><documentTitle>A PHASE II trial of  PERILLYL ALCOHOL in patients with RESECTABLE PANCREATIC CANCER</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:17"><nciDocumentNumber>B95-0005</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UAB 9505</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of 131I-labeled Anti-TAG-72 Monoclonal antiboldy combined with total body irradiation and Thiotepa with Autologous stem cell rescue in patients with Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:17"><nciDocumentNumber>ADVL0018</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>A0981</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial of the HU14.18-IL2 (IND# BB-IND 9798, NSC# 721298) Fusion Protein in Children with Refractory Neuroblastoma and Other GD2 Positive Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:17"><nciDocumentNumber>T96-0038</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97-C-0052</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study of Autologous T-Cell Transplantation with Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:17"><nciDocumentNumber>S9804</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9804</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Vinorelbine Tartrate (Navelbine) in Patients with Disseminated Malignant Melanoma and One Prior Systemic Therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>TRC-9701</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>TRC-9701</localDocumentNumber><localDocumentNumber>ID99-370</localDocumentNumber></localDocumentNumberList><documentTitle>Compound 506U78 (NSC 686673) in Patients with Relapsed of  Refractory T-cell ALL or T-cell Lymphoblastic Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>77-018</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>77-018</localDocumentNumber></localDocumentNumberList><documentTitle>Bruceantin, Phase I Study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>T84-0305</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>84-CC-61</localDocumentNumber></localDocumentNumberList><documentTitle>Vocational Status Of Childhood Cancer Survivors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>SEG-244</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-244</localDocumentNumber></localDocumentNumberList><documentTitle>Ph. ii tumors of oral methyl-ccnu in solid tumors + lymphomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>SEG-252</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-252</localDocumentNumber></localDocumentNumberList><documentTitle>5-Azacytidine Broad Study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>COG-7340</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Adjuvant Therapy For Breast Cancer Following Mastectomy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>SEG-AML-P30</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-AML-P30</localDocumentNumber></localDocumentNumberList><documentTitle>A phase ii pilot study of vinblastine in refractory acute myelogenous leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>T93-0012</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I Study of Penclomedine</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T94-0138</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>96-C-0107</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment Of Patients With Metastatic Melanoma Using Peripheral Blood Lymphocytes Sensitized In Vitro, To The Gp209-2m Immunodominant Peptide</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T95-0050</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>95-81-01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Continuous Infusion Carboplatin and Topotecan in the Treatment of Relapsed Acute Leukemia and Blast Crisis Chronic Myelogenous Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T95-0075</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>FCCC 95-004</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Evaluation Of Topotecan In Combination With Paclitaxel And Carboplatin</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T95-0092</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>95-083</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study Of Buthionine Sulfoximine (BSO) in Combination With Melphalan For High Risk Neuroblastoma Or Melanoma Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T96-0036</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97-C-0040</localDocumentNumber></localDocumentNumberList><documentTitle>EPOCH Plus Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients with AIDS-Associated Lymphoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T96-0048</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>8254</localDocumentNumber></localDocumentNumberList><documentTitle>A phase ii trial of ci-980 in patients with stage d2, hormone refractory prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T95-0025</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PH2/031</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Bryostatin-1 in Low Grade Non-Hodgkins Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T96-0059</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UPCI 96-035</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Percutaneous Injections of Adeno-Virus p53 Construct (Adeno-p53) for Hepatocellular Carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T96-0073</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM96-172</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial of Intravesical AD-p53 Treatment in Locally Advanced and Metastatic Bladder Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T97-0026</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97-C-0119</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of 2'-BETA-FLUORO-2',3'-DIDEOXYADENOSINE (F-DDA) in Children with HIV Infection</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T97-0062</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CWRU 3Y97</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial of Combination Bryostatin 1 (NSC 339555) and Vincristine in B-Cell Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T98-0024</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97-50-02</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Dolastatin-10 in Patients with Advanced Renal Cell Carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>NCCTG-96-92-51</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCC-96-29</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Chemoprevention Study of Acitretin versus Placebo in Solid Organ Transplant Recipients with Multiple Prior Treated Skin Cancers
</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>RTOG-99-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-99-04</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Preoperative Chemotherapy and Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Stomach</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T99-0036</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ASTA  D-21266</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial of  Perifosine on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>T90-0023</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>5853</localDocumentNumber></localDocumentNumberList><documentTitle>5-Fluorouracil, Hydroxyurea And Escalating Doses Of Iododeoxyuridine In Multimodal Therapy For Previously Untreated Patients With Anaplastic Astrocytoma And Glioblastoma Multiforme</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>T89-0187</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-89U2</localDocumentNumber></localDocumentNumberList><documentTitle>Phase ii pilot study of continuous-infusion 5-fluorouracil in the treatment of patients with advanced hormone-refractory adenocarcinoma of the prostate</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>T83-0994</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>83-634</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot Study Of 14 Mv Dt Neutron Irradiation Of Selected Patients With Advanced Pelvic Malignancies: Recurrent Or Inoperable Adenocarcinoma Of The Rectum, Stage D Adenocarc Of The Prostrate, Stage D Carc Of The Bladder</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>SEG-366</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase III Randomized Comparison Of Bcnu, Cyclophosphamide, Vinblastine, Procarb., Prednisone, And Bleo. In Hodgkin'S Disease</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>C76-0560</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>76-31-01</localDocumentNumber></localDocumentNumberList><documentTitle>An Assessment Of Oophorectomy With Adjuvant Chemotherapy Versus Cytotoxic Chemotherapy Alone In Premenopausal Patients With Advanced Breast Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>T85-0108</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>82-03-178</localDocumentNumber></localDocumentNumberList><documentTitle>Intradermal intralymphatic immunotherapy for stage ii (spread to local lymph nodes) malignant melanoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>PVSG-11</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PVSG-11</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Randomized Trial Comparing High-Dose Oral Vs High-Dose Intramuscular Androgens In The Treatment Of Refractory Anemia Associated With Myeloproliferative Diseases</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>T91-0086</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Pilot Study Of Tumor Kinetics In Carcinoma Of The Uterine Cervix</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>T91-0168</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>91-C-232</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study Of Taxol, Cisplatin, Cyclophosphamide And Granulocyte Colony-Stimulating Factor (G-Csf) In Previously Nontreated Ovarian Cancer Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>T91-0271</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I Clinical And Pharmacokinetic Study Of Topotecan In Cancer Patients With Hepatic Or Renal Dysfunction</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>T92-0018</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>92-C-0161</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot Study of High Dose  Ice (Ifosfamide, Carboplatin, Etoposide) Chemotherapy and Autologous Bone Marrow Transplant (ABMT) with Neo-Transduced Bone Marrow and Peripheral Blood Stem Cells in Patients with Metastatic Breast Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>B93-0001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IRB PROTOCOL#93-049</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot Trial Of Weekly Chimeric Anti-Gd2ganglioside Monoclonal Antibody, Chimeric 14.18 With Radionuclide Imaging In Patients With Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>B93-0006</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>3272-G</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial Of Continuous Infusion Recombinant Human Interleukin-4 (Rhuil-4) In Patients With Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>T93-0067</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>LU 5887</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial Of Carboplatin, Hydroxyurea, And Cytarabine In Refractory Adult Acute Myeloid Leukemia Or Chronic Myeloid Leukemia In Blast Crisis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>TRC-9301</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Randomized Study Of Taxol (Nsc 125973) Versus Vinblastine In Patients With Advanced Breast Cancer Previously Treated With Anthracycline Or Anthracene Chemotherapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>T94-0001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C-1087-93</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Clinical Evaluation Of PYRAZOLOACRIDINE In Patients With Advanced Non-Small Cell Lung Carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>T94-0003</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C-1148-93</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Clinical Evaluation of Pyrazoloacridine in Patients with Metastatic Breast Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0113</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>94-30</localDocumentNumber></localDocumentNumberList><documentTitle>Sequential Administration of INTRAVENOUS 6-THIOGUANINE after INTRAVENOUS METHOTREXATE In Patients with Relapsed HODGKIN'S DISEASE (Phase II)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0107</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>94-C-0204</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I And Pharmacokinetic Trial Of Paclitaxel(Taxol) Given As A Short Infusion In Pediatric Patients With Refractory Malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0136</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IDD 94-32</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Rebeccamycin (NSC 655649) Given by Bolus Infusion Every 21 Days</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0171</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UAB-9441</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Bryostatin-1 for the Treatment of Patients with Metastatic Malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0175</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2O-94-1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Feasibility Trial of 9-Aminocamptothecin (NSC 603071) Plus G-CSF in Extensive Stage Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T95-0059</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Recurrent, Platinum-Refractory Ovarian Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T95-0063</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase ii clinical trial of 9 cis retinoic acid (9cra) in patients with advanced, locally advanced, recurrent or inoperable carcinoma of the cervix: a new york gog study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T95-0080</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NYU-94-40</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial Of 9-Cis Retinoic Acid (Lgd-1057, Nsc #659772) And Tamoxifen In Patients With Metastatic Carcinoma Of The Breast</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>95C0172</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>95-C-0172</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study To Evaluate The Safety And Immunogenicity Of Hiv-1 Immunogen In Children With Hiv-1 Infection</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T95-0106</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I/Ii Study Of Suramin (Nsc 34936) And Topotecan (Nsc 609699) In Patients With Hormone Refractory Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T95-0008</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>95-2BA</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of IV L-PAM and BSO in Patients with Relapsed or Refractory Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T96-0044</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/><localDocumentNumber>97-C-0051</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients with Refractory Malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T96-0091</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>96-77</localDocumentNumber></localDocumentNumberList><documentTitle>An Open-Label, Non-Randomized Phase I Study of the Protein Kinase C Inhibitor Flavopiridol Administered in Combination with Paclitaxel in Patients with Advanced Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T96-0095</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>8551</localDocumentNumber></localDocumentNumberList><documentTitle>A  Phase II Trial of  Flavopiridol (NSC 649890) Administered as a 72-Hour Continuous Infusion Every 2 Weeks in Patients with Previously Treated Multiple  Myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0002</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CWRU 4Y96</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Clinical and Pharmacokinetic Study of Rebeccamycin Analogue NSC 655649 Given Daily for 5 Consecutive Days</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0020</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>96-01-05</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial of  SURAMIN with Sequential DOXORUBICIN Patients  with Advanced  SOLID TUMORS</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0033</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97-118</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Study of Sequential Vaccinations with ALVAC-CEA  and Vaccinia-CEA with the Addition of IL-2 and GM-CSF in Patients with CEA Expressing Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0059</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97-C-0144</localDocumentNumber></localDocumentNumberList><documentTitle>Cellular Immunotherapy With Autologous T Lymphocytes Stimulated With The Patient'S Tumor-Specific Mutated Ras Peptides</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0081</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>98-C-0139</localDocumentNumber></localDocumentNumberList><documentTitle>Vaccine Therapy with Tumor Specific Mutated VHL Peptides in Adult Cancer Patients with Renal Cell Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T98-0007</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II Trial of Dolastatin 10 in Indolent Lymphoma and Chronic Lymphocytic Leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>A3973</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>A3973</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>NCCTG-97-92-51</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-97-92-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (Lmwh) Versus Placebo In Patients With Advanced Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>NCCTG-95-92-58</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MCCTG-95-92-58</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II randomized controlled study of ANDROGEN DEPRIVATION ( with FLUDAMIDE and DEPOT LEUPROLIDE ACETATE) in patients with PROSTATE CANCER prior to RADICAL PROSTATECTOMY to evaluate modulation of high-grade prostatic INTRAEPITHELIAL NEOPLASIA (PIN) and other POTENTIAL SURROGATE ENTPOINT BIOMARKERS</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T98-0042</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>H-63-21</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients with Progressive or Recurrent CNS Malignancy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>ACOSOG-Z0020</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACOSOG-Z0020</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion and Melphalan with or without Tumor Necrosis Factor in the Patient with Localized, Advanced, Extremity Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T98-0059</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase 2 Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients with Recurrent or Progressive Cerebral Anaplastic Gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T98-0074</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID98-270</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Thalidomide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T99-0009</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase II Study of Oxaliplatin  in Urothelial  Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T99-0012</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>99-C-0129</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Decitabine Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Patients with Cancers Involving the Lung, Esophagus, or Pleura</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T99-0017</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I Study of Oxaliplatin in Combination with Paclitaxel</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T99-0024</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Pilot Study on the Use of Combined Hydroxyurea and Lodenosine in HIV-1 Infected Individuals</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>RTOG-99-03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-99-03</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated with Radiotherapy for Carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T99-0033</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>99-C-0092</localDocumentNumber></localDocumentNumberList><documentTitle>Immunization of Patients with Metastatic Melanoma Using MART-1 and gp100 Peptides Modified to Increase Binding to HLA-0201</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>S9902</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9902</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of the Combination of Docetaxel (Taxotere) Carboplatin in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-04-1999 14:35:37"><nciDocumentNumber>S9904</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9904</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Thrombopoietin (RH-TPO) with High Dose Cytarabine (HDAC) and Idarubicin (IDA) Induction and Consolidation Therapy Followed by Autologous Peripheral Blood Stem Cell Transplant (APBSCT) and Post-APBSCT Interleukin-2 (IL-2) for Adult Patients of Age &lt; 56 with Previously Untreated De Novo, Non-M3 Acute Myeloid Leukemia (AML)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-25-1999 09:50:15"><nciDocumentNumber>GOG-0126K</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-126K</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Evaluation of Oxaliplatin in Recurrent Platinum Resistant  nd Refractory Ovarian Cancer and Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="06-18-1999 11:23:19"><nciDocumentNumber>P9761</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>P9761</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Irinotecan in Children with Refractory Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="07-29-1999 10:01:20"><nciDocumentNumber>T99-0055</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO99910</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Endostatin in Advanced Cancer Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="08-03-1999 11:10:09"><nciDocumentNumber>T99-0062</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II Study of Arsenic Trioxide (NSC #706363) in Relapsed and Refractory Intermediate and High-Grade Non-Hodgkin Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="08-03-1999 14:26:05"><nciDocumentNumber>T99-0086</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHI-30</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial of  SU5416 in Combination with Weekly Paclitaxel in Patients with Advanced Malignancies</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-17-1999 14:21:49"><nciDocumentNumber>T99-0113</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase 2 Study of Rebeccamycin Analog in Renal Cell Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-19-1999 10:55:59"><nciDocumentNumber>20</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RRC 56-99</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of R115777 (NSC 702818) an Inhibitor of Farnesyl Protein Transferase, in Patients with Hormone Refractory Prostate Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="08-23-1999 12:34:01"><nciDocumentNumber>26</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Family Home Care for Cancer-A Community-based Model</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-24-1999 12:50:11"><nciDocumentNumber>T99-0083</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC9973</localDocumentNumber></localDocumentNumberList><documentTitle>Melanoma Vaccines:  Differentiation Antigen Peptides (MART-1:27-35, Tyrosinase and gp-100) as Immune Targets</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-25-1999 09:18:45"><nciDocumentNumber>T99-0074</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>99-C-0137</localDocumentNumber></localDocumentNumberList><documentTitle>Vaccine Therapy with Tumor Specific p53 Peptides in Adult Patients with Low Burden Adenocarcinoma of the Ovary</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-26-1999 12:41:21"><nciDocumentNumber>E4896</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4896</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Carboxyamidotriazole (CAI, NSC #609974) in Patients with Advanced Renal Cell Carcinoma Refractory to Immunotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-26-1999 17:28:23"><nciDocumentNumber>50</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GCC 9948</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Weekly Paclitaxel and Bryostatin-1 in Hormone Refractory Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-31-1999 13:56:56"><nciDocumentNumber>T99-0066</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>00-C-0128</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-16-1999 10:21:04"><nciDocumentNumber>89</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CWRU 1298</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of O6 Benzylguanine and BCNU in Patients with Colon and Rectal Carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-30-1999 10:33:49"><nciDocumentNumber>150</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IDD99-32</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of BMS-247550 (NSC 710428) Given on a Continuous Weekly Schedule in Patients with Advanced Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-07-1999 07:35:00"><nciDocumentNumber>N9831</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N9831</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel with or without Trastuzumab as Adjuvant Treatment for Women with HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-13-1999 10:12:34"><nciDocumentNumber>213</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>00-C-0206</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Yttrium 90-labeled Monoclonal Antibody B3 with Autologous Stem Cell Support for Metastatic Breast Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-20-1999 15:53:11"><nciDocumentNumber>CCG-1991</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-1991</localDocumentNumber></localDocumentNumberList><documentTitle>Escalating Dose Intravenous Methotrexate without Leucovorin Rescue vs. Oral Methotrexate and Single vs. Double Delayed Intensification for Children with Standard Risk Acute Lymphoblastic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-21-1999 10:39:00"><nciDocumentNumber>314</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NYGOG 99-001</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Thalidomide (NSC #66847) in Patients with Sarcomas of Gynecologic Origin</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-21-1999 14:45:46"><nciDocumentNumber>330</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>00-002</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of SU5416 (NSC # 696819) in Previously Treated Patients with Advanced, Metastatic and/or Locally Recurrent Soft Tissue Sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-12-1999 16:12:18"><nciDocumentNumber>571</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHI-31</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Tirapazamine (NSC 130181), Paclitaxel, and Carboplatin with Concurrent Radiation Followed by Paclitaxel/Carboplatin Consolidation for Stage III Non-Small Cell Lung Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-17-1999 08:33:45"><nciDocumentNumber>610</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID99-334</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Fenretinide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-13-1999 13:08:13"><nciDocumentNumber>CALGB-39901</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-39901</localDocumentNumber><localDocumentNumber>CALGB-39901</localDocumentNumber><localDocumentNumber>CALGB-39901</localDocumentNumber><localDocumentNumber>CALGB-39901</localDocumentNumber><localDocumentNumber>CALGB-39901</localDocumentNumber><localDocumentNumber>CALGB-39901</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive Stage Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-15-1999 10:17:53"><nciDocumentNumber>N9982</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N9982</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study of Thalidomide as an Inhibitor of Angiogenesis in the Treatment of Myelofibrosis with Myeloid Metaplasia (MMM)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="01-10-2000 12:15:48"><nciDocumentNumber>955</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>URCC-3997</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized PHASE II trial of ACUPRESSURE and ACUSTIMULATION WRIST BAND for prevention of chemotherapy-induced nausea and vomiting</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-12-2000 13:29:04"><nciDocumentNumber>RTOG-BR-0013</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-00-13</localDocumentNumber></localDocumentNumberList><documentTitle>A PHASE II trial of conventional RADIATION THERAPY followed by intratumoral BLEOMYCIN delivered using a refillable, sustained release device (IND#46,592) for the treatment of supratentorial GLIOBLASTOMA</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-01-2000 15:15:53"><nciDocumentNumber>S9917</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9917</localDocumentNumber></localDocumentNumberList><documentTitle>L-Selenium-Based Chemoprevention of Prostate Cancer Among Men With High Grade Prostatic Intraepithelial Neoplasia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 14:51:01" createdDate="02-02-2000 10:41:43"><nciDocumentNumber>24</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>00-166</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial of Gemcitabine Followed by Flavopiridol in Patients with Solid Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-08-2000 13:21:04"><nciDocumentNumber>1230</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase II Study of Arsenic Trioxide (NSC #706363) for Induction Therapy of Adult Patients with Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia and Previously Untreated or Relapsed or Refractory Blast Crisis of Chronic Myeloid Leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-11-2000 13:24:32"><nciDocumentNumber>1192</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II Study of Immunization with PSMA Peptide-Pulsed Autologous PBMC Plus rhIL-12 in Patients with Metastatic Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-08-2000 10:01:17"><nciDocumentNumber>S0000</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0000</localDocumentNumber></localDocumentNumberList><documentTitle>Selenium and Vitamin E Cancer Prevention Trial (SELECT)</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-16-2000 08:57:20"><nciDocumentNumber>P9934</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>P9934</localDocumentNumber></localDocumentNumberList><documentTitle>Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 months and &lt;3 Years with Non-metastatic Medulloblastoma: A Children's Oncology Group Phase III Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-21-2000 11:00:34"><nciDocumentNumber>GOG-9908</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9908</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-06-2000 13:05:29"><nciDocumentNumber>2030</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II Evaluation of FTI (R115777) in Treatment of Advanced Multiple Myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-11-2000 14:17:16"><nciDocumentNumber>1311</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OO-DK-0166</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study of 5-Azacytidine and Oral Phenylbutyrate in Severe Thalassemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-15-2000 09:12:44"><nciDocumentNumber>GOG-0126L</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0126L</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Gemcitabine and Cisplatin in Recurrent, Platinum Resistant and Refractory Ovarian and Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-19-2000 08:22:50"><nciDocumentNumber>RTOG-P-0019</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-P-0019</localDocumentNumber></localDocumentNumberList><documentTitle>A PHASE II STUDY OF EXTERNAL BEAM RADIATION THERAPY COMBINED WITH PERMANENT SOURCE BRACHYTHERAPY FOR INTERMEDIATE RISK CLINICALLY LOCALIZED ADENOCARCINOMA OF THE PROSTATE</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-02-2000 14:19:07"><nciDocumentNumber>N0074</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0074</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of ZD1839 (NSC 715055) in Newly Diagnosed Patients with Glioblastoma (Grade 4 Astrocytoma)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-05-2000 14:58:38"><nciDocumentNumber>N9946</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N9946</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), and Leucovorin (CF) in Patients with Metastatic Colorectal Carcinoma Previously Treated with Irinotecan (CPT-11)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-06-2000 13:57:59"><nciDocumentNumber>GOG-0186B</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0186B</localDocumentNumber></localDocumentNumberList><documentTitle>A PHASE II EVALUATION OF 9-NITRO-CAMPTOTHECIN IN THE THIRD-LINE-TREATMENT OF RECURRENT OVARIAN OR PRIMARY PERITONEAL CANCER</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-22-2000 13:13:59"><nciDocumentNumber>E4A98</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4A98</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Autologous Stem Cell Transplant Followed by Mini-Allogeneic Stem Cell Transplant in Lieu of Standard Allogeneic Bone Marrow Transplantation for Treatment of Multiple Myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-05-2000 11:27:50"><nciDocumentNumber>PBTC-005</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PBTC-005</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-09-2000 10:30:36"><nciDocumentNumber>3410</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID00-156</localDocumentNumber></localDocumentNumberList><documentTitle>A Prospective Randomized Phase III Trial Comparing Consolidation Therapy with or without Strontium-89 Following Induction Chemotherapy in Adrogen-Independent Prostate Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-16-2000 15:52:55"><nciDocumentNumber>GOG-0127Q</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0127Q</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Gemcitabine and Cisplatin in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-23-2000 16:20:33"><nciDocumentNumber>CALGB-99903</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-99903</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Arsenic Trioxide (NSC #706363, IND #57974) in Urothelial Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-07-2000 13:17:15"><nciDocumentNumber>N0031</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0031</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Topical Ceramide Lipids as Treatment For Cutaneous Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-07-2000 13:35:53"><nciDocumentNumber>PBTC-NO4</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PBTC-NO4</localDocumentNumber></localDocumentNumberList><documentTitle>Gene Expression Profiling of Infant Embryonal Central Nervous System Tumors by Microarray Gene Chip Analysis: Angiogenesis, Invasion and Metastasis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-02-2012 12:45:43" createdDate="09-12-2000 11:11:42"><nciDocumentNumber>ADVL0015</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0015</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of  PS-341 in Pediatric Patients with Refractory Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-15-2000 10:58:24"><nciDocumentNumber>GOG-0182</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0182</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Trial of Paclitaxel and Carboplatin Versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-29-2000 09:08:01"><nciDocumentNumber>CALGB-159805</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-159805</localDocumentNumber></localDocumentNumberList><documentTitle>Laboratory Studies in Elderly Women with Breast Cancer:  Companion to CALGB 9343</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="10-16-2000 13:00:38"><nciDocumentNumber>S0023</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0023</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Trial of Cisplatin/Etoposide/Radiotherapy with Consolidation Docetaxel Followed by Maintenance Therapy with ZD1839 (NSC-715055) or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-24-2000 15:50:50"><nciDocumentNumber>RTOG-S-0121</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-S-0121</localDocumentNumber></localDocumentNumberList><documentTitle>A PHASE I/II STUDY OF NEOADJUVANT CHEMOTHERAPY, ANGIOGENESIS INHIBITOR SU5416 (NSC #696819; A TK INHIBITOR ANTI-ANGIOGENESIS COMPOUND), AND RADIATION THERAPY IN THE MANAGEMENT OF HIGH-RISK, HIGH-GRADE, SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND BODY  WALL</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-07-2000 13:21:24"><nciDocumentNumber>RTOG 0123</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0123</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II RandomizedTrial with Captopril (CAPOTEN) in Patients Who Have Received Radiation Therapy =/- Chemotherapy for Stage II-IIIA Non-Small Cell Lung Cancer or Limited-Stage Small-Cell Lung Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-08-2000 08:58:22"><nciDocumentNumber>RTOG-0117</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG L-0117</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy and Concurrent Chemotherapy for Patients with Inoperable, Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="11-21-2000 14:26:52"><nciDocumentNumber>1858</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I Study of PS-341 in Combination with Docetaxel in Patients with Advanced Solid Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-27-2000 10:59:58"><nciDocumentNumber>3634</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>01-064</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 and Randomized Phase 2 Trial of Epothilone B Analogue BMS 247550 (NSC# 710428) Administered Every 21 Days  with or without Oral Estramustine Phosphate in Patients with Androgen Independent Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="01-09-2001 10:36:54"><nciDocumentNumber>S0102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0102</localDocumentNumber></localDocumentNumberList><documentTitle>Docetaxel and Vinorelbine Plus Filgrastim for Her-2 Negative, Stage IV Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-10-2001 13:44:50"><nciDocumentNumber>4031</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>The Specific Role of Isoflavones in Reducing Prostate Cancer Risk</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-22-2001 09:48:27"><nciDocumentNumber>2716</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>01-013</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Bevacizumab in Combination with Vinorelbine in Stage IV Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="01-23-2001 14:49:30"><nciDocumentNumber>4170</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>000-048</localDocumentNumber></localDocumentNumberList><documentTitle>Mature Dendritic Cell Immunotherapy of Metastatic Melanoma - A Phase I Trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-25-2001 12:09:01"><nciDocumentNumber>GOG-0192</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0192</localDocumentNumber></localDocumentNumberList><documentTitle>A RANDOMIZED PHASE III TRIAL OF AMIFOSTINE VS. NO TREATMENT FOR PLATINUM INDUCED PERIPHERAL NEUROPATHY</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 14:13:23" createdDate="01-29-2001 15:05:46"><nciDocumentNumber>E1A00</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1A00</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial of Thalidomide (NSC #66847) Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-05-2001 16:53:17"><nciDocumentNumber>MC9944</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC9944</localDocumentNumber></localDocumentNumberList><documentTitle>Colorectal Cancer Screening: Fecal Blood vs. DNA</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-09-2001 13:45:02"><nciDocumentNumber>5321</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WFU-62299</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-12-2001 14:02:14"><nciDocumentNumber>N0044</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0044</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Preoperative Radiation and Chemotherapy (Paclitaxel, Carboplatin, and Continuous Infusion 5-FU) for Locally Advanced Esophageal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-13-2001 11:49:40"><nciDocumentNumber>GOG-0076CC</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0076CC</localDocumentNumber></localDocumentNumberList><documentTitle>A Limited Access Phase II Trial of Capecitabine (NSC #712807) in the Treatment of Advanced, Persistent or Recurrent Squamous Cell Carcinoma of the Cervix.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-15-2001 13:12:26"><nciDocumentNumber>CALGB-500001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-500001</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Interleukin-12 (NSC # 672423, IND # 6798 ) Followed by Interferon Alfa-2B in Patients with Metastatic Malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-16-2001 12:50:28"><nciDocumentNumber>5327</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC9555</localDocumentNumber></localDocumentNumberList><documentTitle>Phase IIb Chemoprevention trial of Difluoromethylornithine (DFMO) in Human Subjects with Intestinal-type Barrett's Esophagus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-02-2001 09:56:28"><nciDocumentNumber>CALGB-50002</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-50002</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Thalidomide (NSC #66847, IND #48832) for Patients with Relapsed or Refractory Low Grade Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-05-2001 16:44:51"><nciDocumentNumber>5353</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OC-01-01</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of the Toxicities, Biologic and Clinical Effects of Daily 5-Aza-2'Deoxycytidine (DAC) for Four Weeks in Patients with Advanced Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-07-2001 10:13:47"><nciDocumentNumber>N0071</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0071</localDocumentNumber></localDocumentNumberList><documentTitle>Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="03-28-2001 11:58:59"><nciDocumentNumber>EORTC-30987</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EORTC-30987</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients with Metastatic or Locally Advanced Urothelial Cancer without Prior Systemic Therapy</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-02-2001 16:15:47"><nciDocumentNumber>RTOG-P-0014</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-P-0014</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Study of Patients with High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade with 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade with Delayed Chemotherapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-05-2001 14:57:58"><nciDocumentNumber>GOG-0227C</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0227-C</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Bevacizumab (rhuMAB VEGF) (NSC #704865, IND #7921) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix (Group A)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-23-2001 15:34:53"><nciDocumentNumber>3654</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CC-02-C-0130</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-01-2001 10:52:14"><nciDocumentNumber>GOG-0195</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0195</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Clinical Trial Use of Tissel VH Fibrin Sealant to Reduce Lymphedema Incidence After Inguinal Lymph Node Dissection Performed in the Management of Vulvar Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-07-2001 10:26:12"><nciDocumentNumber>5326</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>01-097</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial of PS-341 (NSC 681239, IND #58443) and Carboplatin in Recurrent or Progressive Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-06-2001 14:20:40"><nciDocumentNumber>4950</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>1301</localDocumentNumber></localDocumentNumberList><documentTitle>Assessment of Hypoxia in Malignant Gliomas Using EF5</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-12-2001 14:16:56"><nciDocumentNumber>AALL01P2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AALL01P2</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive Induction Therapy for Children with Acute Lymphoblastic Leukemia (ALL) Who Experience a Bone Marrow Relapse</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-20-2001 15:09:27"><nciDocumentNumber>N00C3</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-N00C3</localDocumentNumber></localDocumentNumberList><documentTitle>THE EFFICACY OF GABAPENTIN IN THE MANAGEMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY:  A PHASE III RANDOMIXED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER TRIAL.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-25-2001 08:27:45"><nciDocumentNumber>5403</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>02-C-0061</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study to Evaluate Epidermal Growth Factor Receptor Signaling After Treatment with Oral OSI-774 in Patients with Locally Advanced or Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-24-2001 12:16:32"><nciDocumentNumber>5380</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-002</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Study of OSI-774 in Combination with Cisplatin in Patients with Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-15-2001 10:55:37"><nciDocumentNumber>RTOG-0211</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0211</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), ZD 1839 (Iressa), [NSC #715055] with Radiation Therapy in Glioblastoma Multiforme</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="08-15-2001 15:45:06"><nciDocumentNumber>5375</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I Study of OSI-774 in Combination with Standard Fractionation Radiation Therapy in Patients with Oral Cavity or Oropharyngeal Cancer Stage II or III and in Combination with Standard Fractionation Radiation Therapy and Low Dose Daily Cisplatin in Patients with Oral Cavity or Oropharyngeal Cancer Stage III and IV</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-17-2001 09:32:25"><nciDocumentNumber>CALGB-79805</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-79805</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Soy Protein to Treat Vasomotor Symptoms in Postmenopausal Women With Breast Cancer Taking Tamoxifen</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-25-2001 16:02:05"><nciDocumentNumber>5757</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered with Irinotecan (CPT-11) and Fluorouracil/Leucovorin in Patients with Advanced Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-13-2001 10:28:01"><nciDocumentNumber>AMC-035</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AMC-035</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="11-13-2001 16:26:56"><nciDocumentNumber>CALGB-10002</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-10002</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Rituximab and Short Duration, High Intensity Chemotherapy with G-CSF Support in Previously Untreated Patients with Burkitt Lymphoma/Leukemia</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-05-2001 16:19:52"><nciDocumentNumber>5791</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>02-C-0229</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Clinical Trial of Ixabepilone (BMS-247550, NSC 710428), an Epothilone B Analog, in Patients with Breast Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-07-2001 15:02:38"><nciDocumentNumber>NABTT-2116</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT-2116</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial to Evaluate Repetitive Intravenous Doses of Gadolinium-Texaphyrin as a Radiosensitizer in Patients with Glioblastoma Multiforme</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-12-2001 10:48:57"><nciDocumentNumber>CALGB-30106</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-30106</localDocumentNumber></localDocumentNumberList><documentTitle>ZD1839 (NSC #715055, IND #61187) with Induction Paclitaxel and Carboplatin Followed by Either Radiation or Concomitant Radiation with Weekly Paclitaxel and Carboplatin in Stage III Non-Small Cell Lung Cancer, A Phase II Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-18-2001 10:46:04"><nciDocumentNumber>CALGB-90102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-90102</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Cisplatin, Gemcitabine, and ZD1839 (Iressa) (IND # 61187; NSC 715055) for the Treatment of Advanced Urothelial Tract Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-19-2001 09:20:01"><nciDocumentNumber>CALGB-90105</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-90105</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Imatinib Mesylate (Gleevec, formerly known as STI571; IND 61,135; NSC 716051) in Patients with Refractory Seminoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="01-03-2002 10:53:00"><nciDocumentNumber>S0218</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0218</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) in Patients with Malignant Pleural Mesothelioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-26-2012 12:15:51" createdDate="01-12-2002 13:34:44"><nciDocumentNumber>5599</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0131</localDocumentNumber></localDocumentNumberList><documentTitle>Phase Ib/II Neoadjuvant Trial of the Farnesyltransferase Inhibitor, R115777 with Docetaxel and Capecitabine for Patients with Stage IIIA or IIIB Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-14-2002 11:03:22"><nciDocumentNumber>ADVL0114</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0114</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Decitabine (DAC) (IND # 50733) in Children with Relapsed or Refractory Acute Leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="01-24-2002 11:07:18"><nciDocumentNumber>CALGB-80101</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-80101</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-13-2002 14:42:05"><nciDocumentNumber>5824</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>21-0421</localDocumentNumber></localDocumentNumberList><documentTitle>A Multi-Center Phase 2 Study of Genasense in Combination with Thalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-04-2002 13:50:23"><nciDocumentNumber>5856</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHI-40</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of PS-341 in Combination with Gemcitabine and Carboplatin in Selected Stage IIIB or IV Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-04-2002 14:11:12"><nciDocumentNumber>5750</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>03-C-0038</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of HeFi-1 in Refractory CD30-Positive Malignancy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-03-2012 11:17:51" createdDate="04-18-2002 14:48:51"><nciDocumentNumber>5808</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID02-148</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of G3139 (Bcl-2 Antisense) and Rituximab in Patients with Recurrent B-Cell Non-Hodgkin's Lymphomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-23-2002 12:41:01"><nciDocumentNumber>GOG-8003</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8003</localDocumentNumber></localDocumentNumberList><documentTitle>Vaginal Length, Elasticity, Lubrication and Sexual Function in Women with Stage IB2 Cervix Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-09-2002 10:05:02"><nciDocumentNumber>PBTC-010</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PBTC-010</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Oxaliplatin in Children with Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-14-2002 10:16:22"><nciDocumentNumber>6000</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WFU-98101</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Double-Blind Randomized Trial Comparing Setraline (Zoloft) and Hypericum Perforatum (St. John's Wort) in Cancer Patients with Mild to Moderate Depression</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:15" createdDate="05-17-2002 09:18:52"><nciDocumentNumber>5869</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J0220 02-07-25-06</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination with FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients with Advanced Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-17-2002 13:38:19"><nciDocumentNumber>GOG-9912</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9912</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Whole Pelvic Radiation Therapy with Concomitant Cisplatin and Gemcitabine Chemotherapy in Patients with Cervical Carcinoma (Stages I-IV) Limited to the Pelvis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-26-2002 14:40:05"><nciDocumentNumber>5890</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-012</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of PS-341 in Patients with Metastatic Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-02-2002 15:29:03"><nciDocumentNumber>5886</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NYU 02-30</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of OSI-774 in Combination with Carboplatin and Paclitaxel in Patients with Ovarian, Cancer of the Fallopian Tube or Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="07-16-2002 15:35:35"><nciDocumentNumber>CALGB-140202</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-140202</localDocumentNumber></localDocumentNumberList><documentTitle>The CALGB Lung Cancer Tissue Bank</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-21-2002 15:34:34"><nciDocumentNumber>5814</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UC 12044B</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Pharmacokinetic Interaction Study of Irinotecan (NSC 616348) and Thalidomide (NSC 66847) in Patients with Advanced Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-17-2002 14:55:10"><nciDocumentNumber>5513</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>03-C-0110</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) in Classical (HIV-Negative) and in AIDS-Associated Kaposi's Sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-18-2002 15:14:41"><nciDocumentNumber>5978</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHII-44</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Perifosine (IND 58,156; NSC# 639966) in Biochemically Recurrent, Hormone Sensitive Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-23-2002 17:35:48"><nciDocumentNumber>5906</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>00-142</localDocumentNumber></localDocumentNumberList><documentTitle>Injection of AJCC Stage IIB, IIC, III and IV Melanoma Patients with a Multi-Epitope Peptide Vaccine Using GM-CSF DNA as an Adjuvant: A Pilot Trial to Assess Safety and Immunity</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-02-2002 12:33:56"><nciDocumentNumber>E2A01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2A01</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan with Stem Cell Reconstitution for Patients with Primary Systemic Amyloidosis</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-15-2002 14:39:31"><nciDocumentNumber>6053</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID00-193</localDocumentNumber></localDocumentNumberList><documentTitle>Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135]</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-04-2002 16:00:50"><nciDocumentNumber>GOG-0206</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0206</localDocumentNumber></localDocumentNumberList><documentTitle>Lymphatic Mapping and Sentinel Node Identification in Patients with Stage1B1 Cervical Carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-06-2002 12:03:19"><nciDocumentNumber>ACRIN-6667</nciDocumentNumber><sponsorOrganization>CIP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACRIN-6667</localDocumentNumber></localDocumentNumberList><documentTitle>MRI Evaluation of the Contralateral Breast in Women with a Recent Diagnosis of Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-09-2002 13:44:43"><nciDocumentNumber>GOG-9915</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9915</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study Using Low Dose Abdominal Radiotherapy as a Docetaxel Chemosensitizer for Recurrent, Persistent or Advanced Ovarian, Peritoneal or Fallopian Tube Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-2002 10:04:01"><nciDocumentNumber>CALGB-500104</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-500104</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of R115777 in Patients with Metastatic Malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-23-2002 10:01:15"><nciDocumentNumber>N0222</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0222</localDocumentNumber></localDocumentNumberList><documentTitle>Parallel Phase II Trials of ZD1839 (Iressa®) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa®) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients >/= 65 Years of Age</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-23-2002 14:11:30"><nciDocumentNumber>6104</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-017</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1/2 Study of GTI-2040 Combined with Docetaxel in Metastatic or Unresectable Locally Advanced Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-23-2002 14:51:48"><nciDocumentNumber>AEWS0331</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AEWS0331</localDocumentNumber></localDocumentNumberList><documentTitle>European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-07-2003 11:06:02"><nciDocumentNumber>N0234</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0234</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of OSI-774 (Tarceva¿) and Gemcitabine for Patients with Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-13-2003 11:32:39"><nciDocumentNumber>ACOSOG-Z05031</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACOSOG-Z05031</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Interferon-Based Adjuvant Chemoradiation in Patients with Resected Pancreatic Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-21-2003 09:00:29"><nciDocumentNumber>CALGB-50201</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-50201</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study to Evaluate the Safety and Efficacy of Zevalin? (IND # BB-IND 11023 ) Therapeutic Regimen in Patients with Transformed CD20+ B-Cell Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-04-2003 08:37:40"><nciDocumentNumber>6015</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMGCC #0307</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Single Agent Depsipeptide (NSC 630176) Followed by a Phase I Study of Rituximab/Fludarabine Combination with an Escalating Dose of Depsipeptide in Relapsed or Refractory Low Grade B Cell Lymphomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-04-2003 12:19:27"><nciDocumentNumber>6249</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>01-C-0011</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-06-2003 09:07:38"><nciDocumentNumber>6090</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IDD#03-06</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Pharmacokinetics and Pharmacodynamic Study of GTI2040 in Combination with Gemcitabine in Patients with Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-26-2003 12:21:44"><nciDocumentNumber>AOST0221</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AOST0221</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Aerosolized GM-CSF (NSC # 613795, IND# 11042) in Patients with First Pulmonary Recurrence of Osteosarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-26-2012 12:15:51" createdDate="03-04-2003 13:52:38"><nciDocumentNumber>6113</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0279</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-18-2003 10:47:10"><nciDocumentNumber>E1302</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1302</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-07-2003 12:59:00"><nciDocumentNumber>ACRIN-6666</nciDocumentNumber><sponsorOrganization>CIP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACRIN-6666</localDocumentNumber></localDocumentNumberList><documentTitle>ACRIN 6666:  Screening Breast Ultrasound in High-Risk Women</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-08-2003 16:42:59"><nciDocumentNumber>RTOG-0319</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0319</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Trial to Evaluate Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I and IIA Breast Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-29-2003 10:55:11"><nciDocumentNumber>AAML03P1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML03P1</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-05-2003 12:46:06"><nciDocumentNumber>6006</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UPCC# 03903</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Study of STI-571 (Imatinib Mesylate (NSC 716051) and Bevacizumab (NSC 704865) in Patients with Advanced Melanoma and Other Advanced Cancers</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="05-13-2003 14:39:32"><nciDocumentNumber>S0331</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0331</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-15-2003 11:11:40"><nciDocumentNumber>ADVL0221</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0221</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Trabectedin ( ET-743, Yondelis®) in Children with Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-15-2003 12:43:51"><nciDocumentNumber>ANHL0221</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ANHL0221</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of the Combination of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults with CD20 Positive Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-22-2003 10:11:01"><nciDocumentNumber>6236</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>0336</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Decitabine in Combination with Valproic Acid in Patients with Selected Hematologic Malignancies</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-27-2003 15:31:00"><nciDocumentNumber>AALL03B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AALL03B1</localDocumentNumber></localDocumentNumberList><documentTitle>Classification of Acute Lymphoblastic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-29-2003 07:22:20"><nciDocumentNumber>ADVL0311</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0311</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Pemetrexed (LY231514, Alimta) (NSC# 698037, IND # 67,952) in Children and Adolescents with Recurrent Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-10-2003 11:40:55"><nciDocumentNumber>TRC-0301</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>TRC-0301</localDocumentNumber></localDocumentNumberList><documentTitle>A Multicenter Study of the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) Plus 5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal Cancers that Have Progressed After Standard Chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-30-2003 14:01:37"><nciDocumentNumber>AALL0232</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AALL0232</localDocumentNumber></localDocumentNumberList><documentTitle>High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="07-01-2003 08:59:16"><nciDocumentNumber>6459</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2003-0922</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Study of Bone-Targeted Therapy in Metastatic Androgen-Dependent Prostate Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-10-2003 13:09:19"><nciDocumentNumber>6466</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>IDE 8139: NHLBI/Dr. A John Barrett IDE Studies with MoAb 3A1 (NSC 603570), MoAb 3-275 (NSC 603571), and MoAb 3-276 (NSC 603572)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-18-2003 14:41:18"><nciDocumentNumber>E2902</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2902</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-21-2003 11:08:07"><nciDocumentNumber>6365</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>03-146A</localDocumentNumber></localDocumentNumberList><documentTitle>An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered with Oxaliplatin and Fluorouracil/Leucovorin in Patients with Advanced Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="07-21-2003 13:20:32"><nciDocumentNumber>ACNS02B3</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACNS02B3</localDocumentNumber></localDocumentNumberList><documentTitle>A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="08-01-2003 09:36:39"><nciDocumentNumber>S0349</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0349</localDocumentNumber></localDocumentNumberList><documentTitle>Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense - NSC-683428) Therapy for Young Patients (&lt; Age 60) with Advanced Stage Diffuse Large B-Cell NHL of Low and Low-Intermediate IPI Risk</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="08-11-2003 13:58:43"><nciDocumentNumber>ADVL0214</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0214</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 with Temozolomide for Patients with Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="08-27-2003 13:06:54"><nciDocumentNumber>NABTT-0303</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT-0303</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients with MTAP-Deficient High Grade Recurrent Malignant Gliomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="09-08-2003 10:29:53"><nciDocumentNumber>CALGB-30206</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-30206</localDocumentNumber></localDocumentNumberList><documentTitle>Induction Cisplatin/Irinotecan Followed by Combination Carboplatin, Etoposide, and Chest Radiotherapy in Limited Stage Small Cell Lung Cancer:  A Phase II Study</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-09-2003 18:13:59"><nciDocumentNumber>RTOG-0247</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0247</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II Trial of Neoadjuvant Combined Modality Therapy for Locally Advanced Rectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-10-2003 08:48:57"><nciDocumentNumber>ADVL0317</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0317</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of PS-341 (Velcade, Bortezomib) in Pediatric Patients with Refractory/Recurrent Leukemias</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-17-2003 10:14:29"><nciDocumentNumber>NABTT-0305</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT-0305</localDocumentNumber></localDocumentNumberList><documentTitle>CD4 Count and Risk of Infection in Patients with Brain Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-26-2003 07:14:33"><nciDocumentNumber>6345</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHII-49</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 2 Study of Single Agent Depsipeptide(FK228) in the Treatment of Hepatocellular Carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-02-2003 09:26:22"><nciDocumentNumber>6447</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>04-021</localDocumentNumber></localDocumentNumberList><documentTitle>A Multicenter, Open-Label, Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients with Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-02-2003 14:43:32"><nciDocumentNumber>P-1G4</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>P-1G4</localDocumentNumber></localDocumentNumberList><documentTitle>Sex Hormones and the Risk of Breast Cancer: An Ancillary Study in the Breast Cancer Prevention (P-1) Trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-06-2003 15:29:37"><nciDocumentNumber>6102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-024</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 2 Study of GTI-2040 in Combination with Docetaxel and Prednisone in Hormone-Refractory Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-14-2003 08:45:19"><nciDocumentNumber>CALGB-50206</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-50206</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of PS-341 (Bortezomib) in Patients with Relapsed or Refractory Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-27-2003 13:06:50"><nciDocumentNumber>GOG-9916</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9916</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients with Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-31-2003 14:11:31"><nciDocumentNumber>N0341</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0341</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Irinotecan + 5-Fluorouracil + Leucovorin + Oxaliplatin as First-Line Treatment for Metastatic Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-13-2003 12:14:36"><nciDocumentNumber>CALGB-30304</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-30304</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Single Agent Depsipeptide (FK228) (NSC 630176; IND 51,810) in Relapsed Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-26-2003 14:20:17"><nciDocumentNumber>RTOG-0234</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0234</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Randomized Trial of Surgery Followed by Chemoradiotherapy Plus C225 (Cetuximab) for Advanced Squamous Cell Carcinoma of the Head and Neck</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="01-08-2004 11:51:32"><nciDocumentNumber>6618</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>10M-03-8</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Continuation Booster Trial After a Vaccine Combining Tyrosinase/gp100/MART-1 Peptides Emulsified with Montanide ISA 51 or ISA 51 VG with or Without GM-CSF for Patients with Resected Stages IIB/C, III and IV Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 10:59:22" createdDate="01-21-2004 14:08:27"><nciDocumentNumber>6533</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2004-0040</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Prolonged Low Dose Decitabine (5-Aza-Deoxycytidine, NSC #127716) in Patients with Biopsiable Advanced Cancers Refractory to Standard Therapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="01-22-2004 08:07:14"><nciDocumentNumber>6547</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PH1/102</localDocumentNumber></localDocumentNumberList><documentTitle>A Cancer Research UK Phase 1 Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of 17-Dimethylaminoethyl-Amino-17-Demethoxygeldanamycin (17-DMAG) Given as a Once Weekly Infusion in Patients with Advanced Solid Tumours</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="01-28-2004 12:20:34"><nciDocumentNumber>CALGB-50203</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-50203</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Doxorubicin, Vinblastine and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="01-28-2004 14:48:14"><nciDocumentNumber>CALGB-100104</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB 100104/ECOG 100104</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC # 703813, IND # 70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-03-2012 10:59:22" createdDate="02-04-2004 15:04:22"><nciDocumentNumber>5563</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2004-0674</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of 5-Aza-2'-Deoxycytidine and Depsipeptide in Patients with Relapsed/Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disease</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="02-23-2004 10:15:28"><nciDocumentNumber>6588</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IDD-03-32</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I, and Biologic Correlative Study of Erlotinib, in Combination with Cetuximab and Bevacizumab in Patients with Metastatic Renal Cell Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 11:07:50" createdDate="03-02-2004 12:02:03"><nciDocumentNumber>6482</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0476</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of 17-Allylaminogeldanamycin (17-AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-08-2004 13:38:32"><nciDocumentNumber>E1Y03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1Y03</localDocumentNumber></localDocumentNumberList><documentTitle>Master Protocol for Pharmacogenetic and Genomic Studies</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="03-23-2004 08:28:36"><nciDocumentNumber>CALGB-30307</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-30307</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of BAY 43-9006 (NSC #724772) in Patients with Malignant Mesothelioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-01-2004 09:31:00"><nciDocumentNumber>AALL04B2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AALL04B2</localDocumentNumber></localDocumentNumberList><documentTitle>Single Nucleotide Polymorphisms and Relapse Risk in Standard Risk ALL</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-02-2004 12:45:31"><nciDocumentNumber>NABTT-0307</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT-0307</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot Study of Thrombophilic States in Newly Diagnosed Patients With High-Grade Gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="04-09-2004 08:46:37"><nciDocumentNumber>CALGB-10101</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-10101</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Fludarabine + Rituximab Induction Followed by Alemtuzumab (Campath-1H, NSC #715969, IND #10864) Administered Subcutaneously as Consolidation in Untreated Patients with B-Cell Chronic Lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 10:59:22" createdDate="04-13-2004 08:16:07"><nciDocumentNumber>6934</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2005-0607</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of SJG-136 in Patients with Advanced Leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-26-2004 08:58:44"><nciDocumentNumber>E5803</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E5803</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of GW572016 in Patients with Recurrent Prostate Cancer as Evident by a Rising PSA</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="05-11-2004 11:11:14"><nciDocumentNumber>S0418</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0418</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Taxane-Resistant Androgen-Independent Metastatic Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-18-2004 09:23:45"><nciDocumentNumber>5999</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UPCC 01304</localDocumentNumber></localDocumentNumberList><documentTitle>Microenvironment: Imaging/Implications in Brain Tumors; A Preliminary Investigation of the Biodistribution of [F-18]-EF5 in Patients with Brain Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-18-2004 13:26:37"><nciDocumentNumber>RTOG 0229</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG 0229</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy for Locally Advanced Non-Small Cell Lung Carcinoma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-26-2004 11:38:09"><nciDocumentNumber>NCIC-168</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.168</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of SB-715992 (NSC 727990) in Patients with Locally Advanced, Recurrent or Metastatic Hepatocellular Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-04-2004 09:32:47"><nciDocumentNumber>5785</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>04-037</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Intravenous CCI-779 in Combination with Bryostatin-1 in Solid Tumors (10038414)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-07-2004 10:28:49"><nciDocumentNumber>6617</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NYU 04-38</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of BAY 43-9006 (NCS 724772) in Unresectable Stage III and IV Melanoma (IND 69,869)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-08-2004 08:31:28"><nciDocumentNumber>N0377</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0377</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of RAD-001 in Metastatic Malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 11:59:47" createdDate="06-09-2004 13:55:01"><nciDocumentNumber>NABTC-04-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTC-04-01</localDocumentNumber></localDocumentNumberList><documentTitle>A Biomarker and Phase II Study of GW 572016 in Recurrent Malignant Glioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-09-2004 17:09:24"><nciDocumentNumber>N03C5</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N03C5</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Randomized Trial of Gabapentin Alone or in Conjunction with an Antidepressant in the Management of Hot Flashes in Women Who Have Inadequate Control with an Antidepressant Alone</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-29-2004 08:01:31"><nciDocumentNumber>NABTT-0404</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT-0404</localDocumentNumber></localDocumentNumberList><documentTitle>An Open-Label, Dose Confirmation and Dosimetry Study of Interstitial 131 I-chTNT-1/B MAb (COTARA) for the Treatment of Glioblastoma Multiforme (GBM) at 1st or 2nd Relapse</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-14-2004 14:37:08"><nciDocumentNumber>ACOSOG-Z4033</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACOSOG-Z4033</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study of Radiofrequency Ablation in High-Risk Patients with Stage IA Non-Small Cell Lung Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="05-03-2012 10:59:22" createdDate="09-15-2004 15:02:19"><nciDocumentNumber>6742</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2004-0702</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of BAY 43-9006 (NSC 724772) in Patients with Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="09-21-2004 09:48:27"><nciDocumentNumber>BMTCTN-0102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BMTCTN-0102</localDocumentNumber></localDocumentNumberList><documentTitle>A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy Versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients with Multiple Myeloma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-22-2004 13:59:49"><nciDocumentNumber>E1B03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1B03</localDocumentNumber></localDocumentNumberList><documentTitle>Pemetrexed Plus Gemcitabine or Carboplatin in Patients with Advanced Malignant Mesothelioma: A Randomized Phase II Trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-19-2004 13:38:05"><nciDocumentNumber>GOG-0146Q</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0146Q</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Topotecan (NSC #609699) Administered Weekly in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-22-2004 10:08:47"><nciDocumentNumber>GOG-0219</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0219</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine (IND# 46525) and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 11:07:50" createdDate="11-09-2004 10:27:10"><nciDocumentNumber>6902</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>04110</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients with Metastatic Thyroid Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-29-2004 16:41:07"><nciDocumentNumber>6789</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>I 55305</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX) in Patients with Colorectal Cancer and Other Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="11-30-2004 14:26:53"><nciDocumentNumber>S0334</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0334</localDocumentNumber></localDocumentNumberList><documentTitle>Cytogenetic and Fluorescence In Situ Hybridization Studies in Multiple Myeloma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-01-2004 09:43:50"><nciDocumentNumber>6623</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>05020</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of R115777 (Zarnestra) in Combination with Induction Chemotherapy in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-02-2004 11:04:22"><nciDocumentNumber>N044J</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N044J</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of AZD2171 in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-26-2012 12:17:26" createdDate="12-08-2004 08:41:08"><nciDocumentNumber>7097</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHII-64</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of AZD2171 in Patients with Recurrent Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="01-21-2005 15:54:50"><nciDocumentNumber>S0408</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0408</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Neoadjuvant Capecitabine, Oxaliplatin and Bevacizumab for Resectable Colorectal Metastases in the Liver</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="01-26-2005 10:13:45"><nciDocumentNumber>7225</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHI-52</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I and Pharmacokinetic Study of Oral 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in  the Treatment of Advanced Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-02-2005 14:43:33"><nciDocumentNumber>7303</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0419</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Study of Daily Oral Polyphenon E in Asymptomatic, Rai Stage 0-II Patients with Chronic Lymphocytic Leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="03-07-2005 08:16:07"><nciDocumentNumber>C80405</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C80405</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-16-2005 16:25:33"><nciDocumentNumber>6813</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>04-04</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Pharmacokinetic and Pharmacodynamic Study of Temsirolimus (CCI-779) in Patients with Advanced Malignancies and Normal and Impaired Liver Function: An NCI Organ Dysfunction Working Group Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-05-2005 09:41:04"><nciDocumentNumber>N0422</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0422</localDocumentNumber></localDocumentNumberList><documentTitle>Cetuximab (C225) and Radiation in Elderly and/or Poor Performance Status Patients with Locally Advanced Non-Small Cell Lung Cancer:  A Phase II Study to Evaluate Survival and Toxicity</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-18-2005 09:27:38"><nciDocumentNumber>ADVL0414</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0414</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Temozolomide, Oral Irinotecan and Vincristine for Children with Refractory Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-18-2005 10:31:24"><nciDocumentNumber>RTOG-0522</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0522</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-18-2005 15:43:33"><nciDocumentNumber>6835</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GCC 0514</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of SAHA in Combination with Bortezomib in Relapsed and Refractory Multiple Myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-21-2005 08:40:15"><nciDocumentNumber>7082</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0511</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of the Raf Kinase/VEGFR Inhibitor BAY 43-9006 in Combination with the Proteasome Inhibitor PS-341 in Patients with Advanced Malignancies</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-12-2005 08:20:36"><nciDocumentNumber>NABTT-0502</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT-0502</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients with Progression or Recurrent Glioblastoma Multiforme</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-17-2005 10:27:10"><nciDocumentNumber>7281</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>COMIRB 05-0705</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 Study of PXD101 in Combination with Bortezomib (PS-341) in Patients with Advanced Solid Tumors and Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-18-2005 11:56:02"><nciDocumentNumber>ACNS0222</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACNS0222</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Motexafin-Gadolinium (NSC 695238, IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-25-2005 08:55:35"><nciDocumentNumber>AALL05B2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AALL05B2</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Determinants of Methotrexate Metabolism in ALL
</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-25-2005 11:16:51"><nciDocumentNumber>ACOSOG-Z5041</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACOSOG-Z5041</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-24-2005 09:11:17"><nciDocumentNumber>N047A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N047A</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Carboplatin, Weekly Paclitaxel and Biweekly Bevacizumab in Patients with Unresectable Stage IV Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="06-14-2012 09:44:17" createdDate="07-14-2005 09:34:11"><nciDocumentNumber>AALL05B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AALL05B1</localDocumentNumber></localDocumentNumberList><documentTitle>A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens</documentTitle><currentStatus>Temporarily Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="07-18-2005 14:14:42"><nciDocumentNumber>N0437</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0437</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of CT-2103 (Xyotax?) with Capecitabine as First-Line Chemotherapy for Patients with Metastatic Breast Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="07-18-2005 16:07:47"><nciDocumentNumber>ARST0531</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ARST0531</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="08-03-2005 15:18:58"><nciDocumentNumber>6898</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Azacitidine in Patients with the Myelodysplastic Syndrome (MDS)</documentTitle><currentStatus>Temporarily Closed to Accrual</currentStatus></document><document updatedDate="04-26-2012 12:15:51" createdDate="09-26-2005 08:09:54"><nciDocumentNumber>7208</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC044I</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Bevacizumab Plus Erlotinib in Patients with Advanced Hepatocellular Cancer (HCC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-27-2005 09:34:59"><nciDocumentNumber>7537</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CASE 5Y05</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Bevacizumab in Combination with SU11248</documentTitle><currentStatus>Temporarily Closed to Accrual</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="09-28-2005 11:30:56"><nciDocumentNumber>S0351</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0351</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of CNTO 328, a Monoclonal Antibody Against Interleukin-6 (IL-6), in Patients with Advanced or Metastatic Renal Cell Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-04-2005 13:04:20"><nciDocumentNumber>GOG-0229E</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0229E</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Bevacizumab (NCI-Supplied Agent: NSC #704865, IND #7921) in the Treatment of Recurrent or Persistent Endometrial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-07-2005 09:54:42"><nciDocumentNumber>RTOG-0513</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0513</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Trial of Temozolomide, Motexafin Gadolinium, and 60 Gy Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-17-2005 11:16:15"><nciDocumentNumber>AAML0523</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML0523</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73,789) in Combination with Cytarabine in Pediatric Patients with Refractory/Relapsed Leukemia</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-19-2005 10:11:36"><nciDocumentNumber>ANHL06P1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ANHL06P1</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Pilot Study of Ifosfamide, Carboplatin and Etoposide Therapy (ICE) and SGN-30 (NSC #731636, IND # 100057) in Children with CD30+ Recurrent Anaplastic Large Cell Lymphoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-21-2005 13:40:14"><nciDocumentNumber>S9313A-ICSC</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9313-INT-0137-ICSC</localDocumentNumber></localDocumentNumberList><documentTitle>Prediction of Therapeutic Response using AQUA¿ Quantitative Protein Expression analysis of ER, PgR, and HER2 of Breast Cancer Tissue Microarrays from SWOG Protocol 9313</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-07-2005 08:48:56"><nciDocumentNumber>E2805</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2805</localDocumentNumber></localDocumentNumberList><documentTitle>ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-15-2005 10:01:14"><nciDocumentNumber>GOG-0127V</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0127V</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Non Squamous Cell Carcinoma of the Cervix (Abraxis BioScience, LLC Study # CA026 / ABX257-GYN08US)</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-28-2005 08:06:17"><nciDocumentNumber>N0528</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0528</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Study of Gemcitabine and Carboplatin with or without AZD2171 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-26-2012 12:17:26" createdDate="01-10-2006 14:13:00"><nciDocumentNumber>7583</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHII-79</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of AZD0530 in Hormone Refractory Prostate Cancer (HRPC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 11:17:51" createdDate="01-11-2006 13:01:29"><nciDocumentNumber>7565</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2005-0977</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of AZD0530 (NSC 735464) in Patients with Previously Treated Metastatic Colorectal Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-03-2012 11:07:50" createdDate="01-18-2006 13:21:49"><nciDocumentNumber>7703</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>06-05-291</localDocumentNumber></localDocumentNumberList><documentTitle> Phase I/II Study of a Combination of Suberoylanilide Hydroxyamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="01-18-2006 16:05:37"><nciDocumentNumber>S0605</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0605</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Lenalidomide (Revlimid®, NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="01-24-2006 08:39:27"><nciDocumentNumber>N0574</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0574</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-26-2012 12:17:26" createdDate="01-30-2006 07:22:50"><nciDocumentNumber>7518</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHII-73</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of VEGF Trap (NSC 724770) in Patients with MDS</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="02-07-2006 09:27:34"><nciDocumentNumber>GOG-0233</nciDocumentNumber><sponsorOrganization>CIP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0233-ACRIN 6671</localDocumentNumber></localDocumentNumberList><documentTitle>Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients with Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA>/=4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 or 2 Endometrioid Endometrial Carcinoma with Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="02-08-2006 09:51:49"><nciDocumentNumber>7704</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J0638</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Triapine (IND #68338, NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults with Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="02-22-2006 11:30:47"><nciDocumentNumber>E4805</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4805</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma</documentTitle><currentStatus>Temporarily Closed to Accrual</currentStatus></document><document updatedDate="05-02-2012 13:03:11" createdDate="02-24-2006 13:59:56"><nciDocumentNumber>7627</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC057H</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="03-21-2006 09:59:08"><nciDocumentNumber>S0530</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0530</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Cytarabine and Clofarabine in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 11:17:51" createdDate="03-24-2006 09:37:35"><nciDocumentNumber>7700</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2006-0208</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-03-2012 11:07:50" createdDate="03-29-2006 10:04:57"><nciDocumentNumber>7745</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>06060</localDocumentNumber></localDocumentNumberList><documentTitle>A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-29-2006 15:18:23"><nciDocumentNumber>7718</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-063</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Sunitinib Malate (Sutent®; SU11248) in Patients with Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-29-2006 16:22:44"><nciDocumentNumber>URCC-04-01</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>URCC-04-01</localDocumentNumber></localDocumentNumberList><documentTitle>Yoga for Persistent Sleep Disturbance in Cancer Survivors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-12-2006 10:09:15"><nciDocumentNumber>7358</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>07-C-0058G</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-08-2006 11:02:43"><nciDocumentNumber>SCUSF-0501</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HLMCC 05-01</localDocumentNumber></localDocumentNumberList><documentTitle>Stress Management Training for Patients Undergoing Chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-18-2006 12:12:39"><nciDocumentNumber>AALL06B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AALL06B1</localDocumentNumber></localDocumentNumberList><documentTitle>Childhood Cancer Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk ALL Pilot Project: Application of Array-Based Methods and Gene Re-sequencing to Identify Candidate Molecular Targets for High-Risk Pediatric Acute Lymphoblastic Leukemia</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="06-05-2006 10:58:25"><nciDocumentNumber>S0600</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0600</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-06-2006 10:56:45"><nciDocumentNumber>AMC-048</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AMC-048</localDocumentNumber></localDocumentNumberList><documentTitle>Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-21-2006 09:07:47"><nciDocumentNumber>NCIC-184</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCIC-184</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) an Oral Multi-Targeted Tyrosine Kinase Inhibitor in Patients with Unresectable, Locally Advanced or Metastatic Cervical Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-11-2006 08:04:19"><nciDocumentNumber>ASCT0631</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ASCT0631</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="07-19-2006 11:32:49"><nciDocumentNumber>GOG-0170I</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0170I</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of CCI-779 (Temsirolimus, NCI-Supplied Agent, NSC #683864, IND #61010) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-26-2012 12:17:26" createdDate="07-20-2006 11:08:30"><nciDocumentNumber>7792</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHII-83</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-17-2006 09:01:00"><nciDocumentNumber>N063D</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N063D</localDocumentNumber></localDocumentNumberList><documentTitle>ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study:  A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-07-2006 14:13:48"><nciDocumentNumber>E4206</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4206</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-18-2006 10:47:42"><nciDocumentNumber>E1A05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1A05</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) - Lenalidomide (Revlimid®) - Dexamethasone (VRD) Versus Bortezomib (Velcade®) - Dexamethasone (VD) for Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="05-01-2012 09:22:15" createdDate="09-27-2006 08:58:52"><nciDocumentNumber>7889</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J06133</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 649890, IND 46,211) Given in Timed Sequential Combination with Cytosine Arabinoside (ara-C) and Mitoxantrone for Adults with Relapsed and Refractory Acute Leukemias</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="10-05-2006 13:46:26"><nciDocumentNumber>CALGB-30504</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-30504</localDocumentNumber></localDocumentNumberList><documentTitle>Combination Chemotherapy with or without Maintenance Sunitinib Malate (IND 74019; NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB / Randomized Phase II Study</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="11-07-2006 14:41:23"><nciDocumentNumber>CALGB-80502</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-80502</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Irinotecan and AZD2171 (CALGB IND# 101263) in Patients with Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="11-21-2006 08:41:09"><nciDocumentNumber>BMTCTN-0401</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BMTCTN-0401</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Rituxan/BEAM vs Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 14:51:01" createdDate="12-14-2006 09:16:27"><nciDocumentNumber>7945</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>07-100</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 Study of Obatoclax Mesylate (GX15-070MS) in Combination with Fludarabine-Based Chemoimmunotherapy in Previously Treated Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)</documentTitle><currentStatus>Temporarily Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-18-2006 15:12:37"><nciDocumentNumber>ADVL06B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL06B1</localDocumentNumber></localDocumentNumberList><documentTitle>A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-03-2012 11:07:50" createdDate="01-03-2007 15:00:55"><nciDocumentNumber>7932</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>07056</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 2 Study of AZD6244 in Biliary Cancers</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-16-2007 14:46:22"><nciDocumentNumber>E3F05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E3F05</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-22-2007 13:14:37"><nciDocumentNumber>AEWS07B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AEWS07B1</localDocumentNumber></localDocumentNumberList><documentTitle>A COG Study for Collecting and Banking Ewing Sarcoma Specimens</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="02-09-2007 10:56:31"><nciDocumentNumber>7862</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2007-0025</localDocumentNumber></localDocumentNumberList><documentTitle>Phase Ib Study of Limited Androgen Ablation and Two Dose Levels of Temsirolimus (NSC#683864) in Patients with Prostate Cancer Who Have a Biochemical Relapse After Prostatectomy and/or Radiotherapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="02-21-2007 09:21:17"><nciDocumentNumber>RTOG-0436</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG 0436</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated Without Surgery</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-30-2007 14:52:34"><nciDocumentNumber>8016</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>050905</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 Study of R-(-)-gossypol (Ascenta's AT-101) in Combination with Paclitaxel and Carboplatin in Solid Tumors</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-06-2007 09:42:42"><nciDocumentNumber>8046</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU 08056</localDocumentNumber></localDocumentNumberList><documentTitle>Phase 1 Trial of Flavopiridol in Combination with Lenalidomide in Patients with Relapsed or Refractory B-Cell CLL/SLL</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-27-2007 13:55:05"><nciDocumentNumber>8183</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>P07210</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study in Patients with Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-27-2007 16:08:34"><nciDocumentNumber>NABTT-0703</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT 0703</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II Study of the BSI-201 (iniparib) in Patients with Newly Diagnosed Malignant Glioma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-20-2007 09:31:06"><nciDocumentNumber>ADVL0712</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0712</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, IND #100947, NSC #742460) in Children with Relapsed/Refractory Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="10-02-2007 13:06:42"><nciDocumentNumber>S0727</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0727</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First-Line Treatment in Patients with Metastatic Pancreatic Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="11-07-2007 15:48:26"><nciDocumentNumber>S0717</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0717</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I and a Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) with or without MEDI-522 (NSC-719850)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="11-20-2007 13:01:38"><nciDocumentNumber>S0713</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0713</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-Operative Therapy of Rectal Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-29-2007 16:38:50"><nciDocumentNumber>GOG-0236</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0236</localDocumentNumber></localDocumentNumberList><documentTitle>A Prospective Randomized Single Blind Phase III Trial Comparing Flexitouch Home Maintenance Therapy to Standard Home Maintenance Therapy for Lower Extremity Lymphedema Resulting from Treatment of Gynecologic Malignancy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-14-2007 11:09:47"><nciDocumentNumber>AMC-058</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AMC-058</localDocumentNumber></localDocumentNumberList><documentTitle>A Companion Protocol to Evaluate Anogenital Human Papillomavirus (HPV) Infection and Anogenital Squamous Intraepithelial Lesions (ASIL) in Subjects Participating in AMC Clinical Trials</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-14-2007 11:48:31"><nciDocumentNumber>GOG-8007</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8007</localDocumentNumber></localDocumentNumberList><documentTitle>Morphometric Diagnosis of Atypical Glandular Lesions Using a Conventional Pap Smear From GOG-0171 Patients (Enrolled by GOG-Japan) with a Cytologic Diagnosis of Atypical Glandular Cells of Unspecified Significance (AGUS)</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-19-2007 10:36:13"><nciDocumentNumber>ADVL0821</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0821</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, IND #100947, NSC #742460) in Children with Relapsed/Refractory Solid Tumors</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-18-2008 08:47:04"><nciDocumentNumber>GOG-0240</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0240</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, with and without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-23-2008 10:16:56"><nciDocumentNumber>N0724</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0724</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Study of Oligometastatic Stage IV Non-Small Cell Lung Cancer (NSCLC) Treated with Systemic Therapy Plus Either Radiotherapy to All Sites of Gross Residual Disease or No Radiotherapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="02-13-2008 16:24:52"><nciDocumentNumber>8236</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IUCRO-0214</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of AZD0530 for Patients with Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma)</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="02-27-2008 14:03:58"><nciDocumentNumber>CALGB-150601</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-150601</localDocumentNumber></localDocumentNumberList><documentTitle>The Impact of KRAS and EGFR Mutations on Outcome of Patients with Stage IB NSCLC in CALGB 9633</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-17-2008 12:12:14"><nciDocumentNumber>GOG-0225</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>G0G-0225</localDocumentNumber></localDocumentNumberList><documentTitle>Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-28-2008 14:44:09"><nciDocumentNumber>WFU-07-02-03</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WFU-07-02-03</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized, Double-Blind, Placebo Controlled Trial of North American Ginseng Extract (CVT-E002; COLD-fX) to Prevent Respiratory Infection and Reduce Antibiotic Use in Patients with Chronic Lymphocytic Leukemia.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-16-2008 14:19:09"><nciDocumentNumber>GOG-0076GG</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0076GG</localDocumentNumber></localDocumentNumberList><documentTitle>A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination with Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="04-30-2008 14:18:31"><nciDocumentNumber>S0800</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0800</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) with or without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced HER-2/Neu Negative Breast Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-06-2008 08:56:19"><nciDocumentNumber>NCIC-MA.27(B)-MAYO-ICSC</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>TBCI-MA.27A</localDocumentNumber></localDocumentNumberList><documentTitle>A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer.  A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-09-2008 09:30:43"><nciDocumentNumber>ADVL0812</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0812</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children with Relapsed/Refractory Solid Tumors</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-20-2008 11:11:35"><nciDocumentNumber>E5803T1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E5803T1</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Polymorphisms, Mutations, and Protein Expression by Automated Quantitative Immunohistochemistry (AQUA) in the Lapatinib Targets and Metabolic Pathway in Samples from E5803</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-25-2008 08:04:31"><nciDocumentNumber>AAML0631</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML0631</localDocumentNumber></localDocumentNumberList><documentTitle>Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND #103, 331) during Consolidation</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-26-2008 09:01:04"><nciDocumentNumber>ANBL08B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>COG-NB-2008-01</localDocumentNumber></localDocumentNumberList><documentTitle>Prognostic Multigene Expression Classification of Neuroblastoma Patients</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-10-2008 16:47:36"><nciDocumentNumber>ACOSOG-Z4082</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACOSOG-Z4082</localDocumentNumber></localDocumentNumberList><documentTitle>The Cancer Genome Atlas (TCGA) Utilizing Z0030 NSCLC Patient Samples</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="05-03-2012 10:18:42" createdDate="10-21-2008 13:05:56"><nciDocumentNumber>PBTC-026</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PBTC-026</localDocumentNumber></localDocumentNumberList><documentTitle>A Feasibility Study of SAHA Combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-05-2008 10:04:55"><nciDocumentNumber>ADVL0815</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0815</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Pazopanib as a Single Agent for Children with Relapsed or Refractory Solid Tumors, Including CNS Tumors</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-24-2008 11:17:25"><nciDocumentNumber>RTOG-0724</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG 0724/ GOG-0724</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-06-2009 10:27:53"><nciDocumentNumber>NCCTG-N08C2</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N08C2</localDocumentNumber></localDocumentNumberList><documentTitle>N08C2, A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-15-2009 15:11:33"><nciDocumentNumber>GOG-8009</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8009</localDocumentNumber></localDocumentNumberList><documentTitle>Genome-Wide Association Study (GWAS) for Modifiers of Breast Cancer Risk BRCA1 Mutation Carriers</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-26-2009 10:58:44"><nciDocumentNumber>8267</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU 09089</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Feasibility Trial of Cyclophosphamide, Alvocidib (Flavopiridol) and Rituximab (CAR) in Patients with High Risk B-Cell CLL/SLL</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-27-2009 15:38:18"><nciDocumentNumber>NCCTG-N9831(C)-NCCTG-ICSC</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-N9831(C)-NCCTG-ICSC</localDocumentNumber></localDocumentNumberList><documentTitle>Round-Robin Clinico-Pathological Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (N9831, BCIRG 006, and BCIRG 005)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="02-10-2009 12:23:38"><nciDocumentNumber>S8516-S8736-S9125-S9240-S9349A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S8516-S8736-S9125-S9240-S9349A</localDocumentNumber></localDocumentNumberList><documentTitle>Pharmacogenomics of Oxidative Stress-Related Genes in Lymphoma</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-26-2012 15:46:20" createdDate="03-02-2009 13:13:44"><nciDocumentNumber>PBTC-025B</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PBTC-025B</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="03-10-2009 11:36:48"><nciDocumentNumber>CALGB-150803</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-150803</localDocumentNumber></localDocumentNumberList><documentTitle>A Validation of the 64-Gene Signature Using Affymetrix-HG_U133A Array in Stage I NSCLC from the CALGB Lung Cancer Study (140202)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 15:20:46" createdDate="03-20-2009 13:31:51"><nciDocumentNumber>CALGB-100701</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-100701/BMT CTN 0804</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-23-2009 15:43:56"><nciDocumentNumber>AHOD0831</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AHOD0831</localDocumentNumber></localDocumentNumberList><documentTitle>A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-03-2012 13:46:11" createdDate="04-27-2009 16:36:23"><nciDocumentNumber>8418</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>09-068</localDocumentNumber></localDocumentNumberList><documentTitle>A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients with Metastatic Pancreatic Cancer (10052747)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-02-2012 10:16:55" createdDate="05-07-2009 11:03:57"><nciDocumentNumber>8342</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>050909</localDocumentNumber></localDocumentNumberList><documentTitle>Autophagic Modulation with Anti-Angiogenic Therapy in Patients with Advanced Malignancies: A Phase I Trial of Sunitinib and Hydroxychloroquine</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 15:50:57" createdDate="05-07-2009 14:38:39"><nciDocumentNumber>CALGB-30801</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB 30801</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-02-2012 10:56:08" createdDate="06-19-2009 07:51:55"><nciDocumentNumber>E4A08</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4A08</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-Chain (AL) Amyloidosis Ineligible for Autologous Stem-Cell Transplantation</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-15-2009 14:40:12"><nciDocumentNumber>AREN10B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AREN10B1</localDocumentNumber></localDocumentNumberList><documentTitle>Validation of Prognostic Markers for Very Low Risk Wilms Tumors</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-03-2012 10:34:22" createdDate="08-11-2009 09:32:13"><nciDocumentNumber>8474</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2009-165</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects with Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) (IND 71976)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-25-2009 09:28:36"><nciDocumentNumber>8561</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-076</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-02-2009 14:01:55"><nciDocumentNumber>MDA-2009-0288</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2009-0288</localDocumentNumber></localDocumentNumberList><documentTitle>Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-04-2012 10:16:51" createdDate="09-15-2009 12:42:51"><nciDocumentNumber>8506</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2009-0649</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II/Pharmacodynamic Study of the Gamma-Secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-22-2009 11:06:10"><nciDocumentNumber>S9032-S9300-A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9032-S9300-A</localDocumentNumber></localDocumentNumberList><documentTitle>Gene Expression and Function Associated with Chronic Myeloid Leukemia Progression</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-06-2009 10:56:32"><nciDocumentNumber>ACOSOG-Z4097</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>Z4097</localDocumentNumber></localDocumentNumberList><documentTitle>CK19/P-cadherin Ratio as Predictor of Recurrence in Early Stage Adenocarcinoma of Lung</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="10-08-2009 08:42:12"><nciDocumentNumber>S0916</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0916</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II, Window Trial of the Anti-CCR2 Antibody MLN1202 (NSC-751448) in Patients with Bone Metastases</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-27-2009 09:05:39"><nciDocumentNumber>CALGB-SWOG-150506-80405-PTEN</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-SWOG-150506-80405-PTEN</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluating PTEN Gene Sequence as a Predictor of Efficacy in Cetuximab-Treated Colorectal Cancer Patients : A Retrospective Study of Tissues from CALGB / SWOG 80405</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="05-02-2012 11:17:36" createdDate="10-30-2009 09:47:30"><nciDocumentNumber>RTOG-0937</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0937</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-02-2012 14:55:48" createdDate="11-03-2009 15:27:29"><nciDocumentNumber>PBTC-029</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PBTC-029</localDocumentNumber></localDocumentNumberList><documentTitle>Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-02-2009 10:33:24"><nciDocumentNumber>E2108</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2108</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-08-2009 10:19:38"><nciDocumentNumber>S0933</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0933</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-18-2009 10:19:07"><nciDocumentNumber>AAML10B16</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML10B16</localDocumentNumber></localDocumentNumberList><documentTitle>Stat3 Activation as a Potential Prognostic Marker and Therapeutic Target in Pediatric AML</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-15-2010 15:58:10"><nciDocumentNumber>8627</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO10901</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 Study of AZD6244 in Combination with Cetuximab in Refractory Solid Tumors</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-03-2012 13:45:49" createdDate="01-25-2010 09:43:37"><nciDocumentNumber>8445</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>10-324-B</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Study of Multipeptide Vaccination with or Without IL-12, then Combined with Regulatory T Cell Depletion Using Daclizumab in Patients with Metastatic Melanoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-26-2010 08:45:08"><nciDocumentNumber>E3108</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E3108</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="02-17-2010 07:25:03"><nciDocumentNumber>ECOG E2100D-ECOG-ICSC</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2100T4</localDocumentNumber></localDocumentNumberList><documentTitle>VEGF Gene Amplification/Deletion and Haplotype as Biomarkers for Bevacizumab in Breast Cancer</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="02-18-2010 16:40:12"><nciDocumentNumber>8335</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0915</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients with Advanced Solid Malignancies</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-15-2010 09:59:48"><nciDocumentNumber>8760</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>10.258</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II, 2-stage, 2-arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-19-2010 13:40:57"><nciDocumentNumber>AMC-075</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AMC-075</localDocumentNumber></localDocumentNumberList><documentTitle>A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-27-2010 14:15:12"><nciDocumentNumber>ANBL10B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ANBL10B1</localDocumentNumber></localDocumentNumberList><documentTitle>Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Neuroblastoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-03-2010 08:00:43"><nciDocumentNumber>ARST0921</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ARST0921</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-03-2012 13:45:49" createdDate="05-03-2010 09:11:38"><nciDocumentNumber>8692</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>10-428-B</localDocumentNumber></localDocumentNumberList><documentTitle>A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients with Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-07-2010 08:13:17"><nciDocumentNumber>8709</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO10904</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of MK-2206 in Combination with Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-10-2010 13:07:55"><nciDocumentNumber>GOG-0186H</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0186H</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) Versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysin® NSC # 729968, BB-IND # 13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-10-2010 15:36:32"><nciDocumentNumber>AEWS1031</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AEWS1031</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-20-2010 14:23:06"><nciDocumentNumber>N2008-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N2008-02</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Vorinostat in Combination with 13-Cis-Retinoic Acid in Patients with Refractory/Recurrent Neuroblastoma.</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-20-2010 14:32:49"><nciDocumentNumber>GOG-8199</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8199</localDocumentNumber></localDocumentNumberList><documentTitle>Prospective Study of Risk-Reducing Salpingo-Oophorectomy (RRSO) and Longitudinal CA-125 Screening Among Women At Increased Genetic Risk of Ovarian Cancer: Extended Follow-up of Select GOG-0199 Study Participants</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-03-2012 11:07:50" createdDate="05-24-2010 09:35:36"><nciDocumentNumber>8617</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>10100</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients with Advanced NSCLC</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-01-2010 09:29:42"><nciDocumentNumber>8803</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU 10093</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 Study of Azacitidine in Combination with MEC (Mitoxantrone, Etoposide, Cytarabine) in Relapsed and Refractory Acute Myeloid Leukemia</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-11-2010 15:27:57"><nciDocumentNumber>8818</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>10-174</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1b/2a Study of ABT-888 in Combination with Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-01-2010 15:12:56"><nciDocumentNumber>8610</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>11-C-0042</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study of Weekly EZN-2208 (PEGylated SN-38) in Combination with Bevacizumab in Refractory Solid Tumors</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-23-2010 09:58:35"><nciDocumentNumber>E3303T1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E3303T1</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Correlates of Response to C225 (Erbitux or Cetuximab) in Combination with Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck (E3303): A Phase II Trial of Eastern Cooperative Oncology Group</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-28-2010 08:20:55"><nciDocumentNumber>E1900T4</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1900T4</localDocumentNumber></localDocumentNumberList><documentTitle>Somatic Mutations in Stem and Progenitor Cells in AML</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-12-2010 14:13:42"><nciDocumentNumber>8846</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>11-C-0060</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-13-2010 15:41:12"><nciDocumentNumber>GOG-0269</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0269</localDocumentNumber></localDocumentNumberList><documentTitle>A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated with the Surgical Management of a Vulvar Cancer</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-26-2012 14:03:14" createdDate="08-18-2010 11:53:23"><nciDocumentNumber>AAML1031</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML1031</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Trial for Patients with de novo AML Using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-05-2010 07:56:55"><nciDocumentNumber>8799</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>11-C-0161</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 Study of the Mitogen Activated Protein Kinase (MEK) 1 Inhibitor AZD6244 Hydrogen Sulfate (Selumetinib Sulfate) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-03-2010 11:53:05"><nciDocumentNumber>ADVL1112</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL1112</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphomas</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="02-01-2011 15:14:32"><nciDocumentNumber>NCCTG-N10C1</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N10C1</localDocumentNumber></localDocumentNumberList><documentTitle>Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo-Controlled Trial</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="02-07-2011 09:48:14"><nciDocumentNumber>AAML11B9</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML11B9</localDocumentNumber></localDocumentNumberList><documentTitle>Pediatric Myeloid Leukemia-Specific miRNA Expression Profiles Induced by the Leukemic Stem Cell Niche</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-02-2011 10:59:57"><nciDocumentNumber>ANBL11B2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ANBL11B2</localDocumentNumber></localDocumentNumberList><documentTitle>ROR1 as a Novel Target for Neuroblastoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="06-06-2011 14:17:38"><nciDocumentNumber>CALGB-151107</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-151107</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Characterization of Lung Cancer: A Collaboration with the Cancer Genome Atlas Project (TGCA)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-27-2011 09:16:45"><nciDocumentNumber>E4402T3</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4402T3</localDocumentNumber></localDocumentNumberList><documentTitle>The Influence of KIR and HLA Genotype on the Response to Rituximab Immunotherapy in Patients with Follicular Lymphoma</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-27-2011 10:23:36"><nciDocumentNumber>E2496T1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2496T1</localDocumentNumber></localDocumentNumberList><documentTitle>Outcome Prediction in Hodgkin Lymphoma by Low-Density Gene Expression Profiling of Formalin Fixed Paraffin Embedded Tissues: A Correlative Study of Inter-Group Trial E2496</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-07-2011 11:41:55"><nciDocumentNumber>N1048</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N1048</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="07-07-2011 15:27:33"><nciDocumentNumber>8992</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J11116</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study of Sorafenib in Patients with Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-17-2011 11:24:46"><nciDocumentNumber>AEPI10N1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AEPI10N1</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Epidemiology of Pediatric Germ Cell Tumors</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-06-2011 12:50:38"><nciDocumentNumber>9136</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II Study in Patients with Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of MART-1 Reactive Peripheral Blood Lymphocytes (PBL) with or without High Dose Aldesleukin</documentTitle><currentStatus>Temporarily Closed to Accrual &amp;Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-13-2011 08:24:20"><nciDocumentNumber>ABTR12B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ABTR12B1</localDocumentNumber></localDocumentNumberList><documentTitle>Gene Expression (GE) and MicroRNA (MIRNA) Expression Profiles of Malignant Rhabdoid Tumors (MRT) of the Kidney (RTK) and Atypical Teratoid Rhabdoid Tumor (ATRT)</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-18-2011 10:38:41"><nciDocumentNumber>E5397T2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E5397T2</localDocumentNumber></localDocumentNumberList><documentTitle>Detection of DNA Mutations in Head and Neck Squamous Cell Carcinoma</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-19-2011 11:30:51"><nciDocumentNumber>GOG-0275</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0275</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-29-2011 07:06:46"><nciDocumentNumber>AHOD12B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AHOD12B1</localDocumentNumber></localDocumentNumberList><documentTitle>Role of the IL-2 Inducible Tcell Kinase in EBV-HLH and EBV+ Hodgkin's Lymphoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-01-2011 11:58:53"><nciDocumentNumber>S1200</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-S1200</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Blinded Sham-and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women With Early Stage Breast Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-02-2011 18:32:42"><nciDocumentNumber>ARST12B4</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ARST12B4</localDocumentNumber></localDocumentNumberList><documentTitle>CRKL Expression at the Protein Level in Rhabdomyosarcoma Tumors by Tissue Microarray (TMA)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:23" createdDate="03-05-2012 09:18:59"><nciDocumentNumber>AREN12B5</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AREN12B5</localDocumentNumber></localDocumentNumberList><documentTitle>Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>EST-P-A881</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A881</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of cis-platinum, bleomycin, and standard dose methotrexate with leucovorin rescue in advanced squamous cancer of the uterine cervix</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>EST-P-A882</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A882</localDocumentNumber></localDocumentNumberList><documentTitle>Interferon Phase II study of lymphoblastoid interferon in patients with chemotherapy-resistant ovarian cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>EST-P-A280</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A280</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of 5-fu and pala in patients with metastatic colorectal cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>EST-P-C381</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C381</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study for advanced, incurable head and neck squamous cancer with a combination of cis-platinum and 5-fluorouracil infusion</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-6608</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-6608</localDocumentNumber></localDocumentNumberList><documentTitle>Controlled study of periodic inducer doses of vincristine and prednisone versus daunomycin and prednisone in the course of 6-mercaptopurine maintained remissions of acute lymphocytic leukemia in children</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>RTOG-84-14</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-84-14</localDocumentNumber></localDocumentNumberList><documentTitle>Dose-searching randomized study of fast neutrons for tumors located in the pelvis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>RTOG-85-31</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-85-31</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Study of Zoladex Adjuvant to Radiotherapy in Unfavorable Prognosis Carcinoma of the Prostate</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-8175</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8175</localDocumentNumber></localDocumentNumberList><documentTitle>Aclacinomycin-a Phase II in recurrent and metastatic Breast ca</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-8001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8001</localDocumentNumber></localDocumentNumberList><documentTitle>Bleomycin infusion followed by ctx, mtx + 5-fu for advanced head and neck malignancies - pilot</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>SWOG-9119</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9119</localDocumentNumber></localDocumentNumberList><documentTitle>Primary chemotherapy of poor prognosis soft tissue sarcomas:  Phase II pilot</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>NCCTG-91-78-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-91-78-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Interleukin-4 (IL-4) in Patients with Previously Treated Measurable Low- and Intermediate-Grade Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>E5593</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E5593</localDocumentNumber></localDocumentNumberList><documentTitle>Early detection of second primary lung cancers by sputum cytology immunostaining</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>SWOG-9428</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9428</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of dna ploidy and p53 in patients registered to swog-8794 and swog-9024</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>SWOG-9426</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9426</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of antiandrogen withdrawal in patients with progressive prostate cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>SWOG-7622</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7622</localDocumentNumber></localDocumentNumberList><documentTitle>Combined modality treatment for mycosis fungoides, stage i and ii</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>S9628</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9628</localDocumentNumber><localDocumentNumber>S9628</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Dexamethasone/Alpha-Interferon in AL  Amyloidosis</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>SWOG-9427</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9427</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of SURAMIN in  advanced ADRENAL  CORTICAL  CARCINOMA,  Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>POG-7810</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7810</localDocumentNumber><localDocumentNumber>SWOG-7810</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of anguidine in children with ALL in relapse</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CCG-B971</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-B971</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Biology of Pediatric Brain Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>POG-9405</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9405</localDocumentNumber></localDocumentNumberList><documentTitle>ALINC 16: protocol for patients with newly diagnosed standard risk AcuteLymphoblastic Leukemia (ALL).</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>POG-8823-24</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8823/24</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II: Recombinant A-Interferon in childhood Chronic Myelogenous Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>E4494</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4494</localDocumentNumber><localDocumentNumber>E4494</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients with Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>SWOG-9519</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9519</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>RTOG-97-03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97-03</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase II of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>E2196</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2196</localDocumentNumber><localDocumentNumber>E2196</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase III trial of Marimastat versus placebo in patients with Metastatic Breast Cancer who have responding or stable disease after induction chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>CALGB-9682</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9682</localDocumentNumber></localDocumentNumberList><documentTitle>Prognostic Significance of Endorectal MRI in Predicting Outcome After Combined Radiation and Androgen Suppresion for Prostate Cancer: A Prospective Phase II Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>CCG-B961</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-B961</localDocumentNumber></localDocumentNumberList><documentTitle>Prognostic Significance of Ki-67 Proliferative Index Utilizing the MIB-1 Antibody in Low Grade Gliomas in Young Children</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>INT-0165</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>D9501</localDocumentNumber><localDocumentNumber>D9501</localDocumentNumber><localDocumentNumber>D9501</localDocumentNumber><localDocumentNumber>D9501</localDocumentNumber></localDocumentNumberList><documentTitle>Topotecan and cyclophosphamide, followed by multimodal, multiagent therapy for children and adolescents with newly diagnosed stage iv/clinical group iv rhabdomyosarcoma, an irs-v pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>GOG-P-5</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-P-5</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II evaluation of Melphalan-Adriamycin in Advanced Ovarian Cancer in patients without prior radiation</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>GOG-21</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Randomized study of Adriamycin with and without Dimethyl Triazenoimidazole Carboxamide in Advanced Uterine Sarcomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CALGB-7803</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7803</localDocumentNumber></localDocumentNumberList><documentTitle>Therapy for acute myelocytic leukemia using a ten day infusion of cytosine arabinoside and a three day course of adriamycin</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CALGB-8043</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8043</localDocumentNumber></localDocumentNumberList><documentTitle>Cis-platinum in the treatment of advanced or recurrent pancreatic cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>NCCTG-96-32-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-96-32-52</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II study of sequential Docetaxel and Doxorubicin/Cyclophosphamide (AC) in patients with metastatic breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-9237</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9237</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of topotecan in resistant and relapsing multiple myeloma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>E4293</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4293</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of topotecan 21-day infusion in advanced colorectal cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>RTOG-D-6275</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-942</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of medull0blastoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>GOG-33</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-33</localDocumentNumber></localDocumentNumberList><documentTitle>A clinical-pathologic study of stage I and II Carcinoma of the Endometrium</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-8993</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8993</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of High Dose Melphalan with Hemopoietic Stem Cell Support and GM-CSF in Refractory Multiple Myeloma (MM)</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>NSABP-B-23</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-23</localDocumentNumber></localDocumentNumberList><documentTitle>A Clinical Trial Comparing Short, Intensive AC + or - Tamoxifen with Conventional CMF + or - Tamoxifen in Node-Negative Breast Cancer Patients with ER-Negative Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>EST-P-A682</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A682</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of 4-epiadriamycin in malignant melanoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CCG-611</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-611</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for the treatment of histiocytosis x</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>EST-P-E282</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-E282</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of tamoxifen in the malignant carcinoid syndrome</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>EST-P-D282</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-D282</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16, 213 Phase II pilot in metastatic carcinoid tumor</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>EST-P-C377</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C377</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of bleomycin in soft tissue sarcoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CALGB-9251</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9251</localDocumentNumber></localDocumentNumberList><documentTitle>High Intensity, Brief Duration Chemotherapy for Diffuse Small Noncleaved Cell Lymphoma and the l-3 Subtype of all:  A Pilot Study of a Multidrug Regimen</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>EST-3573</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3573</localDocumentNumber></localDocumentNumberList><documentTitle>Bcg lung cancer immunotherapy protocol</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-9249</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9249</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive carboplatin/cyclophosphamide/g-csf therapy followed by either standard dose paclitaxel (Taxol) or intensive paclitaxel (Taxol)/g-csf for patients with stage iii suboptimal disease ovarian cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-9126</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9126</localDocumentNumber></localDocumentNumberList><documentTitle>A controlled trial of cyclosporine as a chemotherapy-resistance modifier in high risk acute myeloid leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CCG-6921</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-6921</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study for the treatment of patients with rhabdomyosarcoma and other soft tissue sarcomas with metastatic disease at diagnosis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-7431</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7431</localDocumentNumber></localDocumentNumberList><documentTitle>Methyl ccnu-adriamycin (mad) for patients with metastatic sarcoma refractory to actinomycin-d and/or cyclophosphamide</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-731/733</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-731/733</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for chemotherapy of patients with multiple myeloma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-7326</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7326</localDocumentNumber></localDocumentNumberList><documentTitle>Icrf-159 Phase II eval in solid tumors and acute leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>POG-9357</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9357</localDocumentNumber></localDocumentNumberList><documentTitle>The use of Cyclosporin A to overcome multiple drug resistance in Osteogenic Sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-9320</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9320</localDocumentNumber></localDocumentNumberList><documentTitle>Study of PROMACE-CYTABOM with TRIMETHOPRIM SULFAMETHOXAZOLE, GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) and ANTIRETROVIRAL therapy in patients with AIDS RELATED LYMPHOMA, PHASE II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>E5Y92</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E5Y92</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Interleukin-4 (Schering) in Indolent B-Cell Non-Hodgkin's Lymphoma and B-Cell Chronic Lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>CCG-0956</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-0956</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of a continuous 21 day infusion of topotecan (nsc # 609699) in children with relapsed solid tumors.</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>SWOG-9430</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9430</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Complete Surgical Resection for Stage IV Melanoma - Surgical Resection with Biological Evaluation and Clinical Follow-Up</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>POG-9574</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9574</localDocumentNumber></localDocumentNumberList><documentTitle>INTERLEUKIN-4 in Pediatric patients with REFRACTORY ACUTE LEUKEMIA:  A Pediatric Oncology Group Phase I cooperative agreement study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>GOG-9501</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9501</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot evaluation of sequential courses of high-dose Carboplatin and Paclitaxel followed by high-dose Melphalan rescued with Cyclophosphamide/Paclitaxel Primed Peripheral Progenitor Cells in patients with Advanced Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>A9952</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-9952</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>NCCTG-94-32-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>94-32-52</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot Study of Tamoxifen Plus Letrozole with Evaluation for Pharmacokinetic Interaction in Women with Metastatic Breast Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>NSABP-B-29</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-29</localDocumentNumber><localDocumentNumber>NSABP-B-29</localDocumentNumber></localDocumentNumberList><documentTitle>A Clinical Trial to Evaluate the Benefit of Adding Octreotide (SMS 201-995 pa LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Patients with Axillary Node-Negative, Estrogen-Receptor-Positive, Primary Invasive Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>SWOG-7625</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7625</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy for advanced sarcomas of bone mesothelioma utilizing rubidazone and dic</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>E2696</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2696</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II trial of adjuvant gm2-klh/qs-21 vaccine with or without interferon-a2b (intron a) in patients with high risk melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>E2296</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2296</localDocumentNumber></localDocumentNumberList><documentTitle>Combined modaltiy therapy of unresectable adenocarcinoma of the pancreas with radiation, 5-fu and gemcitabine - a Phase I trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>E3395</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E3395</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Evaluation of 96 Hour Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head &amp; Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>RTOG-96-15</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-96-15</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Multi-institutional Trial of Targeted Supradose Cisplatin Chemoradiation for Stage IV Squamous Cell Carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>SWOG-8040</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8040</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II drug vs fam-s in pancreatic adenocarcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>NSABP-BP-60</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-60</localDocumentNumber></localDocumentNumberList><documentTitle>Interferon in first recurrence breast cancer: Comparison of high dose intravenous infusion with conventional dose intramuscular administration</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>POG-9031</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9031</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of children with high-stage Medulloblastoma:  Cisplatin/VP-16 pre- vs post-irradiation</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>NCCTG-82-81-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-82-81-52</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16-213 in the treatment of Anll for patients 65 years or older</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>CALGB-9550</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9550</localDocumentNumber><localDocumentNumber>AMC-003</localDocumentNumber></localDocumentNumberList><documentTitle>Low-Dose Interleukin-2 in AIDS Lymphoma: A CALGB Pilot Study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>RTOG 94-07</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Pentoxifylline in the treatment of radiation-related Soft Tissue Necrosis:  a randomized double-blind trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-9041</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9041</localDocumentNumber></localDocumentNumberList><documentTitle>Chemoprevention of recurrent adenomas and second primary colorectal carcinoma:  a pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>E1295</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ECOG-E1295</localDocumentNumber><localDocumentNumber>E1295</localDocumentNumber><localDocumentNumber>E1295</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Trial of High Dose vs Conventional Dose Octreotide vs Loperamide in the Treatment of Chemo-related Diarrhea in Patients with Colorectal Ca.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>E2193</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ECOG-E2193</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy in Postmenopausal Women with a History of Breast Cancer who are Receiving Adjuvant Tamoxifen</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>CALGB-8583</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8583</localDocumentNumber></localDocumentNumberList><documentTitle>Subcutaneous Alpha2 Interferon in Chronic Phase Myelogenous Leukemia:  A Pilot Study of Ph1-Positive Chromosome Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-1275</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1275</localDocumentNumber></localDocumentNumberList><documentTitle>Pahse ii evaluation of diglycoaldehyde, vp-16 and the combination of methyl-ccnu and b-2-deoxythioguanosine in previously treated patients with colorectal cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-P-D582</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-D582</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot study of vindesine infusion &amp; cis-platinum in advanced non-small cell bronchogenic carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-P-C581</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C581</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II pilot study: a study of intensive vinblastine and high dose cis-platinum in advanced non-small cell lung cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-P-C181</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C181</localDocumentNumber></localDocumentNumberList><documentTitle>Bisantrene Phase II pilot in patients w/metastatic Breast cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-560/561</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-560/561</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III protocol: remission induction and remission maintenance therapy for adult acute leukemia. coap, doap, oap combination chemotherapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-2374</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Comparison of adriamycin vs vincristine and cyclophosphamide vs vincristine, actinomycin-d and cyclophosphamide</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7432</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7432</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy of previous melphalan or cytoxan treated patients with multiple myeloma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-734/736</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-734/736</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for chemotherapy of patients with multiple myeloma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7376</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7376</localDocumentNumber></localDocumentNumberList><documentTitle>Quality of survival in histiocytosis x: a southwest oncology group study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7861</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7861</localDocumentNumber></localDocumentNumberList><documentTitle>Combined therapy with 5-fu, mitomycin-c, and rt for treatment of localized adenocarcinoma of the exocrine pancreas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-8118</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8118</localDocumentNumber></localDocumentNumberList><documentTitle>Bisantrene straight Phase II refractory malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-8061</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8061</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of vindesine in gastrointestinal cancer: Phase II pilot</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-8063</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8063</localDocumentNumber></localDocumentNumberList><documentTitle>Anguidine Phase II pilot eval of refractory adult acute non-lymphocytic leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-8066</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8066</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant Intrahepatic Chemotherapy with Mitomycin-C and 5-FU Combined with Hepatic Radiation in High Risk Patients with Carcinoma of the Colon; Phase II Pilot</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-8068</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8068</localDocumentNumber></localDocumentNumberList><documentTitle>Combined modality treatment for limited adenocarcinoma and large cell carcinoma of the lung:  radiation therapy and 5-fu, mitomycin-c, and vincristine</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-9486</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-9486</localDocumentNumber></localDocumentNumberList><documentTitle>The treatment of MULTIPLE MYELOMA utilizing VBMCP chemotherapy with or without intensification or ALPHA-2 INTERFERON: a Phase III study for previously untreated MULTIPLE MYELOMA</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>POG-9005</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9005</localDocumentNumber></localDocumentNumberList><documentTitle>ALINC #15 (low risk):  dose intensification of Methotrexate and 6-Mercaptopurine for ALL in childhood- a randomized Pediatric Oncology Group Phase III study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-8914</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8914</localDocumentNumber></localDocumentNumberList><documentTitle>Standard Dose CBDCA/Cyclophosphamide/GM-CSF vs. Intensive CBDCA/Cyclophosphamide/GM-CSF Induction Therapy-Second-Cytoreductive Surgery-High Dose Day 1 and Day 8 IV CDDP for Patients with Stages III and IV Suboptimal Disease Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>NCCTG-82-70-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-82-70-51</localDocumentNumber></localDocumentNumberList><documentTitle>The combination of BCNU + 6-Thioguanine in advanced malignant Melanoma.</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>CCG-1882</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-1882</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of newly diagnosed acute lymphoblastic leukemia in children with a poor prognosis excluding infants and patients with lymphoma-leukemia or fab l3 blasts</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>SWOG-977/978</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-977/978</localDocumentNumber></localDocumentNumberList><documentTitle>Ancillary combination chemotherapy (dopp) protocol for treatment of malignant melanoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>SWOG-8736</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8736</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of localized non-hodgkin's lymphoma: comparison of chemotherapy (chop) to chemotherapy plus radiation therapy: Phase III </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>SWOG-8237</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8237</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of continuous infusion vinblastine sulfate in pancreatic adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>SWOG-8261</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8261</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot; treatment for metastatic non-small cell lung cancer (squamous, adenocarcinoma and large cell undifferentiated histologies) with mipe</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>C9581</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCIC CTG C0.14</localDocumentNumber><localDocumentNumber>C9581</localDocumentNumber><localDocumentNumber>C9581</localDocumentNumber><localDocumentNumber>C9581</localDocumentNumber><localDocumentNumber>C9581</localDocumentNumber><localDocumentNumber>C9581</localDocumentNumber><localDocumentNumber>C9581</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Randomized Study of Adjuvant Immunotherapy with Monoclonal Antibody 17-1A  Versus No Adjuvant Therapy Following Resection for Stage II (Modified Astler-Coller B2) Adenocarcinoma of the Colon</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>EORTC-62933</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EORTC-62933</localDocumentNumber><localDocumentNumber>EORTC-62933</localDocumentNumber><localDocumentNumber>EORTC-62933</localDocumentNumber></localDocumentNumberList><documentTitle>Metastasectomy and chemotherapy for lung metastases from soft tissue sarcoma. a randomized Phase III study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>POG-8079</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8079</localDocumentNumber><localDocumentNumber>SWOG-8079</localDocumentNumber></localDocumentNumberList><documentTitle>A study of the association of HLA Antigen Phenotype susceptibility to malignant diseases and subsequent survival duration</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>POG-8140</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8140</localDocumentNumber></localDocumentNumberList><documentTitle>Cis-Platinum Phase II in recurrent Pediatric Brain Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>POG-8155</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8155</localDocumentNumber></localDocumentNumberList><documentTitle>Alanosine Phase I/II in Pediatric solid Tumors and Leukemias</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>POG-7843</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7843</localDocumentNumber></localDocumentNumberList><documentTitle>Rubidazone Phase II eval inTX of child w/solid Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>POG-7872</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7872</localDocumentNumber></localDocumentNumberList><documentTitle>Determination of maximum tolerated doses and toxicity of Adriamycin and Razoxane when used in combination therapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>POG-8002</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8002</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy with Adriamycin, Cis-Diamminedichloroplatinum, Vincristine and Cytoxan in children with metastatic Neuroblastoma (stage IV) - Phase I/II - originally pilot study SWOG-7875</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>INT-0130</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-91-46-52</localDocumentNumber><localDocumentNumber>E8293</localDocumentNumber><localDocumentNumber>CO.8</localDocumentNumber><localDocumentNumber>RTOG-92-03</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Study of Radiation Therapy, Levamisole and 5-Fluorouracil vs 5-Fluorouracil and Levamisole in Selected Patients with Completely Resected Colon Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 00:00:00"><nciDocumentNumber>INT-0132</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2993</localDocumentNumber><localDocumentNumber>MRC-UKALL-XII</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Randomized Trial of Autologous and Allogeneic Bone Marrow Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>SWOG-9300</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9300</localDocumentNumber><localDocumentNumber>S9300</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Evaluation of All Trans-Retinoic Acid (ATRA) with Interferon-Alfa 2a (IFN-alfa2a) or All-Trans-Retinoic Acid with Hydroxyurea (HU) in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>INT-0137</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9313</localDocumentNumber><localDocumentNumber>CALGB-9394</localDocumentNumber><localDocumentNumber>S9313</localDocumentNumber><localDocumentNumber>NCCTG-93-30-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Comparison of Adjuvant Chemotherapy with High-Dose Cyclophosphamide Plus Doxorubicin (AC) Versus Sequential Doxorubicin Followed by Cyclophosphamide (A->C) in High-Risk Breast Cancer Patients with 0-3 Positive Nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>RTOG-94-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-94-04</localDocumentNumber><localDocumentNumber>NCCTG-94-72-51</localDocumentNumber><localDocumentNumber>SWOG-9340</localDocumentNumber><localDocumentNumber>T91-0056</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III randomized study of radiotherapy with or without BUDR plus Procarbazine, CCNU, and Vincristine (PCV) for the treatment of Anaplastic Astrocytomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>NCCTG-93-72-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-93-72-52</localDocumentNumber><localDocumentNumber>SWOG-9503</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Trial of BCNU and Cisplatin Versus BCNU Alone and Standard Radiation Therapy Versus Accelerated Radiation Therapy in Patients with Grade IV Glioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>T98-0018</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM 98-062</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients with Metastatic Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>INT-0123</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-94-05</localDocumentNumber><localDocumentNumber>R9405</localDocumentNumber><localDocumentNumber>91-40-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Intergroup  Randomized comparison of combined  modality therapy for CARCINOMA  of the  ESOPHAGUS:  high dose vs. Conventional dose Radiation therapy.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>SWOG-7812</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7812</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of anguidine in central nervous system tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>INT-0159</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9480</localDocumentNumber><localDocumentNumber>C9480</localDocumentNumber><localDocumentNumber>SWOG-9452</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Study of Three Different Doses of Suramin (NSC #34936) Administered with a Fixed Dosing Schedule in Patients with Advanced Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>C0190</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-C-0190</localDocumentNumber></localDocumentNumberList><documentTitle>Quality of life on Breast cancer adjuvant trial est 3189</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>C88-0003</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Coping with radiation treatment for prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>C90-0001</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Comparing behavioral strategies for reducing procedural distress in children with cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>CALGB-8971</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8971</localDocumentNumber></localDocumentNumberList><documentTitle>A dose response trial of megestrol acetate for the treatment of cachexia in patients with advanced cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>CALGB-9071</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9071</localDocumentNumber></localDocumentNumberList><documentTitle>House-officer training in smoking cessation</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-85-86-51</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-85-86-51</localDocumentNumber><localDocumentNumber>85-86-51</localDocumentNumber></localDocumentNumberList><documentTitle>Development of a self-administered patient questionnaire for discernment of prognostic variables in advanced malignant disease</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-90-92-51</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-90-92-51</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized, placebo-controlled, double-blind evaluation of Sulindac in patients with Multiple-Polyposis</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-91-92-52</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-91-92-52</localDocumentNumber></localDocumentNumberList><documentTitle>M/N - Phase III randomized comparison of Megestrol Acetate (Megace), Fluoxymesterone (Halotestin) &amp; Dexamethasone (Decadron) for the treatment of cancer Anorexia &amp; Cachexia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-92-49-51</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-92-49-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III evaluation of Carafate versus placebo in the prevention of radiation induced Esophagitis</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-94-92-52</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-94-92-52</localDocumentNumber></localDocumentNumberList><documentTitle>Double-blind study of Sucralfate versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>SWOG-9045</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9045</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of quality of life in patients with advanced colorectal cancer enrolled on swog-8905</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>T83-1400</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>URCC-2182M</localDocumentNumber></localDocumentNumberList><documentTitle>Predictors of relapse for women with stage ii carcinoma of the breast</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>POG-7476</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7476</localDocumentNumber><localDocumentNumber>SWOG-7476</localDocumentNumber></localDocumentNumberList><documentTitle>Ancillary study - an evaluation of the inhibitory nature of Leukemic Serum</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>EST-0471</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-0471</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for Phase I study of 5-Azacytidine</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>EST-1577</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1577</localDocumentNumber></localDocumentNumberList><documentTitle>Surgical adjuvant immunotherapy for resectable Bronchogenic carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>RTOG-97-10</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-97-10</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of conventional Radiation Therapy followed with Recombinant Interferon Beta for Supratentorial Glioblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>EST-8282</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-8282</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of locally unresectable pancreatic cancer by irradiation of the pancreas with or without radiation</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>NSABP-C-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-C-02</localDocumentNumber><localDocumentNumber>NCOG-NSABP-C-02</localDocumentNumber></localDocumentNumberList><documentTitle>A Clinical Trial Evaluating the Post Operative Portal Vein Infusion of 5-Fluorouracil and Heparin in Patients with Resectable Adenocarcinoma of the Colon: Heparin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>NCCTG-81-32-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-81-32-51</localDocumentNumber></localDocumentNumberList><documentTitle>A clinical trial of Tamoxifen versus Tamoxifen plus Fluoxymesterone in post-menopausal women with advanced breast cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>NCCTG-88-72-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-88-72-52</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Study of Radiation Therapy Plus BCNU with or without Recombinant Interferon Alpha in the Treatment of Newly Diagnosed High Grade Gliomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>EST-1484</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1484</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized trial of Chemotherapy alone versus Chemotherapy plus Radiotherapy consolidation for unfavorable (diffuse) histologic subtypes of early stage non-Hodgkin's lymphoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>CCG-521</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-521</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of newly diagnosed advanced hodgkins disease (pathologic stages iii1as macro, iii1a macromediastinum, iii2a, iiib, iva, ivb) a Phase III group-wide study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>CALGB-8582</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8582</localDocumentNumber><localDocumentNumber>SWOG-8694</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of pentostatin (nsc #218321) and alpha interferon (nsc #377523) in splenectomized patients with active hairy cell leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>RTOG-89-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-89-01</localDocumentNumber><localDocumentNumber>EST-2591</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study comparing combination chemotherapy and radiation therapy with preoperative chemotherapy and surgical resection in patients with Non-Small Cell Lung Cancer (NSCLC) with spread to Mediastinal Lymph Nodes (N2)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>CALGB-9254</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9254</localDocumentNumber><localDocumentNumber>C9254</localDocumentNumber></localDocumentNumberList><documentTitle>Anti-b4-blocked ricin (nsc #639185) adjuvant therapy post-autologous bone marrow transplant:  a Phase III study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>URCC-2994</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2994</localDocumentNumber></localDocumentNumberList><documentTitle>Prevention of Weight Loss and Anorexia and Maintenance of Quality of Llife During Chemotherapy Treatment for Metastatic Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>PB491</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PB491</localDocumentNumber></localDocumentNumberList><documentTitle>Quality of life assessment and laboratory study in conjunction with HIV-related Lymphoma trials:  DNA content, S-phase, Molecular biology, and P24 Antigen by flow cytometry</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>CCG-09710</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-09710</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of recurrent CD7 Antigen Positive Leukemia with TXU (Anti-CD7)-Pokeweed Antiviral Protein (PAP) Immunotoxin</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>RTOG-97-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>R9704</localDocumentNumber><localDocumentNumber>R9704</localDocumentNumber><localDocumentNumber>R9704</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>S9635</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9635</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of 5-Fluorouracil plus 776C85 in Patients with Advanced Resistant Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>CALGB-9782</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9782</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of potency-sparing hormonal therapy in patients with elevated serum PSA after radiation therapy or radical prostatectomy for prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>C9732</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C9732</localDocumentNumber><localDocumentNumber>C9732</localDocumentNumber><localDocumentNumber>C9732</localDocumentNumber><localDocumentNumber>C9732</localDocumentNumber><localDocumentNumber>C9732</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized PHASE III study comparing ETOPOSIDE and CISPLATIN with ETOPOSIDE, CISPLATIN, and PACLITAXEL in patients with EXTENSIVE SMALL CELL LUNG CANCER</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>T96-0040</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.100</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of topotecan and etoposide in patients with refractory or relapsed acute myeloid leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>PZ489</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-Z489</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II trial of Promace-Cytabom and RH-G-CSF in patients with diffuse aggressive Lymphomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>E3590</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3590</localDocumentNumber><localDocumentNumber>CALGB-9393</localDocumentNumber><localDocumentNumber>NCCTG-91-24-51</localDocumentNumber><localDocumentNumber>RTOG-9105</localDocumentNumber><localDocumentNumber>SWOG-9252</localDocumentNumber></localDocumentNumberList><documentTitle>Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stage II and stage IIIA non-small cell Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>POG-7799</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7799</localDocumentNumber><localDocumentNumber>SWOG-7799</localDocumentNumber></localDocumentNumberList><documentTitle>Rare tumor registry for childhood solid Tumor malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:54"><nciDocumentNumber>NCCTG-91-50-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-91-50-52</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of high-dose Cimetidine and the combination 5-FU, IFL-RA, Leucovorin in advanced renal cell Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:54"><nciDocumentNumber>GOG-9702</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9702</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of Gemcitabine/Topotecan in combination in recurrent or persistent ovarian or peritoneal cancer or cancer of the fallopian tube</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:55"><nciDocumentNumber>GOG-9405</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9405</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of escalating doses of Paclitaxel (NSC#125973) combined with a fixed dose of Cisplatin (NSC#119875) &amp; Doxorubicin (NSC#123127) in patients with Advanced GYN or Bladder Cancer who have or have not received prior pelvic rt</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:55"><nciDocumentNumber>NCCTG-93-24-53</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>93-24-53</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol to assess whether Neuroendocrine differentiation predicts response to chemotherapy in patients with non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>SWOG-9101</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9101</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of edtatrexate in patients with advanced or recurrent bladder carcinoma: Phase II </documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>SWOG-9158</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9158</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of trans retinoic acid and alpha interferon in patients with squamous cell carcinoma of the lung (stage iv)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>SWOG-9338</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9338</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of combination therapy with 5-fluorouracil, a-interferon and interleukin-2 ("funil") for advanced renal cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>SWOG-9413</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9413</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II treatment with etoposide, leucovorin, 5-fluorouracil, and interferon alpha 2b (elfi) + g-csf for locally advanced or recurrent pancreatic adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>SWOG-9424</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9424</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of high dose tamoxifen plus cisplatin chemotherapy in metastatic non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>CCG-0936</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-0936</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Evaluation of Oral and Intravenous Navelbine (Vinorelbine) in Pediatric Cancer Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>SWOG-9120</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9120</localDocumentNumber></localDocumentNumberList><documentTitle>Investigation of g-csf and trans-retinoic acid in the treatment of myelodysplastic syndrome</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>SWOG-9326</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9326</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of altretamine for consolidation of clinical complete response in patients with stage iii epithelial ovarian cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>RTOG-98-05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-98-05</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Transrectal Ultrasound guided permanent radioactive implantation of the Prostate for definitive management of localized Adenocarcinoma of the Prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0162</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-162</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Trial of Cisplatin (NSC #119875) with Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients with Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>GOG-0076U</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-76U</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Topotecan in patients with Advanced Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>GOG-0087G</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-87G</localDocumentNumber></localDocumentNumberList><documentTitle>A PHASE II trial of PACLITAXEL (Taxol) (NSC #673089) in patients with advanced or recurrent UTERINE SARCOMAS</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>G0134</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-134</localDocumentNumber><localDocumentNumber>G0134</localDocumentNumber><localDocumentNumber>92-61-51</localDocumentNumber><localDocumentNumber>9238</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial of Taxol at two dose levels and G-CSF at two dose levels in Platinum-Resistant Ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>T88-0243</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-88-132</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of homoharringtonine(nsc 141633) in chronic myelogenous leukemia(cml)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>T97-0113</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM97-308</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of MGI-114 (NSC# 683863) Administered Intravenously for Five Days Every 28 Days to Patients with Metastatic Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:00"><nciDocumentNumber>T97-0023</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM 97-022</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Trial of Taxol/VP-16/Estramustine vs. ketoconazole/Doxorubicin/Vinblastine/Estramustine in Androgen Independent Prostate Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:00"><nciDocumentNumber>T98-0002</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I Study of Post Transplant rhIL-12 Following High Dose Cyclophosphamide, Thiotepa, and Carboplatin in the Treatment of Metastatic Breast Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:00"><nciDocumentNumber>RTOG-98-03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-98-03</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II Radiation Dose EscalationStudy Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:00"><nciDocumentNumber>CCG-B977</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-B977</localDocumentNumber></localDocumentNumberList><documentTitle>A study of the mechanisms of intrinsic and acquired methotrexate resistance in acute lymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:00"><nciDocumentNumber>GOG-0171</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-171</localDocumentNumber></localDocumentNumberList><documentTitle>Expression of the MN Protein in Atypical Glandular Cells of Undetermined Significance (AGUS or AGCUS) as a Potential Diagnostic Biomarker of Cervical Dysplasia/Neoplasia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>NABTC-9801</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTC-9081</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II Trial of Irinotecan (CPT-11) in Patients with Recurrent Malignant Glioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>S9811</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9811</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Hydroxyurea for Unresectable Meningioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>NCCTG-98-32-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-98-32-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Dolastatin-10 in Patients with Advanced Breast Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POG-8532</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8532</localDocumentNumber><localDocumentNumber>RTOG-8532</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of intracranial Ependymomas-A Phase III study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POG-8315</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8315</localDocumentNumber></localDocumentNumberList><documentTitle>Laboratory study and subclassification of NHL</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POG-8361</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8361</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of VP-16-213 and 5-Azacytidine in combination for refractory Acute Non-Lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>51-17</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>51-17</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of 5-azacytidine</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>113-09A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ST-66</localDocumentNumber></localDocumentNumberList><documentTitle>Hexamethylmelamine in ovarian ca</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POG-8047</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8047</localDocumentNumber></localDocumentNumberList><documentTitle>Histiocytosis X  in Bone - Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POG-7866</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7866</localDocumentNumber><localDocumentNumber>SWOG-7866</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot ALINC 13 study: Acute Lymphoblastic Leukemia treatment portion</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>GOG-102A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-102A</localDocumentNumber></localDocumentNumberList><documentTitle>Master protocol for Phase II intraperitoneal drug studies in treatment of Minimal Residual Ovarian Malignancies documented at second-look surgery</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>GITSG-9482</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-9482</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trials in Advanced Measurable Pancreatic Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POA-91185</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-91185</localDocumentNumber></localDocumentNumberList><documentTitle>High dose Cytosine Arabinoside (HIDAC) and Cisplatin (CDDP) for Brain Tumors  A Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>EST-P-B390</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ECOG-P-B390</localDocumentNumber><localDocumentNumber>T90-0098</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of amonafide in head and neck cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>T90-0092</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HMC-2045</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of tnf + il2 + alfa interferon</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>INT-0114</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9081</localDocumentNumber><localDocumentNumber>EST-4290</localDocumentNumber><localDocumentNumber>NCCTG-90-47-51</localDocumentNumber><localDocumentNumber>CO.6</localDocumentNumber><localDocumentNumber>RTOG-90-14</localDocumentNumber><localDocumentNumber>SWOG-9040</localDocumentNumber></localDocumentNumberList><documentTitle>Intergroup Rectal Adjuvant Protocol-A Phase III Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>POG-9000</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9000</localDocumentNumber></localDocumentNumberList><documentTitle>POG-9000 ALINC 15 classification (C) protocol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>T90-0077</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>90-126</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of prolonged infusions of suramin in patients with advanced cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>CALGB-9051</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9051</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of etoposide, vinblastine, doxorubicin (eva) and subtotal nodal radiation in poor risk, early stage hodgkin's disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>SWOG-8911</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8911</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of piroxantrone in refractory carcinoma of the Breast</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>WCG-103</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WCG-103</localDocumentNumber></localDocumentNumberList><documentTitle>Streptozotocin in broad study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>T84-0280</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>840407</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of CBDCA in the treatment of Small Cell Carcinoma of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>SWOG-8936</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8936</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of piroxantrone in gastric carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>SWOG-8917</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8917</localDocumentNumber></localDocumentNumberList><documentTitle>5-fluorouracil, leucovorin and roferon-a in advanced colorectal cancer, Phase II pilot</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>SWOG-8842</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8842</localDocumentNumber></localDocumentNumberList><documentTitle>Dihydroxyazacytidine in malignant mesothelioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1468</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-8192</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II study of local hyperthermia and electron-beam irradiation in the treatment of superficial human tumors(recurrent or metastatic)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T84-0103</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AUSSIE</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol i for the management of neuroblastoma in childhood</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T84-0109</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.2</localDocumentNumber></localDocumentNumberList><documentTitle>Acivicin in lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCOG-7O-81</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-7O-81</localDocumentNumber><localDocumentNumber>RTOG-79-08</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I - II study of heavy charged particle radiotherapy of localized Ocular Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1370</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-72-18B</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1379</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-82-49</localDocumentNumber></localDocumentNumberList><documentTitle>Hyperfractionated radiation therapy of radioresistant metastatic brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1250</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>83-C-53</localDocumentNumber></localDocumentNumberList><documentTitle>Use of isotretinoin in prevention of basal cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>CALGB-8962</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8962</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of initial and sequential computed tomographic scans of the thorax (ct) in bulky mediastinal hodgkin's disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCOG-P-0H-82(H-01M)</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-P-0H-82(H-01M)</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of human Neoplasms by microwave-induced Hyperthermia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>CALGB-8933</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8933</localDocumentNumber></localDocumentNumberList><documentTitle>Trimetrexate (nsc #352122) for malignant mesothelioma: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCCTG-85-78-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-85-78-51</localDocumentNumber><localDocumentNumber>85-78-51</localDocumentNumber></localDocumentNumberList><documentTitle>5fu/pala/thymidine in refractory NHL</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCCTG-84-72-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-84-72-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of Fludarabine Phosphate in primary brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T89-0056</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>89-66</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I trial of combination chemoimmunotherapy in metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCCTG-82-50-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-82-50-51</localDocumentNumber></localDocumentNumberList><documentTitle>Vm-26 Phase II in Advanced Renal Cell Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>NBCCGA-4</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NBCCGA-4</localDocumentNumber></localDocumentNumberList><documentTitle>A protocol to determine the results of external irradiation and combined irradiation and surgery as definitive therapy for patients with invasive primary bladder carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>CALGB-8869</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8869</localDocumentNumber></localDocumentNumberList><documentTitle>Laboratory Studies in Breast Cancer Tissue</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T88-0208</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>554-88</localDocumentNumber></localDocumentNumberList><documentTitle>Phase ib trial of levamisole in metastatic colorectal cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>POG-8870</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8870</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I trial of  Ifosfamide/VP-16-213/Mesna in children with resistant/recurrent Acute Leukemias- A Pediatric Oncology Group study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>POG-8890</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8890</localDocumentNumber></localDocumentNumberList><documentTitle>A limited-institution pilot study of Cisplatin, Etoposide, and Ifosfamide in children with advanced malignant disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0270</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UH8789</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of 6-thioguanine in patients with metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0198</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>87-898</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of amonafide (nsc 308847) in recurrent or metastatic colorectal cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0205</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-87N2</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of new agents in the treatment of patients with esophageal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0141</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>88-479</localDocumentNumber><localDocumentNumber>7064</localDocumentNumber></localDocumentNumberList><documentTitle>A study of the effect of surgery and tumor debulking on in vivo human tumor cell kinetics</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>T86-0153</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>251403-01</localDocumentNumber></localDocumentNumberList><documentTitle>Cell kinetics of human bone marrow in hematologic malignancies studied by 5-bromo-deoxyuridine labeling</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>T83-0987</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>81-093</localDocumentNumber><localDocumentNumber>POG-8107</localDocumentNumber></localDocumentNumberList><documentTitle>Multi-institutional controlled trial of adjuvant chemotherapy in the treatment of osteosarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>T83-0958</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>77-010</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of non-metastatic osteogenic sarcoma after primary ablative surgery</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8804</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8804</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of cis-platinum and dtic in inoperable stage iii and stage iv melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8614</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8614</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy for gastric cancer with vm-26: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8561</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8561</localDocumentNumber></localDocumentNumberList><documentTitle>V-tad for patients greater than fifty years of age with acute non-lymphocytic leukemia, Phase II pilot</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8509</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8509</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of menogaril (nsc-269148) in adenocarcinoma of the prostate: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8373</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8373</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of l-phenyl-alanine mustard (melphalan) in patients with metastatic colorectal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8106</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8106</localDocumentNumber></localDocumentNumberList><documentTitle>Azq straight Phase II central nervous system tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8008</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8008</localDocumentNumber></localDocumentNumberList><documentTitle>Mitoxantrone in refractory Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8010</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8010</localDocumentNumber></localDocumentNumberList><documentTitle>Mitoxantrone in advanced prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-7903</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7903</localDocumentNumber></localDocumentNumberList><documentTitle>Advanced (stages iii, iv) hodgkin's disease: remission induction with chop</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-7624</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7624</localDocumentNumber></localDocumentNumberList><documentTitle>Adr vs. adr+cacp in transitional cell bladder carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SWOG-7220/21</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7220/21</localDocumentNumber></localDocumentNumberList><documentTitle>Comparison of prednisolone, vincristine, methotrexate and 6-mercaptopurine vs vincristine and prednisone induction therapy in childhood acute leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SWOG-545/46</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-545/46</localDocumentNumber></localDocumentNumberList><documentTitle>Study of busulfan in chronic granulocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SWOG-690/691</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-690/691</localDocumentNumber></localDocumentNumberList><documentTitle>Cns prophylaxis in acute lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>MAOP-5282</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-5282</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of 5-Fluorouracil vs 5-Fluorouraci + Teniposide + Mitomycin-C in adv Colorectal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>MAOP-2287</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-2287</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Etoposide infusional Cisplatin and infusional 5-FU for metastatic or locally advanced (t>5 cm) Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-5883</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-5883</localDocumentNumber></localDocumentNumberList><documentTitle>A study of primary hormone treatment of advanced(stage D2) Prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-2880</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2880</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II master protocol for the evaluation of new treatments in patients with Endometrial cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-2181</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2181</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III combination Chemotherapy of metastatic Breast cancer followed by maintenance or no maintenance therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-2276</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2276</localDocumentNumber></localDocumentNumberList><documentTitle>Surgical adjuvant protocol for resectable Colon carcinoma modified Duke's B-2 and C</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1675</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1675-G1-5</localDocumentNumber></localDocumentNumberList><documentTitle>Methyl-CCNU master protocol Phase II in malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1687</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1687</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of IV Melphalan in malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1879</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1879</localDocumentNumber><localDocumentNumber>N81-0987</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy of Adrenal Cortical carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1480-17/18/19</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1480-G2</localDocumentNumber></localDocumentNumberList><documentTitle>Deoxycoformycin Phase II master protocol Eval of new agents and comb in pts w/lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1584</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1584</localDocumentNumber><localDocumentNumber>LCSG-862</localDocumentNumber><localDocumentNumber>T86-0282</localDocumentNumber></localDocumentNumberList><documentTitle>Immunohistochemical analysis of Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-P-H482</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-H482</localDocumentNumber></localDocumentNumberList><documentTitle>Methyl-g Phase II pilot in refractory chronic lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-P-Y987</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-Y987</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of recombinant Interleukin-2 and recombinant Interferon Gamma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-P-C482</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C482</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot study, high-dose Cytosine Arabinoside and M-amsa in acute non-lymphocytic Leukemias</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-P-A885</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A885</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of Menogaril in advanced Prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>D83-047-0669</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>153</localDocumentNumber></localDocumentNumberList><documentTitle>High dose melphalan and autologous marrow for malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>D83-043-0249</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-82-72</localDocumentNumber></localDocumentNumberList><documentTitle>Tissue and fluid penetration of vp-16</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>D82-043-0151</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>P79-04</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment and investigation of osteosarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D82-006-0763</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC-2501</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of adult acute lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D81-050-0885</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NB-79B</localDocumentNumber></localDocumentNumberList><documentTitle>Therapy for patients with neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D81-044-0077</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Treatment of acute non-lymphocytic leukemia in adults</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D81-030-0958</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>81-15</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of azq straight advanced malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D81-010-0451</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>182-81</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot study of amsa and ara-c as induction therapy for pts with newly dx or relap anll,all &amp; as intensive con solidation therapy for pts in remission with anll all</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D81-011-0693</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HOG-8130</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II tx of acute myelogenous leukemia in children</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D80-038-0293</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>80-488</localDocumentNumber></localDocumentNumberList><documentTitle>Dibromodulcitol Phase II eval tx of adv Breast ca</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D80-002-0159</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>01734</localDocumentNumber></localDocumentNumberList><documentTitle>Bcg-mer Phase II in melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D80-012-0103</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-79I1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of new agents in advanced colon cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>T86-0127</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.25</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of trimetrexate in ovarian carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D79-006-0216</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC-1971</localDocumentNumber></localDocumentNumberList><documentTitle>Dibromodulcitol Phase II in metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D78-035-0100</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Cis-platinum and methotrexate and adriamycin in advanced non-oat cell carcinomas of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D78-035-0205</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Combination chemotherapy for metastatic epidermoid carcinoma of head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D78-044-0067</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>112</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II chemotherapy with cis-platinum plus radiotherapy vs radiotherapy alone for stage iii/iv resectable head and neck carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>DT-77-50</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-77-50</localDocumentNumber></localDocumentNumberList><documentTitle>Thermochemotherapy of metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>T86-0032</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-86-05</localDocumentNumber></localDocumentNumberList><documentTitle>Efficacy study of deoxycoformycin in interferon-resistant hairy cell leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>SEG-BRM-81-118P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-BRM-81-118P</localDocumentNumber></localDocumentNumberList><documentTitle>A southeastern cancer study group Phase I clinical trial of adr-022 in cancer patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>T85-0199</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BTRC-8521</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II study if azq for the treatment of recurrent childhood and adult malignant brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>SEG-BRE-77-324</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-BRE-77-324</localDocumentNumber></localDocumentNumberList><documentTitle>Primary cytotoxic chemotherapy for "poor risk" patients with metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>COG-7320</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>COG-7320</localDocumentNumber></localDocumentNumberList><documentTitle>Yoshi-864 Phase II in human malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CIC-76-25</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-76-25</localDocumentNumber></localDocumentNumberList><documentTitle>Clinical trial of pyrazofurin with f3tdr</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CCG-8607</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-8607</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of 13-cis-retinoic acid for the treatment of children with metastatic neuroblastoma who do not respond to converntional chemotherapy:  Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>SEG-AE-83-320</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-AE-83-320</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized study of nabilone and dexamethasone as antiemetic therapy for patients with disseminated testicular cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CCG-371</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-371</localDocumentNumber></localDocumentNumberList><documentTitle>Cyclic combination chemotherapy for newly diagnosed stage iv neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CCG-161TH</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-161TH</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of thyroid function in children with acute lymphoblastic leukemia on ccg-161</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-8642</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8642</localDocumentNumber></localDocumentNumberList><documentTitle>Single agent induction chemotherapy vs standard chemotherapy for stage iv breast carcinoma: phase iii</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-8435</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8435</localDocumentNumber></localDocumentNumberList><documentTitle>Mitomycin-c and cisplatin vs. adriamycin and cisplatin for malignant mesothelioma:  a Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-8361</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8361</localDocumentNumber></localDocumentNumberList><documentTitle>Immunological diagnostic studies in aml</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-8211</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8211</localDocumentNumber></localDocumentNumberList><documentTitle>Autologous bone marrow transplantation for calla positive all</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-81-15</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-81-15</localDocumentNumber><localDocumentNumber>EST-8283</localDocumentNumber></localDocumentNumberList><documentTitle>Combined preoperative &amp; postoperative radiation therapy of operable colorectal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-79-05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-79-05</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II protocol for the evaluation of Misonidazole combined with Radiation in the treatment of patients with Advanced Pelvic Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-78-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-78-04</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of Adjuvant Radiotherapy for Bladder Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-76-11</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-76-11</localDocumentNumber></localDocumentNumberList><documentTitle>Neutron therapy in the treatment of Malignant Gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>POG-8693</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8693</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16, Amsa+/- 5-Azacytidine in refractory ANLL: pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>GOG-7891</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-7891</localDocumentNumber></localDocumentNumberList><documentTitle>A feasibility study to determine the efficacy and morbidity of treatment of women with stage III and stage IV Ovarian Carcinoma with Melphalan therapy plus Levamisole in twenty-five patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>GOG-55</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-55</localDocumentNumber></localDocumentNumberList><documentTitle>Hormonal Contraception and Trophoblastic Sequelae after Hydatidiform Mole Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T90-0139</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I study of ifosfamide, carboplatin, and etoposide (ice) with gm-csf</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>EST-P-C289</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C289</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of intraperitoneal 5-Fluorouracil and calcium leucovorin in advanced, non-measurable Colorectal carcinomatosis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>SWOG-8913</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8913</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of merbarone in disseminated malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0032</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I/II trial of sequential active specific immunotherapy (autologous tumor cell vaccine) and recombinant interleukin-2 (ro 23-6019) for metastatic renal cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0050</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>91-02-059</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of recombinant il-4 in patients with indolent lymphoma and b-cll</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0110</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>91-044</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of liposome-encapsulated doxorubicin (led) &amp; g-csf</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>POG-9193</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9193</localDocumentNumber></localDocumentNumberList><documentTitle>Autologous Bone Marrow Transplantation for recurrent/refractory Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0176</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Intralesional treatment of mycosis fungoides with recombinant interleukin-2</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>RTOG-91-13</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>1054</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of All-Trans-Retinoic Acid (Tretinoin) in patients with recurrent malignant Gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>POG-9280</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9180</localDocumentNumber></localDocumentNumberList><documentTitle>Neuroblastoma epidemiology protocol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0247</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IOU 9206</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of topotecan in metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>POG-9225</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9225</localDocumentNumber></localDocumentNumberList><documentTitle>Study for advanced-stage Hodgkin's Disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>E2892</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-8-05</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of edatrexate in metastatic renal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>GOG-9204</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9204</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of Taxol and Topotecan without and with G-CSF in patients with Advanced Ovarian Epithelial Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T92-0249</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I trial of continuous infusion Taxol with radiotherapy for the treatment of carcinoma of the cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>SWOG-9307</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9307</localDocumentNumber></localDocumentNumberList><documentTitle>Extended aministration of oral etoposide and oral cyclophosphamide for the treatment of poor prognosis extensive disease small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>POG-9398</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9398</localDocumentNumber></localDocumentNumberList><documentTitle> -4 "D":  efficacy of RHG-CSF in an intensive treatment forT-Cell Leukemia and advanced-stage Lymphoblastic Lymphoma of childhood</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T93-0110</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BRMP #9305</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I evaluation of ossirene (as-101 or ivx-q-101) in combination with high dose carboplatin in patients with advanced malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T93-0156</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Dose finding study of the combination of topotecan and etoposide:Phase I </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>SWOG-9212</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9212</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T94-0167</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I/II clinical trial of dexverapamil and doxorubicin in advanced sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T96-0050</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO 9691</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I clinical and pharmacokinetic study of diethylhomospermine (dehspm) administered by subcutaneous injection</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>BTCG-89-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BTCG-89-01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III malignant Glioma: Surgery and external RT and Intravenous BCNU vs. surgery and external RT and Intravenous BCNU + Intra-Arterial Cisplatin vs. surgery and external RT and investigational chemotherapy(defined in subdocument 8901A-N)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8314</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8314</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III trial of local irradiation and chemotherapy vs chemotherapy alone for the treatment of localized Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>75-21-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>75-21-01</localDocumentNumber></localDocumentNumberList><documentTitle>Comparison of dianhydrogalactitol vs. the combination of vp-16 and adriamycin in unresectable adenocarcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>75-22-01/03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>75-22-01/03</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study comparison of radiation therapy plus vincristine and adriamycin with or without immunotherapy with mer in unresectable squamous cell cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8103</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8103</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Hepatoblastoma and Hepatocellular Carcinoma in children with surgery, radiation and chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8107</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8107</localDocumentNumber></localDocumentNumberList><documentTitle>Multi-institutional controlled trial of adjuvant chemotherapy in the treatment of Osteosarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GOG-26Z</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-26Z</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Leuprolide Acetate in patients with Advanced Epithelial Ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GOG-28</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-28</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized comparison of Melphalan, 5-FU and Megace vs Adriamycin, Cytoxan, 5-FU and Megace in the treatment of patients with primary stage III, primary site stage IV, Recurrent or Residual Endometrial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GOG-2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-2</localDocumentNumber></localDocumentNumberList><documentTitle>Post operative treatment of women with stage III Ovarian Cancer by radiotherapy or Melphalan either alone or in both sequences</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GOG-26A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-26A</localDocumentNumber></localDocumentNumberList><documentTitle>Master protocol for Phase II drug studies in treatment of Advanced, Recurrent Pelvic Malignancies</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GITSG-9374</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Randomized Phase II trial of Adriamycin, Methotrexate, and Actinomycin-D in Advanced Measurable Pancreatic Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GITSG-9382</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-9382</localDocumentNumber><localDocumentNumber>MAOP-5783</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III trial in Non-Measurable Pancreatic Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>W83-0146</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC-8234</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of mitoxantrone in advanced prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:15"><nciDocumentNumber>T84-0367</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-84-35</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized trial comparing daunorubicin/arabinosyl cytosine and 4-demethoxydaunorubicin/arabinosyl cytosine in adult patients with untreated acute non-lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:15"><nciDocumentNumber>POA-26183</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-26183</localDocumentNumber><localDocumentNumber>BGSM-26183</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Subcutaneous Alpha2 Interferon in patients with multiple Myeloma resistant to conventional therapy or previously untreated</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:15"><nciDocumentNumber>POA-58184</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-58184</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized phase ii study:  adjuvant intraperitoneal 5-fluorouracil or no therapy for stage b2&amp;3 and c1,2&amp;3 colon cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:17"><nciDocumentNumber>EST-8283</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-8283</localDocumentNumber></localDocumentNumberList><documentTitle>Intergroup study of combined preoperative and postoperative Radiation therapy of operable Rectal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:18"><nciDocumentNumber>T90-0073</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C-882-90</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Clinical Evaluation of NSC #366140(9-methoxy-n,n dimethyl-5-nitropyrazolo (3,4,5-k) acridine-2 (6h)-propanamine)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:18"><nciDocumentNumber>EST-1590</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1590</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Taxol (NSC 125973) in patients with extensive-stage small cell carcinoma of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:18"><nciDocumentNumber>EST-4890</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4890</localDocumentNumber><localDocumentNumber>CALGB-9291</localDocumentNumber><localDocumentNumber>SWOG-9152</localDocumentNumber></localDocumentNumberList><documentTitle>Prediction of recurrence and therapy response in patients with advanced germ cell Tumors by DNA flow cytometry</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:18"><nciDocumentNumber>T90-0063</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>89-48-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of 5-fluorouracil, levamisole and pelvic radiation therapy in patients with locally recurrent, locally unresectable or incompletely resected cancer confined to the pelvis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:19"><nciDocumentNumber>NWTS-3</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NWTS-3</localDocumentNumber><localDocumentNumber>CCG-491</localDocumentNumber><localDocumentNumber>POG-8000</localDocumentNumber><localDocumentNumber>SWOG-8000</localDocumentNumber></localDocumentNumberList><documentTitle>National Wilms Tumor Study III, a Phase III group-wide study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:19"><nciDocumentNumber>NSABP-B-09</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-09</localDocumentNumber></localDocumentNumberList><documentTitle>A Clinical Trial to Compare Combination Chemotherapy With and Without Tamoxifen in the Management of Patients With Surgically "Curable" Breast Cancer Who Have One or More Positive Axillary Nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:20"><nciDocumentNumber>GOG-26II</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-26II</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of 5-Fluorouracil and high dose Leucovorin in Advanced, Metastatic or Recurrent Pelvic Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:21"><nciDocumentNumber>NCCTG-89-49-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-89-49-51</localDocumentNumber><localDocumentNumber>89-49-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III trial of Hydrazine Sulfate in advanced 5FU-Resistant Colorectal Cancer with a randomized comparison of quality of life measurement tools</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>T84-0279</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>058-84</localDocumentNumber></localDocumentNumberList><documentTitle>Cyclophosphamide, m-amsa, hydroxyurea(cmh) combination chemotherapy for refractory acute non-lymphocytic leukemia (anll)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>POG-9074</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9074</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I trial of Xomazyme-H65 in children with T-Cell Acute Lymphoblastic Leukemia/Lymphoma:  A Pediatric Oncology Group study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>T89-0241</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BGSM-83488</localDocumentNumber></localDocumentNumberList><documentTitle>Biochemical modulation of 5-fluorouracil(5-fu) by leucovorin for carcinoma of the ovary</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>EST-3889</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3889</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Ifosfamide in advanced carcinoma of the Urothelium</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>NPCTG-1500</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NPCTG-1500</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of Methotrexate vs. Cyclophosphamide plus Doxorubicin vs. Cisplatin plus Cyclophosphamide plus 5-Fluorouracil in patients with advanced hormonal cancer of the prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>NPCTG-1700</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NPCTG-1700</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of DES or Orchiectomy vs. Buserelin vs. DES or ORCH + Methotrexate in new diag patients with clinical Stage D cancer of the prostrate who have not had hormonal treatment or Orchiectomy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>EST-1589</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1589</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II protocol for Chemotherapy in metastatic non-small cell Bronchogenic carcinoma:  Merbarone, Piroxantrone, Taxol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>EST-P-Z189</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-Z189</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of dose escalation of Cyclophosphamide, Adriamycin, and 5-Fluorouracil (CAF) with Granulocyte-Macrophage colony stimulating factor (GM-CSF) in metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>T89-0204</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>89-39</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of recombinant il-2 and recombinant tnf in patients with metastatic melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>T84-0246</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>83-049</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized, crossover comparison of megestrol acetate with tamoxifen in patients with advanced Breast cancer megestrol acetate in er negative patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>T84-0244</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-8313</localDocumentNumber><localDocumentNumber>EST-P-B184</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II evaluation of cyclic administration of the combination chemotherapy regimens caf, d(dhad)v and t'savb in women with metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>T84-0211</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>4118</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of 4'deoxydoxorubicin for advanced measurable adenocarcinoma of the pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>T84-0172</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>81-071</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of three dose schedules for aminoglutethimide in patients with metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>T89-0176</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>89-045</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of weekly pala, interferon alpha, and 5-fluorouracil by 24 hour continuous infusion in patients with advanced or refractory cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>T89-0177</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Cell kinetic analysis of human non-small cell lung carcinoma :  therapeutic significance of bromodeoxyuridine labelling studies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NPCP-1800</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NPCP-1800</localDocumentNumber></localDocumentNumberList><documentTitle>Survey of patterns of care for patients receiving irradiation for Prostate Cancer who are not admitted to treatment comparison protocols</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCCTG-89-82-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-89-82-51</localDocumentNumber><localDocumentNumber>89-82-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II evaluation of Somatostatin Analogue (SMS 201-995, Sandostatin) in the therapy of measurable or evaluable hematologic malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>T83-1472</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-8254</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of whole body hyperthermia (wbh) and local radiotherapy (lr) for advanced non-small cell lung cancer (nsclc) confined to the thorax</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>NCOG-3R-81-J</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-3R-81-J</localDocumentNumber></localDocumentNumberList><documentTitle>Study of radiation alone vs radiation plus chemotherapy in the treatment of residual inoperable carcinoma of the rectum and Rectosigmoid or pelvic recurrence following colorectal surgery</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1423</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU-8206</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of ametantrone acetate ci-881 in patients with metastatic cancer refractory to conventional therapy or for whom no conventional therapy exists</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1402</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>4K-81-1</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of cl 216,942 in renal adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1375</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-80-58</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant chemotherapy of patients with operable but locally advanced Breast cancer, a randomized study of two programs with and without adriamycin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1347</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-8296</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of recombinant human interferon beta in patients with cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1334</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-83-10</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of mitomycin-c in patients with bidimensionally measurable urothelial cell cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1311</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>83-020</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy for diffuse histiocytic and undifferentiated non-hodgkin's lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1314</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>80-041</localDocumentNumber></localDocumentNumberList><documentTitle>Intravesical adriamycin for bladder cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1319</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>79-061</localDocumentNumber></localDocumentNumberList><documentTitle>Comprehensive multidisciplinary treatment plan for patients with malignant mesothelioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1320</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>78-060</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant chemotherapy in the management of patients with high-grade sarcomas, excluding osteogenic, ewing's and embryonal rhabdomyosarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1175</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>3156</localDocumentNumber></localDocumentNumberList><documentTitle>Allogenic bone marrow grafting for patients who have suffered leukemic recurrence of acute lymphoblastic leukemia (all)- a pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T89-0108</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CHP-512</localDocumentNumber></localDocumentNumberList><documentTitle>Recruitment synchronization and killing of leukemic cells in vivo with recombinant gm-csf followed by high dose ara-c</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCOG-P-7H-83-1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-P-7H-83-1</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of pretreatment chemotherapy for advanced operable head and neck squamous cancers</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCOG-P-7H-85-2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-P-7H-85-2</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of induction chemotherapy with high-dose Cisplatin and 5-Fu followed by a split course radiation therapy with chemotherapy, Mitomycin C and 5-Fu</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>T89-0074</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A feasibility study of budr labelling of human Breast cancer dna in vivo: determination of proliferation fraction and cell viability in individual tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>T83-1152</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>L-PAM-1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II study of l-phenylalamine mustard (l-pam), melphalan) in children with solid tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>T83-1166</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>3143</localDocumentNumber></localDocumentNumberList><documentTitle>High dose induction and consolidation therapy for acute non-lymphocytic leukemia in the adult; a pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCOG-P-0C-83-6</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-P-0C-83-6</localDocumentNumber></localDocumentNumberList><documentTitle>Sequential Methotrexate (MTX) and 5-Fluorouracil (5-Fu) infusions for the treatment of recurrent solid tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCOG-P-0H-82(H-01R)</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-P-0H-82(H-01R)</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of human Neoplasms by radiofrequency-induced Hyperthermia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCOG-P-1B-71</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-1B-71</localDocumentNumber></localDocumentNumberList><documentTitle>Study to determine the activity of the combination of 5FU , Vincristine, Adriamycin and Mitomycin C in patients with metastatic breast carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCOG-P-3L-81</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-P-3L-81</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II pilot study of combined external hepatic irradiation and Intrahepatic infusion with Adriamycin, 5-Fu, Leukovorin, and Methotrexate for unresectable metastatic and Primary Liver Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>RTOG-88-22</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-88-22</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II study to evaluate the effect of fractionated Hemi-Body Irradiation in the treatment of Osseous Metastases</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>T89-0069</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Randomized double-blind Phase III trial of gallium nitrate versus disodium pammidronate (apd) for the treatment of cancer-related hypercalcemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>T89-0058</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-89H1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of high dose azq combined with cyclophosphamide/tbi(total body irradiation) for refractory non-hodgkin's lymphomas in autologous bone marrow transplantation(abmt)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>T89-0034</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BGSM-83288</localDocumentNumber></localDocumentNumberList><documentTitle>Biochemical modulation of 5-fluorouracil (5-fu) by leucovorin for carcinoma of the cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>T89-0041</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-89-019</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of gallium nitrate administered by continuous intravenous infusion in transitional cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-82-32-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-82-32-51</localDocumentNumber><localDocumentNumber>82-32-51</localDocumentNumber></localDocumentNumberList><documentTitle>Adriamycin vs. the combination of Vincristine, Adriamycin, and Mitomycin C in women with Advanced Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-82-52-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-82-52-51</localDocumentNumber><localDocumentNumber>82-52-51</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy of hormonally refractory advanced carcinoma of the prostate:  A comparison of combined vs. sequential treatment with Mitomycin C, 5-Fluorouracil and Adriamycin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-80-41-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-80-41-51</localDocumentNumber><localDocumentNumber>80-41-51</localDocumentNumber></localDocumentNumberList><documentTitle>A controlled evaluation of combined radiotherapy and chemotherapy for the treatment of locally unresectable or local residual Gastric Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>NBCCGA-8</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NBCCGA-8</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of Cis-Platinum combined with small-field pelvic radiation therapy for patients with cliniclly localized invasive primary carcinoma of the bladder who are unsuitable for Cystectomy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>NCCTG-78-48-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-78-48-52</localDocumentNumber></localDocumentNumberList><documentTitle>An evaluation of Immunotherapy or Chemo-Immunotherapy as adjuvant treatment in resectable Adenocarcinoma of colon or rectum</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>CALGB-8961</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8961</localDocumentNumber></localDocumentNumberList><documentTitle>Ras mutations in myelodysplasia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>NBCCGA-15</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NBCCGA-15</localDocumentNumber></localDocumentNumberList><documentTitle>Trial of small pelvic field, high dose, external beam radiation therapy for patients with persistent or recurrent low stage primary bladder carcinoma following surgery and/or immunotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>EST-5488</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-5488</localDocumentNumber></localDocumentNumberList><documentTitle>Prediction of therapy response in large cell Lymphoma by analysis of IA antigen expression in paraffin sections of malignant cells</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T88-0263</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>89-40</localDocumentNumber></localDocumentNumberList><documentTitle>High dose carboplatin(cbdca,nsc 241240) with recombinant human granulocyte-macrophage colony stimulating factor(rhugm-csf, schering, nsc 617589)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T88-0236</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-88-130</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study to evaluate dfmo (eflornithine) for the treatment of recurrent malignant gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T88-0232</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>88-530</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of intraperitoneal carboplatin and etoposide in combination with systemic administration of gm-csf</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T88-0228</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OC-88-7</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of cytoxan, total body irradiation and interleukin 2 activated bone marrow for transplantation therapy of refractory hematologic malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T88-0222</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>88-HO-312</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I clinical and pharmacokinetic investigation of fazarabine(nsc 218272, ara-ac) for patients with acute leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>CCG-1884</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-1884</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of idarubicin to daunomycin in a multi-drug treatment of a.l.l. in marrow relapse a group-wide study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>SWOG-8850</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8850</localDocumentNumber></localDocumentNumberList><documentTitle>Cisplatin and novobiocin in the treatment of stage 3b or stage iv or locally recurrent tumor after radiation therapy of non small cell lung cancer (nsclc), a Phase II pilot</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>EST-4987</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4987</localDocumentNumber></localDocumentNumberList><documentTitle>Feasibility study for determination of Phenotype and functional markers of host Mononuclear(MNC) cell activation and ECOG studies of Cytokines</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>SWOG-8748</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8748</localDocumentNumber></localDocumentNumberList><documentTitle>Alternating induction chemotherapy with weekly adriamycin and 5-fluorouracil/leucovorin followed by adriamycin and cyclophosphamide: a Phase II study in poor risk, stage iv Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>SWOG-8802</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8802</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of echinomycin in renal cell carcinoma, Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>T88-0136</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DS-88-11</localDocumentNumber><localDocumentNumber>88-12-30-2</localDocumentNumber><localDocumentNumber>88-02</localDocumentNumber><localDocumentNumber>88-12-30-2</localDocumentNumber><localDocumentNumber>88-12-30-2</localDocumentNumber></localDocumentNumberList><documentTitle>Intravenous bromodeoxyuridine for the determination of cell cycle characteristics in myeloid leukemias</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>GOG-76Q</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-76Q</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Tricyclic Nucleoside Phosphate (TCN-P, NSC # 280594) in patients with Advanced Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>GOG-8807</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8807</localDocumentNumber><localDocumentNumber>T88-0125</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I evaluation of Intraperitoneal 131I labeled B72.3 monoclonal antibody in patients with Advanced Intraperitoneal Epithelial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>CALGB-8834</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8834</localDocumentNumber></localDocumentNumberList><documentTitle>Intravenous 6-thioguanine or 5-fu, cisplatin, and leucovorin in advanced non-small cell lung cancer (nsclc): a randomized Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>UORG-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UORG-01</localDocumentNumber></localDocumentNumberList><documentTitle>Cooperative study of radiotherapy versus surgery or delayed hormonal therapy in treatment of Prostatic Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>VAP-601</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VAP-601</localDocumentNumber></localDocumentNumberList><documentTitle>Tmca Phase II in leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>T88-0075</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>8901-17</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of tiazofurin in acute non-lymphocytic leukemia, nonlymphoid blast crisis of cml, secondary leukemia and advanced stages of the myelodysplastic syndromes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T88-0040</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-88I1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of new agents in treatment of advanced adenocarcinoma of stomach</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T88-0016</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-88-58</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study for the evaluation of c.i.of azq in combination with hyperfractionated total body irradiation and cytoxan for preparative cytoreduction of patients with refractory non-lymphocytic leukemia prior to marrow transplantation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T88-0017</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DS-87-12</localDocumentNumber></localDocumentNumberList><documentTitle>Ifosfamide and etoposide (vp-16-213) in patients with recurrent sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T88-0037</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>89-031</localDocumentNumber></localDocumentNumberList><documentTitle>Adoptive cellular therapy of cancer with vaccine-primed lymphocytes secondarily sensitized to autologous tumor and expanded in interleukin-2 in vitro</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0291</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.38</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of recombinant tumor necrosis factor in metastatic renal cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0266</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-87-044</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of adjuvant cyclophosphamide/etoposide/cisplatin (cep) plus chest and brain irradiation versus no adjuvant treatment after complete resection of stage ii-iii limited non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0253</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UHC-004</localDocumentNumber></localDocumentNumberList><documentTitle>Study of the adoptive immunotherapy of melanoma with autologous lymphokine activated killer cells plus interleukin 2</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0211</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I study of flavone acetic acid (faa, nsc 347512)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0172</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>870404</localDocumentNumber><localDocumentNumber>4972</localDocumentNumber></localDocumentNumberList><documentTitle>The use of radiolabeled monoclonal antibody b72.3 administered by the intraperitoneal or intravenous route for radioimmunoscintigraphic detection of gynecological malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0150</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC-8714</localDocumentNumber></localDocumentNumberList><documentTitle>Weekly carboplatin (cbdca) and simultaneous conventional radiotherapy for stage iii (mo) unresectable non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0087</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>11S-86-2</localDocumentNumber></localDocumentNumberList><documentTitle>Vincristine, bleomycin, chemotherapy for kaposi's sarcoma in aids patients with cytopenias</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0089</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-87-35</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized trial of gallium nitrate for treatment of bone loss in patients with multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0042</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>85-43-H-06</localDocumentNumber></localDocumentNumberList><documentTitle>The use of radiolabelled monoclonal antibodies in the detection of primary ovarian and colon carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0045</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>419-87</localDocumentNumber></localDocumentNumberList><documentTitle>Interleukin-2 treatment for non hodgkin's lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0054</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-87-56</localDocumentNumber></localDocumentNumberList><documentTitle>Myeloablative combination chemotherapy and local irradiation with autologous bone marrow rescue for neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0061</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I/II protocol for evaluation of recombinant human interferon gamma in pediatric patients with refractory leukemias and lymphomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0003</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>6G-86-1</localDocumentNumber></localDocumentNumberList><documentTitle>Intralesional lak cell-interleukin 2 therapy of malignant glial neoplasms with imaging-directed stereotaxy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0276</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EORTC-16863C</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of pentostatin (2'deoxycoformycin, nsc 218321) in low grade non-hodgkin's lymphomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0260</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC-8619</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I trial of etoposide and diaziquone given as continuous infusions in relapsed/refractory adult leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0230</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>86-065</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive combined modality therapy for multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0203</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AML-87</localDocumentNumber></localDocumentNumberList><documentTitle>T90-0252erapy of childhood nonlymphocytic leukemia using "modelled" plasma drug concentrations - a pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0171</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC-3922</localDocumentNumber></localDocumentNumberList><documentTitle>Stimulative androgen therapy in combination with chemotherapy in hormone resistant prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T86-0145</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-8586</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II clinical and endocrinological study of ketoconazole in metastatic prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T86-0152</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RMSV</localDocumentNumber></localDocumentNumberList><documentTitle>Phase ii-iii protocol for the treatment of previously untreated high risk childhood rhabdomyosarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T83-0911</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-83-16</localDocumentNumber></localDocumentNumberList><documentTitle>Neo-adjuvant - preoperative chemotherapy for osteogenic sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T83-0882</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>82-100</localDocumentNumber></localDocumentNumberList><documentTitle>Combination alkylating agents</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8810</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8810</localDocumentNumber></localDocumentNumberList><documentTitle>Six courses of 5-fu and cis-platinum with correlation of clinical and cellular dna parameters in patients with advanced, untreated and unresectable squamous cell carcinoma of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T83-0872</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC-8029</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II trial of azq in patients with recurrent primary or metastatic brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8726</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8726</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of amonafide in refractory or relapsing multiple myeloma: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8721</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8721</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of trimetrexate in the treatment of esophageal cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8625</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8625</localDocumentNumber></localDocumentNumberList><documentTitle>Weekly cis-platinum - based induction for extensive non-small cell lung cancer with cis-platinum + vp-16 consolidation: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8626</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8626</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of recombinant dna gamma interferon in advanced cancer of the pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8562</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8562</localDocumentNumber></localDocumentNumberList><documentTitle>High-dose cisplatin in hypertonic saline for the treatment of metastatic or recurrent malignant melanoma Phase II pilot</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8567</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8567</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of menogaril (nsc-269148) in non-small cell lung carcinoma: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8417/19</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8417/19</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of two consolidation regimens in the treatment of adult acute lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8460</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8460</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy (cope) and radiation therapy for extensive small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8500</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8500</localDocumentNumber></localDocumentNumberList><documentTitle>Second-line treatment of advanced measurable ovarian cancer with chip: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8376</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8376</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of combination systemic and intraperitoneal chemotheapy for stage iii ovarian cancer: adriamycin, cis-platinum, cyclophosphamide</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8316</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8316</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of fludarabine phosphate in renal cell carcinoma, Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8260</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8260</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot. treatment of Non-Small Cell Bronchogenic Carcinoma (NSCBC) with Vinblastine and Mitomycin-C(VEMI)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8272</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8272</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II pilot treatment of Primary Brain Tumors w/adjuvant chemotherapy and radiation therapy utilizing Intra-Arterial Cis-Platinum and CCNU</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8208</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8208</localDocumentNumber></localDocumentNumberList><documentTitle>Trial of Chlorozotocin and 5-FU in Metastatic Islet Carcinoma; Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8223/24/25</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8223/24/25</localDocumentNumber></localDocumentNumberList><documentTitle>Master protocol:  randomized comparison of combination drug therapy for Squamous Cell Cancer of the Head and Neck with early assessment of Phase II agents; Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8092</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8092</localDocumentNumber></localDocumentNumberList><documentTitle>Use of Human Tumor Cloning System to select chemotherapy for patients with Ovarian Cancer refractory to primary therapy, ancillary study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8110</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8110</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III treatment of advanced Germ Cell Neoplasms of the Testis: Remission induction with VBS vs. VPV; Surgical removal of all Residual Tumor;  maintenance therapy &amp; Cyclophosphamide, Actinomycin-D, ADRIA. &amp; VBL vs observation   bservat</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7984</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7984</localDocumentNumber></localDocumentNumberList><documentTitle>The treatment of Chronic Stage CML with Pulse, Intermittent Busulfan therapy with or without Oral Vitamin-A</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8001</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of two maintenance regimens in the treatment of acute lymphoblastic leukemia in adults</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7963</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7963</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of Amsacrine in Solide Tumors, Myeloma, and Lymphoma: A University of Arizona and Southwest Oncology Group study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7902</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7902</localDocumentNumber></localDocumentNumberList><documentTitle>Combined modality therapy with chemotherapy, radiotherapy and surgery vs. radiotherapy and surgery in advanced previously untreated (unresectable) stage III and IV Epidermoid Cancer of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7916</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7916</localDocumentNumber></localDocumentNumberList><documentTitle>Gallium Nitrate Phase II in Metastatic Urological Malignancies(Testicular, Bladder, Prostate and Kidney)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7918</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7918</localDocumentNumber></localDocumentNumberList><documentTitle>Amsa Phase II evaluation in Hodgkins and Non-Hodgkins Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7808</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7808</localDocumentNumber></localDocumentNumberList><documentTitle>Combined modality treatment for stages III and IV Hodgkin's Disease - MOPP#6</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7813</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7813</localDocumentNumber></localDocumentNumberList><documentTitle>Ifosfamide Phase II TX of Resistant Disseminated Malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7814</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7814</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of methotrexate and Cis-Platinum for patients with advanced Squamous Cell Carcinoma of the Head and Neck Region</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7760</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7760</localDocumentNumber></localDocumentNumberList><documentTitle>Combined chemotherapy-radiation therapy study for stages III &amp; IV Nodular Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7767</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7767</localDocumentNumber></localDocumentNumberList><documentTitle>Methotrexate w/ Citrovorum factor rescue Phase II pilot high dose treatment of advanced/recurrent Gynecological Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7713/14</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7713/14</localDocumentNumber></localDocumentNumberList><documentTitle>Chemoimmunotherapy in Non-Hodgkin's Lymphoma CHOP  vs. CHOP + Levamisole vs. CHOP + Levamisole + BCG for remission induction therapy: Levamisole vs. no maintenance after remission induction</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7521</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7521</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy with or without immunotherapy in high-risk Melanoma patients: an adjuvant study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7424/25</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7424/25</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy utilizing BCNU Hydroxyurea and DTIC (BHD) with and without BCG and DTIC in the treatment of patients with Disseminated Malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-229</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-229</localDocumentNumber></localDocumentNumberList><documentTitle>Study of Dibromomannitol in Chronic Granulocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-76-GU-310</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-76-GU-310</localDocumentNumber></localDocumentNumberList><documentTitle>Study of combined modality therapy with radiation and Lymphadenectomy in stage I &amp; II Non-Seminomatous Germinal Tumors randomizing patients with positive nodes to post operative radiation with or without combination CT</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-78-THY-225</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-78-THY-225</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Adriamycin plus Cis-Platinum in advanced Thyroid Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-346</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-346</localDocumentNumber></localDocumentNumberList><documentTitle>MTX, VCR &amp; PDN in Acute Lymphoblastic Leukemia consolidating remissions with ARA-C/TG followed by L-ASP/VCR/PDN, randomizing to 6-MP/CTX + cranial irradiation &amp; intrathecal MTX</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-347</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-347</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of high, divided oral dose methotrexate with citrovorum factor rescue vs. low divided oral dose methotrexate in Squamous Cell Carcinoma of the Head and Neck and Carcinomas of the Breast and Colon</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-SAR-77-316</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-SAR-77-316</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III adjuvant study of stage I Soft Tissue Sarcomas randomized to C. Parvum or no therapy; stage II-III Soft Tissue Sarcomas and Chondrosarcomas randomized to C. Parvum or Adriamycin, Cyclophosphamide + Methotrexate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-SAR-81-238</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-SAR-81-238</localDocumentNumber></localDocumentNumberList><documentTitle>Studies in Sarcomas - master protocol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-151</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-151</localDocumentNumber></localDocumentNumberList><documentTitle>5-Azacytidine:  a new drug for the treatment of Myeloblastic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-P-229</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-P-229</localDocumentNumber></localDocumentNumberList><documentTitle>Study for stage III and IV Epidermoid Carcinoma of the Oral Cavity, of Hypopharynx and Larynx</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-RM-P54</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-RM-P54</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive Mitomycin C chemotherapy and autologous bone marrow transplantation for the treatment of Refractory Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-MM-82-349</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-MM-82-349</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III induction chemotherapy with BCP (BCNU/CTX/PRED) vs BCP/CACP vs BCP/L-PAM/VCR for previously untreated Myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-NHL-77-317</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-NHL-77-317</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized comparison of BCNU, Cyclophosphamide, Vincristine, Prednisone (BCOP) vs. Cyclophosphamide, Adriamycin, Vincristine, and Prednisone (CHOP) in Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-NHL-82-296</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-NHL-82-296</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II investigation of human Lymphoblastoid Interferon in Refractory Non-Hodgkin's Lymphomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-MEL-77-212</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-MEL-77-212</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II randomized study of Cyclophosphamide and Imidazole Carboxamide Dimethyl Triazeno with or without Peperazinedione in Metastatic Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-MM-76-311</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-MM-76-311</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of induction therapy with BCNU, Cyclophosphamide and Prednisone (BCP) in previously untreated Myeloma patients, randomizing responders to maintenance therapy or to no further therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-LUN-78-328</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-78-328</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy utilizing Cyclophosphamide, Adriamycin &amp; Vincristine with prophylactic brain radiation vs combination CT with Cyclophosphamide, Adriamycin &amp; Vincristine in combination with radiation therapy + prophylactic brain r</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-HN-82-280</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-HN-82-280</localDocumentNumber></localDocumentNumberList><documentTitle>Icrf-187 Phasw II in Squamous Carcinoma of head &amp; neck origin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-HN-82-281</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-HN-82-281</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive consolidation chemotherapy with three, non-cross resistant, two drug combinations after</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-LUN-P31</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-P31</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of disseminated Small Cell Bronchogenic Carcinoma of Lung with CCNU, Procarbazine and VP 16-213</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-LUN-P41</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-P41</localDocumentNumber></localDocumentNumberList><documentTitle>Pala Phase II pilot in advanced Bronchogenic  Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-3285</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-3285</localDocumentNumber></localDocumentNumberList><documentTitle>Favorable histology (nodular) Non-Hodgkin's Lymphoma (NDPL (IWF-B, NML (IWF-C)); a randomized Phase II study of Recombinant Alpha 2 Interferon with or without Naproxen</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-5185</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-5185</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of continuous infusion 5-Flourouracil plus weekly Cis-Platinum for measurable Pancreatic Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-5284</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-5284</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of 5-FU delivered as a constant intravenous systemic infusion vs 5-FU delivered as an intermittment bolus infusion in advanced measurable Colorectal Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-5383</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-5383</localDocumentNumber></localDocumentNumberList><documentTitle>A trial of SMF(Streptozotocin, Mitomycin-C, 5-Fluorouracil) plus irradiation in locally advanced Pancreatic Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>EST-5487</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-5487</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Interferon Alpha2 for the treatment of the chronic Myeloproliferative disorders</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>EST-6282</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-6282</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of dtic and Cis-platinum in the treatment of non-resectable Islet Cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-7181</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-7181</localDocumentNumber></localDocumentNumberList><documentTitle>Chemohormonal therapy of previously treated metastatic Breast cancer patients with no prior exposure to Adriamycin - a comparative evaluation of (Dath) vs (D [Dhad] th)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-4273</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4273</localDocumentNumber></localDocumentNumberList><documentTitle>Survival and response to Chemotherapy for advanced Colorectal adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-4275</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4275</localDocumentNumber></localDocumentNumberList><documentTitle>Combination Chemotherapy of Colon and Rectal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-3877-15</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3877-G2</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study in the treatment of advanced Renal Cell cancer: Pala, Amsa, Indicine-n-oxide</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-3882</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3882</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of combined Chemohormonal therapy in metastatic Prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2582</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2582</localDocumentNumber></localDocumentNumberList><documentTitle>Cis-platinum Phase II in recurrent or metastatic invasive Thymoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2783</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2783</localDocumentNumber></localDocumentNumberList><documentTitle>Master protocol for the evaluation of new treatments in patients with malignant Mesothelioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2879</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2879</localDocumentNumber><localDocumentNumber>N81-0991</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of Chemotherapy of advanced Ovarian cancer using low or high dose Cis-platinum with Hexamethylmelamine</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2479</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2479</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III multiple Myeloma: evaluation of combination Chemotherapy in previously untreated patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2575-13/14</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2575-G4</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III master protocol for the evaluation of new treatments for patients with metastatic non-small cell Bronchogenic carcinoma: generation 4</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2278-14/15</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2278-G1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II master protocol for the evaluation of new agents in patients with esophageal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2379-14/15/16</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2379-G2</localDocumentNumber></localDocumentNumberList><documentTitle>Dibromodulcitol vs Mitoxantrone vs Vinblastine Phase II study of new agents in TX of advanced ca of Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2174</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2174</localDocumentNumber></localDocumentNumberList><documentTitle>Oophorectomy with or without adjuvant Chemotherapy for recurrent and metastatic Mammary carcinoma in pre-menopausal women</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1785</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1785</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II protocol for the evaluation of new treatments in patients with advanced Soft Tissue sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1877</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1877</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of metastatic Testicular Tumors with Cyclophosphamide, Actinomycin-D, Vinblastine, Bleomycin, Cis-platinum followed by maintenance or a cyclic crossover</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1482</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1482</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III protocol for the prospective evaluation of immediate versus delayed Chemotherapy for patients with indolent desseminated (stage III or IV) Non-Hodgkin's malignant Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1579</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1579</localDocumentNumber></localDocumentNumberList><documentTitle>Amsa vs Neocarzinostatin Phase II evaluation of amsa and Neocarzinostatin in Non-small cell Lung ca</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1582</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1582</localDocumentNumber></localDocumentNumberList><documentTitle>Comparison of Cav to an alternating sequence of Cav and intensive Hexameth., VP-16, MTX (HEM) followed by a comparison of maint. vs. no maint. in complete responders in extensive disease small Cell Carc. of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1284-14</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1284-14</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II master protocol for the evaluation of new agents in patients with Esophageal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1377</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1377</localDocumentNumber></localDocumentNumberList><documentTitle>Comparison of Methotrexate alone vs a combination of Methotrexate, Bleomycin, and Cisplatin vs Methotrexate with subcutaneous C.Parvum in metastatic or locally recurrent Squamous Cell carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-P-G484</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-G484</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study for therapy of untreated multiple Myeloma patients with stage I disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-P-H481</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-H481</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II multiple Myeloma: evaluation of the role of sequential hemi-body Irradiation after initial Chemotherapy in previously untreated patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-P-I883</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-I883</localDocumentNumber><localDocumentNumber>V85-0040</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II clinical trial of intraperitoneal Cisplatin with systemic Adriamycin and Cyclophosphamide(IP-CAC) Chemotherapy for stage III/IV adenocarcinoma of the Ovary</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-P-Z386</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-Z386</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Interferon alpha in locally recurrent or metastatic Head and Neck cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-D580</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-D580</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Mitomycin-c, Hexamethymelamine, and Desacetyl Vinblastine Amide Sulfate (Vindesine) in non-small cell Bronchogenic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-D877</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-D877</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy of advanced Ovarian cancer using Cis-diamminedichloroplatinum (II) with Hexamethylmelamine or with Hexamethylmelamine and Adriamycin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-C480</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C480</localDocumentNumber></localDocumentNumberList><documentTitle>Amsa, Ara-c, ctx and Prednisone therapy in the treatment of patients with relapsed acute Non-lymphocytic leukemia: Phase I /II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-C583</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C583</localDocumentNumber></localDocumentNumberList><documentTitle>Trial of Chemotherapy with Vinblastine, and Cis-platinum (VP) followed by Radiotherapy in patients with locally advanced Non-small Cell Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-C885</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C885</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II pilot study of Pentostatin (2'-Deoxycoformycin) in metastatic Renal Cell cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-D178</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-D178</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study to evaluate Hexamethylmelamine, Vincristine, and Methotrexate in metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-C387</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C387</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of adjuvant high-dose Chemotherapy, autologous bone marrow transplant and Cranial Irradiation for patients with primary malignant Brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-B483</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B483</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I pilot study for the treatment of acute Non- lymphocytic leukemia in the elderly (>65 years) with attenuated high dose Cytosine Arabinoside (at HDARAC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-B586</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B586</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot study of Cisplatin, 5-Fluorouacil and Etoposide for advanced measurable Non-small Cell Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-A686</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A686</localDocumentNumber></localDocumentNumberList><documentTitle>GOG-111GOG-111GOG-111of Taxol (NSC 125973) in patients with malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-A386</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A386</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study for the evaluation of Spiromustine in primary Brain Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-A584</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A584</localDocumentNumber></localDocumentNumberList><documentTitle>A study of concurrent Hyperfractionated Radiotherapy and Chemotherapy for the treatment of Small Cell Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-061-0724</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0112</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III intensive consolidation and prolonged intensive maintenance therapy for adult acute non-lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-551</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0102</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot treatment of cytomegalovirus infection in oncolytic patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-043-0187</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>G81-02</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III ovarian cancer study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-043-0443</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-81-92</localDocumentNumber></localDocumentNumberList><documentTitle>High dose cytoxan, bcnu and vp-16,213 followed by allogeneic bone marrow transplant in patients with acute leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-004-0086</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ALL-8001</localDocumentNumber><localDocumentNumber>CTEPIS-0042</localDocumentNumber></localDocumentNumberList><documentTitle>Adult acute lymphoblastic leukemia: a study of a comprehensive therapeutic program</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-006-0762</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC-2571</localDocumentNumber></localDocumentNumberList><documentTitle>Four drug maintenance with vm-26, cytosine arabinoside, methotrexate and l-asparaginase for relapsed acute lymphocytic leukemia and non-hodgkin's lymphomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-012-0899</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-82N5</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of advanced head and neck cancer with htsca directed therapy or Phase II agents</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D81-050-0574</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Pilot study of amsa in combination chemotherapy with high dose methotrexate for refractory acute nonlymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D81-053-0669</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0009</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16,213 &amp; cis-platinum combination chemotherapy for relapse in small cell carcinoma of the lung or advanced malignant lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D81-067-0388</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II study of vp-16 alone, or in combination with platinum +/- bleomycin, in patients with non-resectable germinal cancer failing initial drug treatment</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D81-043-0098</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-80-75</localDocumentNumber></localDocumentNumberList><documentTitle>Comparative study of vp-16,213, vindesine, and cis-diammine- dichloroplatinum in the therapy of advanced non-oat cell- lung carcinoma:  a three arm study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D81-043-0347</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-80-65</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive combined modality treatment of small cell lung cancer with systemic chemotherapy, adjuvant surgery and radiation therapy (echo no. 3)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D81-045-0430</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>The use of galactitol as a "synchronizing agent" in a cell kinetic directed treatment schedule in patients with advanced disseminated cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D81-032-0559</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Adjuvant therapy for patients with dukes b2 and c rectal cancer:  a Phase III comparison of surgery plus post operativeradiation, versus surgery plus radiation, plus one of two forms of chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D81-039-0506</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Autologous bone marrow transplantation for patients with acute nonlymphocytic leukemia in remission</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D80-048-0280</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Dibromodulcitol vs vindesine Phase II rand crossover chemo of metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D81-002-0362</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2L80</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16,213 Phase II trial in carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D80-004-0156</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Dibromodulcitol Phase II stage iv metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D80-005-0113</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>80-01</localDocumentNumber></localDocumentNumberList><documentTitle>Dibromodulcitol Phase II stage iv met malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D80-006-0242</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC-2090</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of small cell carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D80-018-0286</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>80-004</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16 and 5-azacytidine for refractory acute myelogenous leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D80-020-0220</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>80-81-01</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16,213 in treatment of acute non-lymphocytic leukemia for pts older than 65</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D79-035-0229</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>79H0156</localDocumentNumber></localDocumentNumberList><documentTitle>Thc vs haloperidol Phase II randomized study of comparative effects of patients receiving chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>T86-0088</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UAC-226</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of combined gamma interferon and 17-1a monoclonal antibody in metastatic colon cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>T86-0102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-86I1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of fludarabine phosphate in adenocarcinoma of stomach</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:36"><nciDocumentNumber>D79-010-0141</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>457-79</localDocumentNumber></localDocumentNumberList><documentTitle>Autologous marrow transplantation following cyclophosphamide and total body irradiation in leukemia in relapse - a pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>SEG-HN-79-357</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-HN-79-357</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for late stage IV Epidermoid Carcinoma of the Oral Cavity (Floor of Mouth, Anterior Tongue, Retromolar Trigoneand Alveolar Ridge) Larynx and Hypopharynx (Pyriform Sinus) and Oropharynx</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>SEG-HN-82-182P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-HN-82-182P</localDocumentNumber></localDocumentNumberList><documentTitle>Intra-arterial chemotherapy for advanced Squamous Cell Carcinoma of the Oral Cavity Paranasal Sinuses, Tonsillar Fossa and Base of Tongue</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>T86-0044</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>86-777</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of recombinant gamma interferon pre-treatment and murine monoclonal antibody therapy of patients with colorectal cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>T86-0047</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC-8603</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of trimetrexate in advanced ovarian cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>SEG-GU-215L</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-GU-215L</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of Cisplatin plus Ifosfamide plus Mesna plus plant Alkaloid (VP-16 or Vinblastine) as salvage therapy in men with Refractory Germ Cell Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>SEG-GU-303</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-GU-303</localDocumentNumber><localDocumentNumber>SWOG-8788</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III evaluation of high dose versus standard dose Cisplatin combined with Bleomycin and VP-16 for advanced Metastatic Testicular Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>SEG-GU-306</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-GU-306</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III trial of 9 week or 12 weeks of Cisplatin, Etoposide and Bleomycin in minimal or moderate extent disseminated Germ Cell Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>DT-77-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-77-52</localDocumentNumber></localDocumentNumberList><documentTitle>Chemoimmunotherapy of metastatic squamous cell carinoma of the lung with ftorafur, adriamycin, cyclophosphamide and thymosin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>D77-020-0215</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Vp-16,213 for induction of cr in those pts w/anll resistant to conventional therapy (ara-c, daunomycin &amp; adriamycin)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>D78-001-0132</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II study of vp-16, high dose methotrexate with citrovorum factor rescue and ccnu in patients with recurrent or progressive oat cell carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>DT-73-39A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-73-39A</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of pepa program in chemotherapy of non-hodgkin's lymphoma, combination chemotherapy of cytoxan, vincristine, adriamycin, prednisone and bleomycin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>DT-76-25</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-76-25</localDocumentNumber></localDocumentNumberList><documentTitle>Clinical trial of pyrazofurin in combination with trifluorothymidine (f3tdr)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>SEG-GI-81-246</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-GI-81-246</localDocumentNumber></localDocumentNumberList><documentTitle>AZQ Phase II in advanced Gastric Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>T86-0024</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>86/0037</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of homoharringtonine in patients w/recurrent malignant central nervous system tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>C81-0239</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A randomized study of maintenance vs. no maintenance therapy in good risk patients with metastatic germ cell tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:37"><nciDocumentNumber>C81-0511</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-81-24</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemoimmunotherapy for metastatic malignant melanoma using a four-drug regimen + mer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:38"><nciDocumentNumber>SEG-BRE-83-309</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-BRE-83-309</localDocumentNumber></localDocumentNumberList><documentTitle>Sequential methotrexate, 5-Fluorouracil with continuous Tamixofen vs. Sequential Methotrexate, 5-Fluorouracil with "hormonal synchronization" in patients with Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:38"><nciDocumentNumber>SEG-CML-79-358R</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-CML-79-358R</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of previously treated Chronic Myelocytic Leukemia randomizing patients to busulfan, Busulfan plus 13-Cis-Retinoic Acid, Hydroxyurea, or Hydroxyurea + 13-Cis-Retinoic Acid</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:38"><nciDocumentNumber>SEG-CML-83-215L</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-CML-83-215L</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II study of Syngeneic/Allogeneic BMT from genotypically HLA-identical siblings for Chronic Myelogenous Leukemia in chronic, accelerated or second chronic phase after blast crisis, phase STS-V, VYV, TBI.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:40"><nciDocumentNumber>C78-0151</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-78-46-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase ii-iii studies of two drug combinations in colo-rectal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:40"><nciDocumentNumber>T85-0172</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>374-85-7</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of intravenous melphalan (l-phenylalanine mustard, nsc-8806) in the treatment of patients with anaplastic gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:40"><nciDocumentNumber>C76-0620</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-75-10</localDocumentNumber></localDocumentNumberList><documentTitle>Chemoimmunotherapy of disseminated malignant melanoma with dtic bcg transfer factor +/- melphalan</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:41"><nciDocumentNumber>SEG-BRE-80-370</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-BRE-80-370</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III trial of Medical Adrenalectomy with Amino- Glutethimide &amp; Hydrocortisone with or without Cytoxan, Adriamycin &amp; 5-FU in estrogen receptor positive Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:41"><nciDocumentNumber>SEG-BRE-82-281P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-BRE-82-281P</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of intensive consolidation chemotherapy with 3, non-cross resistant, 2 drug combinations after induction chemotherapy with Cyclophosphamide, Adriamycin and 5-FU in patients with aggressive forms of Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:42"><nciDocumentNumber>SEG-BRE-P48</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-BRE-P48</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II pilot study of Inosine Dialdehyde in Metastatic Breast Cancer refractory to standard agents.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:42"><nciDocumentNumber>SEG-BRE-203</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-BRE-203</localDocumentNumber><localDocumentNumber>SWOG-8636</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Echinomycin in Metastatic Carcinoma of the Breast utilizing two concurrent groups, stratified according to previous Anthracycline exposure</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:42"><nciDocumentNumber>COG-7231</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>COG-7231</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III chemotherapy with adr. and with combinations of act-d, l-pam, vcr and cyl for soft tissue and osseous sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:42"><nciDocumentNumber>SEG-AML-83-335</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-AML-83-335</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized study of Duanorubicin plus standard dose Cytosine Arabinoside vs. Daunorubicin plus high dose Cytosine Arabinoside as "salvage" induction therapy in Acute Myelogenous Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:43"><nciDocumentNumber>CCG-881</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-881</localDocumentNumber></localDocumentNumberList><documentTitle>Hepatoma iii study: a protocol for the treatment of hepatoblastoma and hepatocellular carcinoma in children</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>CCG-962</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-962</localDocumentNumber></localDocumentNumberList><documentTitle>Therapy for extraocular retinoblastoma with cyclophosphamide, vincristine sulfate and adriamycin and irradiation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>RTOG-86-12</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-86-12</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of Iododeoxyuridine (IUDR) and radiotherapy in the treatment of primary malignant Brain Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>RTOG-87-05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-87-05</localDocumentNumber></localDocumentNumberList><documentTitle>A Non-Randomized Phase I/II study of efficacy of Radiation and Hyperthermia (45'C for 15 minutes) in the treatment of some measurable superficial Human Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>RTOG-88-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-88-01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II study of Prophylactic Hepatic irradiation with local irradiation and systemic chemotherapy for Adenocarcinoma of the Pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>SEG-A-07</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-A-07</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II randomized study of Daunorubicin, Arabinosyl Cytosine and Lithum Carbonate vs Daunorubicin, Arabinosyl Cytosine as induction therapy of Acute Myelogenous Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>SEG-A-09</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-A-09</localDocumentNumber></localDocumentNumberList><documentTitle>Comparison on an adjuvant, post-operative chemotherapy program with the same chemotherapy plus Levamisole Immunotherapy for stage II and III Breast Cancer patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>CCG-371P/373P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-371P/373P</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy for stage iii and iv neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>CCG-502</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-502</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized trial of modified lsa2l2 vs adcomp and radiation therapy for treatment of non-localized lymphoblastic lymphoma in childhood combined with a study of disease characterization</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:44"><nciDocumentNumber>CCG-243</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-243</localDocumentNumber></localDocumentNumberList><documentTitle>Reinduction therapy of acute non-lymphocytic leukemia from maintenance on ccg-241 (d-zapo)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:45"><nciDocumentNumber>CCG-095</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-095</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I pediatric study of homoharringtonine (nsc 141633) in children with leukemia or solid tumors refractory to standard therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:45"><nciDocumentNumber>CCG-101</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-101</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of newly diagnosed acute lymphocytic or undifferentiated leukemia with intensive chemotherapy and radiation therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:45"><nciDocumentNumber>CCG-102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-102</localDocumentNumber></localDocumentNumberList><documentTitle>Cytosine arabinoside, cyclophosphamide, vincristine, thioguanine and prednisone in previously untreated acute myelocytic, myelomonocytic and erythroleukemia of childhood (non-all, non-aul)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:45"><nciDocumentNumber>T85-0129</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>85-742</localDocumentNumber></localDocumentNumberList><documentTitle>Effect of recombinant gamma interferon pretreatment on the reponse of patients with advanced gastrointestinal adenocarcinoma to murine monoclonal antibody therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:45"><nciDocumentNumber>T85-0132</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>19-85(1)</localDocumentNumber></localDocumentNumberList><documentTitle>A multi-center open label Phase I trial of Suramin in patients with the Acquired Immune Deficiency Syndrome (AIDS)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CCG-E-05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-E-05</localDocumentNumber></localDocumentNumberList><documentTitle>Case-control study of childhood Acute Non-Lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CALGB-8662</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8662</localDocumentNumber></localDocumentNumberList><documentTitle>Monitoring circulating Breast Cancer-Associated Antigens with the 15-3 radioimmunoassay in Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CALGB-8691</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8691</localDocumentNumber><localDocumentNumber>EST-7486</localDocumentNumber></localDocumentNumberList><documentTitle>Cyclophosphamide vs. Cyclophosphamide plus Alpha 2 Interferon in the treatment of Follicular, Low Grade Lymphomas: Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CALGB-8731</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8731</localDocumentNumber></localDocumentNumberList><documentTitle>Etoposide and Carboplatin in Advanced Non-Small Cell Lung Cancer: A Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CALGB-8736</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8736</localDocumentNumber></localDocumentNumberList><documentTitle>Regional stage III Non-Small Cell Lung Carcinoma (NSCLC): Induction Chemotherapy-Radiation Therapy vs. Induction Chemotherapy-Radiation Therapy followed by Adjuvant Chemotherapy: Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CALGB-8623</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8623</localDocumentNumber></localDocumentNumberList><documentTitle>Continuous infusion Etoposide (VP-16) and Mitoxantrone (DHAD) (NSC#301739) in Acute Non Lymphocytic Leukemia: relapsed or failed induction: A limited access Phase I study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CALGB-8652</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8652</localDocumentNumber></localDocumentNumberList><documentTitle>Subcutaneous Alpha2 Interferon Treatment of Previously Treated Hodgkin's Disease: Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:46"><nciDocumentNumber>CALGB-8513</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8513</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial of intensive treatment for Adult Acute Lymphocytic Leukemia: a comparison of combination Chemotherapy plus alternating Mitoxantrone and Daunorubicin vs. combination Chemotherapy plus Daunorubicin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8552</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8552</localDocumentNumber><localDocumentNumber>T84-0293</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Ifosfamide and MESNA in Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8553</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8553</localDocumentNumber></localDocumentNumberList><documentTitle>A tolerance trial of Subcutaneous Alpha-2 Interferon in combination with Oral Cyclophosphamide in Previously Untreated and Treated Favorable Histology Non-Hodgkin's Lymphoma:  A pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>T85-0099</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU-8513</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II investigation of Fludarabine Phosphate in advanced Refractory Hodgkin's disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8411</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8411</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive treatment of Adult Acute Lymphocytic Leukemia (ALL): A limited access pilot: newly diagnosed patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8443</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8443</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive Adjuvant CAF Stage II Breast Cancer: Cyclophosphamide, Adriamycin and 5-Fluorouracil, a pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8462</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8462</localDocumentNumber></localDocumentNumberList><documentTitle>Subrenal Capsule Assay (SRCA) as a predictor of response in Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8173</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8173</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Refractory Adult Acute Lymphoblastic Leukemia with Vincristine/Prednisone plus Tandem L-Asparaginase/Methotrexate and Cytosine Arabinoside/6-Thioguanine</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-7972</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7972</localDocumentNumber></localDocumentNumberList><documentTitle>Amsa Phase II trial for Refractory Hodgkins Disease, Diffuse Histiocytic Lymphoma and Diffuse PDL</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-8083</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8083</localDocumentNumber></localDocumentNumberList><documentTitle>Localized Small Cell Carcinoma of the Lung: a Phase III study: Simutaneous Chemotherapy and Radiotherapy vs Sequential Therapy (CHEM, RADIO, CHEM) vs Chemotherapy alone</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-7481</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7481</localDocumentNumber></localDocumentNumberList><documentTitle>Effect of Long Term Surgical Adjuvant Systemic Chemotherapy in Mammary Carcinoma: a comparative study of CYT/vcr/5-FU/PRED vs observation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>CALGB-7552</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7552</localDocumentNumber></localDocumentNumberList><documentTitle>Combination Chemotherapy and Immunotherapy for previously treated stage IIIB and IV Hodgkin's Disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>RTOG-85-12</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-85-12</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of combined modality program with Organ Preservation in Carcinoma of the Bladder</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>PROG-85-26</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PROG-85-26</localDocumentNumber><localDocumentNumber>RTOG-85-26</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II randomized study of charged particle radiation in the treatment of Chordomas or low grade Chondrosarcomas of the base of Skull or Cervical Spine</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>RTOG-84-21</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-84-21</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study to evaluate surgery vs. surgery and radiation therapy for Oral Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:47"><nciDocumentNumber>RTOG-85-05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-85-05</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II study of resectable, unresectable and localized Adenocarcinoma of Pancreas utilizing external and intraoperative radiotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-82-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-82-01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I treatment of Glioblastoma Multiforme with hyperfractionation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-83-03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-83-03</localDocumentNumber><localDocumentNumber>T83-1251</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I trial of the Hypoxic Cell Radiosensitizer, SR-2508</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-83-06</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-83-06</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III protocol for Adenocarcinoma of the Breast stage T1, T2, N0, M0 comparing boost with electrons versus implant</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-83-07</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-83-07</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II randomized study of Mergestrol and Diethylstilbesterol adjuvant to radiation therapy in Locally Advanced Cancer of the Prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-83-08</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-83-08</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase I/II study to evaluate twice daily fractional radiation for Locally Advanced Transitional Cell Carcinoma of the Bladder</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-83-14</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-83-14</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study to evaluate the treatment of Squamous Cell &amp; Baseloid Carcinoma of the Anal Canal by radiation therapy and chemotherapy for radiosensitization followed by Biopsy +/- A-P Resection</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-81-08</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-81-08</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II study to evaluate 2 fractions per day radiation therapy in Locally Advanced Non-Oat Cell Carcinoma of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>INT-0085</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>8-11-15-5</localDocumentNumber></localDocumentNumberList><documentTitle>Therapy of "high risk" patients in first relapse of acute nonlymphocytic leukemia with a combination of high dose ara c and amsa</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>INT-0090</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Pilot Phase II study of selected high risk newly diagnosed patients with acute nonlymphocytic leukemia:a leukemia intergroup study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>INT-0076</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-7186</localDocumentNumber><localDocumentNumber>SWOG-8696</localDocumentNumber></localDocumentNumberList><documentTitle>Prediction of recurrence and therapy response in the node negative Breast cancer patient by dna flow cytometry</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>INT-0077</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3185</localDocumentNumber><localDocumentNumber>SWOG-8697</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of predominantly hormone insensitive metastatic Breast cancer:  Phase III </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>INT-0078</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-5886</localDocumentNumber><localDocumentNumber>SEG-GU-305</localDocumentNumber><localDocumentNumber>SWOG-8594</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial of cisplatin alone or in combination with doxorubicin, vinblastine and methotrexate in advanced bladder cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-78-32</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-78-32</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II protocol for the evaluation of Misonidazole combined with radiation in the treatment of patients with locally Advanced Squamous Cell Carcinoma of the Esophagus.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-79-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-79-04</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II protocol for the evaluation of toxicity and effectiveness of Misonidazole combined with high fractional dose radiation in the treatment of patients with nonresectable advanced or recurrent Squamous Cell Carcinoma of the Head an</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-79-13</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-79-13</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol to study two radiotherapy fractions per day in the treatment of Advanced Squamous Cell Carcinoma of the Oral Cavity, Pharynx, Larynx and Sinuses using radiation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-79-23</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-79-23</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Radiobiological Effects of Negative PI Mesons on miscellaneous locally advanced and/or recurrent Human Solid Tumors and surrounding normal tissues</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>RTOG-79-24</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-79-24</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Radiobiological effects of negative PI Mesons on miscellaneous Metastatic Lesions</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>INT-0064</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-85-24</localDocumentNumber><localDocumentNumber>SWOG-8609</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II study of neutron vs. photon radiation therapy after induction chemotherapy for inoperable, regional, non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:48"><nciDocumentNumber>T85-0026</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>85-GU-02</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of hormonally Refractory Stage D Carcinoma of the Prostate with chip</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>RTOG-77-05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-77-05</localDocumentNumber></localDocumentNumberList><documentTitle>Non-Randomized study of radiation therapy using neutrons alone or with photons or of either in combination with surgery for the treatment of clinical Stage BI, (Grade III or IV) or Stage BII, C and DI (any grade) Urinary Bladder Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>RTOG-70-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-70-02</localDocumentNumber></localDocumentNumberList><documentTitle>The use of adjunctive Oxygen breathing in the irradiation of Carcinoma of the Oral Cavity, Oropharynx, Nasopharynx, Hypopharynx, Larynx, and Esophagus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>RTOG-75-06</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-75-06</localDocumentNumber></localDocumentNumberList><documentTitle>Radiation therapy in the treatment of stage C and stage B with Pelvic Nodal Metastases Adenocarcinoma of the Prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>RTOG-75-07</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-75-07</localDocumentNumber></localDocumentNumberList><documentTitle>Registry protocol for Adenocarcinoma of the Breast, stage I &amp; II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>BTSG-7501</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BTSG-7501</localDocumentNumber></localDocumentNumberList><documentTitle>Surgery plus radiotherapy and BCNU or Mthylprednisolone or Procarbazine or BCNU and Methylprednisolone</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>BTCG-87-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BTCG-87-01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III: Malignant Glioma -- surgery and interstitial radiotherapy boost and external radiotherapy and BCNU vs. surgery and external radiotherapy and BCNU</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>BTSG-7201</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BTSG-7201</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for the study of BCNU, Methyl-CCNU and irradiation in the treatment of Malignant Glioma of the Brain: Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>INT-0034</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-85-03</localDocumentNumber><localDocumentNumber>CALGB-8591</localDocumentNumber><localDocumentNumber>EST-1384</localDocumentNumber><localDocumentNumber>NCOG-7H-84-2J</localDocumentNumber><localDocumentNumber>SEG-INT-HN-301</localDocumentNumber><localDocumentNumber>SWOG-8590</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study to determine the effect of combining chemotherapy with surgery and radiotherapy for resectable squamous cell carcinoma of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>INT-0029</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/><localDocumentNumber>CCG-785</localDocumentNumber><localDocumentNumber>POG-8095</localDocumentNumber><localDocumentNumber>SWOG-8095</localDocumentNumber></localDocumentNumberList><documentTitle>Multimodal therapy of metastatic ewing's sarcoma with chemotherapy including adriamycin, vincristine, cyclophosphamide,5-fluorouracil , actinomycin-d, plus irradiation and surgery (if feasible)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>PVSG-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PVSG-02</localDocumentNumber></localDocumentNumberList><documentTitle>Myeloproliferative disorders protocol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>GOG-26GG</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-26GG</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Fazarabine (ARA-AC, 1-Beta-D-Arabinofuranosyl-5-Azacytosine, NSC # 281272, IND # 29722) in patients with Advanced and Recurrent Pelvic Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>INT-0010</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/><localDocumentNumber>CCG-784</localDocumentNumber><localDocumentNumber>POG-7896</localDocumentNumber><localDocumentNumber>SWOG-7896</localDocumentNumber></localDocumentNumberList><documentTitle>Radiation therapy and combination chemotherapy for localized ewing's sarcoma, pelvic and sacral bones excluded</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>INT-0011</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1180</localDocumentNumber><localDocumentNumber>CALGB-8693</localDocumentNumber><localDocumentNumber>SWOG-8294</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of adjuvant therapy and biological parameters in node negative operable female Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>POG-8763</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8763</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of response and toxicity of Ifosfamide and VP-16-213 in children with resistant Malignant Tumors: A Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>POG-8764</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8764</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy regimen for early and initial induction failures in childhood Acute Lymphoblastic Leukemia: Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>GOG-87C</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-87C</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Hydroxyurea, Dacarbazine (DTIC), and Etoposide (VP-16) in patients with Advanced or Recurrent Uterine Sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>GOG-8801</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8801</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I evaluation of multiple daily fraction radiation and Hydroxurea in patients with stage II-B, III, and IVA Carcinoma of the Cervix with Negative Para-Aortic Nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>POG-8638</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8638</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II study of Carboplatin (CBDCA) vs. Chip in the treatment of children with progressive or recurrent Brain Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>POG-8692</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8692</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II study of 5-Flourouracil, administered as a continuous 5-day intraveous infusion to Pediatric patients with recurrent Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>GOG-8391</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8391</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I - Phase II toxicology/efficacy/immune pharmacology study of Intraperitoneally-Administered Interferon in Advanced Ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>GOG-76F</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-76F</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Gallium Nitrate (NSC # 15200) in patients with Advanced Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>GOG-76J</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-76J</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Mitomycin-c (NSC#26980) in patients with Advanced Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>GOG-50</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-50</localDocumentNumber></localDocumentNumberList><documentTitle>A study of Adriamycin as postoperative therapy for Ovarian Sarcoma, primary or recurrent, with no prior chemotherapy - Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>GOG-72</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-72</localDocumentNumber></localDocumentNumberList><documentTitle>Ovarian Tumors of low malignant potential: a study of the natural history and a Phase II trial of Melphalan and secondary treatment with Cisplatinum in patients with progressive disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>T84-0544</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-85I1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of new agents in patients with advanced Colon Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:49"><nciDocumentNumber>T85-0004</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>85-03</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of ICRF-187 in aid's related Kaposi's Sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>T85-0010</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BTRC-8022</localDocumentNumber><localDocumentNumber>D80-004-178</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of dibromodulcitol for recurrent medulloblastoma and ependymoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>GOG-3</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-3</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of women with Disseminated or Recurrent Advanced Ovarian Cancer with Melphalan alone in combination with 5-Fluorouracil and Dactinomycin or with the combination of Cytoxan, 5-Fluorouracil and Dactinomycin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>GOG-40</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-40</localDocumentNumber></localDocumentNumberList><documentTitle>A clinical-pathologic study of stage I and II Uterine Sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>POG-8600</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8600</localDocumentNumber></localDocumentNumberList><documentTitle>Laboratory methods for POG-8600 ALINC 14 classification (C) portion</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>T90-0128</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.60</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of 10-Edam in patients with Metastatic Breast Cancer (IND.60)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>POG-9079</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9079</localDocumentNumber></localDocumentNumberList><documentTitle>High dose Melphalan and Cyclophosphamide with Autologous Bone Marrow (ABM) rescue for recurrent/progressive Malignant Brain Tumors in children-A POG</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>EST-1790</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1790</localDocumentNumber></localDocumentNumberList><documentTitle>Immunohistochemical analysis of HLA-DR expression in malignant Fibrous Histiocytoma:  evaluation of potential prognostic significance</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>T90-0167</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>383/90</localDocumentNumber></localDocumentNumberList><documentTitle>Comparative Radiolocalization of Monoclonal Antibodies directed to the TAG-72 Antigen following intravenous administration to patients with Colorectal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>RTOG-90-17</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-90-17</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of combined approach with chemotherapy, radiation therapy, and surgery for locally advanced Thymoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>RTOG-90-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-90-04</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II study of EAP Chemotherapy, Surgery/IORT, external beam Radiotherapy for Adenocarcinoma of the Stomach</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>T90-0197</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BGSM-60190</localDocumentNumber></localDocumentNumberList><documentTitle>Concurrent external Hyperthermia and low dose rate continuous irradiation using permanent Palladium-103 interstitial implants for solid tumors recurrent in the neck after previous radiation therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>SWOG-8955</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8955</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of stage D, Hormone Refractory Carcinoma of the Prostate with 5-Fluorouracil and Roferon-A</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:50"><nciDocumentNumber>T90-0203</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I Study of intensive concomitant chemoradiotherapy with Granulocyte Colony Stimulating Factor for patients with Head and Neck Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T90-0222</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Pilot Study of Recombinant Interleukin-2 After Autologous Bone Marrow Transplantation for Pediatric Patients with Acute Myeloid Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T90-0241</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Master protocol for comparative radiolocalization of monoclonal antibodies directed to the Tag-72 antigen following intravenous administration to patients with Colorectal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T91-0004</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>90-852</localDocumentNumber></localDocumentNumberList><documentTitle>High-dose Carboplatin (CBDCA) with recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Interleukin-3 (IL-3), and peripheral blood stem cell (PBSC) harvesting and reinfusion</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T91-0006</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-91-6</localDocumentNumber></localDocumentNumberList><documentTitle>Sequential administration of intravenous 6-Thioguanine after Methotrexate in children with refractory malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>INT-0122</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-E289</localDocumentNumber><localDocumentNumber>RTOG-90-12</localDocumentNumber></localDocumentNumberList><documentTitle>A prospective Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and radiation for squamous cell carcinoma of the esophagus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>EST-P-Y990</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-Y990</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I trial of Alpha-Interferon and Cyclophosphamide, Adriamycin and 5-Fluorouracil in the treatment of Advanced Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>SWOG-9110</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9110</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II evaluation of Didemnin-B in Central Nervous System Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>GOG-116</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-116</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Adjuvant VP-16 and Carboplatin therapy in Totally Resected Ovarian Dysgerminoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T91-0101</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I trial of Interleukin-1 Alpha and Methotrexate in patients with solid tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T91-0105</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-91-042</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Carboplatin and Edatrexate (10-ETX) with Leucovorin rescue for patients with Recurrent Squamous Cell Carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T91-0159</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>3330</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I clinical trial of a Radioimmunoconjugate (131I MAB CC49) in patients with Upper Gastrointestinal Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>NCCTG-91-41-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-91-41-51</localDocumentNumber><localDocumentNumber>91-41-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of 5FU and Levamisole in patients with advanced Gastric cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:51"><nciDocumentNumber>T91-0163</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CHLA-91LA8</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Auto-BMT in pediatric solid tumors with a preparatory regimen that consists of Melphalan, Carboplatin, VP-16 and escalating doses of Cyclophosphamide</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>SWOG-9104</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9104</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Doxorubicin/Vinblastine combined with inhibitors (Trifluoperazine/Verapamil) of P-Glycoprotein in patients with advanced Renal Cell Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>T91-0242</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-91I1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Cisplatin, Doxorubicin, and Etoposide in the treatment of patients with Adenocarcinoma of the Stomach or Esophagus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>T91-0233</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SLU 6565</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of the modification of Hematopoietic toxicity using high dose Cyclophosphamide, VP-16 &amp; Cisplatin (CVP), IL-3 and GM-CSF in patients with Advanced Cancer, Stage A</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>CALGB-9162</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9162</localDocumentNumber></localDocumentNumberList><documentTitle>Study of pharmacokinetic parameters of potential importance in the Efficacy and Toxicity of Fluoropyrimidines</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>NCCTG-91-64-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-91-64-51</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of maximum debulking surgery and Intra-Operative Radiation Therapy (IORT) in local-regionally recurrent Endometrial, Cervical and Vaginal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>I91-0019</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>2-Chlorodeoxyadenosine for Patients with Active Hairy Cell Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>RTOG-92-09</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-92-09</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II study of hyperfractionated external beam irradiation, Prophylactic Hepatic irradiation with concurrent 5-Fluorouracil and low dose Folinic Acid in patients with unresectable Carcinoma of the Pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:52"><nciDocumentNumber>T92-0009</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>9203-23</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of subcutaneously administered human Interleukin-2 (RHUIL-2) in patients with chemotherapy-refractory Thymoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>T92-0075</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM92-046</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Taxol (NSC# 125973) in patients with Non-Small Cell Lung Cancer who have failed platinum-containing chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>E1592</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-5-04</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Topotecan in patients with Small Cell Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>T92-0130</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>92-106</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized study of Cisplatin (CDDP) and Etoposide verses Carboplatin (CBDCA) + Etoposide in the treatment of good risk patients with advanced germ cell tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>CCG-0924</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-0924</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of GM-CSF/Il-3 Fusion Protein (Pixy321) following Ifosfamide, Carboplatin, and Etoposide (IEC) in children with Recurrent Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>T92-0129</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UPCC 1492</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Topotecan in patients with intermediate grade Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>CALGB-9141</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9141</localDocumentNumber></localDocumentNumberList><documentTitle>. feasibility study of Adjuvant Chemotherapy with Dose-Intensified Cyclophosphamide/Doxorubicin (CA) + G-CSF for patients with Operable Breast Cancer and Histologically Involved Axillary Lymph Nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>RTOG-93-03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-9303</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III comparison of Lort with vs. without the Hypoxic Cell sensitizer Etanidazole (SR-2508) (with surgery, external radiation therapy and 5-FU/Leucovorin) for recurrent or locally advanced primary Colorectal Carcinoma.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:53"><nciDocumentNumber>CALGB-9243</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9243</localDocumentNumber></localDocumentNumberList><documentTitle>Prospective Acetylator Phenotyping to assign Amonafide (NSC #308847) dosage in Breast Cancer Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>NCCTG-92-81-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-92-81-51</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of dose-intensive chemotherapy in patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) refractory to Purine Nucleoside Analogs (PNA)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T93-0026</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DMS 9224</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of IL-6 plus G-CSF in association with high dose chemotherapy and autologous stem cell transplantation in advanced Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T93-0028</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>22193</localDocumentNumber><localDocumentNumber>T88-0081</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of 6-Thioguanine (NSC 752,IND 7258) in relapsed and refractory adult Acute Leukemia (AML, ALL) or untreated CGL in blast crisis (CGL-BC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>CCG-0932</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-00057</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of Temozolomide in Pediatric and Adolescent Patients with Progressive Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>POG-9390</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9390</localDocumentNumber></localDocumentNumberList><documentTitle>High-dose Ifosfamide/Carboplatin/Etoposide (ICE) plus GM-CSF in the treatment of children with recurrent AcuteLymphoblastic Leukemia: A Phase I /pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T93-0048</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>93-014</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of Taxol and Estramustine Phosphate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>SWOG-9314</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9314</localDocumentNumber></localDocumentNumberList><documentTitle>Biologic factors predicting response to Tamoxifen in patients registered to SWOG-8228</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T93-0087</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I and pharmacological study of Penclomedine (NSC 338720) administered daily for five consecutive days without and with Granulocyte colony stimulating factor (G-CSF) in patients with advanced solid tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T93-0102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC# 7063</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Topotecan in combination with Cyclophosphamide in patients with Refractory Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>POG-9361</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9361</localDocumentNumber></localDocumentNumberList><documentTitle>Topotecan in Pediatric patients with recurrent or progressive Solid Ttumors: a Pediatric Oncology Group Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T93-0134</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J9335</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II "window" trial of Topotecan in untreated adult patients with high risk Acute Lymphoblastic Leukemia (ALL) or All in first relapse</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T93-0142</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID-93-017</localDocumentNumber></localDocumentNumberList><documentTitle>"Kinetics and Radiosensitivity as predictors of treatment response in human Cervical Carcinoma"</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>CALGB-9255</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9255</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Cyclophosphamide, Prednisone, and Infusional Doxorubicin, Vincristine, and Etoposide (I-Chope) in Diffuse Lymphomas relapsed/refractory to Bolus therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T93-0129</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC#7078</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of DTIC and BCNU in combination with Thymidine in the treatment of metastic Malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>GOG-127D</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-127D</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Altretamine (Hexamethylamine) in Advanced or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T93-0189</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>94-003</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of Cisplatin (CDDP) plus Topotecan on a daily x 5 schedule in patients with advanced solid tumor malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>T94-0025</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II trial of 5-Fluorouracil, recombinant Alfa-2A-Interferon and Intravenous Hydroxyurea in patients with advanced Pancreatic Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>NCCTG-93-32-53</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>93-32-53</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II trial of two dosage levels of Letrozole in women with Metastatic Breast Cancer and prior hormonal therapy exposure</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>GOG-153</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-153</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of Recurrent and Advanced Endometrial Carcinoma treated with alternating courses of Megestrol Acetate (MEGACE) and Tamoxifen Citrate (Nolvadex)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:54"><nciDocumentNumber>RTOG-94-12</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-94-12</localDocumentNumber></localDocumentNumberList><documentTitle>A prospective study to determine possible racial and socioeconomic differences in pre-treatment PSA levels in patients with local-regional Carcinoma of the Prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>POG-9410</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SIMAL 8</localDocumentNumber></localDocumentNumberList><documentTitle>Simal 8 limited institution pilot: A study of Bone Marrow Transplantation after first marrow relapse of Non-T, Non-B ALL: A Pediatric Group Phase II /III pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T94-0131</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VAMC-407</localDocumentNumber></localDocumentNumberList><documentTitle>Prostate cancer intervention versus observation trial (pivot):  A randomized trial comparing radical Prostatectomy versus palliative expectant management for the treatment of clinically localized Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>E2393</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2393</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of continuous Infusion BCNU and Cisplatin and External Beam Radiotherapy for the treatment of patients with newly diagnosed Glioblastoma Multiforme</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T95-0028</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC-9508</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Aminocamptothecin (9-AC/DMA) in the treatment of hormone refractory Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T95-0084</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>8013</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of Doxorubicin and Taxol given prior to Cisplatin and Etoposide in the treatment of patients with extensive-stage small cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>T95-0095</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I clinical and pharmacokinetic study of oral 9-Aminocamptothecin (NSC-603071) on a 5 days every 2 week schedule</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>IND 5561</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM 93-012</localDocumentNumber></localDocumentNumberList><documentTitle>Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>IND 2973</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I b study of interleukin-2 (il2) for children who have undergone hla-matched allogeneic bone marrow transplantation (bmt) for advanced hematologic malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>POA-74181</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-74181</localDocumentNumber><localDocumentNumber>BGSM-74181</localDocumentNumber></localDocumentNumberList><documentTitle>Megestrol Acetate vs.Tamoxifen: Hormonal therapy in advanced Breast Cancer, a prospective randomized trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>NCOG-1B-81</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-1B-81</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Cardiotoxicity of weekly Adriamycin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>RTOG-79-15</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-79-15</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study to compare Misonidazole combined with irradiation versus radiation therapy alone in the treatment of locally advanced Head and Neck Squamous Carcinomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>79-03-05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>79-03-05</localDocumentNumber></localDocumentNumberList><documentTitle>Early clinical trial of the combination bcnu and 6-thioguanine</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:55"><nciDocumentNumber>CCG-088</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-088</localDocumentNumber></localDocumentNumberList><documentTitle>Amsa Phase II Metastatic Neuroblastoma in Children</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>T87-0034</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>86-133</localDocumentNumber></localDocumentNumberList><documentTitle>Hexamethylene Bisacetamide for Myelodysplastic Syndromes and AML</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>T92-0210</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UCI-92-04</localDocumentNumber><localDocumentNumber>UCI-92-04</localDocumentNumber><localDocumentNumber>UCI-92-04</localDocumentNumber></localDocumentNumberList><documentTitle>A multicenter Phase II study of all trans-retinoic acid and Interferon Alpha-2A in drug resistant multiple Myeloma and Waldenstrom's Macroglobulinemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>RTOG-98-11</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>R9811</localDocumentNumber><localDocumentNumber>R9811</localDocumentNumber><localDocumentNumber>R9811</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinoma of the Anal Canal</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>CCG-S64</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-S64</localDocumentNumber></localDocumentNumberList><documentTitle>Parents' perceptions of randomization: A limited institution pilot protocol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:56"><nciDocumentNumber>T97-0029</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CWRU 6496</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-12-1999 11:01:42"><nciDocumentNumber>T98-0041</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IRB#:  98-095</localDocumentNumber></localDocumentNumberList><documentTitle>A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC #655649 in Pediatric Patients with Relapsed/Refractory Neuroblastoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-12-1999 17:10:54"><nciDocumentNumber>T98-0003</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>98-80-03</localDocumentNumber><localDocumentNumber>98-80-03</localDocumentNumber><localDocumentNumber>98-80-03</localDocumentNumber><localDocumentNumber>98-80-03</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of 4'-IODO-4' Deoxydoxorubicin in Primary Amyloidosis (AL)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-22-1999 11:04:41"><nciDocumentNumber>T98-0039</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>9531</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Clinical Trial to Investigate the Correlation Between UGT1A1 Genotype and Irinotecan (CPT-11) Pharmacokinetics and Toxicity in Cancer Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:17"><nciDocumentNumber>B95-0004</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UAB 9445</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of 90Y-CC49 Monoclonal Antibody Therapy in patients with Advanced Non-Smmall Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:17"><nciDocumentNumber>T98-0030</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>98-C-0162</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of MGI-114 in Patients with Recurrent or Persistent Epithelial Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:17"><nciDocumentNumber>E2598</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2598</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Pilot Trial of Carboplatin, Paclitaxel, and Herceptin in HER2/Neu (+) Advanced NSCLC</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:17"><nciDocumentNumber>T96-0075</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>96-158</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of CHOP and the IDEC-C2B8 Monoclonal Antibody in Patients with Previously Untreated Mantle Cell Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:17"><nciDocumentNumber>T98-0093</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO 99501</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot and Safety Trial of  Carboplatin, Paclitaxel and Thalidomide (NSC 66847) in Advanced Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>T99-0004</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHASE I-24</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Oxaliplatin in Combination with Docetaxel (Taxotere) in Metastatic/Recurring Solid Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>E4998</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4998</localDocumentNumber></localDocumentNumberList><documentTitle>PHASE II STUDY OF THEOPHYLLINE IN CHRONIC LYMPHOCYTIC LEUKEMIA</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>E2997</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2997</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>GOG-0126I</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-126I</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Evaluation of  Aminocamptothecin (9-AC, NSC #603071) in Recurrent, Platinum-Resistant and Refractory  Ovarian Cancer and Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>POG-9822</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9822</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Newly Diagnosed Childhood AML Using a Timed-Sequentail Remission Induciton and Consolidation Followed by Single Dose Melphalan with Peripheral Stem Cell Rescue: A Pilot Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>E1297</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1297</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Preoperative Radiation Therapy with Concurrent Protracted Continuous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, 5-FU, and Leucovorin for Locally Advanced (T3  and T4) Rectal Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>T99-0019</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UICC-LW-02</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial of Humanized 1D10 Monoclonal Antibody (Hu1D10) in Patients with Relapsed Non-Hodgkin's Lymphoma (NHL)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>T83-1428</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>82-C-142</localDocumentNumber></localDocumentNumberList><documentTitle>Bioassay Of Macrophage Stimulating Protein (Msp) In Patients</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>SEG-137</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-137</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study Of 5-Azacytidine (Nsc 102816) In Advanced Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>T91-0148</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UCI-91-10</localDocumentNumber></localDocumentNumberList><documentTitle>Trans-retinoic acid in the treatment of malignant gliomas - a phase ii study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>T91-0248</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IOU 9224</localDocumentNumber></localDocumentNumberList><documentTitle>A phase ii study of topotecan in non-hodgkin's lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>T92-0121</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>9212</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial Of All Trans Retinoic Acid In Patients With Treated Squamous Cell Carcinoma Of The Head And Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>T92-0238</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>93-C-0085</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study Of Intrathecal Topotecan</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:18"><nciDocumentNumber>T94-0033</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DON 9420</localDocumentNumber></localDocumentNumberList><documentTitle>Analysis of the Efficacy of Suramin in Recurrent Malignant Primary Brain Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T94-0050</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PCI 94-09</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial Of Topotecan And Paclitaxel With G-CSF (Filgrastim) Support In Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T94-0073</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C1171-94</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Clinical Evaluation of Bryostatin 1 in Relapsed Lymphoma and CLL</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T94-0108</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-1942</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment Of Newly Diagnosed Children With Lower Risk Leukemia:A Pilot Trial Incorporating 6-Thioguanine</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T95-0081</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OC-94-2 (PHI-05)</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/PHARMACODYNAMIC study of Sequence Dependency of IV HYDROXYUREA in combination with FLUOROURACIL</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T95-0089</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase 2 Treatment of Adults and Children with Primary Brain Tumors with Irinotecan (CPT-11) (NSC# 616348)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 14:51:01" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T96-0001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>96-019</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial Of Krn5500 In Patients With Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T96-0051</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I Study Of Cordycepin (NSC 63984) Plus 2'-Deoxycoformycin (NSC 218321) In Patients With Refractory TdT-Positive Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T96-0084</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I/Pharmacokinetic Trial Of Intraperitoneal Lobaplatin</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T97-0001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase ii trial of pyrazoloacridine (pza) in metastatic gastric carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T97-0006</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase  II trial of  PYRAZOLOACRIDINE  (PZA)  in patients with  CISPLATIN-REFRACTORY GERM CELL TUMORS</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T97-0038</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO 9781</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of  Flavopiridol in Patients with Metastatic Androgen Independent Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>NCCTG-97-46-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-97-46-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Patients with Unresectable Hepatic Metastases from Metastatic Adenocarcinoma of the Colon or Rectum</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T99-0011</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>99-C-0117</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study of Oxaliplatin in Combination with Capecitabine in Adult Cancer Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:19"><nciDocumentNumber>T99-0018</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase II Study of Bryostatin-1 in Combination with Paclitaxel for Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>WCG-113</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Cyclophosphamides, vincristine, prednisone and procarbazine in combination. a phase 1-2 study in stage iii and iv lymphomas and hodgkin's disease</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>WCG-153</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Adriamycin Versus Adriamycin And Bleomycin In Advanced Carcinoma Of Cervix</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>NPCTG-800</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NPCTG-800</localDocumentNumber></localDocumentNumberList><documentTitle>A Comparison Of Estracyt, Vincristine And Estracyt Plus Vincristine In Patients With Advanced Carcinoma Of The Prostate Who Have Had Extensive Irradiation To The Pelvis</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>NCOG-2O-61</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-2O-61</localDocumentNumber></localDocumentNumberList><documentTitle>A phase ii trial of two combination chemotherapy regimens (pocc vs vam/pocc) in combination with rt for small (oat) cell lung cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>T83-1291</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>83-CC-201</localDocumentNumber></localDocumentNumberList><documentTitle>Radioimmunodetection And Treatment Of Malignant Melanoma With Radiolabeled Anti-Melanoma Antibodies</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>NCOG-0C-O1X</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-0C-O1X</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial Of Single Agent Human Leukocyte Interferon For Inoperable Extensive Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>T94-0099</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C09492</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of TOPOTECAN and THORACIC RADIATION</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>SEG-213</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-213</localDocumentNumber></localDocumentNumberList><documentTitle>Phase ii study of acute leukemia in adults using combination chemotherapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>D80-006-0311</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Intra-Arterial Chemotherapy For Hepatic Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>D79-006-0282</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>D79-006-282</localDocumentNumber></localDocumentNumberList><documentTitle>A Study Of Immunotherapy With Bcg Or Bcg Plus Autologous Tumor Vaccine In Patients With Acute Leukemia In Complete Remission After Chemotherapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>82-D-112</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Evaluation Of Submandibular/Sublingual And Minor Salivary Gland Function In Patients Receiving Therapeutic Irradiation Of The Head And Neck</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>T90-0136</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase ii study of high-dose 24 hour continuous infusion of 5-fu and leucovorin and low-dose pala for patients with pancreatic cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:20"><nciDocumentNumber>T92-0059</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CPMCRO 92-01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial Combining Taxol And Radiation Therapy For Treatment Of Locally Advanced Breast Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>T92-0023</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>92-C-0120</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study Of Interferon Gamma-1b In Combination With 5-Fluorouracil, Calcium Leucovorin, And Interferon Alfa-2a (Recombinant Roche) In Patients With Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>T92-0022</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>92-C-0134</localDocumentNumber></localDocumentNumberList><documentTitle>A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrxate Toxicity and Renal Dysfunction</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>T92-0100</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>92-C-0268</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Infusional Chemotherapy with the P-Glycoprotein Antagonist PSC 833</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 14:51:01" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>T93-0009</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>93-117</localDocumentNumber></localDocumentNumberList><documentTitle>All-Trans Retinoic Acid and Bryostatin 1 in Combination: A Phase I Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>T93-0059</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C0 9392</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study Of Iododeoxyuridine and Accelerated Hyperfractionated Radiotherapy for High Grade Gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>T93-0091</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>93-C-0187</localDocumentNumber></localDocumentNumberList><documentTitle>The Treatment Of Patients With Metastatic Melanoma Using Combination Chemotherapy Plus Tumor Infiltrating Lymphocytes And Il-2 Or Gamma-Interferon Plus Tumor Infiltrating Lymphocytes And Il-2</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>B93-0013</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UAC-2153</localDocumentNumber></localDocumentNumberList><documentTitle>Phase ii study of interferon enhanced single dose 131i-cc49 monoclonal antibody therapy in patients with metastatic prostate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:21"><nciDocumentNumber>T93-0198</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>94-04</localDocumentNumber><localDocumentNumber>E2894</localDocumentNumber></localDocumentNumberList><documentTitle>A Multicenter, Randomized Phase III Trial Of Interferon Alpha 2a (Roferon) With Or Without 13-Cis Retinoic Acid (Accutane) In Patients With Advanced Renal Cell Carcinoma.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0054</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>94-C-0209</localDocumentNumber></localDocumentNumberList><documentTitle>Phase ii study of chemotherapy of non-hodgkin's lymphoma arising in the cns or eye</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0096</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>95-C-0105</localDocumentNumber></localDocumentNumberList><documentTitle>Vaccine Therapy with Tumor Specific Mutated p53 or Ras Peptides Alone or in Combination with Cellular Immunotherapy with Peptide Activated Lymphocytes (PAL Cells) Along with Subcutaneous IL-2</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0143</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I Trial And Pharmacokinetic Study Of The Sequential Administration Of Carmustine (BCNU) And Temozolomide In Patients With Advanced Refractory Solid Tumors Or Refractory Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0189</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II trial of 9-Aminocamptothecin In Advanced Cutaneous T Cell Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0190</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>1199412478</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Pyrazine Diazohydroxide (NSC 361456) in Patients with Advanced Stage Non-Small Cell Lung Cancer (NSCLC)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0195</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>95-C-0079</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial in Patients with Metastatic Melanoma of Immunization with a Recombinant Adenovirus Encoding the Mart-1 Melanoma Antigen</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T94-0196</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J9446</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial Of Sodium Phenylbutyrate (El532) In Patients With Myelodysplastic Syndromes (Mds) And Acute Myeloid Leukemia (Aml)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T95-0027</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC 8147</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of TOPOTECAN  (NSC# 609699) and  CYCLOPHOSPHAMIDE,  with G-CSF (FILGRASTIM) in high-risk  SMALL  CELL  LUNG  CANCER</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:22"><nciDocumentNumber>T95-0090</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>96-C-0080</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial Of Tamoxifen and 9-CIS Retinoic  Acid  (NSC 659772) In Breast Cancer Patients.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T96-0028</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PH1-08</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Taxotere in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T96-0046</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97-C-0019</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II Study in Patients with Metastatic Melanoma of Immunization with Dendritic Cells Presenting Epitopes Derived from the Melanoma Associated Antigens  MART-1 and gp100</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T96-0077</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>96</localDocumentNumber></localDocumentNumberList><documentTitle>Proposal For A New Clinical Investigational Project: Phase I Trial ofPerillyl Alcohol In Patients with Advanced Malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T96-0093</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>8552</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Flavopiridol (NSC 649890) Administered as a 72-Hour Continuous Infusion Every 2 Weeks in Patients with Metastatic Renal Cell Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T95-0017</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J-9616</localDocumentNumber></localDocumentNumberList><documentTitle>A PHASE I clinical and pharmacologic evaluation of PHENYLBUTYRATE in patients with refractory SOLID TUMORS study of continuous exposure oral PHENYLBUTYRATE on a three times daily schedule</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0010</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase II Trial Of Pyrazoloacridine (PZA) In Patients With Urothelial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0005</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UAB 9701</localDocumentNumber></localDocumentNumberList><documentTitle>Phase Ib Trial of Intratumoral Injection of a Recombinant Canarypox Virus Encoding the Human Interleukin-12 Gene (Alvac-Hil-12) in Patients with Surgically Incurable Melanoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0007</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I/II Clinical Trial Evaluating the Safety and Biological Activity of Recombinant Vaccinia-Psa Vaccine in Patients with Serological Recurrence of Prostate Cancer Following Radical Prostatectomy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0012</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>9024</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of 9-AMINOCAMPTOTHECIN (9-AC) As A 120-Hour Infusion in Patients with advanced BREAST CANCER</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0044</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97-010</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/Pilot Study of ALVAC CEA-B7.1 Immunization in Patients with Advanced Adenocarcinomas Expressing CEA</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0074</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Bryostatin 1 Therapy Followed by VAD for Multiple Myeloma a Randomized Phase II Study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0077</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I Clinical Trial of Hydroxyurea as an Antiproliferative Agent in Carcinoma of the Cervix</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0084</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97-107</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Clinical Trial of a Recombinant ALVAC-CEA-B7 Vaccine in the Treatment of Advanced CEA-Expressing Adenocarcinomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0100</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND 6170</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized phase ii trial of a vaccine combining tyrosinase/gp100 peptides emulsified with montanide isa 51 alone or with gm-csf for patients with resected stages iia and iib melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:23"><nciDocumentNumber>T97-0112</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>98-C-0012</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Orally  Administered CAI for Patients with Persistent or Refractory  Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal  Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>NCCTG-97-24-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-97-24-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Randomized, Double-Blind Study of CAI and Placebo in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>NSABP-B-30</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-30</localDocumentNumber></localDocumentNumberList><documentTitle>A Three-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC->T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients with Positive Axillary Lymph Nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>NABTT-9803</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT-9803</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Gliadel and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients with Recurrent Malignant Glioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T98-0068</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J9879</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I, Dose-Finding Trial of Sodium Phenylbutyrate (NSC 657802) in Combination with All Trans-Retinoic Acid (ATRA, NSC 122758) in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>CALGB-9862</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9862</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Genetic Features of Acute Leukemia</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T98-0073</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MCC 9809-1B</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study Of Adoptive Cellular Therapy Of Advanced Breast Cancer With Her-2/Neu-Sensitized Lymph Node Cells Activated In Vitro With Bryostatin 1, Ionomycin, And Interleukin-2</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>ACOSOG-Z0011</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACOSOG-Z0011</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Trial of Axillary Node Dissection in Women with Clinical T1 or T2 N0 M0 Breast Cancer Who Have a Positive Sentinel Node</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T98-0085</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>99-C-0051</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Multi-Institutional Randomized Study of Immunization with the gp100:209-217(210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients with Metastatic Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T98-0087</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>99-C-0121</localDocumentNumber></localDocumentNumberList><documentTitle>Study of Trastuzumab (Herceptin) and Paclitaxel in Patients with HER-2 Overexpressing Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>E2298</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2298</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Docetaxel and Carboplatin in patients with advanced Squamous Carcinoma of the Esophagus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T99-0030</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>9802  GCC</localDocumentNumber><localDocumentNumber>980300</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study to Determine Biological Endpoints of Up to 21 Day Dosing of the Farnesyltransferase Inhibitor R115777 (IND #52,302) for Refractory and Relapsed  Adult Leukemias</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>CALGB-49806</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-49806</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Novel Therapeutic Agents Against Breast Cancer:  An Innovative Randomized Phase II Trial Design</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T99-0043</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID 99-060</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of MGI-114  (NSC #683863) In Patients with Refractory Myelodysplastic Syndromes,  Acute Leukemia, Refractory or Transformed Chronic Lymphocytic Leukemia and Chronic Myelogenous Leukemia in Blastic Phase (CML-BP)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T99-0046</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID99-303</localDocumentNumber></localDocumentNumberList><documentTitle>Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small-Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-29-1999 18:06:24"><nciDocumentNumber>T99-0016</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase II Study of Oxaliplatin in Patients  with Advanced Carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-28-1999 15:49:18"><nciDocumentNumber>T99-0050</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHI - 26</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Oxaliplatin in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-25-1999 10:15:58"><nciDocumentNumber>T99-0059</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OXALLI2</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Oxaliplatin in Children with Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="05-25-1999 10:57:33"><nciDocumentNumber>GOG-0180</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0180</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Danazol in Advanced or Recurrent Endometrial Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-03-1999 13:30:00"><nciDocumentNumber>RTOG-99-09</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-99-09</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Postoperative Adjuvant Immunotherapy and Radiation in Patients with Completely Resected Stage II and Stage IIIA Non-Small Cell Lung Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-17-1999 13:31:22"><nciDocumentNumber>T99-0072</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAYO 98-24-01</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients with Advanced Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-03-1999 16:44:54"><nciDocumentNumber>JPR.7</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>JPR.7</localDocumentNumber><localDocumentNumber>JPR.7</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Trial Comparing Intermittent  Versus Continuous Androgen Suppression for Patients with Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-05-1999 09:51:43"><nciDocumentNumber>GOG-9903</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9903</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topetecan with Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients with Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-17-1999 16:40:24"><nciDocumentNumber>T99-0101</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM99-169</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of the Farnesyl Transferase Inhibitor R115777 in Patients with Myelodysplastic Syndrome</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-18-1999 12:24:36"><nciDocumentNumber>T99-0094</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients >/= 65 Years Old</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="08-18-1999 13:32:39"><nciDocumentNumber>T99-0092</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I, Dose De-Escalation to Minimal Effective Pharmacologic Dose Trial of Sodium Phenylbutyrate  (PB, NSC 657802)  in Combination with 5-Azacytidine (5-AZA, NSC 102816) in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-18-1999 14:37:18"><nciDocumentNumber>N9941</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N9941</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Taxotere(R) and Irinotecan (CPT-11) in Patients with Advanced Adenocarcinoma of the Lower Esophagus, Esophagogastric Junction, and Gastric Cardia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-20-1999 10:58:52"><nciDocumentNumber>T99-0090</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>01-C-0222</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients with Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-24-1999 14:25:56"><nciDocumentNumber>T99-0091</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>99-60</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot Study of Sodium Phenylbutyrate Plus Azacytidine</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-26-1999 10:59:05"><nciDocumentNumber>T99-0105</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>99-107</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Arsenic Trioxide (NSC #706363) in Patients with Advanced Renal Cell Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="09-08-1999 08:27:14"><nciDocumentNumber>RTOG-99-13</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-99-13</localDocumentNumber></localDocumentNumberList><documentTitle>A PHASE III comparison of BIAFINE(R) to declared institutional preference for RADIATION induced skin toxicity in patients undergoing radiation therapy for advanced SQUAMOUS CELL CARCINOMA of the HEAD and NECK</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-08-1999 11:46:24"><nciDocumentNumber>RTOG-99-01</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-99-01</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study to test the efficacy and safety of GM-CSF to reduce the Severity and Duration of  MUCOSAL  Injury and pain (MUCOSITIS)  associated with Curative RADIATION  THERAPY in HEAD  and NECK  CANCER  Patients.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-10-1999 11:49:13"><nciDocumentNumber>S9924</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9924</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of R115777 (NSC #702818) in Patients with Advanced Pancreas Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-15-1999 17:39:32"><nciDocumentNumber>ANBL0321</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0024</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Fenretinide (NSC# 374551, IND# 40294) in Children with Recurrent/Resistant High Risk Neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-28-1999 19:41:39"><nciDocumentNumber>103</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID99-255</localDocumentNumber></localDocumentNumberList><documentTitle>PHASE II study of ATRAGEN (Liposomal Tretinoin) in patients with RELAPSED or REFRACTORY HODGKIN'S disease</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-06-1999 14:52:21"><nciDocumentNumber>E1299</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1299</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Orzel (UFT + Leucovorin) in Elderly (>/- 75 Years Old) Patients with Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-07-1999 08:57:31"><nciDocumentNumber>190</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>99-76</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Arsenic Trioxide, NSC 706363, in Relapsed or Refractory Chronic Myelogenous Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-07-1999 14:06:06"><nciDocumentNumber>P9962</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>P9962</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients with Refractory Meningeal Malignancies: A COG Group-Wide Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-02-2012 12:45:43" createdDate="10-13-1999 11:38:58"><nciDocumentNumber>ADVL0011</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>A0993</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Temozolomide and CCNU in Pediatric Patients with Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas
</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-02-2012 12:45:43" createdDate="10-14-1999 09:24:40"><nciDocumentNumber>ADVL0017</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>A0972</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Flavopiridol in Patients with Relapsed or Refractory Pediatric Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-18-1999 13:59:00"><nciDocumentNumber>250</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>99-94</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Bryostatin-1 and Paclitaxel in Patients with Advanced Esophageal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="10-19-1999 14:59:58"><nciDocumentNumber>270</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J9982</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Dose Finding Study of 5-Azacytidine (5 AC, NSC 102816) in Combination with Sodium Phenylbutyrate (PB, NSC 657802) in Patients with Refractory Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-02-2012 12:45:43" createdDate="10-20-1999 10:54:34"><nciDocumentNumber>P9973</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>P9973</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of STI571 in Ph+ Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-23-1999 18:31:11"><nciDocumentNumber>673</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID99-341</localDocumentNumber></localDocumentNumberList><documentTitle>PHASE II TRIAL OF LIPOSOMAL DAUNORUBICIN (DAUNOXOME) AND SU5416 (NSC 696819) IN PATIENTS WITH AML, RAEB, RAEB-T, OR CMML IN TRANSFORMATION REFRACTORY TO ONE COURSE OF INDUCTION CHEMOTHERAPY</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-13-1999 10:04:06"><nciDocumentNumber>GOG-9906</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9906</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Feasibility Trial of Carboplatin and Topotecan Followed by Carboplatin and Paclitaxel (Sequential Doublets) in Patients with Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-06-2000 14:02:03"><nciDocumentNumber>N9975</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N9975</localDocumentNumber></localDocumentNumberList><documentTitle>Aerosolized GM-CSF in the treatment of METASTATIC MELANOMA to the LUNG</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-10-2000 12:00:04"><nciDocumentNumber>E5597</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ECOG-E5597</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-16-2000 08:41:19"><nciDocumentNumber>1290</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID99-291</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of SU5416 (NSC 696819) for Patients with Progressive Metastatic Renal Cancer Failing Prior Biologic Therapy or 5-Fluorouracil Containing Regimens</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="02-23-2000 10:57:42"><nciDocumentNumber>S0010</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0010</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of 506U78 (IND 52611) in Patients with Relapsed or Refractory Non T-Cell Acute Lymphoblastic Leukemia (ALL)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-23-2000 14:11:32"><nciDocumentNumber>833</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I Study of Sequential Vaccinations with Fowlpox-CEA(6D)-TRICOM (B7.1/ICAM/LFA-3) Alone, and in Combination with Vaccinia-CEA(6D)-TRICOM, and the Role of GM-CSF, in Patients with CEA Expressing Carcinomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-23-2000 15:05:15"><nciDocumentNumber>E3899</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E3899</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Trial of Mitoxantrone, Estramustine and Navelbine or 13-cis Retinoic Acid, Interferon and Paclitaxel in Patients with Metastatic Hormone Refractory Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-15-2000 15:19:22"><nciDocumentNumber>NABTT-2002</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT-2002</localDocumentNumber></localDocumentNumberList><documentTitle>Effect of RSR13 on T2 and T2* Cranial MRI Images:  An Imaging Companion Study to NABTT 9806</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-28-2000 15:53:27"><nciDocumentNumber>CALGB-159902</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-159902</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Markers of Pleural Involvement in Resected Non-Small Cell Lung Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-10-2000 17:50:53"><nciDocumentNumber>S0004</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0004</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Tirapazamine/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-02-2000 11:43:28"><nciDocumentNumber>S0019</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0019</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial of Ice Chemotherapy with or without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients Not Suitable for High-Dose Therapy and PBSCT</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-10-2000 10:40:55"><nciDocumentNumber>2331</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DMS 9934</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Dose Escalation Study of  UCN-01 (NSC 638850) Plus Cisplatin in Advanced Malignant Solid Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-23-2000 10:12:44"><nciDocumentNumber>2530</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I Study of Fenretinide Combined with Paclitaxel and Cisplatin for the Treatment of Refractory Solid Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-01-2000 11:35:07"><nciDocumentNumber>CALGB-19902</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-19902</localDocumentNumber></localDocumentNumberList><documentTitle> A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (CMA-676; Mylotarg) with High-Dose Cytarabine for Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML)
</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-02-2000 13:20:17"><nciDocumentNumber>ACRIN-6652</nciDocumentNumber><sponsorOrganization>CIP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACRIN-6652</localDocumentNumber></localDocumentNumberList><documentTitle>Digital vs. Screen-Film Mammography</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-06-2000 13:16:21"><nciDocumentNumber>GOG-9909</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9909</localDocumentNumber></localDocumentNumberList><documentTitle>A PHASE I TRIAL OF COMBINATION CARBOPLATIN AND LIPOSOMAL DOXORUBICIN (DOXIL) IN RECURRENT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="06-12-2000 09:41:23"><nciDocumentNumber>S0001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0001</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Study of Radiation Therapy (RT) and 06-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-27-2000 09:29:52"><nciDocumentNumber>N99C7</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-N99C7</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Comparison of Depomedroxyprogesterone Acetate (DPROV) to a Selective Serotonin Reuptake Inhibitor to Both for Alleviation of Hot Flashes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-18-2000 17:36:13"><nciDocumentNumber>3137</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WFU-74896</localDocumentNumber></localDocumentNumberList><documentTitle>Docetaxel (Taxotere ) and 5-Fluorouracil as Second- or Third- Line Chemotherapy in Women with Metastatic Breast Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-26-2000 14:30:06"><nciDocumentNumber>3210</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>01-DC-0006</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/Pilot Study of Intralesional Immunotherapy with a Recombinant Avipox Virus Engineered to Express a Triad of Co-Stimulatory Molecules in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-08-2000 14:36:54"><nciDocumentNumber>N998B</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N998B</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Thalidomide in the Treatment of Myelodysplastic Syndromes in Adults:  A Clinical and Biologic Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-08-2000 15:17:02"><nciDocumentNumber>GOG-0146M</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0146M</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Tirapazamine (NSC #130181, IND #46,525) in Combination with Cisplatin in the Treatment of Recurrent Platinum Sensitive Ovarian or Primary Peritoneal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-14-2000 13:46:13"><nciDocumentNumber>CALGB-39904</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-39904</localDocumentNumber></localDocumentNumberList><documentTitle>Accelerated Conformal Radiotherapy for Stage I Non-Small Cell Lung Cancer in Patients with Pulmonary Dysfunction:  A Phase I Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-25-2000 09:40:10"><nciDocumentNumber>CALGB-30004</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-30004</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Karenitecin (IND 57250) in Patients with Relapsed or Refractory Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-14-2000 11:58:07"><nciDocumentNumber>2490</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMGCC 0076</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of the Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC# 704865, IND# 7,921) Administered in Timed Sequential Combination with Cytosine Arabinoside (ara-C) and Mitoxantrone for Adults with Refractory and Relapsed Acute Myelogenous Leukemias (AMLs)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-30-2000 09:40:16"><nciDocumentNumber>3358</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>00-1096</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of EMD 121974 in Patients with Advanced Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-05-2000 10:53:57"><nciDocumentNumber>S0020</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0020</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Anti-Thymocyte Globulin and Cyclosporine for Patients with Myelodysplastic Syndrome (MDS)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-07-2000 10:03:10"><nciDocumentNumber>GOG-0189</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0189</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase III Crossover Trial of Chemotherapy (Doxorubicin/Cisplatin/Paclitaxel and G-CSF) Versus Hormonal Therapy (Tamoxifen/Megestrol Acetate) in Patients with Stage III &amp; IV or Recurrent Endometrial Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-11-2000 15:33:55"><nciDocumentNumber>4450</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM99-015</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Multidose, Single Arm, Multicenter Institution Clinical Trial of Cisplatin and Gemcitabine in Combination with Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local (Stage IIIb Pleural Effusion Only) and Metastatic (Stage IV) Non-Small Cell Lung Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-14-2000 11:00:14"><nciDocumentNumber>3670</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase 2 Study of Epothilone B Analog BMS- 247550 (NSC 710428D) in Patients with Advanced Colorectal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="01-04-2001 09:50:36"><nciDocumentNumber>GOG-0191</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0191</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 G/L with Erythropoietin Versus Above 100 G/L without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="01-04-2001 11:50:20"><nciDocumentNumber>RTOG S-0124</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG S-0124</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Multimodality Therapy for Primary and Recurrent Retroperitoneal Sarcomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-12-2001 12:26:05"><nciDocumentNumber>5293</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCCWFU 62400</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients with Advanced Non-Small Cell Lung Cancer (IND #63,366)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-21-2001 12:15:23"><nciDocumentNumber>5332</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>57100</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Induction Gemcitabine/Cpt-11 Followed by Twice-Weekly Infusion Gemcitabine and Concurrent External Beam Radiation for the Treatment of Locally Advanced  Pancreatic Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-28-2001 13:56:57"><nciDocumentNumber>4390</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase 1 Study of SU5416 with Androgen Ablation and Radiation in Patients with Intermediate- and Advanced- Stage Prostate Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-08-2001 12:07:56"><nciDocumentNumber>NABTC-01-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTC-01-01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II Trial of CCI-779 in Patients with Malignant Glioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="04-03-2001 12:33:53"><nciDocumentNumber>S0029</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0029</localDocumentNumber></localDocumentNumberList><documentTitle>Single Agent Docetaxel for Metastatic Breast Cancer in Patients Aged 70 Years and Older (And in a Cohort of Patients Younger than 60 Years)</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-19-2001 08:27:59"><nciDocumentNumber>ACOSOG-Z9000</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACOSOG-Z9000</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Adjuvant STI571 (Gleevec TM) Therapy in Patients Following Completely Resected High-risk Primary GastroIntestinal Stromal Tumor (GIST)</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-24-2001 09:15:30"><nciDocumentNumber>E2100</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2100</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-08-2001 09:55:29"><nciDocumentNumber>CALGB-60001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-60001</localDocumentNumber></localDocumentNumberList><documentTitle>Prospective Evaluation of the Pharmacokinetics, Pharmacogenetics and Pharmacodynamics of CPT-11 and Aging</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-04-2001 13:33:25"><nciDocumentNumber>3950</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UPCC#3300</localDocumentNumber></localDocumentNumberList><documentTitle>Does Hypoxia Predict Radiation/Surgical Tumor Response/a Correlative Trial of EF5, an Agent for the Detection of Tumor Hypoxia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-07-2001 10:25:14"><nciDocumentNumber>5345</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID01-284</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Gleevec (Imatinib Mesylate, STI-571) in Metastatic Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-08-2001 12:02:17"><nciDocumentNumber>RTOG-0132</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG S-0132</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec NSC #716051) for Primary and Recurrent Operable Malignant GIST Expressing the KIT Receptor Tyrosine Kinase (CD117) (ACRIN 6665)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-11-2001 14:07:05"><nciDocumentNumber>RTOG-0126</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0126</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-14-2001 09:14:09"><nciDocumentNumber>ACOSOG-Z05032</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACOSOG-Z05032</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Toxicity Assessment in Two Cohorts of Patients (Resection Alone or Ablation with or without Resection of Hepatic Metastases from Colorectal Cancer) Treated with Adjuvant Hepatic Arterial Infusion (HAI) FUDR Plus Systemic CPT-11</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="07-16-2001 14:06:07"><nciDocumentNumber>S0126</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0126</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Chronic Oral  ZD1839 (Iressa®) (NSC-715055) in Both Previously-Untreated and Previously-Treated Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-19-2001 10:30:16"><nciDocumentNumber>ACNS0121</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACNS0121</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients with Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-31-2001 09:53:11"><nciDocumentNumber>5348</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>01 04</localDocumentNumber></localDocumentNumberList><documentTitle>A Clinical Trial of the Action of Isoflavones in Breast Neoplasa:  Administration Prior to Mastectomy or Lumpectomy - A Pilot Study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-01-2001 10:04:23"><nciDocumentNumber>ACOSOG-Z0300</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACOSOG-Z0300</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-09-2001 14:36:52"><nciDocumentNumber>5550</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>11367</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Study of Interleukin-2 in Combination with Three Different Doses of Bryostatin in Patients with Renal Cell Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-15-2001 15:03:45"><nciDocumentNumber>5410</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IDD 01-27</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II, Pharmacokinetic and Biologic Correlative Study of OSI-774, an EGFR Tyrosine Kinase Inhibitor, in Patients with Advanced Renal Cell Carcinoma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="08-21-2001 14:25:30"><nciDocumentNumber>S0032</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0032</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients With High-Risk Metastatic Adenocarcinoma of the Prostate</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-23-2001 09:37:39"><nciDocumentNumber>ADVL0013</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0013</localDocumentNumber></localDocumentNumberList><documentTitle> A Phase I Study of  90Yttrium-Ibritumomab Tiuxetan (90Y Zevalin, Yttrium (90)-Anti-CD20, NSC #710085) Preceded by Rituximab in Children with Recurrent/Refractory CD20 Positive Lymphoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="08-28-2001 22:52:57"><nciDocumentNumber>5496</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I Study of MEDI-522 (NSC 719580) in Patients with Advanced Solid Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-07-2001 09:32:36"><nciDocumentNumber>E2301</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2301</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients with Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="09-20-2001 14:45:53"><nciDocumentNumber>CALGB-10001</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB 10001/SWOG C10001</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC # 716051, IND #61135), and Transplantation for Adults with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-03-2012 10:59:22" createdDate="10-09-2001 12:09:47"><nciDocumentNumber>5349</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID01-510</localDocumentNumber></localDocumentNumberList><documentTitle>A Dose-Finding, Safety, and Pharmacokinetic Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor OSI-774 (NSC 718781) in Patients with Unresectable Hepatocellular Carcinoma and Moderate Hepatic Dysfunction</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-29-2001 13:03:30"><nciDocumentNumber>GOG-0127R</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0127-R</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Liposomal Doxorubicin (DOXIL) (NSC #712227) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-30-2001 09:05:43"><nciDocumentNumber>5653</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>02-015</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Imatinib (Gleevec TM) in Combination with Irinotecan and Cisplatin in Extensive Stage Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-01-2001 11:08:10"><nciDocumentNumber>5684</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-008</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of STI571 (Gleevec) in Combination with Cisplatin/Irinotecan in Patients with Extensive Stage Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-07-2001 14:48:29"><nciDocumentNumber>N00CA</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-N00CA</localDocumentNumber></localDocumentNumberList><documentTitle>PHASE III DOUBLE-BLIND STUDY OF DEPOT OCTREOTIDE VERSUS PLACEBO IN THE PREVENTION OF ACUTE DIARRHEA IN PATIENTS RECEIVING PELVIC RADIATION THERAPY.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-14-2001 08:35:33"><nciDocumentNumber>CALGB-10003</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-10003</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="11-23-2001 08:52:10"><nciDocumentNumber>S0124</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0124</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase III Trial of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer (E-SCLC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-28-2001 14:34:01"><nciDocumentNumber>ACOSOG-Z0360</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACOSOG-Z0360</localDocumentNumber></localDocumentNumberList><documentTitle>A Trial of Lymphatic Mapping and Sentinel Node Lymphadenectomy for Patients with T1 or T2 Clinically N0 Oral Cavity Squamous Cell Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-30-2001 09:17:24"><nciDocumentNumber>RTOG-0213</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0213</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Trial of a Cox-2 Inhibitor, Celebrex (TM) (Celecoxib) with Limited Field Radiation for Intermediate Prognosis Patients with Locally Advanced Non-Small Cell Lung Cancer, with Analysis of Prognostic Factors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-30-2001 15:47:24"><nciDocumentNumber>S9313B</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9313B</localDocumentNumber></localDocumentNumberList><documentTitle>Construction of Tissue Microarray from Archival SWOG/Intergroup Tumor Samples</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-06-2001 09:17:35"><nciDocumentNumber>5612</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-007</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 2 Study of  R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-11-2001 15:54:11"><nciDocumentNumber>5700</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>02-043A</localDocumentNumber></localDocumentNumberList><documentTitle>An Open-Labeled, Non-Randomized Phase I Study of  Alvocidib (Flavopiridol) Administered with Irinotecan (CPT-11) and Cisplatin in Patients with Advanced Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-11-2001 15:58:56"><nciDocumentNumber>5763</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UPCC 06501</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of PS-341 in Metastatic Non-Small Cell Lung Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-04-2002 08:34:09"><nciDocumentNumber>5867</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>01-177</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Herceptin/Flavopiridol in HER-2 Positive Metastatic Breast Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="01-07-2002 11:38:02"><nciDocumentNumber>CALGB-40101</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-40101</localDocumentNumber></localDocumentNumberList><documentTitle>Cyclophosphamide and  Doxorubicin (CA x 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes:  A Phase III Randomized Study</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-15-2002 14:30:14"><nciDocumentNumber>5880</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T cell Add-Back for Hematological Malignancies - Role of Preparative Regimen and T Cell Dose in Graft Rejection and GVHD</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-06-2002 12:31:54"><nciDocumentNumber>5901</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC-0003</localDocumentNumber></localDocumentNumberList><documentTitle>Proteomics Biomarker Development Laboratory</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-11-2002 17:24:39"><nciDocumentNumber>5904</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO 02901</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin in Combination with Oral Capecitabine in Patients with Advanced Malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-08-2002 07:27:09"><nciDocumentNumber>5701</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>11956A</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Study of Bevacizumab (rhuMab VEGF) in Combination with OSI-774 for Patients with Recurrent or Metastatic Cancer of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="03-14-2002 13:14:35"><nciDocumentNumber>RTOG-0214</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0214</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients with Locally Advanced Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-09-2002 09:10:25"><nciDocumentNumber>N014C</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N014C</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Trial of PS-341 and Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 11:17:51" createdDate="04-16-2002 14:34:05"><nciDocumentNumber>4772</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID02-063</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Bevacizumab and PEG Interferon Alpha-2b (PEG Intron) in Patients with Metastatic, or Unresectable Carcinoid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-19-2002 13:53:37"><nciDocumentNumber>NCIC-MA.20</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCIC-MA.20</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Study of Regional Radiation Therapy in Early Breast Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="04-22-2002 11:55:40"><nciDocumentNumber>AMC-036</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AMC-036</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Topical Halofuginone in Patients with HIV Related Kaposi's Sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-01-2002 16:36:42"><nciDocumentNumber>E1902</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1902</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Reduced Intensity Allogeneic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-09-2002 08:03:17"><nciDocumentNumber>ACCL01P3</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACCL01P3</localDocumentNumber></localDocumentNumberList><documentTitle>Differences in Parental Care Giving Demands in Childhood Acute Lymphoblastic Leukemia by Length of Infusion Therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-22-2002 17:10:41"><nciDocumentNumber>6005</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>URCC CC-1202</localDocumentNumber></localDocumentNumberList><documentTitle>A Clinical Investigation of Chemotherapy Induced Diarrhea in Patients Receiving Treatment for Colorectal Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-09-2002 07:18:51"><nciDocumentNumber>5932</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C-2599</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of the Combination of 17-AAG and Imatinib Mesylate (Gleevec) in Patients with Blastic Phase, Accelerated Phase of Chronic Myeloid Leukemia (CML) or Patients with Chronic Phase CML Who Have not Achieved a Cytogenetic Response with Imatinib Mesylate</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-13-2002 10:54:59"><nciDocumentNumber>GOG-0146O</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0146O</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Irofulven (IND# 55804, NSC# 683863) in the Treatment of Recurrent or Persistent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="08-14-2002 09:24:24"><nciDocumentNumber>S0216</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0216</localDocumentNumber></localDocumentNumberList><documentTitle>Docetaxel (NSC-628503), Cisplatin (NSC-119875), and 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed by Accelerated Fractionation/Concomitant Boost Radiation and Concurrent Single Agent Cisplatin (NSC-119875), in Patients with Advanced Squamous Cell Head and Neck Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-23-2002 13:45:45"><nciDocumentNumber>NCIC-155</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.155</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Perifosine (D-21266) in Patients with Previously Untreated Metastatic or Locally Advanced Soft Tissue Sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-09-2002 15:23:31"><nciDocumentNumber>RTOG-0122</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0122</localDocumentNumber></localDocumentNumberList><documentTitle>A Double-Blind Study of Nutritional Intervention for the Treatment of Cancer Cachexia Using Jeven(R) Nutritional Supplement</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-18-2002 14:27:46"><nciDocumentNumber>5961</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0287</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Depsipeptide, a Histone Deacetylase Inhibitor, in Relapsed or Refractory Mantle Cell or Diffuse Large Cell Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-05-2002 10:19:29"><nciDocumentNumber>RTOG-0239</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0239</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Accelerated High Dose Thoracic Irradiation with Concurrent Chemotherapy for Patients with Limited Small Cell Lung Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-22-2002 16:31:39"><nciDocumentNumber>RTOG-0244</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0244</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Submandibular Salivary Gland Transfer to the Submental Space Prior to Start of Radiation Treatment for Prevention of Radiation-Induced Xerostomia in Head and Neck Cancer Patients</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-25-2002 08:42:29"><nciDocumentNumber>6167</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2003-0288</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients with Advanced Metastatic Pancreatic Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-10-2002 11:05:47"><nciDocumentNumber>RTOG-0246</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0246</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of a Paclitaxel-Based Chemoradiotherapy Regimen with Selective Surgical Salvage for Resectable Locoregionally Advanced Carcinoma of the Esophagus</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-10-2002 14:55:11"><nciDocumentNumber>6048</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>04-C-0014</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of BL22 Immunotoxin in Hairy Cell Leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-31-2002 14:58:49"><nciDocumentNumber>6062</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTRG P18/02</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 2 Study of Fenretinide in Patients with Hormone Refractory Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-13-2003 16:43:56"><nciDocumentNumber>E1A02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1A02</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Pilot Study of Rituximab + CHOP in Patients with Newly Diagnosed Waldenstrom's Macroglobulinemia</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-14-2003 08:38:50"><nciDocumentNumber>5970</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase II Trial of Oral Perifosine in Patients with Metastatic Androgen Independent Prostate Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-06-2003 09:32:48"><nciDocumentNumber>5972</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0276</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Perifosine in Soft Tissue Sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="02-12-2003 14:53:21"><nciDocumentNumber>S0115</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0115</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) and Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) for Patients with AL Amyloidosis or Light Chain Deposition Disease (LCDD) or High Risk (>/= Age 70 or Poor Renal Function) Patients with Multiple Myeloma (A BMT Study)</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="02-20-2003 10:23:02"><nciDocumentNumber>N02C2</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N02C2</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III, Randomized Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients with Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="04-09-2003 14:09:06"><nciDocumentNumber>S0306</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0306</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-09-2003 08:28:53"><nciDocumentNumber>ARST0321</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ARST0321</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Sulindac and Tamoxifen in Patients with Desmoid Tumors that are Recurrent or not Amenable to Standard Therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="05-16-2003 16:23:54"><nciDocumentNumber>GOG-0210</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0210</localDocumentNumber></localDocumentNumberList><documentTitle>A Molecular Staging Study of Endometrial Carcinoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="06-03-2003 10:00:16"><nciDocumentNumber>E1F02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1F02</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Systemic High-Dose Methotrexate for the Treatment of Glioblastoma Multiforme in Newly Diagnosed Patients with Measurable Disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="07-02-2003 14:14:29"><nciDocumentNumber>N0323</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0323</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of the mTOR Inhibitor, CCI-779 in Patients with Advanced Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-08-2003 11:32:25"><nciDocumentNumber>NCIC-160</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.160</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of CCI-779 in Patients with Metastatic and/or Locally Advanced Recurrent Endometrial Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-10-2003 13:13:33"><nciDocumentNumber>6467</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>IND 9511: NHLBI/Dr. A John Barrett IND Studies with MoAb 3A1 (NSC 603570), MoAb 3-275 (NSC 603571), and MoAb 3-276 (NSC 603572)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="07-14-2003 14:59:45"><nciDocumentNumber>CALGB-10105</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-10105</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="07-23-2003 07:53:37"><nciDocumentNumber>ADVL0314</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0314</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Bevacizumab in Refractory Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="08-13-2003 16:53:42"><nciDocumentNumber>6532</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>04-C-0083</localDocumentNumber></localDocumentNumberList><documentTitle>A Study of Intra-Patient Escalating Doses of MDX-010 Given Alone or in Combination with Two gp100 Peptides Emulsified with Montanide ISA-51 in the Treatment of Patients with Stage IV Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="08-20-2003 15:57:26"><nciDocumentNumber>S0339</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0339</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Gemcitabine, Carboplatin and PS-341 (NSC-681239) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="08-27-2003 09:10:26"><nciDocumentNumber>CALGB-150303</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-150303</localDocumentNumber></localDocumentNumberList><documentTitle>Gene Ratios for Prognosis in Lung Cancer Using Tissues from CALGB 9761</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-03-2003 08:31:41"><nciDocumentNumber>NABTT-0304</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT-0304</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Talampanel in Conjunction with Radiation Therapy with Concurrent and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-10-2003 14:02:32"><nciDocumentNumber>ADVL0319</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0319</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of CC-5013 (Lenalidomide NSC# 703813, IND # 70116) in Pediatric Patients with Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="09-17-2003 10:50:34"><nciDocumentNumber>E1303</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1303</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-17-2003 11:09:37"><nciDocumentNumber>6586</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PH1/095</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial of SJG-136 (a Minor Groove DNA Binding Drug) Given Intravenously Every 21 Days to Patients with Advanced Solid Tumours</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-26-2012 12:15:51" createdDate="09-29-2003 08:38:50"><nciDocumentNumber>5876</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0261</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Flavopiridol and Cisplatin in Advanced Epithelial Ovarian and Primary Peritoneal Carcinomas</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="10-09-2003 13:30:43"><nciDocumentNumber>RTOG-0315</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG 0315</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Determine the Efficacy of Sandostatin LAR Depot (Octreotide Acetate) in Prevention or Reducing the Severity of Chemoradiation-Induced Diarrhea in Patients with Anal or Rectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-07-2003 09:39:27"><nciDocumentNumber>E2803</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2803</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Paclitaxel Plus Carboplatin in Patients with Metastatic or Locally Advanced Collecting Duct Renal Cell Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="11-13-2003 10:03:49"><nciDocumentNumber>6368</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>04-C-0167</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Trial of a CEA-TRICOM Based Vaccine and Radiation to Liver Metastasis in Adults with CEA Positive Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 10:59:22" createdDate="11-13-2003 13:53:48"><nciDocumentNumber>5651</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2003-0909</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 Study of  XL119 in Patients with Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphocytic Leukemia, or Chronic Myeloid Leukemia in Blastic-Phase</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-19-2003 08:30:50"><nciDocumentNumber>6449</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CASE1203</localDocumentNumber></localDocumentNumberList><documentTitle> Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 11:17:51" createdDate="12-10-2003 08:42:50"><nciDocumentNumber>6372</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC 2004.030</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Evaluation of EMD 121974 (NSC 707544, Cilengitide) in Asymptomatic Patients with Metastatic Androgen Independent Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="01-21-2004 10:13:43"><nciDocumentNumber>6552</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C-2803</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Clinical Trial of 17-Allyamino-17-Demethoxygeldanamycin (17-AAG) in Chemotherapy Refractory Metastatic Breast Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="01-23-2004 15:00:11"><nciDocumentNumber>6634</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OXALET</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial of the Combination of Oxaliplatin (NSC 266046, IND 57004), Ifosfamide, and Etoposide in Recurrent or Refractory Pediatric Solid Tumors and Lymphomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="02-03-2004 10:17:05"><nciDocumentNumber>6508</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UPCC# 04204</localDocumentNumber></localDocumentNumberList><documentTitle>Distribution of the Photosensitizer Motexafin Lutetium and Hypoxia in Patients with Abdominal Malignancies</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="02-12-2004 09:37:59"><nciDocumentNumber>6399</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>04-C-0238</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Von Hippel Lindau Disease and Renal Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="02-25-2004 13:21:45"><nciDocumentNumber>6557</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CASE 2804</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of BAY 43-9006, a Novel Raf Kinase Inhibitor, Plus Paclitaxel/Carboplatin in Women with Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="03-08-2004 12:54:48"><nciDocumentNumber>6735</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2004-045</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Evaluation of EMD 121974 (NSC 707544, Cilengitide) in Patients with Non-Metastatic Androgen Independent Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="03-10-2004 14:28:05"><nciDocumentNumber>6383</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0313</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I and Pharmacological Trial of 17-Allylamino-17demethoxygeldanamycin (17-AAG) and Cytarabine in Refractory Leukemia and Myelodysplastic Syndrome</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="03-24-2004 10:04:09"><nciDocumentNumber>S0342</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0342</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Selection Design Trial of Concurrent Chemotherapy + Cetuximab vs. Chemotherapy Followed by Cetuximab in Advanced Non-Small Cell Lung Cancer (NSCLC)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-01-2004 10:20:22"><nciDocumentNumber>6701</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-028</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-13-2004 13:07:19"><nciDocumentNumber>RTOG-0320</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG 0320</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus with Temozolomide or Erlotinib in Patients with Non-Small Cell Lung Cancer and 1-3 Brain Metastases</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-14-2004 08:02:56"><nciDocumentNumber>6697</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HEAD AND NECK 04-3</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 2 Trial of GW572016 in Patients with Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-19-2004 08:50:08"><nciDocumentNumber>6121</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0214</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial of 17-Allylaminogeldanamycin (17-AAG) and PS341 in Advanced Malignancies</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-17-2004 13:04:38"><nciDocumentNumber>NCIC-170</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.170</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Study of GW572016 in Patients with Recurrent Malignant Glioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="05-18-2004 10:15:14"><nciDocumentNumber>6991</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GCC 0430</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 2 Study of Prostate Specific Antigen Peptide 3A (PSA: 154-163(155L) (NSC #722932, IND #9787) with Montanide ISA-51 (NSC #675756, IND #9787) or Montanide ISA 51 VG (NSC 737063) Vaccination in Prostate Cancer Recurrent</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="06-15-2004 09:54:47"><nciDocumentNumber>CALGB-50202</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-50202</localDocumentNumber></localDocumentNumberList><documentTitle>Intensive Chemotherapy and Immunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-17-2004 11:37:36"><nciDocumentNumber>7031</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HLMCC 02 03</localDocumentNumber></localDocumentNumberList><documentTitle>Preservation of Ovarian Function in Young Women Treated with (Neo) Adjuvant Chemotherapy for Breast Cancer: A Randomized Trial Using the GnRH Agonist (Triptorelin) During Chemotherapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="07-06-2004 13:43:11"><nciDocumentNumber>S0432</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0432</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Tipifarnib, Zarnestra®, NSC-702818) for Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 11:07:50" createdDate="07-21-2004 08:49:50"><nciDocumentNumber>7003</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHII-57</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Bortezomib (PS-341) for Patients with Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 11:07:50" createdDate="07-27-2004 10:58:55"><nciDocumentNumber>6972</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C-2890</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Dose-Escalation Study of Intravenous 17-allylaminogeldanamycin (17-AAG) [NSC 330507, IND# 57,966] and Oral BAY 43-9006 [NSC 724772, IND #69,896] Administered in Patients with Pretreated Advanced Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="08-12-2004 09:12:47"><nciDocumentNumber>6954</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J04110</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial Oral Etoposide in Combination with the Farnesyltransferase Inhibitor R115777 (Zarnestra, Tipifarnib, NSC #702818, IND #58,359) in Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-01-2004 14:42:41"><nciDocumentNumber>6957</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>6071</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I-II Trial of Fenretinide (4-HPR) + Rituximab in Patients with B-cell Lymphoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-13-2004 10:31:09"><nciDocumentNumber>6584</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2004-251</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Trial of BAY 43-9006 (Sorafenib) in Combination with Anastrozole in Patients with Metastatic Breast Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-16-2004 11:25:15"><nciDocumentNumber>S0000B</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0000B</localDocumentNumber></localDocumentNumberList><documentTitle>Prevention of Cataract and Age-Related Macular Degeneration with Vitamin E and Selenium - SELECT Eye Endpoints (SEE), Ancillary Study to SELECT</documentTitle><currentStatus>Temporarily Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-22-2004 16:02:37"><nciDocumentNumber>E1504</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1504</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-23-2004 10:10:11"><nciDocumentNumber>7034</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UPCC-03804</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Hypoxia by EF5 Binding in Gynecologic Cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-27-2004 09:18:14"><nciDocumentNumber>ARAR0331</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ARAR0331</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study</documentTitle><currentStatus>Temporarily Closed to Accrual</currentStatus></document><document updatedDate="05-03-2012 11:07:50" createdDate="10-05-2004 14:09:11"><nciDocumentNumber>7002</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU 04100</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-26-2012 12:17:26" createdDate="10-15-2004 10:34:29"><nciDocumentNumber>6918</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHII-62</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) as Salvage Therapy in Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-25-2004 15:19:33"><nciDocumentNumber>6860</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO 04510</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed Non-small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-09-2004 11:14:43"><nciDocumentNumber>7204</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU 04111</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study of Flavopiridol in Patients with Advanced Solid Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-16-2004 10:56:35"><nciDocumentNumber>N0338</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0338</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Docetaxel and Carboplatin Administered Every Two Weeks as Induction Therapy for Stage II or III Breast Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-22-2004 10:41:28"><nciDocumentNumber>ADVL0419</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0419</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 Study of Valproic Acid in Children with Recurrent/Progressive Solid Tumors Including CNS Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-29-2004 10:03:17"><nciDocumentNumber>7062</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-036</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 14:51:01" createdDate="12-02-2004 12:35:22"><nciDocumentNumber>6637</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MCC 6637</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory, or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-13-2004 13:41:24"><nciDocumentNumber>RTOG-0421</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0421</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy versus Chemotherapy Alone</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-20-2004 11:32:24"><nciDocumentNumber>6868</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-035</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Capecitabine in Patients with Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-27-2004 11:22:06"><nciDocumentNumber>S0350</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0350</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-27-2004 12:18:46"><nciDocumentNumber>6910</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO 04906</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Bortezomib in Patients with Advanced Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="12-28-2004 14:56:40"><nciDocumentNumber>6862</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC 2005.127</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Evaluation of Suberoylanilide Hydroxamic Acid (NSC 701852) in Patients with Advanced Prostate Cancer that has Progressed on One Prior Chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-03-2012 11:07:50" createdDate="01-04-2005 14:22:54"><nciDocumentNumber>7211</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC048C</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Bevacizumab to Prevent or Delay Disease Progression in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-26-2012 12:15:51" createdDate="03-07-2005 14:08:20"><nciDocumentNumber>7237</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTRG-HC06/21/05</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Study of PXD101 in Patients with Unresectable Hepatocellular Carcinoma with Pharmacokinetic and Pharmacodynamic Evaluation</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-14-2005 08:02:24"><nciDocumentNumber>RTOG-0524</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG 0524</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-05-2005 14:21:06"><nciDocumentNumber>7146</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IDD#05-12</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I, Pharmacokinetic and Pharmacodynamic Study of BAY 43-9006 (Sorafenib) in Combination with CCI-779 (Temsirolimus) in Advanced Solid Malignancies</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-07-2005 13:56:06"><nciDocumentNumber>GOG-0170H</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG 0170H</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Vorinostat (SAHA, NCI-Supplied Agent, {NSC # 701852, IND # 71976} ) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="04-27-2005 10:18:54"><nciDocumentNumber>CALGB-80403</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-80403/E1206</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="05-23-2005 13:59:31"><nciDocumentNumber>S0514</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0514</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-08-2005 10:35:42"><nciDocumentNumber>AHOD04B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AHOD04B1</localDocumentNumber></localDocumentNumberList><documentTitle>Hodgkin Disease (HD) Banking Study</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-03-2012 13:20:40" createdDate="06-09-2005 10:28:04"><nciDocumentNumber>NABTC-05-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTC-05-01</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-20-2005 14:10:55"><nciDocumentNumber>E2404</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2404</localDocumentNumber></localDocumentNumberList><documentTitle>Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="07-07-2005 08:18:05"><nciDocumentNumber>ACNS0332</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACNS0332</localDocumentNumber></localDocumentNumberList><documentTitle>Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-02-2005 15:41:28"><nciDocumentNumber>6829</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GCC 0447</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination with Cytosine Arabinoside (ara-C) and Etoposide for Patients with Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="08-11-2005 11:23:38"><nciDocumentNumber>6970</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MCC14193</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial of Vorinostat (NSC-701852, Suberoylanilide Hydroxamic Acid) and Doxorubicin (NSC-123127, Adriamycin)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="08-26-2005 15:25:10"><nciDocumentNumber>7048</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>06-C-0083</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients with Kaposi's Sarcoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-07-2005 10:44:48"><nciDocumentNumber>7306</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MMC-14796</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-28-2005 15:58:09"><nciDocumentNumber>ACOSOG-Z1041</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>Z1041</localDocumentNumber><localDocumentNumber>NSABP-B-41</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab with a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients with HER-2 Positive Operable Breast Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-07-2005 14:11:25"><nciDocumentNumber>E3204</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E3204</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients with Locally Advanced Rectal Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="05-03-2012 11:17:51" createdDate="10-12-2005 11:12:50"><nciDocumentNumber>7409</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2005-0717</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Tandutinib (MLN518) in Androgen-Independent Prostate Cancer with Bone Metastases</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-12-2005 14:53:47"><nciDocumentNumber>MA.17ICSC</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MA.17ICSC</localDocumentNumber></localDocumentNumberList><documentTitle>Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-21-2005 09:12:34"><nciDocumentNumber>7341</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2005-0839</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, with Pegfilgrastim for the Treatment of Patients with Metastatic Transitional Cell Carcinoma and Renal Insufficiency</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="10-26-2005 13:37:55"><nciDocumentNumber>7440</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>05-087</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Cetuximab and Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-01-2005 15:54:24"><nciDocumentNumber>E2Z04</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ECOG-E2Z04</localDocumentNumber></localDocumentNumberList><documentTitle>Quality of Life in Younger Breast Cancer Survivors</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-02-2005 10:11:38"><nciDocumentNumber>RTOG-0515</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0515</localDocumentNumber></localDocumentNumberList><documentTitle>A Comparative Study of Gross Tumor Volume Definition With or Without PET Fusion for Patients With Non-Small Cell Lung Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="11-03-2005 10:59:02"><nciDocumentNumber>CALGB-150509</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-150509</localDocumentNumber></localDocumentNumberList><documentTitle>Additional Circulating Markers of Angiogenesis and Disease in Mesothelioma Patients Treated on CALGB-30107</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-17-2005 11:51:13"><nciDocumentNumber>NABTT-0504</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT 0504</localDocumentNumber></localDocumentNumberList><documentTitle>A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients with Recurrent Glioblastoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="11-23-2005 14:49:15"><nciDocumentNumber>SCUSF-0502</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SCUSF-0502</localDocumentNumber></localDocumentNumberList><documentTitle>Thyroid Function &amp; Breast Cancer:  A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in Women Diagnosed with Breast Cancer and the Magnitude of Change in Thyroid Function Post-chemotherapy</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-07-2005 14:06:02"><nciDocumentNumber>7448</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-049</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of the Halichondrin B Analog E7389 as Second Line Therapy for Patients with Locally Advanced Unresectable or Metastatic Pancreatic Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-09-2005 14:15:18"><nciDocumentNumber>E5805</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E5805</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of E7389 (Halichondrin B Analog), in Patients with Metastatic Hormone Refractory Prostate Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-26-2012 12:17:26" createdDate="12-14-2005 11:24:17"><nciDocumentNumber>7522</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHII-77</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 2 Study Evaluating the Efficacy of VEGF Trap in Patients with Recurrent Inoperable Stage III or Stage IV Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-22-2005 09:08:47"><nciDocumentNumber>ASCT0431</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ASCT0431</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Selected Patients with CR1 and CR2 ALL</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="01-25-2006 12:09:33"><nciDocumentNumber>7834</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>06-C-0150</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-01-2006 18:09:25"><nciDocumentNumber>FCRB-04-003-P</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>FCRB-04-003-P</localDocumentNumber></localDocumentNumberList><documentTitle>Comparing the Lozenge to the Patch for Smoking Cessation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-07-2006 13:00:00"><nciDocumentNumber>TBCI-S1-ICSC</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>TBCI-S1-ICSC</localDocumentNumber></localDocumentNumberList><documentTitle>Correlative Science Studies for SWOG Protocol S9313: Phase III Comparison of Adjuvant Chemotherapy with High-Dose Cyclophosphamide plus Doxorubicin (AC) versus Sequential Doxorubicin followed by Cyclophosphamide (A'C) in High Risk Breast Cancer Patients with 0-3 Positive Nodes</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-07-2006 15:15:38"><nciDocumentNumber>E2598T1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2598T1</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of HER2 Mutations in Patient Tumors from E2598</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="03-24-2006 14:12:26"><nciDocumentNumber>NABTC-06-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTC06-01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Single Arm Trial of VEGF Trap in Patients with Recurrent Temozolomide-Resistant Malignant Gliomas</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-10-2006 14:33:52"><nciDocumentNumber>NCIC-PR.11</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCIC-PR.11</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer (START)</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="04-11-2006 10:24:59"><nciDocumentNumber>NCIC-185</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCIC-185</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients with Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:22:15" createdDate="04-18-2006 12:16:32"><nciDocumentNumber>7845</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J0669</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Alvocidib (NSC 649890, IND 46,211, Flavopiridol) in Timed Sequential Combination with Cytosine Arabinoside (ara-C) and Mitoxantrone for Adults with Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-02-2006 10:29:15"><nciDocumentNumber>E2100ICSC</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2100ICSC#2</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Profiling of E2100 FFPE Samples Using a Custom 512 Gene set on the DASL Platform</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="06-15-2006 11:33:23"><nciDocumentNumber>GOG-0087M</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0087M</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Trabectedin (Yondelis®, R279741, IND# 75,111) in the Treatment of Advanced, Persistent or Recurrent Uterine Leiomyosarcomas</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="05-03-2012 13:45:49" createdDate="06-26-2006 12:44:00"><nciDocumentNumber>7678</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>07-C-0106</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase 2.5 Study of 153Sm-EDTMP (Quadramet) with or without a PSA/TRICOM Vaccine in Men with Androgen-Insensitive Metastatic Prostate Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="07-14-2006 13:38:56"><nciDocumentNumber>CALGB-140503</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-140503</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (&lt;/= 2 cm) Peripheral Non-Small Cell Lung Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-29-2006 15:58:36"><nciDocumentNumber>7786</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>15431A</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Dasatinib (NSC 732517) in Previously-Treated Patients with Metastatic Colorectal Cancer
</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="09-05-2006 10:57:25"><nciDocumentNumber>S8809-S9800</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S8809/S9800</localDocumentNumber></localDocumentNumberList><documentTitle>Assessment of MUM1 Expression, Lymphoma-Associated Macrophages, and Regulatory T-Cells in Follicular Lymphoma: Prognostic Markers in SWOG S8809 and S9800/S9911 Trials Representing Pre-and Post-Monoclonal Antibody Therapy Protocols</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="09-13-2006 11:11:49"><nciDocumentNumber>GOG-0170J</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0170J</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Enzastaurin (Lilly IND #60,933) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-28-2006 09:35:46"><nciDocumentNumber>N0626</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0626</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Randomized Study of Pemetrexed with Sorafenib Versus Pemetrexed Alone as Second-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-11-2006 12:48:32"><nciDocumentNumber>NABTT-0603</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT 0603</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Trial of Hydroxychloroquine in Conjunction with Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-26-2006 14:20:48"><nciDocumentNumber>GOG-0235</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0235</localDocumentNumber></localDocumentNumberList><documentTitle>A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-04-2006 10:03:37"><nciDocumentNumber>E2993T2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2993T2</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Mechanisms of NOTCH Induced Transformation in T-ALL</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-08-2006 15:27:12"><nciDocumentNumber>E1496T1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1496T1</localDocumentNumber></localDocumentNumberList><documentTitle>Identification of Biomarkers in Follicular Lymphoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-13-2006 16:20:46"><nciDocumentNumber>N0682</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0682</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Clinical Trial of Denileukin Diftitox in Combination with Rituximab in Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-05-2007 10:00:33"><nciDocumentNumber>AREN0534</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AREN0534</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-25-2007 08:19:39"><nciDocumentNumber>RTOG-0618</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0618</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-13-2007 13:30:52"><nciDocumentNumber>8085</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>P07105</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Melanoma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-14-2007 08:47:17"><nciDocumentNumber>AEWS07P1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AEWS07P1</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents with an Interval Compression Schedule in Newly Diagnosed Patients with Localized Ewing Sarcoma Family of Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-16-2007 11:03:35"><nciDocumentNumber>AOST06P1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AOST06P1</localDocumentNumber></localDocumentNumberList><documentTitle>Feasibility and Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-02-2012 12:45:43" createdDate="04-05-2007 13:12:29"><nciDocumentNumber>AAML07P1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML07P1</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Pilot Study of Bortezomib (PS-341, Velcade, IND #58,443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-17-2007 11:49:33"><nciDocumentNumber>AMC-053</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AMC-053</localDocumentNumber></localDocumentNumberList><documentTitle>Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Lymphoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-02-2007 09:34:03"><nciDocumentNumber>AMC-052</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AMC-052</localDocumentNumber></localDocumentNumberList><documentTitle>A Single-Arm, Open-Label Pilot Trial of the Safety and Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-29-2007 10:24:46"><nciDocumentNumber>N057K</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N057K</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="06-08-2007 12:48:45"><nciDocumentNumber>S0777</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0777</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-27-2007 10:55:02"><nciDocumentNumber>7353</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I Study of CCI-779 in Combination with Dexamethasone in Multiple Myeloma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-17-2007 15:52:35"><nciDocumentNumber>7856</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>08-C-0180</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar®) in Children and Young Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-03-2012 13:45:49" createdDate="07-27-2007 09:28:00"><nciDocumentNumber>8064</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MCC-8064</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-26-2012 12:17:26" createdDate="10-03-2007 09:01:52"><nciDocumentNumber>8148</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>COMIRB 08-0044</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/Randomized Phase II Study of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination with Erlotinib Compared with Erlotinib Alone in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-12-2007 14:56:51"><nciDocumentNumber>06-06</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>URCC-06-06</localDocumentNumber></localDocumentNumberList><documentTitle>Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind Placebo-Controlled Clinical Trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-01-2007 11:29:05"><nciDocumentNumber>MDA-2006-0841</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2006-0841</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized, Double-Blind, Placebo-Controlled Trial of Palonosetron/Dexamethasone with or without Dronabinol for the Prevention of Chemotherapy-induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-13-2007 15:31:29"><nciDocumentNumber>AMC-059</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AMC-059</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1/2 Trial of PTC299 in Patients with HIV-Related Kaposi's Sarcoma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-03-2008 14:45:38"><nciDocumentNumber>E4599T1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4599T1</localDocumentNumber></localDocumentNumberList><documentTitle>Angiogenesis Pathway Gene Polymorphisms Associated with Clinical Outcome in Patients Enrolled in ECOG 4599</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="02-15-2008 08:52:00"><nciDocumentNumber>S0709</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0709</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected by Serum Proteomics</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-03-2012 15:48:07" createdDate="02-28-2008 10:15:34"><nciDocumentNumber>8242</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="03-06-2008 12:27:19"><nciDocumentNumber>CALGB-10502</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-10502</localDocumentNumber></localDocumentNumberList><documentTitle>Dose Escalation and Phase II Study of Bortezomib (IND #58443, NSC # 681239) Added to Standard Daunorubicin and Cytarabine Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-31-2008 08:10:04"><nciDocumentNumber>GOG-0170M</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0170M</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-30-2008 13:02:14"><nciDocumentNumber>GOG-0249</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0249</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="05-20-2008 09:48:02"><nciDocumentNumber>8237</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>J0856</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46,211) Given in Timed Sequential Combination with Cytosine Arabinoside (ara-C) and Mitoxantrone for Adults with Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias (AML)</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-02-2008 08:51:08"><nciDocumentNumber>8196</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>08-C-0148</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Imatinib Mesylate in Children and Adults with Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-18-2008 15:07:53"><nciDocumentNumber>E1690T1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1690T1</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Prognostic Factor Analysis in Melanoma</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-09-2008 13:16:15"><nciDocumentNumber>8300</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>09-C-0138</localDocumentNumber></localDocumentNumberList><documentTitle>A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-17-2008 14:02:18"><nciDocumentNumber>AALL07P1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AALL07P1</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND #58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="07-22-2008 08:29:11"><nciDocumentNumber>CALGB-30506</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-30506</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients with Early Stage Non-Small Cell Lung Cancer Associated with Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-22-2008 09:59:36"><nciDocumentNumber>8248</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NA_00034732</localDocumentNumber></localDocumentNumberList><documentTitle>Phase 2 Study of Bevacizumab in Children and Adults with Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-27-2008 08:43:04"><nciDocumentNumber>AAML08B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML08B1</localDocumentNumber></localDocumentNumberList><documentTitle>Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-16-2008 13:00:23"><nciDocumentNumber>E6508</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E6508</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation</documentTitle><currentStatus>Temporarily Closed to Accrual</currentStatus></document><document updatedDate="04-26-2012 12:15:51" createdDate="09-23-2008 11:18:59"><nciDocumentNumber>8288</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC0888</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-09-2008 14:58:46"><nciDocumentNumber>NCCTG-N08C3</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N08C3</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-21-2008 13:56:46"><nciDocumentNumber>8192</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-068</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-13-2008 14:00:03"><nciDocumentNumber>GOG-0129Q</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0129Q</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-19-2008 07:57:46"><nciDocumentNumber>RTOG-0920</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0920</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-29-2008 13:55:55"><nciDocumentNumber>S0826</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0826</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of SCH 727965 (NSC 747135) in Patients with Stage IV Melanoma</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-30-2008 13:24:46"><nciDocumentNumber>S0819</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0819</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-21-2009 15:09:40"><nciDocumentNumber>GOG-0252</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0252</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865, IND #7921)</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-27-2009 12:36:23"><nciDocumentNumber>N0879</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N0879</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="02-03-2009 10:51:05"><nciDocumentNumber>S0904</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0904</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="02-24-2009 16:56:24"><nciDocumentNumber>AMC-064</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AMC-064</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma from Patients with Aggressive B-Cell Lymphomas</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-05-2009 15:23:45"><nciDocumentNumber>GOG-0229I</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0229I</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of Brivanib (BMS582664, IND#105029), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-13-2009 09:33:42"><nciDocumentNumber>RTOG-0815</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG 0815</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-18-2009 14:35:01"><nciDocumentNumber>NSABP-MC083I</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC083I</localDocumentNumber></localDocumentNumberList><documentTitle>A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-13-2009 11:22:16"><nciDocumentNumber>ARST08P1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ARST08P1</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-20-2009 10:38:51"><nciDocumentNumber>ADVL0912</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0912</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-03-2012 13:46:11" createdDate="05-07-2009 14:30:10"><nciDocumentNumber>8376</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NYU 09-0356</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients with Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-06-2009 14:13:24"><nciDocumentNumber>RTOG-0926</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-0926</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-09-2009 08:02:16"><nciDocumentNumber>ACOSOG-Z4093</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACOSOG-Z4093</localDocumentNumber></localDocumentNumberList><documentTitle>Inflammatory and Angiogenic Biomarker Profiles for Early Detection of Lung Cancer</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-22-2009 10:56:59"><nciDocumentNumber>E1308</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1308</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbitux) with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-07-2009 11:01:02"><nciDocumentNumber>AALL08B2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AALL08B2</localDocumentNumber></localDocumentNumberList><documentTitle>Genome-Wide Interrogations in Childhood Acute Lymphoblastic Leukemia (ALL)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-18-2009 11:55:55"><nciDocumentNumber>AAML10B8</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML10B8</localDocumentNumber></localDocumentNumberList><documentTitle>NOD-SCID Mouse Engraftment: Characterization of LIC Phenotype and Assessment of LIC Frequency/Function in Cytogenetically-Defined Risk Groups in AML</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-18-2009 14:30:29"><nciDocumentNumber>AAML10B10</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML10B10</localDocumentNumber></localDocumentNumberList><documentTitle>Stat3 Signaling Pathway Aberrancies in Pediatric AML</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-18-2009 14:38:50"><nciDocumentNumber>8485</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU # 09150</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-19-2009 12:49:58"><nciDocumentNumber>8417</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCC 2010-003</localDocumentNumber></localDocumentNumberList><documentTitle>Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination with Gemcitabine</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-27-2009 09:40:12"><nciDocumentNumber>S9031-S9126-S9333-S9500-B</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9031-S9126-S9333-S9500-B</localDocumentNumber></localDocumentNumberList><documentTitle>Topoisomerase 2 Expression and Acute Myeloid Leukemia (AML)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-08-2009 11:13:36"><nciDocumentNumber>8331</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHL-074</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Azacitidine Combined with Mitoxantrone and Etoposide (A-NOVE) Chemotherapy for Patients Age >/= 60 with Poor Prognosis Acute Myeloid Leukemia (AML)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="09-23-2009 10:27:57"><nciDocumentNumber>S9346A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9346A</localDocumentNumber></localDocumentNumberList><documentTitle>Germline Polymorphisms Associated with the PSA Response in Men with Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-30-2009 13:19:21"><nciDocumentNumber>PBTC-030</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PBTC-030</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-07-2009 10:10:26"><nciDocumentNumber>ADVL0921</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL0921</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:22:14" createdDate="10-19-2009 11:37:31"><nciDocumentNumber>8490</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>10-0273</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-23-2009 10:57:45"><nciDocumentNumber>8436</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MCC-16066</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of mTOR Inhibitor Temsirolimus Combined with MEK Inhibitor AZD 6244 in Patients with BRAF Mutant Stage IV Melanoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-28-2009 10:30:03"><nciDocumentNumber>8531</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NYU #</localDocumentNumber></localDocumentNumberList><documentTitle>A Pilot Trial to Evaluate the Molecular Effects of RO4929097 as Neoadjuvant Therapy for Resectable Stage IIIB, IIIC or IV Melanoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-04-2012 10:24:05" createdDate="10-30-2009 14:22:06"><nciDocumentNumber>8508</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2009-0769</localDocumentNumber></localDocumentNumberList><documentTitle>Addition of the Gamma-Secretase Inhibitor RO4929097 (IND 109291) to Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-03-2012 11:07:50" createdDate="11-04-2009 10:33:41"><nciDocumentNumber>8457</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>10-03-055</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination with Bortezomib in Women with ER Positive Metastatic Breast Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-02-2012 11:06:43" createdDate="11-04-2009 12:05:38"><nciDocumentNumber>GOG-9924</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9924</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239, IND# 58443) and Carboplatin (NSC# 241240) in Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-05-2009 12:57:23"><nciDocumentNumber>GOG-8012</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8012</localDocumentNumber></localDocumentNumberList><documentTitle>ERCC1 Expression as a Predictor of Progression Free and Overall Survival in Patients with Epithelial Ovarian Cancer Treated on GOG Protocols 0172 and 0182</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-06-2009 15:07:14"><nciDocumentNumber>8593</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>10-C-0132</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 Study of AZD6244 in Combination with Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum</documentTitle><currentStatus>Closed to Accrual &amp; Treatment</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-09-2009 08:49:57"><nciDocumentNumber>8274</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CASE 6307</localDocumentNumber></localDocumentNumberList><documentTitle>O6-Benzylguanine (BG) and Temozolomide (TMZ) Therapy of Glioblastoma Multiforme (GBM) with Infusion of Autologous P140KMGMT+ Hematopoietic Progenitors to Protect Hematopoiesis</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-27-2009 15:28:05"><nciDocumentNumber>GOG-8013</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8013</localDocumentNumber></localDocumentNumberList><documentTitle>Topoisomerase 2-Alpha (TOPO2A) Genomic Alterations And Immunohistochemical Expression as Well as Chromosome 17 Polysomy In Advanced or Recurrent Endometrial Carcinoma Treated with Anthracycline-Based Therapy</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-18-2009 12:29:53"><nciDocumentNumber>S0941</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0941</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients with Advanced Gallbladder Carcinoma or Cholangiocarcinoma</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="05-02-2012 02:59:24" createdDate="12-21-2009 10:11:27"><nciDocumentNumber>S0833</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0833</localDocumentNumber></localDocumentNumberList><documentTitle>Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients with Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged &lt;/= 65 Years</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-05-2010 11:04:17"><nciDocumentNumber>E3A06</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E3A06</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma</documentTitle><currentStatus>Temporarily Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-28-2010 11:18:16"><nciDocumentNumber>SWOG 8897B-SWOG-ICSC</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG 8897B-SWOG-ICSC</localDocumentNumber></localDocumentNumberList><documentTitle>Gene Variants in Drug Cytotoxicity Pathways and Breast Cancer Survival and Toxicity in SWOG 8897</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="05-03-2012 13:46:11" createdDate="02-22-2010 09:41:31"><nciDocumentNumber>8703</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHII-102</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Randomized Study of Vorinostat or Placebo in Combination with Carboplatin and Paclitaxel for Patients with Advanced Non-small Cell Lung Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-10-2010 14:11:36"><nciDocumentNumber>AALL10B2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AALL10B2</localDocumentNumber></localDocumentNumberList><documentTitle>Identifying Rare Genetic Variants Involved in High Risk Acute Lymphoblastic Leukemia (ALL) via Pooled DNA Sequencing</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-16-2010 14:19:34"><nciDocumentNumber>S0812</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-S0812</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of High Dose Vitamin D in Premenopausal Women at High Risk for Breast Cancer Phase IIB</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-18-2010 11:18:19"><nciDocumentNumber>AAML10B17</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML10B17</localDocumentNumber></localDocumentNumberList><documentTitle>SCOR in Targeted Therapies for Infant Leukemias Project 2: Targeting Apoptosis in Leukemia in Infants</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-18-2010 13:41:30"><nciDocumentNumber>AAML10B19</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML10B19</localDocumentNumber></localDocumentNumberList><documentTitle>Preclinical Evaluation of Novel CD33-Targeting Therapeutics for Treatment of Acute Myeloid Leukemia (AML)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-23-2010 10:25:04"><nciDocumentNumber>8604</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>C010903</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of ABT-888 in Combination with Oxaliplatin and Capecitabine in Advanced Solid Tumors

</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="03-31-2010 13:05:44"><nciDocumentNumber>AMC-072</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AMC-072</localDocumentNumber></localDocumentNumberList><documentTitle>Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males who have Sex with Males</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-01-2010 15:42:57"><nciDocumentNumber>PBTC-N11</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PBTC-N11</localDocumentNumber></localDocumentNumberList><documentTitle>Immunologic Profile of Patients with Newly Diagnosed Medulloblastoma at Initial Diagnosis and During Standard Radiation and Chemotherapy</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-03-2012 11:18:22" createdDate="04-13-2010 14:32:36"><nciDocumentNumber>8731</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2010-0243</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients with Relapsed/Refractory Acute Myelogenous Leukemia</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-13-2010 15:01:18"><nciDocumentNumber>E2501T2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2501T2</localDocumentNumber></localDocumentNumberList><documentTitle>BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated with Sorafenib Monotherapy (ECOG2501)</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-16-2010 11:37:50"><nciDocumentNumber>AMC-076</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AMC-076</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-06-2010 10:45:18"><nciDocumentNumber>GOG-8015</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8015</localDocumentNumber></localDocumentNumberList><documentTitle>Role of Sex Hormone and Insulin/IGF Axes in Endometrial Cancer Recurrence</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-13-2010 10:46:00"><nciDocumentNumber>E2997T2</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2997T2</localDocumentNumber></localDocumentNumberList><documentTitle>Genome Wide Association Study Evaluating Genetic Factors Related to the Efficacy and Tolerability of Fludarabine Treatment in Patients with CLL</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="05-18-2010 14:58:38"><nciDocumentNumber>ADVL1013</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL1013</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors or Leukemia</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-11-2010 11:13:38"><nciDocumentNumber>8828</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>11-C-0029</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of the Hsp90 Inhibitor, AT13387, in Adults with Refractory Solid Tumors</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-03-2012 13:46:11" createdDate="06-17-2010 08:36:51"><nciDocumentNumber>8698</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PHII-108</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients with Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response (including Stable Disease) with Erlotinib Therapy</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-22-2010 09:12:28"><nciDocumentNumber>GOG-8016</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8016</localDocumentNumber></localDocumentNumberList><documentTitle>Genomic and Proteomic Profiles Associated with Recurrence in Stage I Endometrioid Endometrial Carcinoma</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-06-2010 10:06:26"><nciDocumentNumber>GOG-0127W</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0127W</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of ABT-888 (IND# 77840, NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC #609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="07-06-2010 10:21:59"><nciDocumentNumber>CALGB-50904</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-50904</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients with Untreated Follicular Lymphoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-21-2010 16:49:31"><nciDocumentNumber>RTOG-1008</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-1008</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-27-2010 13:33:23"><nciDocumentNumber>8866</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>P8480</localDocumentNumber></localDocumentNumberList><documentTitle>An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients with Advanced Solid Tumors and Lymphomas</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-28-2010 11:11:41"><nciDocumentNumber>8842</nciDocumentNumber><sponsorOrganization>CIP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>11-C-0098</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="07-30-2010 14:09:52"><nciDocumentNumber>8821</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MC093C</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-03-2010 14:17:43"><nciDocumentNumber>GOG-0265</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0265</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Evaluation of ADXS11-001 (NSC 752718, BB-IND#13,712) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-04-2010 11:17:09"><nciDocumentNumber>GOG-8022</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8022</localDocumentNumber></localDocumentNumberList><documentTitle>The Relationship of Racial Genetic Admixture with Endometrial Cancer Outcomes</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-19-2010 07:52:33"><nciDocumentNumber>8850</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>090906</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Trial of Riluzole and Sorafenib in Patients with Advanced Solid Tumors and Melanoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-30-2010 10:51:30"><nciDocumentNumber>S0927</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-S0927</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness in Women with Early Stage Breast Cancer, Phase III</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-08-2010 13:31:33"><nciDocumentNumber>CALGB-9343A-CALGB-ICSC</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9343A-CALGB-ICSC</localDocumentNumber></localDocumentNumberList><documentTitle>PIK3CA Mutation Status as a Biomarker in Elderly Women with Breast Cancer</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-09-2010 09:58:18"><nciDocumentNumber>GOG-0076HH</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0076HH</localDocumentNumber></localDocumentNumberList><documentTitle>A Limited Access Phase I/II Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Velaparib) (IND#77840, NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-14-2010 11:13:47"><nciDocumentNumber>ACCL1032</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>COG-ACCL1032</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Cisplatin</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="10-18-2010 14:10:31"><nciDocumentNumber>8860</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>11010</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Head and Neck</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-17-2010 08:50:32"><nciDocumentNumber>AAML11B7</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML11B7</localDocumentNumber></localDocumentNumberList><documentTitle>MLL Rearrangements in Acute Myeloid Leukemia: A Pilot Project to Expand and Study MLL-ENL in NOD SCID Gamma Mice</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-19-2010 12:17:14"><nciDocumentNumber>GOG-0271</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0271</localDocumentNumber></localDocumentNumberList><documentTitle>A Study of the Local and Systemic Effects of Intraperitoneal Chemotherapy in the Treatment of Previously-Untreated, Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-13-2010 13:08:39"><nciDocumentNumber>GOG-9925</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9925</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of VTX-2337 (IND #78,416) in Combination with Pegylated Liposomal Doxorubicin (PLD: NSC# 712227) or in Combination with Weekly Paclitaxel(R) (NSC #673089) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-14-2010 15:40:40"><nciDocumentNumber>8976</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>11-C-0150</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients with Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-03-2012 13:45:49" createdDate="12-21-2010 08:36:02"><nciDocumentNumber>8977</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase 2 Trial of R115777 in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-22-2010 11:36:47"><nciDocumentNumber>GOG-0186I</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0186I</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab with Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="01-25-2011 11:15:00"><nciDocumentNumber>N1085</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N1085</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I and Feasibility Study of Everolimus (RAD001) plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="02-23-2011 15:38:09"><nciDocumentNumber>CALGB-40903</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB 40903</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in SITU (DCIS)</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="04-12-2011 10:51:20"><nciDocumentNumber>S0106A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S0106A</localDocumentNumber></localDocumentNumberList><documentTitle>Proteomic Signatures Associated with Complete Response (CR) and Complete Continuous Response at One Year (CCR1) Following Cytarabine-Based Induction Chemotherapy in Younger Adult Patients (18-60 Years of Age) with a Newly Diagnosed Non-M3 AML</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="04-27-2011 15:24:53"><nciDocumentNumber>WFU-99211</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WFU-99211</localDocumentNumber></localDocumentNumberList><documentTitle>Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="05-19-2011 15:10:17"><nciDocumentNumber>S1106</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S1106</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients &lt;/= 65 Years of Age with Previously Untreated Mantle Cell Lymphoma
</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-06-2011 10:26:42"><nciDocumentNumber>AOST11B1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AOST11B1</localDocumentNumber></localDocumentNumberList><documentTitle>Methylation Status as Predictor of Response to Neoadjuvant Chemotherapy in Osteosarcoma</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="06-28-2011 13:35:28"><nciDocumentNumber>NSABP-B28-ICSC-A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B28-ICSC-A</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular Predictors of Loco-Regional Recurrence in Node Positive Breast Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-30-2011 07:57:36"><nciDocumentNumber>N1153</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>N1153</localDocumentNumber></localDocumentNumberList><documentTitle>Study of Sorafenib + TH-302:  Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-30-2011 10:04:37"><nciDocumentNumber>9012</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Randomized Gene Fusion Stratified Phase 2 Trial of Abiraterone with or Without ABT-888 for Patients with Metastatic Castration-Resistant Prostate Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="08-31-2011 09:50:52"><nciDocumentNumber>WFU-10-05-16</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97211</localDocumentNumber></localDocumentNumberList><documentTitle>A Feasibility Study of Donepezil in Female Breast Cancer Survivors with Self-Reported Cognitive Dysfunction Following Chemotherapy

</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-15-2011 14:20:19"><nciDocumentNumber>GOG-9928</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9928</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination with Pegylated Liposomal Doxorubicin (PLD, Doxil (NSC #712227) or Lipodox (NSC #673089) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="09-27-2011 14:33:05"><nciDocumentNumber>ADVL1115</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ADVL1115</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase 1 Study of AMG 386 (IND# 114215), an Angiopoietin Neutralizing Peptibody, in Children with Relapsed or Refractory Solid Tumors, Including CNS Tumors</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-25-2012 13:48:26" createdDate="10-18-2011 10:27:47"><nciDocumentNumber>CALGB-51101</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-51101</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="10-20-2011 11:38:36"><nciDocumentNumber>S1201</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S1201</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="11-23-2011 08:22:45"><nciDocumentNumber>ACRIN-6698</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ACRIN-6698</localDocumentNumber></localDocumentNumberList><documentTitle>Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A Sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And MoLecular Analysis)</documentTitle><currentStatus>Approved</currentStatus></document><document updatedDate="04-24-2012 18:00:23" createdDate="04-03-2012 10:01:13"><nciDocumentNumber>AAML12B8</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>AAML12B8</localDocumentNumber></localDocumentNumberList><documentTitle>Development of Pediatric Acute Myeloid Leukemia Xenograft Models for the Testing of Targeted Therapeutic Agents</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="05-01-2012 11:32:43" createdDate="04-11-2012 16:36:30"><nciDocumentNumber>ANBL12B7</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ANBL12B7</localDocumentNumber></localDocumentNumberList><documentTitle>Prognostic Impact of Segmental Chromosome Aberrations in Non MYCN Amplified Neuroblastomas in Different Age Groups</documentTitle><currentStatus>Active</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>EST-P-A278</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A278</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of advanced gastric and pancreatic adenocarcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CCA-020</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCA-020</localDocumentNumber></localDocumentNumberList><documentTitle>The effect of azacytidine in acute leukemia of childhood: a Phase I/II pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>EST-P-B477</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B477</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of adult acute non-lymphocytic leukemia with combination drug induction, intensive consolidation and central nervous prophylaxis using doxorubicin, cytosine arabinoside and 5-azacytidine</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>EST-P-B180</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B180</localDocumentNumber></localDocumentNumberList><documentTitle>Pcnu Phase II pilot metastatic Breast adenocarcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-7111</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7111</localDocumentNumber></localDocumentNumberList><documentTitle>Vincristine/prednisone/dexamethasone (unduction) 6-mp/methotrexate/bcnu (intensification) with cns treatment in untreated acute lymphocytic leukemia in patients under 20 years</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-9211</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9211</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of 2-chlorodexyadenosine in b-cell chronic lymphocytic leukemia patients who have previously failed therapy with fludarabine phosphate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>E3993</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4-09</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of priming with granulocyte-macrophage colony stimulating factor (rhu-gm-csf)and of three induction regimens in adult patients (over 55) with acute non-lymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>RTOG-92-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-92-02</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial of the use of long term total androgen suppression as an adjunct to hormonal cytoreduction and radiotherapy in unfavorable prognosis carcinoma of the prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CALGB-9342</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9342</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Study of Taxol at Three Dose Levels in the Treatment of Patients with Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>E1Y92</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E-1Y92</localDocumentNumber></localDocumentNumberList><documentTitle>Brief physician-initiated quit smoking strategies for community clinical oncology settings</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 00:00:00"><nciDocumentNumber>E3A93</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E3A93</localDocumentNumber></localDocumentNumberList><documentTitle>Biologic Correlates of Response and Survival in Myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CCG-7943</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-7943</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II window of topotecan (nsc #609699) in children with newly diagnosed metastatic osteosarcoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>CCG-L941</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-L941</localDocumentNumber></localDocumentNumberList><documentTitle>Study of selected late effects in patients treated for non-hodgkin's lymphoma (nhl) during childhood</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>SWOG-9510</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9510</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of  Topotecan  in  Hormone Refractory  Prostate Cancer, Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>POG-9605</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9605</localDocumentNumber></localDocumentNumberList><documentTitle>ALINC 16: protocol for patients with newly diagnosed standard risk Acute LYMPHOBLASTIC LEUKEMIA (ALL).</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>SWOG-9461</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9461</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation  of  SURAMIN in  advanced  RENAL  CARCINOMA.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:45"><nciDocumentNumber>POG-7516</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7516</localDocumentNumber></localDocumentNumberList><documentTitle>Cyclocytidine Phase I/II in Pediatric and solid Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>POG-8625/26</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8625/26</localDocumentNumber></localDocumentNumberList><documentTitle>Combined therapy and restaging on the treatment of stages I, IIA, and IIA, Hodgkin's disease in Pediatric patients: A Pediatric Oncology Group Phase III study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>NCCTG-94-46-54</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>94-46-54</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of 9-Amino-20(s)-Camptothecin (9-AC) in previously untreated patients with measurable metastatic Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>SWOG-9305</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9305</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of topotecan in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>NCCTG-93-46-03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-93-46-03</localDocumentNumber></localDocumentNumberList><documentTitle>Pharmacologic studies of Levamisole and 5-Fluorouracil addendum to protocol 91-46-53</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>NCCTG-92-12-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-92-12-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Topotecan for the treatment of Mesothelioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>E2593</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E50192</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of chemotherapy plus all-trans-retinoic acid in patients with extensive-stage small cell lung cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>POG-9310</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9310</localDocumentNumber></localDocumentNumberList><documentTitle>Simal #7:  Escalating rotational Drug Therapy after first Marrow relapse of Non-T, Non-B ALL: A Pediatric Oncology Group pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>CALGB-9670</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9670</localDocumentNumber></localDocumentNumberList><documentTitle>Barriers to participation of older women with Breast cancer in clinical trials: a pilot study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>RTOG-93-11</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-93-11</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II Dose Escalation Study Using Three Dimensional Conformal Radiation Therapy in Patients with Inoperable, Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>GOG-LAP1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-LAP1</localDocumentNumber></localDocumentNumberList><documentTitle>Orientation and evaluation study in performing a GOG standardized data recording and reporting procedure for Laparoscopic Figo Staging in Adenocarcinoma of the Endometrium and Uterine Sarcoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>S9709</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9709</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study to Evaluate Transoral CO2 Laser Supraglottic Laryngectomy and Irradiation in Stage I, II and III Squamous Cell Carcinoma of the Supraglottic Larynx</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>S9708</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9708</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Gemcitabine (Gemzar) in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>RTOG-97-08</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-97-08</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of adjuvant postoperative irradiation combined with cisplatin/Taxol chemotherapy following tah/bso for patients with high-risk endometrial cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>E1Z95</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1Z95</localDocumentNumber></localDocumentNumberList><documentTitle>Flecainide for the Treatment of Chronic Neuropathic Pain:  A Phase II Trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>NCCTG-96-43-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-96-43-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II evaluation of Fazarabine and G-CSF in previously untreated patients with measurable metastatic Adenocarcinoma of the pancreas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>S9712</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9712</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Trial of Concurrent Carboplatin/VP-16 and Radiation Followed by Paclitaxel (Taxol) for Poor-Risk Stage III Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>CCG-B973</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-B973</localDocumentNumber></localDocumentNumberList><documentTitle>Laboratory-Clinical Studies of Neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>NCCTG-96-43-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-96-43-52</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Gemcitabine, Cisplatin and Radiation Therapy in Patients with Locally Advanced Pancreatic and Gastric Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>S9720</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9720</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Paclitaxel and Carboplatin with Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>E1E97</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1E97</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Study of Intraperitoneal (IP) Therapy of Floxuridine (FUDR) with Cisplatin and/or Carboplatin as Consolidation for Ovarian Cancer with Minimal Residual Disease Confined to the Peritoneal Cavity</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>E1997</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1997</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of fludarabine and cyclophosphamide in patients with previously untreated chronic lymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>NCCTG-96-32-54</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-96-32-54</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of oral Etoposide with intravenous Paclitaxel in patients with refractory metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>GOG-P-4</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-P-4</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II evaluation of Melphalan -Adriamycin in Advanced Ovarian Cancer in patients previously treated with radiation therapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:46"><nciDocumentNumber>POG-7695</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7695</localDocumentNumber><localDocumentNumber>CCG-862</localDocumentNumber></localDocumentNumberList><documentTitle>An evaluation of surgery, radiation therapy and chemotherapy in the treatment of previously untreated primary Malignanthepatoma in children (A Phase I -II, group-wide study)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-7410</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7410</localDocumentNumber></localDocumentNumberList><documentTitle>Chronic Lymphocytic Leukemia-Cap in Remission Induction, Prednisone and Cyclophosphamide for Maintenance</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CALGB-7482</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7482</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of patients with metastatic, recurrent or inoperative carcinoma of the Breast</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CALGB-8142</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8142</localDocumentNumber></localDocumentNumberList><documentTitle>Bisantrene straight Phase II advanced Breast cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CALGB-7721</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7721</localDocumentNumber></localDocumentNumberList><documentTitle>A comparitive study of adriamycin versus daunorubicin at two dose levels for induction and of 4 week cycle versus 8 week cycle for maintenance chemotherapy in acute myelocytic leukemia - Phase III </documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>S9718</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9718</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Trial of Gemcitabine plus Cisplatin in Patients with Extensive Disease Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CCG-B953</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-B953</localDocumentNumber></localDocumentNumberList><documentTitle>Use of g-csf causing in vivo seeding of neuroblastoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>GOG-7993</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-7993</localDocumentNumber></localDocumentNumberList><documentTitle>Cisplatin and Doxorubicin in Advanced Carcinoma of the Cervix</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>POG-9243</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9143</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment for children with intermediate-risk Neuroblastoma: POG stage B (all ages) and POG stages C, D, and DS (&lt;365 days at diagnosis)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CALGB-6703</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-6703</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of untreated lymphoma ; evaluation of streptonigrin in combination</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>EST-P-B381</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B381</localDocumentNumber></localDocumentNumberList><documentTitle>Vindesine + bcnu in malignant glioma |</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>EST-P-A678</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A678</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of vindesine in metastatic melanoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>EST-P-C278</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C278</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of chemotherapy for inoperable gastric cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-380</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-380</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of procarbazine in the treatment of histiocytosis in childhood</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-6919</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-6919</localDocumentNumber></localDocumentNumberList><documentTitle>Amsa therapy for children with lymphoblastic malignancy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>EST-2272</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2272</localDocumentNumber></localDocumentNumberList><documentTitle>Nitrosoureas:  useful agents for the treatment of advanced gastrointestinal cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>GOG-9302</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9302</localDocumentNumber></localDocumentNumberList><documentTitle>Laparoscopic Staging in patients with Incompletely Staged Cancer of the Ovary, Primary Fallopian Tube Carcinoma and Primary Peritoneal Carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>SWOG-9312</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9312</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of cisplatin + 5-fu + radiation therapy in patients with locally advanced/inoperable bladder cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:47"><nciDocumentNumber>CCG-B944</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-B944</localDocumentNumber></localDocumentNumberList><documentTitle>Biology studies in childhood hodgkin's and non-hodgkin's lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>CALGB-9511</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9511</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot trial with limited pharmacokinetic monitoring of peg-asparaginase during remission induction and consolidation chemotherapy for adult acute lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>POG-9575</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9575</localDocumentNumber></localDocumentNumberList><documentTitle>Topotecan For Children With Refractory Leukemia:  A Pediatric Oncology Group Phase I Cooperative Agreement Study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>POG-9436</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9436</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Cyclophosphamide, Vincristine, and Carboplatin for children with progressive Astrocytoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>SWOG-7809</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7809</localDocumentNumber></localDocumentNumberList><documentTitle>Maytansine minimal single-agent activity in refractory Breast cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>SWOG-7836</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7836</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy for metastatic epidermal carcinoma of the anal canal</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>E1395</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1395</localDocumentNumber><localDocumentNumber>E1395</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Phase III Evaluation of Paclitaxel + Cisplatin Versus Cisplatin + 5-FU in Advanced Head and Neck Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>SWOG-8108</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8108</localDocumentNumber></localDocumentNumberList><documentTitle>Bisantrene straight Phase II refractory multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>CCG-0902</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-0902</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Fazarabine in Children with Recurrent Solid Tumor Malignancies</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>SWOG-8370</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8370</localDocumentNumber></localDocumentNumberList><documentTitle>Vinblastine and Cis-Platinum in the Treatment of Refractory Sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:48"><nciDocumentNumber>E3293</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E3293</localDocumentNumber><localDocumentNumber>E3293</localDocumentNumber></localDocumentNumberList><documentTitle>Biologic correlates to response and survival in colon cancer</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>RTOG-97-09</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-97-09</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III Study To Test The Efficacy Of The Prophylactic Use Of Oral Pilocarpine To Reduce Hyposalivation And Mucositis Assoiciated With Curative Radiation Therapy In Head And Neck Cancer Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>E8292</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ECOG-E8292</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Double Blind Chemoprevention Trial of High Dose Folic Acid Versus Placebo in Patients with Resected Colorectral Polyps</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>CALGB-9170</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9170</localDocumentNumber></localDocumentNumberList><documentTitle>A multi-center randomized trial of hospital versus early discharge therapy of low-risk patients with fever and neutropenia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>NCCTG-96-92-54</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCC-96-09</localDocumentNumber></localDocumentNumberList><documentTitle>Placebo-controlled evaluation of Bupropion for prevention of relapse to smoking following nicotine patch replacement therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>P9480</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9480</localDocumentNumber></localDocumentNumberList><documentTitle>Prospective analysis of Enalapril therapy in late survivors of childhood Cancer with elevated afterload</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>CCA-242</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCA-242</localDocumentNumber></localDocumentNumberList><documentTitle>5-azacytidine in combination with daunomycin for reinduction of acute myelocytic, acute myelomonocytic, and erythroleukemia (non-all, non-aul): groupwide Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-P-C580</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C580</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study evaluating the role of surgery in the management of patients with small cell carcinoma of the lung</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-P-C282</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C282</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of 4-epiadriamycin in advanced colo-rectal carcinoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-367</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-367</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for the remission induction of generalized rhabdomyosarcoma with vincristine, dactinomycin and cyclophosphamide chemotherapy</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-5275</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-5275</localDocumentNumber><localDocumentNumber>N81-0984</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II studies of streptozotocin combined with 5-fu versus adriamycin in the treatment of islet cell carcinoma and carcinoid tumor</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-1985</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1985</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III comparison of short-duration versus long-duration cooling after doxorubicin extravasation</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>EST-1875</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1875</localDocumentNumber></localDocumentNumberList><documentTitle>Phase ii: a comparison of 5-fluorouracil and adriamycin in the treatment of carcinoma of the bladder</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7304</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7304</localDocumentNumber></localDocumentNumberList><documentTitle>Phase iii, cyclophosphamide, oncovin, procarbazine and prednisone in the treatment of histiocytosis</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7318</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7318</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of cis-platinum (cis-plt) in childhood malignancies</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7835</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7835</localDocumentNumber></localDocumentNumberList><documentTitle>High-dose vincristine, prednisone, hydroxyurea and cytosine arabinoside (hoap) in the blastic phase of chronic granulocytic leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7761</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7761</localDocumentNumber></localDocumentNumberList><documentTitle>Combined chemotherapy/radiation therapy study of stages iii and iv diffuse non-hodgkin's lymphoma</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-7803</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7803</localDocumentNumber></localDocumentNumberList><documentTitle>Triazinate Phase II trtmt of metastatic renal cell ca</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-8091</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8091</localDocumentNumber></localDocumentNumberList><documentTitle>In vitro chemotherapy sensitivity testing of leukemic stem cells using a cloning culture assay, ancillary</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>SWOG-8103</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8103</localDocumentNumber></localDocumentNumberList><documentTitle>Adriamycin + cis-platinum + vinblastine for advanced recurrent endometrial carcinoma, Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:49"><nciDocumentNumber>NCCTG-89-46-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-89-46-52</localDocumentNumber><localDocumentNumber>89-46-52</localDocumentNumber></localDocumentNumberList><documentTitle>A Prospectively Randomized Trial of Intensive Course 5-FU Combined with: A) The l-Isomer of Intravenous Leucovorin; b) Oral (d,l) Leucovorin; or  c) Intravenous (d,l) Leucovorin for the Treatment of Advanced Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>SWOG-8304</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8304</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of l-alanosine in metastatic carcinoma of the Breast</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>RTOG-91-11</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-91-11</localDocumentNumber><localDocumentNumber>R9111</localDocumentNumber><localDocumentNumber>SWOG-9201</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III trial to preserve the Larynx:  induction chemotherapy and Radiation Therapy versus concomitant chemotherapy and Radiation Therapy versus Radiation Therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>INT-0133</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-7921</localDocumentNumber><localDocumentNumber>POG-9351</localDocumentNumber></localDocumentNumberList><documentTitle>Trial of doxorubicin, cisplatin and methotrexate with and without ifosfamide, with and without muramyl tripeptide phosphatidyl ethanolamine (mtp-pe) for treatment of osteogenic sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>CALGB-9343</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9343</localDocumentNumber><localDocumentNumber>C9343</localDocumentNumber><localDocumentNumber>C9343</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Lumpectomy, Tamoxifen, &amp; Irradiation of the Breast Compared with Llumpectomy + Tamoxifen in Women 70 Years of Age or Older who have Carcinoma of the Breast that is Less Than or Equal to 2cm &amp; Clinicaly Negative Axillary Nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>INT-0139</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-9309</localDocumentNumber><localDocumentNumber>CALGB-9592</localDocumentNumber><localDocumentNumber>R9309</localDocumentNumber><localDocumentNumber>R9309</localDocumentNumber><localDocumentNumber>NCIC CTG BR.13</localDocumentNumber><localDocumentNumber>93-17</localDocumentNumber><localDocumentNumber>SWOG-9336</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III comparison between concurrent chemotherapy plus radiotherapy, and concurrent chemotherapy plus radiotherapy followed by surgical resection for stage iiia (n2) non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>RTOG-95-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-95-01</localDocumentNumber><localDocumentNumber>R9501</localDocumentNumber><localDocumentNumber>S9515</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III intergroup trial of surgery followed by (1) radiotherapy vs. (2) radiochemotherapy for resectable high risk Squamous Cell Carcinoma of the Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>INT-0158</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-93-46-52</localDocumentNumber><localDocumentNumber>PENDING</localDocumentNumber><localDocumentNumber>PENDING</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Tumor Thymidylate Synthase, Ki-67, DCC, and p53 as Prognostic Parameters in Patients with High-Risk Primary Colon Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>E1695</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E1695</localDocumentNumber><localDocumentNumber>E1695</localDocumentNumber></localDocumentNumberList><documentTitle>An evaluation of the immunologic mechanism of GM2-KLH/QS-21 vaccination in the context of ECOG trial E1694: a Phase III comparison of GM2-KLH/QS-21 vaccination and high-dose interferon Alfa-2B therapy for high-risk lymph node-metastatic..</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>INT-0102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8897</localDocumentNumber><localDocumentNumber>CALGB-8897</localDocumentNumber><localDocumentNumber>EST-2188</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Comparison of Adjuvant Chemotherapy with or without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients, and a Natural History Follow-Up Study in Low-Risk, Node Negative Patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>NSABP-B-21</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-21</localDocumentNumber><localDocumentNumber>NSABP-B-21</localDocumentNumber></localDocumentNumberList><documentTitle>A Clinical Trial to Determine the Worth of Tamoxifen and the Worth of Breast Radiation in the Management of Patients with Node-Negative, Occult, Invasive Breast Cancer Treated by Lumpectomy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:50"><nciDocumentNumber>INT-0083</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8790</localDocumentNumber><localDocumentNumber>EST-8887</localDocumentNumber><localDocumentNumber>GOG-133</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized trial of adjuvant intraperitoneal recombinant interferon alpha-2 in stage iii ovarian carcinoma in patients who have no evidence of disease after surgery and chemotherapy: Phase III</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>C0187</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-C-0187</localDocumentNumber></localDocumentNumberList><documentTitle>Increasing ecog physician accrual of eligible patients- part i descriptive survey</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>C0488</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-C-0488</localDocumentNumber></localDocumentNumberList><documentTitle>Sexual and reproductive functioning in premenopausal women after adjuvant therapy for Breast cancer:  an ecog pilot study</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>C0587</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-C-0587</localDocumentNumber></localDocumentNumberList><documentTitle>Physician attitudes towards cancer pain management</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>C87-0007</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A study of constitutional chromosome abnormalities in patients with small cell cancer of the lung</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>C89-0003</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Effect of a behavioral relaxation technique on quality of life of Breast cancer patients</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>CALGB-8872</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8872</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized study of patient-controlled analgesia versus continuous intravenous morphine for sever cancer pain</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>CALGB-8963</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8963</localDocumentNumber></localDocumentNumberList><documentTitle>Psychosocial adaption of survivors of acute leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>CALGB-9072</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9072</localDocumentNumber></localDocumentNumberList><documentTitle>Smoking cessation in relatives of cancer patients:  a randomized study of repetitive intervention vs minimal intervention by oncologists in initiating the cessation process</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>ID94-022</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID 94-022</localDocumentNumber></localDocumentNumberList><documentTitle>Study comparing women's comprehension of written informed consent when participating in a randomized clinical trial with paclitaxel by 3-hr vs 96 hr infusion</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-89-92-57</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-89-92-57</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III evaluation of Ocular Cryotherapy as a means of preventing 5-FU induced Ocular toxicity</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>E4195</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E4195</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Doxorubicin plus Paclitaxel plus G-CSF in metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-90-92-55</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-90-92-55</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III controlled trial of low dose Megestrol acetate in the management of hot flushes</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-91-92-53</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-91-92-53</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III double-blind placebo-controlled trial to assess the effectiveness of Olsalazine in the prevention of acute radiation-induced diarrhea</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-91-92-54</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-91-92-54</localDocumentNumber></localDocumentNumberList><documentTitle>M/N - Phase II evaluation of Pentoxifylline in patients with cancer Anorexia/Cachexia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>NCCTG-96-92-58</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCC-96-21</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of soy Phytoestrogen for alleviating hot flashes in breast cancer survivors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:51"><nciDocumentNumber>SWOG-8711</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8711</localDocumentNumber></localDocumentNumberList><documentTitle>A study of reproductive function in patients with testicular cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>SWOG-8861</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8861</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of quality of life in patients with clinical stage a2 or b adenocarcinoma of the prostate enrolled on swog-8890</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>INT-0117</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-6901</localDocumentNumber><localDocumentNumber>CCG-6901</localDocumentNumber><localDocumentNumber>POG-9150</localDocumentNumber></localDocumentNumberList><documentTitle>Intergroup rhabdomyosarcoma study-iv for stage i disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>CALGB-7542</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7542</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for the treatment of non-hodgkin's lymphomas in children</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>SWOG-8819</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8819</localDocumentNumber></localDocumentNumberList><documentTitle>Central Lymphoma Repository Tissue Procurement Protocol</documentTitle><currentStatus>Closed to Accrual</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>EST-1682</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1682</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Radiotherapy fractionation study of malignant melanoma recurrent or metastatic to skin and lymph nodes</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>NCCTG-92-72-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-92-72-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of Topotecan in recurrent Gliomas</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-01-2012 09:21:00" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>S9624</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>S9624</localDocumentNumber><localDocumentNumber>S9624</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Ifosfamide/Mesna for Aggressive Meningeal tumors (Malignant Meningioma, Hemangiopericytoma and Primary Nervous System Sarcoma)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="05-02-2012 12:45:43" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>CCG-09709</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-09709</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I Study of Fenretinide (NSC #374551) in Children with High Risk Solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>NSABP-B-15</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-15</localDocumentNumber><localDocumentNumber>MAOP-1784</localDocumentNumber><localDocumentNumber>NCOG-NSABP-B-15</localDocumentNumber></localDocumentNumberList><documentTitle>A Three Arm Clinical Trial Comparing Short Intensive Adriamycin-Cyclophosphamide Chemotherapy With and Without Interval Reinduction Chemotherapy (CMF) to "Conventional" CMF in Positive Node Patients Having the Following Age and Receptor Criteria: &lt;/= 49 Years - All Patients; 50-59 Years - PR &lt; 10 fmol, Regardless of ER</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>CALGB-8923</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8923</localDocumentNumber></localDocumentNumberList><documentTitle>Gm-csf vs. placebo during remission-induction and mitoxantrone/ara-c vs. ara-c intensification in elderly patients with acute myeloid leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>NCCTG-85-24-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-85-24-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III surgical adjuvant trial in completely resected Stage I (T1 N1, T2 N0) II, and III Non-small cell lung cancer comparing post-operative adjuvant Chemotherapy vs. observation</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>CALGB-8534</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8534</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy with intensive ace/pce and radiotherapy to the primary tumor and prophylactic whole- brain radiotherapy with or without warfarin in limited small cell carcinoma of the lung.  Phase III </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:50:52"><nciDocumentNumber>GOG-81C</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-81C</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial of high vs intermediate dose Medroxyprogesterone Acetate (MPA) in patients with Advanced or Recurrent Endometrial Carcinoma negative for Estrogen and Progesterone Receptors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>POG-9285</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9284-85</localDocumentNumber></localDocumentNumberList><documentTitle>Barriers to patient enrollment onto frontline therapeutic clinical trials and development of intervention strategies to increase the proporation of enrollments</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>POG-9284</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9284/85</localDocumentNumber></localDocumentNumberList><documentTitle>Barriers to Patient Enrollment onto Frontline Therapeutic Clinical Trials and Development of Intervention Strategies to Increase the Proporation of Enrollments</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>E2597</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2597</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial of induction Paclitaxel and Carboplatin followed by standard Radiotherapy (64 GY/7 weeks) vs. Hyperfractionated accelerated Radiotherapy (Hart 57.6 GY/2.5 weeks) for patients with unresectable stage IIIA and IIIB Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>E2297</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2297</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III , randomized study of Gemcitabine and 5-Fluorouracil vs. Gemcitabine alone in Pancreatic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>T96-0089</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.104</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase II study of two schedules of bryostatin 1 (nsc 339555) in patients with advanced malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:53"><nciDocumentNumber>E1485</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1485</localDocumentNumber></localDocumentNumberList><documentTitle>Antigenic surface markers, Karyotypes and bone marrow biopsies in acute and chronic Leukemias and Myelodysplasias</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:54"><nciDocumentNumber>NCCTG-86-30-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-86-30-01</localDocumentNumber><localDocumentNumber>86-30-01</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot evaluation of alternating chemotherapy regimens as initial treatment for local-regionally advanced breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:54"><nciDocumentNumber>SWOG-9139</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9139</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant therapy of primary osteogenic sarcomas, Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:55"><nciDocumentNumber>NCCTG-89-42-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-89-42-51</localDocumentNumber><localDocumentNumber>89-42-51</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of sequential systemic 5-FU + Leucovorin and Intrahepatic FUDR for treatment of metastatic colorectal cancer confined to the liver</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:22" createdDate="12-17-1998 16:50:55"><nciDocumentNumber>SWOG-8629</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8629</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant therapy with adriamycin plus cisplatin for endometrial sarcomas at high risk of recurrence: Phase II </documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>SWOG-8816</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8816</localDocumentNumber></localDocumentNumberList><documentTitle>Study of 13-cis Retinoic Acid (Accutane) plus RIFN-Alpha A (Roferon-A) in Mycosis Fungoides, Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>SWOG-8829</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8829</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Amonafide in the Treatment of CNS Tumors, Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>CCG-9951</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-9951</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of stereotactic radiosurgery for recurrent brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>E1290</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1290</localDocumentNumber></localDocumentNumberList><documentTitle>T92-0022I protocol for the evaluation of combined modalities in the treatment of surgically resected Colonic carcinoma with positive nodes, Duke's C</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>E2690</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>E2690</localDocumentNumber><localDocumentNumber>CALGB-9390</localDocumentNumber><localDocumentNumber>SWOG-9325</localDocumentNumber></localDocumentNumberList><documentTitle>Eval. of the in vivo mech. of Ifn A-2B in the context of ECOG trial EST1690 comparing Ifn administered for 1 yr at high dosage to Ifn long-term therapy at lower dosage as prophylaxis for high risk lymph node-metastatic cutanuous Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:56"><nciDocumentNumber>NCCTG-90-20-53</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-90-20-53</localDocumentNumber><localDocumentNumber>90-20-53</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of utility of serum neuron-specific enolase in the management of patients with small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>INT-0109</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8890</localDocumentNumber><localDocumentNumber>ECOG-6888</localDocumentNumber><localDocumentNumber>RTOG-8819</localDocumentNumber></localDocumentNumberList><documentTitle>Radical prostatectomy versus radiation therapy for clinical stage a2 and b adenocarcinoma of the prostate (no, mo)</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>SWOG-9043</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9043</localDocumentNumber></localDocumentNumberList><documentTitle>Phase iii randomized trial of beta-carotene vs placebo in prevention of second primaries in stages i and ii head and neck cancer</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>GOG-9704</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9704</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of LIPOSOMAL DOXORUBICIN (DOXIL) and prolonged ETOPOSIDE as second line therapy in recurrent or persistent OVARIAN, TUBAL and PERITONEAL CARCINOMA</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>GOG-0120</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-120</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized comparison of Hydroxyurea versus Hydroxyurea, 5-FU infusion &amp; Bolus Cisplatin versus weekly Cisplatin as adjunct to radiation therapy in patients with stages II-B,III,IV-A Carcinoma of the Cervix &amp; Negative Para-aortic Nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>GOG-0122</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-122</localDocumentNumber></localDocumentNumberList><documentTitle>Whole Abdominal Radiotherapy versus Circadian-Timed Combination Doxorubicin-Cisplatin Chemotherapy in Advanced Endometrial Carcinoma (Phase III)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>GOG-0126D</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-126D</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Pyrazoloacridine (PZA)(NSC #366140) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:57"><nciDocumentNumber>GOG-0126G</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-126G</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of CI-958 (NSC #635371) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0129H</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-129H</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Doxil in the treatment of Recurrent or Persistent Endometrial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0141</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-141</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Patients with suboptimal ("bulky") stage IB Carcinoma of the Cervix: a randomized comparison of Radical Hysterectomy and Pelvic &amp; Para-Aortic Lymphadenectomy with or without neoadjuvant Vincristine and CISPLATIN Chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0146C</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-146C</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Topotecan (SKF 104868-A) (NSC #609699) in Recurrent, Platinum-Sensitive Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0152</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-152</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized study of Cisplatin (NSC #119875) and Taxol (Paclitaxel) (NSC #125973) with Interval Secondary Cytoreduction versus Cisplatin and Paclitaxel in patients with suboptimal stage III Epithelial Ovarian Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0165</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-165</localDocumentNumber></localDocumentNumberList><documentTitle>A Randomized Comparison of Radiation vs Radiation Plus Weekly Cisplatin vs Radiation Plus PVI (Protracted Venous Infusion) 5-FU in Patients with Stage II-B, III-B and IV-A Carcinoma of the Cervix with Negative Paraaortic Nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0167</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-0167</localDocumentNumber></localDocumentNumberList><documentTitle>A Two-part Study of the Treatment of Atypical Endometrial Hyperplasia.  Part A:  A Prospective Study of Immediate Hysterectomy; Part B: A Randomized Phase II Study of Medroxyprogesterone Acetate versus Deproprovera</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:58"><nciDocumentNumber>GOG-0170B</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-170B</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Recombinant Human Interleukin-12 (rhIL-12) in Recurrent, and Refractory Ovarian Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>GOG-0076Z</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-76Z</localDocumentNumber></localDocumentNumberList><documentTitle>A Limited Access Phase II Trial of Cisplatin and Navelbine (Vinorelbine) in Advanced and Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>GOG-0099</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-99</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III randomized study of adjunctive radiation therapy in Intermediate Risk Endometrial Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>T91-0052</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-91-013</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of homoharringtonine (nsc 141633) and alpha interferon (ifn-a) in chronic myelogenous leukemia (cml)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:50:59"><nciDocumentNumber>T97-0053</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>97-1083</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Clinical Trials of IV rhIL-12 with or without a Test-Dose in Patients with Advanced Malignancies (rhIL-12 NSC# 672423)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:00"><nciDocumentNumber>T97-0050</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM 97-073</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:00"><nciDocumentNumber>CALGB-9863</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9863</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of irinotecan (cpt-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>A2971</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-29701</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of Children with Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>NABTT-9801</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NABTT-9801</localDocumentNumber></localDocumentNumberList><documentTitle>A Multi-Center, Open-Label Clinical Study to Evaluate the Safety and Performance of the Proxima Gliasite RTS, a Radiation Delivery System, in Patients with Recurrent Malignant Brain Tumors Undergoing Surgical Resection</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>T98-0019</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>D-1644</localDocumentNumber><localDocumentNumber>D-1644</localDocumentNumber><localDocumentNumber>D-1644</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II Evaluation of Dolastatin-10 in Patients with Hormone Refractory Prostate Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-02-2012 12:45:43" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>CCG-09718</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>0</localDocumentNumber></localDocumentNumberList><documentTitle>A Pediatric Phase I Study of Intravenous Dolastatin-10 (NSC 376128) in Patients with Refractory Solid Tumors</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:01"><nciDocumentNumber>GOG-0076BB</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-76-BB</localDocumentNumber></localDocumentNumberList><documentTitle>A Limited Access Phase II Trial of Cisplatin and Irinotecan in Advanced, Persistent and Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>76-32-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>76-32-04</localDocumentNumber></localDocumentNumberList><documentTitle>Additive hormonal therapy in perimenopausal and postmenopausal patients with advanced Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>76-77-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>76-77-01</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy single agent pyrazofurin therapy for treatment of advanced sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>T84-0514</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>URCC-2584M</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of misonidazole, cyclophosphamide, ccnu, and methotrexate in the treatment of small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>T84-0489</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.17</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II study of at-125 and cisplatin in patients with non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>T84-0495</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IRB-29594</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of echinomycin in the treatment of advanced renal cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POG-8231</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8231</localDocumentNumber></localDocumentNumberList><documentTitle>Long-term effects of radiation with or without chemotherapy on the Nervous System of children with Medulloblastoma, a retrospective analysis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>75-03-02/05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>75-03-02/05</localDocumentNumber></localDocumentNumberList><documentTitle>Combination of cytoxan, adriamycin, dianhydrogalactitol, vp-16, piperazinedione, and triazinate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>75-25-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>75-25-02</localDocumentNumber></localDocumentNumberList><documentTitle>Platinum-based polychemotherapy vs dianhydrogalactitol in advanced non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POG-7770</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7770</localDocumentNumber><localDocumentNumber>SWOG-7770</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot stage IV Neuroblastoma protocol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>GITSG-9376</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-9376</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trials in Advanced Measurable Pancreatic Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>T84-0433</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I and pharmacokinetic study of trimetrexate in adults with cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>T84-0441</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.13</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of nmf in malignant glioma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POG-7411</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7411</localDocumentNumber><localDocumentNumber>SWOG-7411</localDocumentNumber></localDocumentNumberList><documentTitle>VM-26 in childhood Leukemia and solid Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POA-27183</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-27183</localDocumentNumber><localDocumentNumber>BGSM-27183</localDocumentNumber></localDocumentNumberList><documentTitle>The treatment of Chronic Lymphocytic Leukemia with Levamisole and Lithium - A Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:02"><nciDocumentNumber>POA-62182</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-62182</localDocumentNumber></localDocumentNumberList><documentTitle>Interferon Phase II Interferon-Alpha2 in extensive Small Cell Lung Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>EST-8177</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-8177</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III management of non-resectable Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>NSABP-C-03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-C-03</localDocumentNumber><localDocumentNumber>NCOG-NSABP-C-03</localDocumentNumber></localDocumentNumberList><documentTitle>A Study to Compare Leucovorin and 5-FU with Adjuvant MECCNU, Vincristine and 5-FU (MOF) in Patients with Dukes' B and C Carcinoma of the Colon</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>SWOG-8944</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8944</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II study of carboplatin (cbdca) in refractory multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>T84-0282</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>83-084</localDocumentNumber></localDocumentNumberList><documentTitle>Induction chemotherapy for advanced previously untreated squamous carcinoma of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>WCG-020</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WCG-020</localDocumentNumber></localDocumentNumberList><documentTitle>Tmca Phase II broad study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>NPCTG-200</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NPCTG-200</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of Estramustine Phosphate and Streptozotocin in patients with advanced prostatic Carcinoma who have had extensive irradiation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:03"><nciDocumentNumber>T84-0173</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>75-122</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant therapy of early Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCOG-9L-82</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-9L-82</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Prednimustine in all over 60, smouldering Leukemia and refractory acute Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NPCP-300</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NPCP-300</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of Procarbazine, DTIC, and Cyclophosphamide in patients with advanced carcinoma of the prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCOG-9L-62</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-9L-62</localDocumentNumber></localDocumentNumberList><documentTitle>5-Azacytidine and 6-Thioguanine in the treatment of refractory adult acute Non-Lymphocytic leukemia (anll)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>RTOG-89-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-89-04</localDocumentNumber></localDocumentNumberList><documentTitle>Interstitial irradiation for the treatment of recurrent malignant brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCOG-4P-81</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-4P-81</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of Adriamycin versus Adriamycin + Cis-Platinum in patients with Endocrine unresponsive metastatic Prostatic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1401</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>URCC-3182M</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized trial of front-line chemotherapy for advanced Breast cancer (cnf vs caf)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1385</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU-8011</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy of epithelial ovarian carcinoma, stage iii or iv previosly untreated</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1351</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>D-332</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of cis-platinum and 5-fu infusion for advanced squamous cancer of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1322</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>82-474</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II trials of t101 murine monoclonal antibody therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1339</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-8091</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II evaluation in man of human leukocyte interferon given by intramuscular injection and intraarterial tumor infusion</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1342</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-8231</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of interferon for glioblastoma multiforme</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T83-1313</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>81-087</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of ara-c for advanced squamous carcinoma of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>NCOG-0C-84-1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-0C-84-1</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of Vincristine infusion for treatment of Kaposi's Sarcoma in patients with Aids</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>GOG-8902</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-8902</localDocumentNumber></localDocumentNumberList><documentTitle>Correlation of specific HPV types and amplification and expression of the C-MYC gene with the behavior of Squamous Carcinoma of the Cervix.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>CALGB-8932</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8932</localDocumentNumber></localDocumentNumberList><documentTitle>High-dose etoposide and cisplatin in advanced non-small cell lung cancer (nsclc) : a limited access Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T89-0037</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-89-M1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of new agents in metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T89-0032</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I study of thiotepa and gm-csf</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:04"><nciDocumentNumber>T89-0033</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-89-008</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I and clinical pharmacologic evaluation of liposomal encapsulated doxorubicin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>POG-8935</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8935</localDocumentNumber></localDocumentNumberList><documentTitle>A study of the biological behavior of Optic Pathway Tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>CCG-E15</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-E15</localDocumentNumber></localDocumentNumberList><documentTitle>Case-control study of acute lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>RTOG-88-06</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-88-06</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II protocol for the treatment of primary Central Nervous System Lymphomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>NBCCGA-13</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NBCCGA-13</localDocumentNumber></localDocumentNumberList><documentTitle>BCG (TICE) Phase II study of the activity of intravesical bacillus of clamette-guerin on carcinoma of the bladder</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T88-0156</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GYN-88-002</localDocumentNumber></localDocumentNumberList><documentTitle>Radiolocalization of moabs to tag-72 following ip administration to ovarian carcinoma patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>EST-P-Z288</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-Z288</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of Murine monoclonal antibody 17-1A in patients with advanced adenocarcinoma of the Pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>VASOG-17</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VASOG-17</localDocumentNumber></localDocumentNumberList><documentTitle>Cytoxan and preoperative radiotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>VASOG-20</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VASOG-20</localDocumentNumber></localDocumentNumberList><documentTitle>Proven colorectal carcinoma and preoperative x-ray</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>VASOG-21</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VASOG-21</localDocumentNumber></localDocumentNumberList><documentTitle>Study using prolonged, intermittent courses of chemotherapy following surgery in selected patients with bronchogenic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>VASOG-23</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VASOG-23</localDocumentNumber></localDocumentNumberList><documentTitle>Study using prolonged, intermittent courses of 5-fluorouracil following surgery for selected patients with carcinoma of the colon</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>VASOG-26</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VASOG-26</localDocumentNumber></localDocumentNumberList><documentTitle>Lung, ccnu and hydroxyurea trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0313</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-87-150</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of gallium nitrate for treatment of patients with advanced paget's disease of bone</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0237</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-87-092</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study: hormone-modulated chemotherapy for Breast carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0179</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Clinical treatment of advanced solid tumors with il-2 and lak</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0144</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>13NHL-87-1</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of recombinant tumor necrosis factor in patients with low grade lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0135</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CRT-87-003</localDocumentNumber></localDocumentNumberList><documentTitle>Estimation of potential doubling time of human carcinomas by 5-bromodeoxyuridine labeling</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0097</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II trial of homoharringtonine in patients with myelodysplastic syndromes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:05"><nciDocumentNumber>T87-0037</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>84-86</localDocumentNumber></localDocumentNumberList><documentTitle>B72.3 monoclonal antibody scintigraphy trials: ovarian adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>T87-0016</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>87-850</localDocumentNumber><localDocumentNumber>UMCC-8702</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of pala in combination with 5-fluorouracil in unresectable adenocarcinoma of the pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>T86-0220</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I evaluation of flavone acetic acid in children with malignant solid tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>T86-0191</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I trial of WR-2721 alone and Cis-Platinum with Mannitol Diuresis one week later</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>T86-0163</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>86-06-169</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Taxol (nsc 125973) in renal cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>T83-0892</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU-8311</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of 2'deoxycoformycin (dcf) in refractory lymphoma - a Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>T83-0895</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DMS-83-03</localDocumentNumber></localDocumentNumberList><documentTitle>Mitoxantrone in the treatment of refractory non-lymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8715</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8715</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of amonafide in advanced sarcomas: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8717</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8717</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of amonafide and didemnin-b in the treatment of ovarian cancer: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8722</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8722</localDocumentNumber></localDocumentNumberList><documentTitle>Phase ii: evaluation of amonafide in adenocarcinoma of the prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8386</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8386</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of fludarabine phosphate in colorectal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8275</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8275</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot alternating combination chemotherapy in advanced pancreatic carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8322</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8322</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of fludarabine phosphate in advanced sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8217</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8217</localDocumentNumber></localDocumentNumberList><documentTitle>Spirogermanium Phase II in adenocarcinoma of the prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8031</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8031</localDocumentNumber></localDocumentNumberList><documentTitle>Mitoxantrone Phase II in refractory multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-8005</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8005</localDocumentNumber></localDocumentNumberList><documentTitle>Mitoxantrone Phase II pilot in refractory malignant lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-7927</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7927</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy for multiple myeloma - Phase III </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-7911</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7911</localDocumentNumber></localDocumentNumberList><documentTitle>Gallium nitrate Phase II in soft tissue and bone sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-7817</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7817</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of advanced germ cell neoplasms of the testis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:06"><nciDocumentNumber>SWOG-7820</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7820</localDocumentNumber></localDocumentNumberList><documentTitle>Maytansine Phase II in advanced sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SWOG-7308/09</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7308/09</localDocumentNumber><localDocumentNumber>POG-7308/09</localDocumentNumber></localDocumentNumberList><documentTitle>Comparison of treatment regimens for meningeal involvement in children with acute leukemia #5</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-82-293P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-82-293P</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II study of high-dose etoposide and high-d cyclophosphamide for extensive small cell lung ca</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-MSAR76-102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-MSAR76-102</localDocumentNumber></localDocumentNumberList><documentTitle>Piperazinedione Phase II study in refractory sarcomas and malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-MEL-P02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-MEL-P02</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I pilot study of dtic (high dose), cyclophosphamide, and c parvum in melanoma patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-MM-P37</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-MM-P37</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II study of hemi-body irradiation in multiple myeloma relapsing after or resistant to chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>SEG-LUN-P23</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-P23</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot study of squamous cell carcinoma of the lung:  ctx, adr, cis-platinum (cap)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>MAOP-2682</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-2682</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of combination chemotherapy in advanced, widely metastatic Large Cell Carcinoma of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>MAOP-5482</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-5482</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II trial of FAM chemotherapy plus irradiation in the treatment of locally advanced Gastric and Pancreatic Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-4587</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4587</localDocumentNumber><localDocumentNumber>RTOG-8533</localDocumentNumber><localDocumentNumber>SEG-LUN-82-260</localDocumentNumber><localDocumentNumber>SWOG-8490</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of PAC (Cis-Platinum, Adriamycin, and Cyclophosphamide) in treatment of invasive Thymoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-2782</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2782</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Chemotherapy of advanced soft tissue sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1283</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1283</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for the evaluation of new treatments in patients with advanced Pancreatic adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1382</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1382</localDocumentNumber></localDocumentNumberList><documentTitle>Master protocol for the evaluation of new agents or combinations in malignant Gliomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-1178</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1178</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant therapy with Tamoxifen vs. placebo in older (> 65 yrs) postmenopausal patients with stage II Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-P-F179</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-F179</localDocumentNumber></localDocumentNumberList><documentTitle>A pilot study of Adriamycin and M-amsa in patients with advanced Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-P-C678</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C678</localDocumentNumber></localDocumentNumberList><documentTitle>Amsa Phase II pilot in pts with malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EST-P-B480</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B480</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of high-dose Cytosine Arabinoside and M-amsa in refractory acute non-lymphocytic Leukemias</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>EORTC-06852</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EORTC-06852</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II protocol for the evaluation of Pentostatin in therapy of refractory lymphoid neoplasms</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>D82-058-0897</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0132</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for autologous bone marrow transplantation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>D83-047-0102</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>11</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for treatment of adult acute non- lymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>D82-051-1053</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0138</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of advanced stage childhood non-hodgkins lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:07"><nciDocumentNumber>D82-052-1051</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>81-02</localDocumentNumber></localDocumentNumberList><documentTitle>Therapy of adult acute non-lymphoblastic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D82-006-0645</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC-2467</localDocumentNumber></localDocumentNumberList><documentTitle>Dianhydrogalactitol Phase II tx of astrocytomas (glioblastoma multiforme) who have failed primary therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D81-046-0604</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Combination of methyl ccnu and adriamycin for treatment of uterine sarcoma:  Phase II trial</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D81-032-0301</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II chemotherapy for advanced melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D81-039-0767</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CHP-436</localDocumentNumber></localDocumentNumberList><documentTitle>Cis-plat diamm dich &amp; vp-16 for children with recur-rent soft tissue sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D81-001-0272</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>176-516</localDocumentNumber></localDocumentNumberList><documentTitle>Hyperthermic isolation-perfusion for melanoma of extremities</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D80-026-0053</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PPC-463</localDocumentNumber></localDocumentNumberList><documentTitle>Hexamethylmelamine, cytoxan and vp-16 in small cell lung carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D80-026-0182</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>998001</localDocumentNumber></localDocumentNumberList><documentTitle>Methyl-g in recurrent tumors of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D80-004-0178</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BTRC-8022</localDocumentNumber><localDocumentNumber>T85-0010</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II chemotherapy with dibromodulcitol for recurrent medulloblastoma &amp; ependymoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D79-020-0117</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>78-81-01</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of adult acute lymphoblastic leukemia in relapse with l-asparaginase and methotrexate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D79-032-0258</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>476-79-10</localDocumentNumber></localDocumentNumberList><documentTitle>Dibromodulcitol Phase II stage iv metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D78-035-0080</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Methyl-ccnu Phase I/II in disseminated colorectal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D78-014-0203</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Protocol for the treatment of advanced carcinoma of the uterine cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>D78-018-0092</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>77-060</localDocumentNumber></localDocumentNumberList><documentTitle>Vp-16,213 a Phase II trial using a weekly schedule</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>SEG-HN-81-231</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-HN-81-231</localDocumentNumber></localDocumentNumberList><documentTitle>Mitoxantrone in squamous cell ca of head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>SEG-GU-209</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-GU-209</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of gallium nitrate in patients with metastatic renal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:08"><nciDocumentNumber>DT-75-40</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DT-75-40</localDocumentNumber></localDocumentNumberList><documentTitle>Sequential l-asparaginase and methotrexate in patients with refractory sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>SEG-GI-77-221</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-GI-77-221</localDocumentNumber></localDocumentNumberList><documentTitle>Anguidine Phase II study in a cyclic daily schedule in adenocarcinoma of gastrointestinal tract</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>C76-0627</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>75-116</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy for advanced non-hodgkin's lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>C77-0158</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-77-6</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy in head and neck cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>SEG-BRE-77-401</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-BRE-P19</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I dose-seeking pilot study of caf and levamisole in good risk metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>COG-630</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CDE-630</localDocumentNumber></localDocumentNumberList><documentTitle>Dibromodulcitol Phase II broad study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>SEG-AML-P27</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-AML-P27</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of vinblastine in refractory acute myelogenous leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CCG-985</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-985</localDocumentNumber><localDocumentNumber>RTOG-78-23</localDocumentNumber></localDocumentNumberList><documentTitle>Misonidazole plus xrt in the treatment of recurrent brain tumors in children</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CDEP-019</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CDEP-019</localDocumentNumber></localDocumentNumberList><documentTitle>F3tdr Phase II in colon and Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>SEG-A-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-A-04</localDocumentNumber></localDocumentNumberList><documentTitle>An evaluation of the efficacy of broad-spectrum primary antibiotic therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CCG-331</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-331</localDocumentNumber></localDocumentNumberList><documentTitle>Metastatic neuroblastoma: cpm, dtic, vcr</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CCG-741</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-741</localDocumentNumber></localDocumentNumberList><documentTitle>Osteogenic sarcoma, primary and metastatic disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CCG-192P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-192P</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of previously untreated acute lymphoblastic leukemia for patients with poor prognosis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:09"><nciDocumentNumber>CCG-134P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-134P</localDocumentNumber></localDocumentNumberList><documentTitle>Therapy of acute lymphoblastic leukemia in high risk patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-8762</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8762</localDocumentNumber></localDocumentNumberList><documentTitle>Molecular subtypes in philadelphia chromosome-positive acute lymphoblastic leukemia</documentTitle><currentStatus>Administratively Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-8631</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8631</localDocumentNumber></localDocumentNumberList><documentTitle>Etoposide (vp-16, nsc# 14540) and carboplatin (cbdca, nsc# 241240) or etoposide and cisplatin (ddp 119875) for extensive small cell lung cancer: Phase I -ii</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-8638</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8638</localDocumentNumber></localDocumentNumberList><documentTitle>Carboplatin (nsc#241240) for malignant mesothelioma: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-7632</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7632</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy in indolent chronic lymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-7661</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-7661</localDocumentNumber></localDocumentNumberList><documentTitle>Multiple myelomas resistant to melphalan treated with cyclophosphamide, adriamycin, bcnu and prednisone</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>CALGB-6802</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-6802</localDocumentNumber></localDocumentNumberList><documentTitle>A study of aniline mustard in patients with multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-85-07</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-85-07</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II study of Intraoperative Radiation Therapy and External Beam Radiation Therapy of Retroperitoneal Sarcomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>LCSG-85Q</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>LCSG-85Q</localDocumentNumber></localDocumentNumberList><documentTitle>Assessment of quality of life in lcsg patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-81-17</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-81-17</localDocumentNumber></localDocumentNumberList><documentTitle>Cis-Platinum Phase I/II chemo concurrent with radio therapy in unresectable Cancer of Oral Cavity, Pharynx, Larynx and Maxillary Sinus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-83-05</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-83-05</localDocumentNumber></localDocumentNumberList><documentTitle>Metastatic Melanoma determination of optimal fraction size</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>INT-0057</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VA-280</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of multiple myeloma directed by in vitro chemosensitivity testing</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-78-25</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-78-25</localDocumentNumber></localDocumentNumberList><documentTitle>PI Meson radiotherapy of Adenocarcinoma of the Rectum or Rectosigmoid (inoperable, non-resectable or recurrent)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-76-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-76-01</localDocumentNumber></localDocumentNumberList><documentTitle>Registry of Radiation Injury</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>RTOG-77-03</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-77-03</localDocumentNumber></localDocumentNumberList><documentTitle>Hyper-fractionated Radiotherapy in Advanced Carcinoma of the Head and Neck and Esophagus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>BTSG-7620</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BTSG-7620</localDocumentNumber></localDocumentNumberList><documentTitle>Therapy of patients with brain tumors - Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:10"><nciDocumentNumber>INT-0008</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-GU-81-332</localDocumentNumber><localDocumentNumber>MAOP-4283</localDocumentNumber></localDocumentNumberList><documentTitle>Chemotherapy of disseminated testicular cancer with cis- platinum, plus bleomycin with either vinblastine or vp-16, 213</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>HTSG-3283</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HTSG-3283</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of chemotherapeutic regimens in the treatment of metastatic liver neoplasia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>GOG-76P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-76P</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Didemnin B (NSC #325319) in patients with Advanced Squamous Cell Carcinoma of the Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>GOG-65</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-65</localDocumentNumber></localDocumentNumberList><documentTitle>Interferon, Human Leukocyte Phase II in Advanced Ovarian Malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>CCG-E14</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-E14</localDocumentNumber></localDocumentNumberList><documentTitle>Epidemiology of acute non-lymphoblastic leukemia in children</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T90-0212</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I trial of 10-edam plus carboplatin in advanced solid tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0045</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/><localDocumentNumber>90-33</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of anti-b4 blocked ricin immunoconjugate in the therapy of hiv associated non-hodgkin's lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0111</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>91-285</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of intraperitoneal ormaplatin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>SWOG-9125</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9125</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of cvad/verapamil/quinine for treatment of non-hodgkins lymphomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>RTOG-91-04</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-91-04</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III comparison of accelerated hyperfractionation vs. standard fractionation in patients with Brain Metastases</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0196</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.67</localDocumentNumber><localDocumentNumber>IND.67</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of fostriecin given as an intravenous bolus daily for 5 consecutive days</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0224</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-91M1</localDocumentNumber><localDocumentNumber>ICC-91M1</localDocumentNumber><localDocumentNumber>ICC-91M1</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II investigation of all-trans retinoic acid in the treatment of aids-related kaposi's sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>SWOG-9135</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9135</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of Taxol and granulocyte-colony stimulating factor (g-csf) in patients with pancreatic adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:11"><nciDocumentNumber>T91-0269</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>92-247</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of acute myelogenous leukemia with recombinant tumor necrosis factor-alpha</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>SWOG-9207</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-9207</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of edatrexate plus carboplatin in metastatic non-small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>PROG-92-14</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>PROG-92-14</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II study employing proton therapy for the treatment of Squamous Cell Carcinoma of the Oropharynx</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T93-0056</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Staging of bronchogenic carcinoma using computed tomography and monoclonal antibody cc49</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>CALGB-9332</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-9332</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of navelbine or navelbine plus doxorubicin in previously treated patients with small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T93-0069</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II study of biomodulation of 5fu with hydroxyurea and leucovorin in metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T93-0068</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II Study of Irinotecan (CPT-11) in Advanced Carcinoma of the Uterine Cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="05-01-2012 14:51:01" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T93-0140</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I trial of tnp-470, a new inhibitor of angiogenesis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>GOG-9402</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-9402</localDocumentNumber></localDocumentNumberList><documentTitle>Laparoscopic staging in patients with Incompletely Staged Cancers of the Uterus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T94-0165</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO9495</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I Clinical Trial of Flavopiridol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>T94-0192</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase II trial of paclitaxel over three hours followed by topotecan (nsc#609699) administered daily for five days in patients with metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:12"><nciDocumentNumber>IND 2960</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>L91-0492</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of moab 14g2a</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>76-20-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>76-20-01</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for the management of small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>76-48-01</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>76-48-01</localDocumentNumber></localDocumentNumberList><documentTitle>A study of 5-fu-methyl ccnu as surgical adjuvant treatment for resectable hepatocellular carcinoma and isolated hepa- tic metastasis from colorectal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>T84-0499</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.32</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of trimetrexate glucuronate (tmtx)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8304</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8304</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy for remission induction and maintenance for recurrent childhood Lymph Leukemia occurring 6 months or more after elective cessation of TX; children with ALLl after 3 yrs continuous CR; children w/ 1s tCNS relapse</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8319</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8319</localDocumentNumber></localDocumentNumberList><documentTitle>High doseCytosine Arabinoside, fractionated total body irradiation, and BoneMarrow Transplantation to treat children with Acute Lymphoblastic Leukemia in 2nd Hematologic remission</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8340</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8340</localDocumentNumber></localDocumentNumberList><documentTitle>Allogeneic or Autologous Bone Marrow Transplantation (BMT) for stage D Neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-8346</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8346</localDocumentNumber></localDocumentNumberList><documentTitle>Comprehensive therapy for Ewing's Sarcoma using chemotherapy and a tailored radiation therapy port</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>75-20-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>75-20-02</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II studies in limited small cell lung cancer using cytoxan, adriamycin, cis-platinum and vp-16</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>63-30</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Streptozotocin in advanced small cell bronchogenic carcinoma: an ineffective nonmyelosuppressive agent  bunn,p</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>113-256C</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2001</localDocumentNumber><localDocumentNumber>87-27</localDocumentNumber></localDocumentNumberList><documentTitle>Icrf-159 Phase II tx of adv bronchogenic ca and adv adenocarcinoma of colon</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-7837</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7837</localDocumentNumber><localDocumentNumber>SWOG-7837</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of systemic therapy for children with Lymphoblastic Lymphoma including T-Cell disease - Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-7905</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7905</localDocumentNumber></localDocumentNumberList><documentTitle>A-COP plus for Non-Hodgkin's Llymphoma in children - Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-7906</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7906</localDocumentNumber><localDocumentNumber>SWOG-7906</localDocumentNumber></localDocumentNumberList><documentTitle>Multidrug adjuvant chemotherapy in Non-Metastatic Osteosarcoma, comparison of Conpadri-I with Compadri-V</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-7919</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7919</localDocumentNumber><localDocumentNumber>SWOG-7919</localDocumentNumber></localDocumentNumberList><documentTitle>Amsa eval in children with ALL and Non-Hodgkins Lymphoma  in relap, random study 5 days schedule vs/10 days</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>T84-0468</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.16</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of at-125 in poor prognosis non-hodgkin's lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:13"><nciDocumentNumber>POG-7796</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7796</localDocumentNumber><localDocumentNumber>SWOG-7996</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant chemotherapy for localized unilateral Retenoblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GOG-26T</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-26T</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial 0f 4'-Deoxydoxorubicin in patients with Advanced Pelvic Malignancies other than Epithelial Cervical or Endometrial Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GOG-100</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-100</localDocumentNumber></localDocumentNumberList><documentTitle>Monoclonal antibody against free beta HCG to predict development of persistent Gestational Trophoblastic Disease (PGDT) in patients with Hydatidiform Mole</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GITSG-5377</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-5377</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Cyclophosphamide and Mitomycin-C in Advanced Squamous Cell Carcinoma of the Esophagus</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>GITSG-7175</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GITSG-7175</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of adjuvant therapy of surgically operable Rectal Carcinoma, stages B2 and C</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>POG-7420/21</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-7420/21</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of various systemic and prophylactic CNS regimens in the treatment of Acute Leukemia of childhood - Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>POA-62285</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-62285</localDocumentNumber></localDocumentNumberList><documentTitle>High dose Cytosine Arabinoside (HIDAC) and Cisplatin (CDDP) for refractory Small Cell Carcinoma of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>POA-74185</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BGSM-74185</localDocumentNumber></localDocumentNumberList><documentTitle>Tamoxifen vs high dose oral Medroxyprogresterone Acetate (MPA) for patients with advanced Breast Cancer:  a Phase III study (BG85-0049)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>POA-83181</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-83181</localDocumentNumber></localDocumentNumberList><documentTitle>Feasibility study of combined high dose plus whole Abdominal &amp; Pelvic radiation and selective chemotherapy in patients with advanced Ovarian Cancer failing prior chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:14"><nciDocumentNumber>T84-0384</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase I/II trial of amsacrine with high dose cytarabine in the treatment of resistant leukemia or acute leukemia in relapse</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:15"><nciDocumentNumber>W81-0945</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU-8111</localDocumentNumber></localDocumentNumberList><documentTitle>Deoxycoformycin in refractory chronic lymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:15"><nciDocumentNumber>T84-0352</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>84-10-195</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I/II study of deoxydoxorubicin in patients with previously treated acute leukemia with pharmacokinetic analysis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:15"><nciDocumentNumber>POA-62184</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POA-62184</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of VP-16, CDDP, and Vincristine in advanced Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:16"><nciDocumentNumber>T84-0335</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GN-1</localDocumentNumber></localDocumentNumberList><documentTitle>Gallium nitrate continuous infusion therapy for refractory small cell cancer of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:17"><nciDocumentNumber>EST-7487</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-7487</localDocumentNumber></localDocumentNumberList><documentTitle>Modified Vad in the treatment of resistant or relapsing chronic lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:17"><nciDocumentNumber>EST-8487</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-8487</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Mitoxantrone, Cytosine Arabinoside with Etoposide in patients with refractory or relapsed acute lymphoblastic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:17"><nciDocumentNumber>CALGB-8984</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CALGB-8984</localDocumentNumber><localDocumentNumber>ECOG-1291</localDocumentNumber><localDocumentNumber>RTOG-9109</localDocumentNumber><localDocumentNumber>SWOG-9306</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II intergroup study of conservative treatment of adenocarcinoma of the distal rectum: local excision plus adjuvant radiation and concurrent 5-fu in selected patients</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:17"><nciDocumentNumber>T90-0083</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IND.55</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of 10-edam in patients with recurrent or metastatic soft tissue sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:18"><nciDocumentNumber>T90-0060</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BGSM-60189</localDocumentNumber></localDocumentNumberList><documentTitle>Multimodal therapeutic protocol for local and regional squamous cell esophageal cancer using chemotherapy with mitomycin c and continuous intravenous infusion 5-fu plus synchronous radiation therapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:18"><nciDocumentNumber>T90-0056</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A Phase I study of carboplatin/cytoxan/etanidazole in advanced ovarian cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:20"><nciDocumentNumber>EST-P-B589</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B589</localDocumentNumber></localDocumentNumberList><documentTitle>Cisplatin plus chronic oral Etoposide (VP-16) therapy for previously untreated extensive stage small cell Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:21"><nciDocumentNumber>T90-0035</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BRM-90-01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of patients with advanced bladder cancer and cancer of the uroepithelium treated with il-2 and autologous lymphokine activated killer cells</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:21"><nciDocumentNumber>SWOG-8910</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8910</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of low dose continuous 5-fluorouracil (5-fu) and weekly cis-platinum (cddp) in advanced adenocarcinoma of the stomach</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>WPL-74-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WPL-74-52</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of extensive adenocarcinoma and large cell carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>WPL-75-11</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WPL-75-11</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant radiotherapy with adjuvant reductive surgery of stage iii squamous cell (epidermoid) carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>T84-0267</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>84-011</localDocumentNumber></localDocumentNumberList><documentTitle>Bone marrow transplantation for stage iv neuroblastoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>SWOG-8933</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8933</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of piroxantrone in pancreatic adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>T89-0216</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>90-019</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of pala, 5-fluorouracil and leucovorin in patients with advanced cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>NSABP-B-06</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NSABP-B-06</localDocumentNumber></localDocumentNumberList><documentTitle>A Protocol to Compare Segmental Mastectomy and Axillary Dissection with and without Radiation of the Breast and Total Mastectomy and Axillary Dissection</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:22"><nciDocumentNumber>CCG-0896</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-0896</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of thiotepa in children with recurrent solid tumor malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>T84-0169</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-82-158</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of mitomycin, vindesine, adriamycin in adenocarcinoma of an unknown primary site</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:23"><nciDocumentNumber>NCCTG-89-24-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-89-24-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III double blind trial of VP-16/Cisplatin with or without Hydrazine Sulfate in Advanced Non-Small Cell Lung Cancer.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>B89-0008</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>A pilot Phase I B study of Cyclophosphamide, Autologous tumor-infiltrating Lymphocytes and recombinant human Interleukin-2 (Roche) in the treatment of patients with metastatic malignant melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>SWOG-8940</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8940</localDocumentNumber></localDocumentNumberList><documentTitle>A study of the combination of recombinant human interleukin 1-beta, etoposide, and carboplatin in patients with metastatic cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>T89-0158</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>JH-90-31</localDocumentNumber></localDocumentNumberList><documentTitle>Upregulation of hla-dr receptor levels and possible potentiation of a graft vs. tumor effect by the use of ifn-g in patients receiving csa to induce gvhd following high dose chemotherapy and autologous bmt for metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NPCP-2000</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NPCP-2000</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of definitive therapies, surgery versus radiotherapy, for stage a Prostate Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>T84-0111</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MASTER</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of chemotherapeutic agents (drug name) in (disease site) master protocol</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-6G-91</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-6G-91</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of 5-Fu + CCNU before radiotherapy + HU + Misonidazole followed by alternating courses of Procarbazine and Vincristine + BCNU + 5-Fu for the treatment of primary malignant brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-7H-61</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-7H-61</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase  III study of radiation therapy with or without CT for remission induction and multi-drug program for remission consolidation and maintenance in inoperable Advanced Squamous Cell Carcinoma of Head and Neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-7O-85-1</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-7O-85-1</localDocumentNumber><localDocumentNumber>NCOG-7O-85-1</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized Phase III study of heavy charged particle radiotherapy versus Iodine (125I) plaque radiotherapy in the treatment of localized uveal Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-9L-80-3</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-9L-80-3</localDocumentNumber></localDocumentNumberList><documentTitle>Prednimustine Phase II intermittent therapy in refractory Chronic Lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>SWOG-8907</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8907</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II trial of combination chemotherapy plus verapamil in drug refractory intermediate grade and selected high grade non-hodgkin's lymphomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-5C-72</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-5C-72</localDocumentNumber></localDocumentNumberList><documentTitle>Conventional radiatherapy vs. heavy charged particle radiotherapy in the treatment of advanced carcinoma of the uterine cervix</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-5O-82-1J</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-5O-82-1J</localDocumentNumber><localDocumentNumber>RTOG-84-10</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of pelvic and abdominal radiotherapy versus Cis-Platinum, Adriamycin, and Cyclophosphamide chemotherapy in Stages I, II and Optimal III Epithelial Carcinoma of the Ovary</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-2N-92</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-2N-92</localDocumentNumber></localDocumentNumberList><documentTitle>PCNU Phase II study in metastatic or recurrent cancer of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-2O-83-1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-2O-83-1</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III trial of seven-drug versus three-drug chemotherapy regimens with or without Prophylactic Cranial irradiation for undifferentiated small cell lung cancer: extensive disease</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:24"><nciDocumentNumber>NCOG-3L-82-1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-3L-82-1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of continuous infusion FUDR:  Intravenous versus intraarterial in patients with colon cancer metastatic to liver only</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>NCOG-3S-62</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-3S-62</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study comparing Adriamycin + 5-Fu vs BCNU + Adriamycin + Ftorafur vs Mitomycin C + Adriamycin + Ftorafur vs Mitomycin C + Adriamycin + Ftorafur for patients with Disseminated Gastric Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1420</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>697-83-12</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for a Phase II study of diaziquone (azq) plus procarbazine (pcb) in the treatment of patients with primary anaplastic brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1396</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>URCC-2281M</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy for advanced colorectal carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1367</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC-1257</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of stage iii &amp; iv diffused histiocytic lymphoma: adriamycin, cytoxan, vincristine, prednisone,bleomycin vs. adria. cyt,. vinc,. mtx-ca leuc., ara-c.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1372</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-79-60</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant therapy of gastric carcinoma- a randomized study of comparing 5-fu, adriamycin, and mitomycin-c (fam) vs. no post-operative chemotherapy [ga2]</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1378</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-82-39</localDocumentNumber></localDocumentNumberList><documentTitle>Double-blind randomized trial of 13-cis retinoic acid (ro 4-3780) vs. placebo in the myelodysplastic syndromes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1346</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-8284</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of high-dose prolonged intravesical infusion of 5-fu in refractory, superficial bladder cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1366</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>1221</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy using cytosine arabinoside, cisplatin and etoposide: vp-16 (ace) in patients with non-hodgkin's lymphoma, refractory to standard treatment</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1307</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BGSM-22183</localDocumentNumber></localDocumentNumberList><documentTitle>Master section for Phase II studies in refractory adult acute leukemia (anll, cgl with blast crisis)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>NCOG-1B-80-1</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCOG-1B-80-1</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III randomized study comparing effective, non-cross-resistant, alternating combinations (CMF, FOAMcmf,) with sequential use of the same combinations for Metastatic Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1232</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>82-10-476</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of m-amsa, high dose ara-c for resistant leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:25"><nciDocumentNumber>T83-1189</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-3</localDocumentNumber><localDocumentNumber>IRB-2-83-7D</localDocumentNumber><localDocumentNumber>T83-1024</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II single agent chemotherapy with cbdca for metastatic bladder carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>RTOG-88-24</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>RTOG-88024</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial to determine the feasibility of post-operative concurrent Cisplatin and Radiotherapy in patients with resected Head and Neck Cancers</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>INT-0106</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-9048</localDocumentNumber><localDocumentNumber>CCG-8891</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of children with localized malignant germ cell tumors: a Phase II study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>T83-1173</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>HIC-3044</localDocumentNumber></localDocumentNumberList><documentTitle>Hepatic artery dichloromethotrexate and 5-fluorouracil in colorectal cancinoma metastatic to liver</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>GOG-102F</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>GOG-102F</localDocumentNumber></localDocumentNumberList><documentTitle>Intraperitoneal administration of ALPHA RECOMBINANT INTERFERON (ALPHA aIFN) (NSC# 377523) in residual OVARIAN CARCINOMA</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-87-46-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-87-46-51</localDocumentNumber><localDocumentNumber>87-46-51</localDocumentNumber></localDocumentNumberList><documentTitle>A controlled evaluation of Recombinant Interferon-Gamma (IFL-GM) and 5-Fu and Folinic Acid as adjuvant treatment for resectable Adenocarcinoma of the colon</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-86-72-54</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-86-72-54</localDocumentNumber><localDocumentNumber>86-72-54</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of infusional Cis Platinum and Etoposide in Recurrent Primary Brain Tumor</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-87-32-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-87-32-52</localDocumentNumber><localDocumentNumber>87-32-52</localDocumentNumber></localDocumentNumberList><documentTitle>Randomized clinical trial in women with Metastatic Breast Cancer: Integration of Phase II testing of new agents into a Phase III trial examining Estrogenic recruitment as a means of increasing the efficacy of combination chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-86-30-52</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-86-30-52</localDocumentNumber><localDocumentNumber>86-30-52</localDocumentNumber></localDocumentNumberList><documentTitle>A retrospective study of the value of the tumor cell kinetic parameters DNA Ploidy and %s Phase I n patients with Breast Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-86-47-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-86-47-51</localDocumentNumber><localDocumentNumber>CALGB-8894</localDocumentNumber><localDocumentNumber>EST-1288</localDocumentNumber><localDocumentNumber>RTOG-88-11</localDocumentNumber><localDocumentNumber>SWOG-8896</localDocumentNumber><localDocumentNumber>86-47-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III Protocol for Surgical Adjuvant Therapy of Rectal Carcinoma:  A Controlled Evaluation of Protracted Infusion 5 Fluorouracil as a Radiation Enhancer and 5-Fu Plus Methyl-CCNU Chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-84-48-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-84-48-51</localDocumentNumber><localDocumentNumber>84-48-51</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Pala, Thymidine and 5-Fluorouracil in advanced measurable Gastric Cancer and Anaplastic Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:26"><nciDocumentNumber>NCCTG-83-32-02</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-83-32-02</localDocumentNumber><localDocumentNumber>83-32-02</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II evaluation of Trilostane plus Hydrocortisone in women with Advanced Breast Cancer prior to hormonal therapy exposure</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>NCCTG-88-24-53</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-88-24-53</localDocumentNumber><localDocumentNumber>88-24-53</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of observation versus adjuvant therapies in completely resected Stage II and IIIA Non-Small Cell Carcinoma of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>NBCCGA-4A</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NBCCGA-4A</localDocumentNumber></localDocumentNumberList><documentTitle>A feasibility (Pilot) study of Adjuvant Preoperative Radiation Therapy followed by radical Cystectomy and urinary diversion for patients with invasive primary Carcinoma of the bladder</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:27"><nciDocumentNumber>T88-0261</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>BGSM-99189</localDocumentNumber></localDocumentNumberList><documentTitle>Vincristine with high-dose vp-16:a Phase I study in advanced refractory malignancy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>SWOG-8811</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8811</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of 5-fluorouracil and high dose folinic acid as first or second line therapy for advanced Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>T88-0194</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UMCT-8816</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of wr-2721 administered with high dose cisplatin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>INT-0096</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3588</localDocumentNumber><localDocumentNumber>RTOG-88-15</localDocumentNumber><localDocumentNumber>SWOG-8991</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase III study of cisplatin plus etoposide combined with standard fractionation thoracic radiotherapy vs cisplatin plus etoposide combined with multiple daily fractionated thoracic radiotherapy for limited stage small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:18" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>CCG-1883</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CCG-1883</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of newly diagnosed acute lymphoblastic leukemia in infants less than 12 months of age</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>NCCTG-88-24-51</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NCCTG-88-24-51</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of accelerated Hyperfractionated split course Thoracic Radiation Therapy in patients with unresectable Stage III Non-Small Cell Carcinoma of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>POG-8871</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>POG-8871</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase I study of Recombinant Human Tumor Necrosis Factor (RTNF) in children with Refractory Tumors:  a Pediatric Oncology Group study</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>VASOG-30</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>VASOG-30</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for study of effects of methyl-ccnu and 5-fluorouracil in patients with carcinoma of stomach</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>VAL-E-11</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>111</localDocumentNumber></localDocumentNumberList><documentTitle>Dibromodulcitol Phase II rand eval of pts malignant bronchogenic tumor</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>T88-0066</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ABMT-1</localDocumentNumber></localDocumentNumberList><documentTitle>Timed sequential high-dose carboplatin (cbdca) plus high-dose etoposide (vp-16) and autologous bone marrow rescue (abmt) for the treatment of selected pediatric malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:28"><nciDocumentNumber>T88-0074</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WVU-11496</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of interleukin 2 (il-2) in localized and in situ transitional cell carcinoma of the bladder</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0316</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ID-87-003</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I pilot study of combination therapy with tumor necrosis factor(tnf) and interleukin-2 (il-2) in patients with unresectable or metastatic (stage iiib or stage iv) non small cell lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0318</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OC-87-8</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study with high-dose carboplatin, thiotepa, etoposide and autologous marrow transplantation in patients with refractory malignancies</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T88-0013</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>UPCC-4487</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study of interleukin-2 therapy in acute non-lymphocytic leukemia in second remission</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0224</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-87-98</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III trial of cisplatin, high dose ara-c, and caffeine vs streptozotocin, mitomycin c and 5-fluorouracil for advanced pancreatic cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0204</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-87N1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of new agents in the treatment of patients with advanced carcinoma of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0206</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>ICC-87U3</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of new agents in the treatment of patients with advanced transitional cell carcinoma of bladder, ureter, and renal pelvis</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0177</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>M1184-01</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I trial of 6-thioguanine by continuous infusion in refractory leukemia with cytokinetics and pharmacokinetics</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0164</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CIC-87-77</localDocumentNumber></localDocumentNumberList><documentTitle>Flow cytometric analysis of soft tissue sarcoma with bromodeoxyuridine (budr)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:29"><nciDocumentNumber>T87-0151</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>1730</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of the combination of indomethacin and recombinant interleukin-2 in patients with advanced renal cell cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:16" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0119</nciDocumentNumber><sponsorOrganization>DCP</sponsorOrganization><localDocumentNumberList><localDocumentNumber> RCC-2487M</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for the treatment of advanced Non-Hodgkin's Lymphomas refractory to "chop" induction chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0068</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NYU-87-05</localDocumentNumber></localDocumentNumberList><documentTitle>Phase i study of intraperitoneal recombinant interleukin ii (ril2) in patients with ovarian cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0044</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>79H01</localDocumentNumber></localDocumentNumberList><documentTitle>Carcinoembryonic and other tumor-antigen specific radioantibody imaging in patients with neoplasms</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T87-0035</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>IFOS-I1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I study of ifosfamide in pediatric patients: a study for determination of alternative dosages and schedules (daily x 3)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:30"><nciDocumentNumber>T86-0214</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>KCRG-8601</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of carboplatin (cbdca) in patients with advanced adenocarcinoma of the stomach</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T83-1073</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase III study comparing azq with bcnu in the treatment of patients with primary anaplastic brain tumors</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T83-1038</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>NYU-83-05</localDocumentNumber><localDocumentNumber>T85-0009</localDocumentNumber></localDocumentNumberList><documentTitle>A randomized study of cardioprotection with icrf-187 in patients with advanced Breast cancer receiving 5- fluorouracil,adriamycin and cyclophosphamide</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T83-1050</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OSU-83</localDocumentNumber></localDocumentNumberList><documentTitle>Does pretreatment with icrf-187 prevent doxorubicin cardiotoxicity?</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T83-1029</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>H-0382</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of spirogermanium in refractory multiple myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T83-0933</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-82-46</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of dhad and ddp combination in metastatic adenocarcinoma and large cell cancer of the lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>T83-0949</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>DM-82-86</localDocumentNumber></localDocumentNumberList><documentTitle>Therapy of adult acute leukemia according to predicted individual outcome</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8742</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8742</localDocumentNumber></localDocumentNumberList><documentTitle>A Phase II study of recombinant tumor necrosis factor (rtnf) in patients with metastatic sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8707</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8707</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of recombinant gamma interferon in renal cell carcinoma: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8606</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8606</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of small cell lung cancer using an intensive, multidrug, weekly treatment program of short duration: Phase II pilot</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8530</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8530</localDocumentNumber></localDocumentNumberList><documentTitle>Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors: Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:31"><nciDocumentNumber>SWOG-8508</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8508</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy of intermediate and high-grade non-hodgkin's lymphoma with macop-b, Phase II </documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8300</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8300</localDocumentNumber></localDocumentNumberList><documentTitle>Treatment of limited non-small cell lung cancer: radiation versus radiation plus chemotherapy (fomi/cap)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8308</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8308</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II combination cis-platinum and dichloromethotrexate in patients with advanced bladder cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8320</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8320</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of Fludarabine Phosphate in Endometrial Cancer: Phase II</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8232</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8232</localDocumentNumber></localDocumentNumberList><documentTitle>TX of limited Small Cell Lung Cancer with VP-16, 213/Cis-Platinum, alternating with Vincristine/Adriamycin/Cyclophosphamide and radiation therapy versus concurrent VP-16/Vincristine/Adriamycin/Cyclophosphamide and radiation</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8235</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8235</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of continuous infusion Vinblastine in Gastric Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8210</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8210</localDocumentNumber></localDocumentNumberList><documentTitle>A comparison of aggressive radiotherapy plus chemotherapy versus aggressive chemotherapy in the treatment of Limited Carcinoma of the Pancreas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8219</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8219</localDocumentNumber></localDocumentNumberList><documentTitle>Evaluation of combined or sequential chemo-endocrine therapy in the treatment of Advanced Adenocarcinoma of the Prostate</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-8049</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-8049</localDocumentNumber></localDocumentNumberList><documentTitle>The treatment of Resected, Poor Prognosis Malignant Melanoma: stage I: surgical excision vs surgical excision plus vitamin a, Phase III</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7941</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7941</localDocumentNumber></localDocumentNumberList><documentTitle>Methyl-G vs 5-Fluorouracil vs Mitoxantrone in met Adenoca of Large Bowel (appendix VI swog-7940 Phase II portion)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7828</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7828</localDocumentNumber></localDocumentNumberList><documentTitle>Combined modality therapy for extensive Small Cell Carcinoma of the Lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7768</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7768</localDocumentNumber></localDocumentNumberList><documentTitle>Adriamycin-Ifosfamide combination Chemotherapy of previously treated Acute Leukemia in relapse</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7804</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7804</localDocumentNumber></localDocumentNumberList><documentTitle>Adjuvant chemotherapy with 5-fluorouracil, adriamycin and mitomycin-c (fam) versus surgery alone for patients with locally advanced gastric adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7634</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7634</localDocumentNumber></localDocumentNumberList><documentTitle>MECCNU or Mitomycin-C + BTGDR in Refractory Colorectal Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7639</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7639</localDocumentNumber></localDocumentNumberList><documentTitle>Two Adriamycin, Mitomycin C and 5-Fluorouracil combinations in the management of Gastric Adenocarcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7515</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7515</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of Asaley in children with late-stage Acute Lymphocytic Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7524</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7524</localDocumentNumber></localDocumentNumberList><documentTitle>Chemoimmunotherapy in stages iii and iv ovarian and endometrial carcinoma, phase iii.</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7436</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7436</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy (CMFVP) vs L-Phenylalanine mustard (L-Pam) for operable Breast Cancer with positive axillary nodes</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-7313</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SWOG-7313</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III chemotherapy with L-PAM/CTX/BCNU/pred and Azathioprine/pred. for remission maintenance of Multiple Myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:32"><nciDocumentNumber>SWOG-442</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:nil="true"/></localDocumentNumberList><documentTitle>Phase II evaluation of Adriamycin in Human Neoplasia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-360R</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-360R</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of surgical adjuvant immunotherapy using C. Parvum in patients with resectable stage II Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-78-PR-342</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-78-PR-342</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized comparison of des therapy followed by Cyclophosphamide at the time of progression vs. Des plus Cyclophosphamide as initial therapy for stage IV Prostatic Carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-359</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-359</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized adjuvant study of Corynebacterium Parvum vs. no therapy in stage I Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-360</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-360</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III randomized adjuvant study of Corynebacterium Parvum vs. not therapy in stage II Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-LY-201P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LY-201P</localDocumentNumber></localDocumentNumberList><documentTitle>High dose Adriamycin, Dexamethasone, Vincristine, and Cytosine Arabinoside for treatment of intermediate and high grade Lymphomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>SEG-LUN-81-213P</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>SEG-LUN-81-213P</localDocumentNumber></localDocumentNumberList><documentTitle>Vindesine and Mitomycin-C for the treatment of advanced Non-Oat Cell Carcinoma of the Lung in patients having no prior chemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-3182</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-3182</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III multicenter study of Amsacrine DMA/Lactate (CI-880) in comb. with Thioguanine &amp; ARA-C vs.Dauno., Thioguanine, &amp; ARA-C in front line therapy of pts with ANLL</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-5182</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-5182</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of FAM-Triazinate in advanced Gastric Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-8185</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-8185</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Tiazofurin in advanced recurrent or metastatic malignant Melanoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-2185</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-2185</localDocumentNumber></localDocumentNumberList><documentTitle>Stage three locally advanced bulky (t>5 cm) unresectable and metastatic Non-Small Cell Lung Cancer - outpatient study of Echinomycin</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:20" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-2283</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-2283</localDocumentNumber></localDocumentNumberList><documentTitle>Locally advanced non-bulky unresectable and post surgical residual Non-Small Cell Lung Cancer:  a randomized Phase III trial of radiation therapy +/- Synthetic Thymosin Alpha</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>MAOP-2485</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>MAOP-2485</localDocumentNumber></localDocumentNumberList><documentTitle>Outpatient protocol for Phase II study of Menogaril in stage III locally advanced bulky (t > 5 cm) unresectable and metastatic Non-Small Cell Lung Cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>EST-5484</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-5484</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of the treatment of the resistant phase of Chronic myelogenous leukemia with 5-Azacytidine and Mitoxantrone</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>EST-6177</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-6177</localDocumentNumber></localDocumentNumberList><documentTitle>A clinical trial to compare adjuvant therapy with Cytoxan, Mtx, 5-FU and Prednisone (CMFP) versus CMFP and Tamoxifen versus no adjuvant therapy in post-menopausal patients with stage II Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:33"><nciDocumentNumber>EST-6484</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-6484</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III comparative evaluation of Cyclophosphamide, Vincristine, Prednisone, and Adriamycin (Copa) with or without recombinant a Interferon Alpha in patients with moderately aggressive Non-Hodgkin's lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-4883</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4883</localDocumentNumber><localDocumentNumber>SEG-INT-GU-202</localDocumentNumber></localDocumentNumberList><documentTitle>Intergroup randomized Phase II evaluation of Carboplatin and chip in patients with advanced Transitional Cell carcinoma of the Urethelium</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-3888</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3888</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II protocol for the evaluation of Amonafide, Caracemide, and Homoharringtonine in advanced Renal Cell carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-4472</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-4472</localDocumentNumber><localDocumentNumber>SEG-343</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III study of intermittent BCNU, Cyclophosphamide and Prednisone vs intermittent Melphalan and Prednisone in Myeloma and of the addition of Fluoxymesterone, Sodium Fluoride and Calcium Gluconate vs placebo</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-3278</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-3278</localDocumentNumber><localDocumentNumber>N81-0986</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II - III studies in Chemotherapy of Islet Cell carcinoma: evaluations of Streptozotocin plus 5-Fluorouracil, Streptozotocin plus Adriamycin and Chlorozotocin alone</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2878</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2878</localDocumentNumber></localDocumentNumberList><documentTitle>Phase III combination Chemotherapy of advanced Ovarian carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-2182-14</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-2182-14</localDocumentNumber></localDocumentNumberList><documentTitle>Aminothiadiazole in the treatment of Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1480-15/16</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1480-G1</localDocumentNumber></localDocumentNumberList><documentTitle>Amsa vs Pala Phase II evaluation of Pala and Amsa in patients with Lymphomas</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1487</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1487</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of Mitoxantrone and Etoposide in patients with relapsed and refractory acute Non-Lymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1575</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1575</localDocumentNumber></localDocumentNumberList><documentTitle>Radiation therapy and multi-agent Chemotherapy in the therapy of localized Small Cell Undifferentiation carcinoma of the Lung (including Oat Cell)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1176</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1176</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II combination Chemotherapy with and without Immunotherapy for metastatic Breast cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-1182</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-1182</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II single arm pilot study: combination hormonotherapy for metastatic Breast carcinoma: a study of Megesterol Acetate plus Aminoglutethimide-hydrocortisone</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-P-H882</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-H882</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot study of combined Chemohormonal therapy with Adriamycin and Estramustine in metastatic Prostrate cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:34"><nciDocumentNumber>EST-P-Z586</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-Z586</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of recombinant Interleukin 2 with and without recombinant beta Interferon in patients with advanced non-small cell Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-F278</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-F278</localDocumentNumber></localDocumentNumberList><documentTitle>Amsa Phase II pilot study in Hepatocellular carcinoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-D482</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-D482</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study for advanced refractory malignant Lymphoma and hodgkin's disease with VM-26 and CCNU</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-D882</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-D882</localDocumentNumber></localDocumentNumberList><documentTitle>Phase I/II pilot study of simultaneous intraperitoneal Melphalan and Cis-platinum in advanced Ovarian cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-C484</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-C484</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II evaluation of alternating cycles of VBMCP Chemotherapy &amp; recombinant Interferon Alpha2 therapy in previously untreated patients with multiple Myeloma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-B582</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B582</localDocumentNumber></localDocumentNumberList><documentTitle>Trial of Chemotherapy with Mitomycin-C, Vinblastine, and Cisplatin followed by Radiotherapy in patients with locally advanced Non-small Cell Lung cancer</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-B585</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-B585</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of high-dose Cisplatin Chemotherapy of Non-small Cell Lung cancer with chemosensitivity assay correlation, followed by assay-directed monochemotherapy</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-A285</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A285</localDocumentNumber></localDocumentNumberList><documentTitle>Large field, low dose/fraction external Beam Abdominal Irradiation as a surgical adjuvant for resectable Colon carcinoma above the peritoneal reflection with positive regional nodes (a second generation pilot study)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>EST-P-A484</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>EST-P-A484</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot study of continuous infusion Homoharringtonine in refractory acute Leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:21" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-070-0092</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>WRAMC-8002</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II trial of mitoguazone in patients with advanced squamous cell carcinoma of the head and neck</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D83-002-0103</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>02582</localDocumentNumber></localDocumentNumberList><documentTitle>Combination chemotherapy (chop/ama) for patients with t-cell immunoblastic sarcoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-048-0403</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CO-8251</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II pilot: new induction regimen containing vp-16, ddp, hmm for extensive stage small cell carcinoma lung</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:19" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-050-0542</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0091</localDocumentNumber></localDocumentNumberList><documentTitle>Protocol for evaluation of the combination of vp16 and cyclophosphamide in acute non-lymphocytic leukemia</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-042-0572</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>81-1</localDocumentNumber></localDocumentNumberList><documentTitle>Phase II study of amsa (nci #249992) methanesulfon m-anisidide 4'-(acridinylamino) in refractory adult acute leukemia    (a non-randomized study)</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-018-0544</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>80-051</localDocumentNumber></localDocumentNumberList><documentTitle>Chronic myelogenous leukemia acute and chronic phase</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-018-1415</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>2-82</localDocumentNumber></localDocumentNumberList><documentTitle>Aclacinomycin-a, Phase II trial in refractory lymphoma</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-030-0091</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>CTEPIS-0030</localDocumentNumber></localDocumentNumberList><documentTitle>Pilot study for advanced refractory malignant lymphoma &amp; hodgkin's disease w/teniposide &amp; lomustine</documentTitle><currentStatus>Complete</currentStatus></document><document updatedDate="04-24-2012 18:00:17" createdDate="12-17-1998 16:51:35"><nciDocumentNumber>D82-002-0547</nciDocumentNumber><sponsorOrganization>CTEP</sponsorOrganization><localDocumentNumberList><localDocumentNumber>OC-81-1</localDocumentNumber></localDocumentNumberList><documentTitle>